compound_id,dc50_(nm),dmax_(percent),dc50_(nm)_origin,dmax_(percent)_origin,uniprot,target,e3_ligase,pdb,name,smiles,assay_(dc50/dmax),percent_degradation_(percent),assay_(percent_degradation),"ic50_(nm,protac_to_target)","assay_(protac_to_target,ic50)","ec50_(nm,protac_to_target)","assay_(protac_to_target,ec50)","kd_(nm,protac_to_target)","assay_(protac_to_target,kd)","ki_(nm,protac_to_target)","assay_(protac_to_target,ki)","delta_g_(kcal/mol,protac_to_target)","delta_h_(kcal/mol,protac_to_target)",#NAME?,"assay_(protac_to_target,g/h/-ts)","kon_(1/ms,protac_to_target)","koff_(1/s,protac_to_target)","t1/2_(s,protac_to_target)","assay_(protac_to_target,kon/koff/t1/2)","ic50_(nm,protac_to_e3)","assay_(protac_to_e3,ic50)","ec50_(nm,protac_to_e3)","assay_(protac_to_e3,ec50)","kd_(nm,protac_to_e3)","assay_(protac_to_e3,kd)","ki_(nm,protac_to_e3)","assay_(protac_to_e3,ki)","delta_g_(kcal/mol,protac_to_e3)","delta_h_(kcal/mol,protac_to_e3)",#NAME?,"assay_(protac_to_e3,g/h/-ts)","kon_(1/ms,protac_to_e3)","koff_(1/s,protac_to_e3)","t1/2_(s,protac_to_e3)","assay_(protac_to_e3,kon/koff/t1/2)","ic50_(nm,ternary_complex)","assay_(ternary_complex,ic50)","ec50_(nm,ternary_complex)","assay_(ternary_complex,ec50)","kd_(nm,ternary_complex)","assay_(ternary_complex,kd)","ki_(nm,ternary_complex)","assay_(ternary_complex,ki)","delta_g_(kcal/mol,ternary_complex)","delta_h_(kcal/mol,ternary_complex)",#NAME?,"assay_(ternary_complex,g/h/-ts)","kon_(1/ms,ternary_complex)","koff_(1/s,ternary_complex)","t1/2_(s,ternary_complex)","assay_(ternary_complex,kon/koff/t1/2)","ic50_(nm,cellular_activities)","assay_(cellular_activities,ic50)","ec50_(nm,cellular_activities)","assay_(cellular_activities,ec50)","gi50_(nm,cellular_activities)","assay_(cellular_activities,gi50)","ed50_(nm,cellular_activities)","assay_(cellular_activities,ed50)","gr50_(nm,cellular_activities)","assay_(cellular_activities,gr50)","pampa_papp_(nm/s,permeability)","assay_(permeability,pampa_papp)","caco-2_a2b_papp_(nm/s,permeability)","assay_(permeability,caco-2_a2b_papp)","caco-2_b2a_papp_(nm/s,permeability)","assay_(permeability,caco-2_b2a_papp)",article_doi,molecular_weight,exact_mass,xlogp3,heavy_atom_count,ring_count,hydrogen_bond_acceptor_count,hydrogen_bond_donor_count,rotatable_bond_count,topological_polar_surface_area,molecular_formula,inchi,inchi_key,warhead_id,e3_ligand_id_x,linker_id,linker_smiles,linker_smiles_r,linker_molecular_weight,linker_exact_mass,linker_xlogp3,linker_heavy_atom_count,linker_ring_count,linker_hydrogen_bond_acceptor_count,linker_hydrogen_bond_donor_count,linker_rotatable_bond_count,linker_topological_polar_surface_area,linker_molecular_formula,linker_inchi,linker_inchi_key,warhead_uniprot,warhead_target,warhead_name,warhead_smiles,warhead_ic50_(nm),warhead_assay_(ic50),warhead_ec50_(nm),warhead_assay_(ec50),warhead_kd_(nm),warhead_assay_(kd),warhead_ki_(nm),warhead_assay_(ki),warhead_article_doi,warhead_molecular_weight,warhead_exact_mass,warhead_xlogp3,warhead_heavy_atom_count,warhead_ring_count,warhead_hydrogen_bond_acceptor_count,warhead_hydrogen_bond_donor_count,warhead_rotatable_bond_count,warhead_topological_polar_surface_area,warhead_molecular_formula,warhead_inchi,warhead_inchi_key,warhead_bindingdb,warhead_pubchem,warhead_chembl,e3_merge_id,e3_ligand_id_y,e3_ligand_uniprot,e3_ligand_target,e3_ligand_name,e3_ligand_smiles,e3_ligand_ic50_(nm),e3_ligand_assay_(ic50),e3_ligand_ec50_(nm),e3_ligand_assay_(ec50),e3_ligand_kd_(nm),e3_ligand_assay_(kd),e3_ligand_ki_(nm),e3_ligand_assay_(ki),e3_ligand_article_doi,e3_ligand_molecular_weight,e3_ligand_exact_mass,e3_ligand_xlogp3,e3_ligand_heavy_atom_count,e3_ligand_ring_count,e3_ligand_hydrogen_bond_acceptor_count,e3_ligand_hydrogen_bond_donor_count,e3_ligand_rotatable_bond_count,e3_ligand_topological_polar_surface_area,e3_ligand_molecular_formula,e3_ligand_inchi,e3_ligand_inchi_key,e3_ligand_bindingdb,e3_ligand_pubchem,e3_ligand_chembl,half_life,k_deg_p,e0,alpha,kcat,alpha_dmax,alpha_dc50,kdegp,dmax,dc50,warhead_binding_energy,e3_ligand_binding_energy,kdp,kde
11,560,80,560,80,Q9H8M2,BRD9,VHL,,,COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN1CCN(CCOCCOCCOC2=CC(C3=C(C)N=CS3)=CC=C2CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)CC1,Degradation of BRD9 in HeLa cells after 4 h treatment,,,,,,,8.8,ITC,,,-11,-11.4,0.44,ITC,,,,,,,,,87/70,ITC/FP,,,-9.64,-6.56,-3.1,ITC,,,,,,,,,83/60,ITC/FP,,,-9.7,-6.4,-3.3,ITC between VHL and BRD9-BD:PROTAC,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01413,1041.257,1040.48414,3.69,74,8,16,3,22,199.15,C54H69FN8O10S,"InChI=1S/C54H69FN8O10S/c1-34-47(74-33-58-34)35-8-9-36(28-57-49(65)43-27-38(64)30-63(43)51(67)48(53(2,3)4)59-52(68)54(55)11-12-54)44(24-35)73-23-22-72-21-20-71-19-18-61-14-16-62(17-15-61)32-42-45(69-6)25-37(26-46(42)70-7)41-31-60(5)50(66)40-29-56-13-10-39(40)41/h8-10,13,24-26,29,31,33,38,43,48,64H,11-12,14-23,27-28,30,32H2,1-7H3,(H,57,65)(H,59,68)/t38-,43+,48-/m1/s1",MXAKQOVZPDLCDK-UDVNCTHFSA-N,1,26,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,Q9NPI1,BRD7,BI-7273,COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN(C)C,117,BRD7 H3 AlphaScreen assay,,,0.3,BROMOScan platform of DiscoveRx,,,10.1021/acs.jmedchem.5b01865,353.422,353.1739416,1.4,26,3,6,0,5,56.59,C20H23N3O3,"InChI=1S/C20H23N3O3/c1-22(2)11-17-18(25-4)8-13(9-19(17)26-5)16-12-23(3)20(24)15-10-21-7-6-14(15)16/h6-10,12H,11H2,1-5H3",RBUYFHLQNPJMQM-UHFFFAOYSA-N,50183448,118796358,CHEMBL3823478,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.8,560,6.361812853,5.76802278,434.6975,1705.9929
22,1.76,95,1.76,95,Q9H8M2,BRD9,VHL,,VZ185,COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN1CCN(CCCCCOC2=CC(C3=C(C)N=CS3)=CC=C2CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)CC1,Degradation of BRD9 in RI-1 cells after 8 h treatment,,,,,,,5.1,ITC,,,-11.35,-12.8,1.485,ITC,,,,,,,,,26/35,ITC/FP,,,-10.4,-7.04,-3.4,ITC,,,,,,,,,27/35,ITC/FP,,,-10.33,-5.1,-5.3,ITC between VHL and BRD9-BD:PROTAC,,,,,,,3/40,Inhibit proliferation of EOL-1/A-402 cells,,,,,,,0.01,Compounds were administered at 10000 nM and incubated for 5 h,,,,,10.1021/acs.jmedchem.8b01413,995.232,994.4786603,5.06,71,8,14,3,19,180.69,C53H67FN8O8S,"InChI=1S/C53H67FN8O8S/c1-33-46(71-32-57-33)34-11-12-35(27-56-48(64)42-26-37(63)29-62(42)50(66)47(52(2,3)4)58-51(67)53(54)14-15-53)43(23-34)70-22-10-8-9-17-60-18-20-61(21-19-60)31-41-44(68-6)24-36(25-45(41)69-7)40-30-59(5)49(65)39-28-55-16-13-38(39)40/h11-13,16,23-25,28,30,32,37,42,47,63H,8-10,14-15,17-22,26-27,29,31H2,1-7H3,(H,56,64)(H,58,67)/t37-,42+,47-/m1/s1",ZAGCLFXBHOXXEN-JPTLTNPLSA-N,1,26,15,CCCCC,[R1]CCCCC[R2],72.151,72.09390038,2.92,5,0,0,0,2,0,C5H12,"InChI=1S/C5H12/c1-3-5-4-2/h3-5H2,1-2H3",OFBQJSOFQDEBGM-UHFFFAOYSA-N,Q9NPI1,BRD7,BI-7273,COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN(C)C,117,BRD7 H3 AlphaScreen assay,,,0.3,BROMOScan platform of DiscoveRx,,,10.1021/acs.jmedchem.5b01865,353.422,353.1739416,1.4,26,3,6,0,5,56.59,C20H23N3O3,"InChI=1S/C20H23N3O3/c1-22(2)11-17-18(25-4)8-13(9-19(17)26-5)16-12-23(3)20(24)15-10-21-7-6-14(15)16/h6-10,12H,11H2,1-5H3",RBUYFHLQNPJMQM-UHFFFAOYSA-N,50183448,118796358,CHEMBL3823478,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,1.76,6.719254403,6.17956252,190.8735,661.3593
22,1.76,95,1.76,95,Q9H8M2,BRD9,VHL,,VZ185,COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN1CCN(CCCCCOC2=CC(C3=C(C)N=CS3)=CC=C2CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)CC1,Degradation of BRD9 in RI-1 cells after 8 h treatment,,,,,,,5.1,ITC,,,-11.35,-12.8,1.485,ITC,,,,,,,,,26/35,ITC/FP,,,-10.4,-7.04,-3.4,ITC,,,,,,,,,27/35,ITC/FP,,,-10.33,-5.1,-5.3,ITC between VHL and BRD9-BD:PROTAC,,,,,,,3/40,Inhibit proliferation of EOL-1/A-402 cells,,,,,,,0.01,Compounds were administered at 10000 nM and incubated for 5 h,,,,,10.1021/acs.jmedchem.8b01413,995.232,994.4786603,5.06,71,8,14,3,19,180.69,C53H67FN8O8S,"InChI=1S/C53H67FN8O8S/c1-33-46(71-32-57-33)34-11-12-35(27-56-48(64)42-26-37(63)29-62(42)50(66)47(52(2,3)4)58-51(67)53(54)14-15-53)43(23-34)70-22-10-8-9-17-60-18-20-61(21-19-60)31-41-44(68-6)24-36(25-45(41)69-7)40-30-59(5)49(65)39-28-55-16-13-38(39)40/h11-13,16,23-25,28,30,32,37,42,47,63H,8-10,14-15,17-22,26-27,29,31H2,1-7H3,(H,56,64)(H,58,67)/t37-,42+,47-/m1/s1",ZAGCLFXBHOXXEN-JPTLTNPLSA-N,1,26,15,CCCCC,[R1]CCCCC[R2],72.151,72.09390038,2.92,5,0,0,0,2,0,C5H12,"InChI=1S/C5H12/c1-3-5-4-2/h3-5H2,1-2H3",OFBQJSOFQDEBGM-UHFFFAOYSA-N,Q9NPI1,BRD7,BI-7273,COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN(C)C,117,BRD7 H3 AlphaScreen assay,,,0.3,BROMOScan platform of DiscoveRx,,,10.1021/acs.jmedchem.5b01865,353.422,353.1739416,1.4,26,3,6,0,5,56.59,C20H23N3O3,"InChI=1S/C20H23N3O3/c1-22(2)11-17-18(25-4)8-13(9-19(17)26-5)16-12-23(3)20(24)15-10-21-7-6-14(15)16/h6-10,12H,11H2,1-5H3",RBUYFHLQNPJMQM-UHFFFAOYSA-N,50183448,118796358,CHEMBL3823478,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,1.76,6.520273596,6.17956252,301.805,661.3593
2038,5.1,95,5.1,>95,Q00534,CDK6,VHL,,CST651,CC(=O)C1=C(C)C2=CN=C(NC3=CC=C(N4CCN(CCOCCOCCOC5=CC(C6=C(C)N=CS6)=CC=C5CNC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@@H](NC(=O)C5(F)CC5)C(C)(C)C)CC4)C=N3)N=C2N(C2CCCC2)C1=O,Degradation of CDK6 in MM.1S cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,450,Inhibit viability of HEL cells,,,,,,,,,,,,,,,10.1039/d0sc00167h,1094.325,1093.521922,4.76,78,9,18,4,22,235.57,C56H72FN11O9S,"InChI=1S/C56H72FN11O9S/c1-34-42-31-60-54(64-49(42)68(39-9-7-8-10-39)51(72)46(34)36(3)69)62-45-14-13-40(30-58-45)66-19-17-65(18-20-66)21-22-75-23-24-76-25-26-77-44-27-37(47-35(2)61-33-78-47)11-12-38(44)29-59-50(71)43-28-41(70)32-67(43)52(73)48(55(4,5)6)63-53(74)56(57)15-16-56/h11-14,27,30-31,33,39,41,43,48,70H,7-10,15-26,28-29,32H2,1-6H3,(H,59,71)(H,63,74)(H,58,60,62,64)/t41-,43+,48-/m1/s1",WYPMPGWHIPETEB-VZUPZQALSA-N,61,26,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,P40763,STAT3,,CC(=O)N1CC[C@H]2CC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C3=CC=CC=C3)C3=CC=CC=C3)N2C(=O)[C@@H](NC(=O)/C=C(\C)C2=CC=C(C(F)(F)P(=O)(O)O)C=C2)C1,,,,,,,164,FP,10.1021/acs.jmedchem.9b01530,836.83,836.3110202,1.86,59,5,7,6,14,228.54,C41H47F2N6O9P,"InChI=1S/C41H47F2N6O9P/c1-25(27-13-15-30(16-14-27)41(42,43)59(56,57)58)23-36(52)45-33-24-48(26(2)50)22-21-31-17-19-34(49(31)40(33)55)39(54)46-32(18-20-35(44)51)38(53)47-37(28-9-5-3-6-10-28)29-11-7-4-8-12-29/h3-16,23,31-34,37H,17-22,24H2,1-2H3,(H2,44,51)(H,45,52)(H,46,54)(H,47,53)(H2,56,57,58)/b25-23+/t31-,32+,33+,34+/m1/s1",RKOSUZNTELZISV-XZUNAFFLSA-N,50514304,155549005,CHEMBL4538737,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,12.98,0.053389831,1,1,1,1,1,0.053389831,0.95,5.1,6.927357568,5.797367425,118.2068,1594.5296
796,250,70,250,70,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,Degradation of SMARCA4 in MV-4-11 cells after 18 h treatment,,,3000/1300,IC50 of SMARCA4 BD was tested by TR-FRET/AlphaLISA,,,4800,SPR in SMARCA4 BD,,,,,,,,,,,,,,,234/98,ITC/SPR,210,FP,-37.9,-21,-17,ITC,,,,,230/330,TR-FRET/AlphaLISA,,,,,26,FP,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-019-0294-6,918.106,917.4269591,3.22,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",QCULBRPVCWJUKY-OUMVKTTMSA-N,139,26,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,250,5.609234345,5.847495895,2459.0403,1420.7056
796,250,70,250,70,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,Degradation of SMARCA4 in MV-4-11 cells after 18 h treatment,,,3000/1300,IC50 of SMARCA4 BD was tested by TR-FRET/AlphaLISA,,,4800,SPR in SMARCA4 BD,,,,,,,,,,,,,,,234/98,ITC/SPR,210,FP,-37.9,-21,-17,ITC,,,,,230/330,TR-FRET/AlphaLISA,,,,,26,FP,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-019-0294-6,918.106,917.4269591,3.22,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",QCULBRPVCWJUKY-OUMVKTTMSA-N,139,26,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,250,6.053719707,5.847495895,883.65,1420.7056
796,300,65,300,65,P51531,SMARCA2,VHL,6HAY,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,Degradation of SMARCA2 in MV-4-11 cells after 18 h treatment,,,2400/600,IC50 of SMARCA2 BD was tested by TR-FRET/AlphaLISA,,,4500,SPR in SMARCA2 BD,,,,,,,,,,,,,,,234/98,ITC/SPR,210,FP,-37.9,-21,-17,ITC,,,,,205/120,TR-FRET/AlphaLISA,,,49,ITC,48,FP,-41.8,-27,-15,ITC between VHL and PROTAC:SMARCA2,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-019-0294-6,918.106,917.4269591,3.22,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",QCULBRPVCWJUKY-OUMVKTTMSA-N,139,26,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.65,300,5.609234345,5.847495895,2459.0403,1420.7056
796,300,65,300,65,P51531,SMARCA2,VHL,6HAY,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCOCCOCCN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)=C2)SC=N1,Degradation of SMARCA2 in MV-4-11 cells after 18 h treatment,,,2400/600,IC50 of SMARCA2 BD was tested by TR-FRET/AlphaLISA,,,4500,SPR in SMARCA2 BD,,,,,,,,,,,,,,,234/98,ITC/SPR,210,FP,-37.9,-21,-17,ITC,,,,,205/120,TR-FRET/AlphaLISA,,,49,ITC,48,FP,-41.8,-27,-15,ITC between VHL and PROTAC:SMARCA2,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-019-0294-6,918.106,917.4269591,3.22,65,7,15,5,19,217.83,C46H60FN9O8S,"InChI=1S/C46H60FN9O8S/c1-29-39(65-28-50-29)30-9-10-31(26-49-42(59)36-24-32(57)27-56(36)43(60)40(45(2,3)4)51-44(61)46(47)11-12-46)38(23-30)64-22-21-63-20-19-62-18-17-54-13-15-55(16-14-54)35-25-34(52-53-41(35)48)33-7-5-6-8-37(33)58/h5-10,23,25,28,32,36,40,57-58H,11-22,24,26-27H2,1-4H3,(H2,48,53)(H,49,59)(H,51,61)/t32-,36+,40-/m1/s1",QCULBRPVCWJUKY-OUMVKTTMSA-N,139,26,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.65,300,6.053719707,5.847495895,883.65,1420.7056
797,221,53,221,53,P51531,SMARCA2,VHL,8G1P,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1130000,0.12,5.9,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,920.125,919.4214798,5.27,66,8,13,5,15,199.37,C49H58FN9O6S,"InChI=1S/C49H58FN9O6S/c1-30-42(66-29-53-30)33-13-14-34(26-52-45(62)39-24-35(60)28-59(39)46(63)43(48(2,3)4)54-47(64)49(50)16-17-49)41(23-33)65-22-15-31-9-11-32(12-10-31)27-57-18-20-58(21-19-57)38-25-37(55-56-44(38)51)36-7-5-6-8-40(36)61/h5-14,23,25,29,35,39,43,60-61H,15-22,24,26-28H2,1-4H3,(H2,51,56)(H,52,62)(H,54,64)/t35-,39+,43-/m1/s1",UTZVLJZPTDCKCT-XBPZXCMESA-N,139,26,385,CCC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)CC[R2],120.195,120.0939004,3.08,9,1,0,0,1,0,C9H12,"InChI=1S/C9H12/c1-3-9-6-4-8(2)5-7-9/h4-7H,3H2,1-2H3",JRLPEMVDPFPYPJ-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.53,221,5.945377243,6.04924669,1134.0253,892.7982
2131,26,99,26,99,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(OCCN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.44,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-11-12-34(28-53-46(63)40-26-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(25-33)67-23-15-32-9-13-36(14-10-32)66-24-22-58-18-20-59(21-19-58)39-27-38(56-57-45(39)52)37-7-5-6-8-41(37)62/h5-14,25,27,30,35,40,44,61-62H,15-24,26,28-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",CVBRBVVZZZJXQO-HOPMZIQWSA-N,139,26,1054,CCOC1=CC=C(CC)C=C1,[R1]CCOC1=CC=C(C=C1)CC[R2],150.221,150.1044651,3.06,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-9-5-7-10(8-6-9)11-4-2/h5-8H,3-4H2,1-2H3",BQBROHBMIBOPFU-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,26,6.074542869,6.142137446,842.2812,720.8793
2131,26,99,26,99,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(OCCN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.44,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-11-12-34(28-53-46(63)40-26-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(25-33)67-23-15-32-9-13-36(14-10-32)66-24-22-58-18-20-59(21-19-58)39-27-38(56-57-45(39)52)37-7-5-6-8-41(37)62/h5-14,25,27,30,35,40,44,61-62H,15-24,26,28-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",CVBRBVVZZZJXQO-HOPMZIQWSA-N,139,26,1054,CCOC1=CC=C(CC)C=C1,[R1]CCOC1=CC=C(C=C1)CC[R2],150.221,150.1044651,3.06,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-9-5-7-10(8-6-9)11-4-2/h5-8H,3-4H2,1-2H3",BQBROHBMIBOPFU-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,26,6.070851963,6.142137446,849.47,720.8793
2131,41,99,41,99,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(OCCN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.44,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-11-12-34(28-53-46(63)40-26-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(25-33)67-23-15-32-9-13-36(14-10-32)66-24-22-58-18-20-59(21-19-58)39-27-38(56-57-45(39)52)37-7-5-6-8-41(37)62/h5-14,25,27,30,35,40,44,61-62H,15-24,26,28-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",CVBRBVVZZZJXQO-HOPMZIQWSA-N,139,26,1054,CCOC1=CC=C(CC)C=C1,[R1]CCOC1=CC=C(C=C1)CC[R2],150.221,150.1044651,3.06,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-9-5-7-10(8-6-9)11-4-2/h5-8H,3-4H2,1-2H3",BQBROHBMIBOPFU-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.99,41,6.074542869,6.142137446,842.2812,720.8793
2131,41,99,41,99,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(OCCN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.44,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-11-12-34(28-53-46(63)40-26-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(25-33)67-23-15-32-9-13-36(14-10-32)66-24-22-58-18-20-59(21-19-58)39-27-38(56-57-45(39)52)37-7-5-6-8-41(37)62/h5-14,25,27,30,35,40,44,61-62H,15-24,26,28-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",CVBRBVVZZZJXQO-HOPMZIQWSA-N,139,26,1054,CCOC1=CC=C(CC)C=C1,[R1]CCOC1=CC=C(C=C1)CC[R2],150.221,150.1044651,3.06,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-9-5-7-10(8-6-9)11-4-2/h5-8H,3-4H2,1-2H3",BQBROHBMIBOPFU-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.99,41,6.070851963,6.142137446,849.47,720.8793
2132,16,99.9,16,100,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCOC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.34,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-12-13-34(27-53-46(63)40-25-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(24-33)67-23-7-22-66-36-14-10-32(11-15-36)28-58-18-20-59(21-19-58)39-26-38(56-57-45(39)52)37-8-5-6-9-41(37)62/h5-6,8-15,24,26,30,35,40,44,61-62H,7,16-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",LPYXXDVKMQAWIP-HOPMZIQWSA-N,139,26,1055,CCCOC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)OCCC[R2],150.221,150.1044651,3.15,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-8-11-10-6-4-9(2)5-7-10/h4-7H,3,8H2,1-2H3",QLTKVDKXTKKJOX-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.999,16,5.835038375,6.147101352,1462.048,712.6867
2132,16,99.9,16,100,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCOC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.34,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-12-13-34(27-53-46(63)40-25-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(24-33)67-23-7-22-66-36-14-10-32(11-15-36)28-58-18-20-59(21-19-58)39-26-38(56-57-45(39)52)37-8-5-6-9-41(37)62/h5-6,8-15,24,26,30,35,40,44,61-62H,7,16-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",LPYXXDVKMQAWIP-HOPMZIQWSA-N,139,26,1055,CCCOC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)OCCC[R2],150.221,150.1044651,3.15,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-8-11-10-6-4-9(2)5-7-10/h4-7H,3,8H2,1-2H3",QLTKVDKXTKKJOX-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.999,16,6.025180814,6.147101352,943.6679,712.6867
2132,26,99,26,99,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCOC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.34,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-12-13-34(27-53-46(63)40-25-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(24-33)67-23-7-22-66-36-14-10-32(11-15-36)28-58-18-20-59(21-19-58)39-26-38(56-57-45(39)52)37-8-5-6-9-41(37)62/h5-6,8-15,24,26,30,35,40,44,61-62H,7,16-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",LPYXXDVKMQAWIP-HOPMZIQWSA-N,139,26,1055,CCCOC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)OCCC[R2],150.221,150.1044651,3.15,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-8-11-10-6-4-9(2)5-7-10/h4-7H,3,8H2,1-2H3",QLTKVDKXTKKJOX-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.99,26,5.835038375,6.147101352,1462.048,712.6867
2132,26,99,26,99,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCOC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,950.151,949.4320445,5.34,68,8,14,5,17,208.6,C50H60FN9O7S,"InChI=1S/C50H60FN9O7S/c1-31-43(68-30-54-31)33-12-13-34(27-53-46(63)40-25-35(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)16-17-50)42(24-33)67-23-7-22-66-36-14-10-32(11-15-36)28-58-18-20-59(21-19-58)39-26-38(56-57-45(39)52)37-8-5-6-9-41(37)62/h5-6,8-15,24,26,30,35,40,44,61-62H,7,16-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t35-,40+,44-/m1/s1",LPYXXDVKMQAWIP-HOPMZIQWSA-N,139,26,1055,CCCOC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)OCCC[R2],150.221,150.1044651,3.15,11,1,1,0,3,9.23,C10H14O,"InChI=1S/C10H14O/c1-3-8-11-10-6-4-9(2)5-7-10/h4-7H,3,8H2,1-2H3",QLTKVDKXTKKJOX-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.99,26,6.025180814,6.147101352,943.6679,712.6867
2133,25,92,25,92,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,934.152,933.4371299,5.63,67,8,13,5,16,199.37,C50H60FN9O6S,"InChI=1S/C50H60FN9O6S/c1-31-43(67-30-54-31)34-15-16-35(27-53-46(63)40-25-36(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)17-18-50)42(24-34)66-23-7-8-32-11-13-33(14-12-32)28-58-19-21-59(22-20-58)39-26-38(56-57-45(39)52)37-9-5-6-10-41(37)62/h5-6,9-16,24,26,30,36,40,44,61-62H,7-8,17-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t36-,40+,44-/m1/s1",KKFAKGWHXAANIL-OTIWGHMISA-N,139,26,1056,CCCC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)CCC[R2],134.222,134.1095504,3.63,10,1,0,0,2,0,C10H14,"InChI=1S/C10H14/c1-3-4-10-7-5-9(2)6-8-10/h5-8H,3-4H2,1-2H3",JXFVMNFKABWTHD-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.92,25,6.293836135,6.163050937,508.3512,686.9879
2133,25,92,25,92,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,934.152,933.4371299,5.63,67,8,13,5,16,199.37,C50H60FN9O6S,"InChI=1S/C50H60FN9O6S/c1-31-43(67-30-54-31)34-15-16-35(27-53-46(63)40-25-36(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)17-18-50)42(24-34)66-23-7-8-32-11-13-33(14-12-32)28-58-19-21-59(22-20-58)39-26-38(56-57-45(39)52)37-9-5-6-10-41(37)62/h5-6,9-16,24,26,30,36,40,44,61-62H,7-8,17-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t36-,40+,44-/m1/s1",KKFAKGWHXAANIL-OTIWGHMISA-N,139,26,1056,CCCC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)CCC[R2],134.222,134.1095504,3.63,10,1,0,0,2,0,C10H14,"InChI=1S/C10H14/c1-3-4-10-7-5-9(2)6-8-10/h5-8H,3-4H2,1-2H3",JXFVMNFKABWTHD-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.92,25,5.959297556,6.163050937,1098.2531,686.9879
2133,58,90,58,90,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,934.152,933.4371299,5.63,67,8,13,5,16,199.37,C50H60FN9O6S,"InChI=1S/C50H60FN9O6S/c1-31-43(67-30-54-31)34-15-16-35(27-53-46(63)40-25-36(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)17-18-50)42(24-34)66-23-7-8-32-11-13-33(14-12-32)28-58-19-21-59(22-20-58)39-26-38(56-57-45(39)52)37-9-5-6-10-41(37)62/h5-6,9-16,24,26,30,36,40,44,61-62H,7-8,17-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t36-,40+,44-/m1/s1",KKFAKGWHXAANIL-OTIWGHMISA-N,139,26,1056,CCCC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)CCC[R2],134.222,134.1095504,3.63,10,1,0,0,2,0,C10H14,"InChI=1S/C10H14/c1-3-4-10-7-5-9(2)6-8-10/h5-8H,3-4H2,1-2H3",JXFVMNFKABWTHD-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.9,58,6.293836135,6.163050937,508.3512,686.9879
2133,58,90,58,90,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,934.152,933.4371299,5.63,67,8,13,5,16,199.37,C50H60FN9O6S,"InChI=1S/C50H60FN9O6S/c1-31-43(67-30-54-31)34-15-16-35(27-53-46(63)40-25-36(61)29-60(40)47(64)44(49(2,3)4)55-48(65)50(51)17-18-50)42(24-34)66-23-7-8-32-11-13-33(14-12-32)28-58-19-21-59(22-20-58)39-26-38(56-57-45(39)52)37-9-5-6-10-41(37)62/h5-6,9-16,24,26,30,36,40,44,61-62H,7-8,17-23,25,27-29H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t36-,40+,44-/m1/s1",KKFAKGWHXAANIL-OTIWGHMISA-N,139,26,1056,CCCC1=CC=C(C)C=C1,[R1]CC1=CC=C(C=C1)CCC[R2],134.222,134.1095504,3.63,10,1,0,0,2,0,C10H14,"InChI=1S/C10H14/c1-3-4-10-7-5-9(2)6-8-10/h5-8H,3-4H2,1-2H3",JXFVMNFKABWTHD-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.9,58,5.959297556,6.163050937,1098.2531,686.9879
2134,33,95,33,95,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C(F)=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,938.115,937.412058,5.37,67,8,13,5,15,199.37,C49H57F2N9O6S,"InChI=1S/C49H57F2N9O6S/c1-29-42(67-28-54-29)31-11-12-32(25-53-45(63)39-23-34(61)27-60(39)46(64)43(48(2,3)4)55-47(65)49(51)14-15-49)41(22-31)66-20-13-30-9-10-33(36(50)21-30)26-58-16-18-59(19-17-58)38-24-37(56-57-44(38)52)35-7-5-6-8-40(35)62/h5-12,21-22,24,28,34,39,43,61-62H,13-20,23,25-27H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t34-,39+,43-/m1/s1",TWFCHBNLUUPMHG-SQKKEFIPSA-N,139,26,1057,CCC1=CC=C(C)C(F)=C1,[R1]CC1=C(C=C(C=C1)CC[R2])F,138.185,138.0844786,3.18,10,1,0,0,1,0,C9H11F,"InChI=1S/C9H11F/c1-3-8-5-4-7(2)9(10)6-8/h4-6H,3H2,1-2H3",DYKMICWOBLSRIW-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,33,6.146303919,6.443668664,713.9965,360.0239
2134,33,95,33,95,P51532,SMARCA4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C(F)=C3)=C2)SC=N1,Degradation of SMARCA4 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,938.115,937.412058,5.37,67,8,13,5,15,199.37,C49H57F2N9O6S,"InChI=1S/C49H57F2N9O6S/c1-29-42(67-28-54-29)31-11-12-32(25-53-45(63)39-23-34(61)27-60(39)46(64)43(48(2,3)4)55-47(65)49(51)14-15-49)41(22-31)66-20-13-30-9-10-33(36(50)21-30)26-58-16-18-59(19-17-58)38-24-37(56-57-44(38)52)35-7-5-6-8-40(35)62/h5-12,21-22,24,28,34,39,43,61-62H,13-20,23,25-27H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t34-,39+,43-/m1/s1",TWFCHBNLUUPMHG-SQKKEFIPSA-N,139,26,1057,CCC1=CC=C(C)C(F)=C1,[R1]CC1=C(C=C(C=C1)CC[R2])F,138.185,138.0844786,3.18,10,1,0,0,1,0,C9H11F,"InChI=1S/C9H11F/c1-3-8-5-4-7(2)9(10)6-8/h4-6H,3H2,1-2H3",DYKMICWOBLSRIW-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,33,6.111175392,6.443668664,774.1491,360.0239
2134,55,95,55,95,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C(F)=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,938.115,937.412058,5.37,67,8,13,5,15,199.37,C49H57F2N9O6S,"InChI=1S/C49H57F2N9O6S/c1-29-42(67-28-54-29)31-11-12-32(25-53-45(63)39-23-34(61)27-60(39)46(64)43(48(2,3)4)55-47(65)49(51)14-15-49)41(22-31)66-20-13-30-9-10-33(36(50)21-30)26-58-16-18-59(19-17-58)38-24-37(56-57-44(38)52)35-7-5-6-8-40(35)62/h5-12,21-22,24,28,34,39,43,61-62H,13-20,23,25-27H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t34-,39+,43-/m1/s1",TWFCHBNLUUPMHG-SQKKEFIPSA-N,139,26,1057,CCC1=CC=C(C)C(F)=C1,[R1]CC1=C(C=C(C=C1)CC[R2])F,138.185,138.0844786,3.18,10,1,0,0,1,0,C9H11F,"InChI=1S/C9H11F/c1-3-8-5-4-7(2)9(10)6-8/h4-6H,3H2,1-2H3",DYKMICWOBLSRIW-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.95,55,6.146303919,6.443668664,713.9965,360.0239
2134,55,95,55,95,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCC3=CC=C(CN4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)C(F)=C3)=C2)SC=N1,Degradation of SMARCA2 in A549 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00347,938.115,937.412058,5.37,67,8,13,5,15,199.37,C49H57F2N9O6S,"InChI=1S/C49H57F2N9O6S/c1-29-42(67-28-54-29)31-11-12-32(25-53-45(63)39-23-34(61)27-60(39)46(64)43(48(2,3)4)55-47(65)49(51)14-15-49)41(22-31)66-20-13-30-9-10-33(36(50)21-30)26-58-16-18-59(19-17-58)38-24-37(56-57-44(38)52)35-7-5-6-8-40(35)62/h5-12,21-22,24,28,34,39,43,61-62H,13-20,23,25-27H2,1-4H3,(H2,52,57)(H,53,63)(H,55,65)/t34-,39+,43-/m1/s1",TWFCHBNLUUPMHG-SQKKEFIPSA-N,139,26,1057,CCC1=CC=C(C)C(F)=C1,[R1]CC1=C(C=C(C=C1)CC[R2])F,138.185,138.0844786,3.18,10,1,0,0,1,0,C9H11F,"InChI=1S/C9H11F/c1-3-8-5-4-7(2)9(10)6-8/h4-6H,3H2,1-2H3",DYKMICWOBLSRIW-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.95,55,6.111175392,6.443668664,774.1491,360.0239
2439,440,77,440,77,O15379,HDAC3,VHL,,JPS036,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(F)CC3)C(C)(C)C)C(OCCCCCCCCCCCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)=C2)SC=N1,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,9670,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,940.196,939.4728467,8.28,67,6,10,6,23,205.08,C51H66FN7O7S,"InChI=1S/C51H66FN7O7S/c1-33-44(67-32-55-33)35-19-20-36(30-54-47(63)41-29-38(60)31-59(41)48(64)45(50(2,3)4)58-49(65)51(52)25-26-51)42(28-35)66-27-15-11-9-7-5-6-8-10-12-18-43(61)56-37-23-21-34(22-24-37)46(62)57-40-17-14-13-16-39(40)53/h13-14,16-17,19-24,28,32,38,41,45,60H,5-12,15,18,25-27,29-31,53H2,1-4H3,(H,54,63)(H,56,61)(H,57,62)(H,58,65)/t38-,41+,45-/m1/s1",NAADBQUVFJWCFU-XVYMMXEDSA-N,129,26,41,CCCCCCCCCCC,[R1]CCCCCCCCCCC[R2],156.313,156.1878008,6.17,11,0,0,0,8,0,C11H24,"InChI=1S/C11H24/c1-3-5-7-9-11-10-8-6-4-2/h3-11H2,1-2H3",RSJKGSCJYJTIGS-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,26VHL,26,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)C1(C#N)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,28.6,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,594.738,594.2624393,1.83,42,4,8,4,9,164.52,C30H38N6O5S,"InChI=1S/C30H38N6O5S/c1-17-24(42-16-33-17)19-8-6-18(7-9-19)21(13-23(38)32-5)34-26(39)22-12-20(37)14-36(22)27(40)25(29(2,3)4)35-28(41)30(15-31)10-11-30/h6-9,16,20-22,25,37H,10-14H2,1-5H3,(H,32,38)(H,34,39)(H,35,41)/t20-,21+,22+,25-/m1/s1",TXOUIGUFBKWBLO-HXKBJWFLSA-N,,153633209,,62.9,0.011017488,1,1,1,1,1,0.011017488,0.77,440,6.894292458,6.101878907,127.558,790.8991
181,40.1,92.6,40.1,92.6,Q16539,p38alpha,VHL,,SJF-6693,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-018-08027-7,1078.205,1077.411783,7.21,77,8,14,5,23,228.87,C56H61F2N7O11S,"InChI=1S/C56H61F2N7O11S/c1-33-49(77-32-61-33)35-8-6-34(7-9-35)30-60-51(68)43-27-39(66)31-65(43)52(69)50(55(2,3)4)64-48(67)17-21-73-22-23-74-24-25-75-47-29-42-40(28-46(47)72-5)44(16-20-59-42)76-45-15-14-38(26-41(45)58)63-54(71)56(18-19-56)53(70)62-37-12-10-36(57)11-13-37/h6-16,20,26,28-29,32,39,43,50,66H,17-19,21-25,27,30-31H2,1-5H3,(H,60,68)(H,62,70)(H,63,71)(H,64,67)/t39-,43+,50-/m1/s1",FCEBHUUCGVQXGJ-XPMRVQNBSA-N,71,19,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.926,40.1,5.849525836,5.575285054,1414.0806,2658.9792
181,40.1,92.6,40.1,92.6,Q16539,p38alpha,VHL,,SJF-6693,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-018-08027-7,1078.205,1077.411783,7.21,77,8,14,5,23,228.87,C56H61F2N7O11S,"InChI=1S/C56H61F2N7O11S/c1-33-49(77-32-61-33)35-8-6-34(7-9-35)30-60-51(68)43-27-39(66)31-65(43)52(69)50(55(2,3)4)64-48(67)17-21-73-22-23-74-24-25-75-47-29-42-40(28-46(47)72-5)44(16-20-59-42)76-45-15-14-38(26-41(45)58)63-54(71)56(18-19-56)53(70)62-37-12-10-36(57)11-13-37/h6-16,20,26,28-29,32,39,43,50,66H,17-19,21-25,27,30-31H2,1-5H3,(H,60,68)(H,62,70)(H,63,71)(H,64,67)/t39-,43+,50-/m1/s1",FCEBHUUCGVQXGJ-XPMRVQNBSA-N,71,19,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.926,40.1,5.845362481,5.575285054,1427.7018,2658.9792
182,18.8,99.4,18.8,99.4,Q16539,p38alpha,VHL,,SJF-6690,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-018-08027-7,1092.232,1091.427433,7.57,78,8,14,5,24,228.87,C57H63F2N7O11S,"InChI=1S/C57H63F2N7O11S/c1-34-50(78-33-62-34)36-9-7-35(8-10-36)31-61-52(69)44-28-40(67)32-66(44)53(70)51(56(2,3)4)65-49(68)18-24-75-26-25-74-22-6-23-76-48-30-43-41(29-47(48)73-5)45(17-21-60-43)77-46-16-15-39(27-42(46)59)64-55(72)57(19-20-57)54(71)63-38-13-11-37(58)12-14-38/h7-17,21,27,29-30,33,40,44,51,67H,6,18-20,22-26,28,31-32H2,1-5H3,(H,61,69)(H,63,71)(H,64,72)(H,65,68)/t40-,44+,51-/m1/s1",PCRYOGWRHSLIEZ-XZVMHGATSA-N,71,19,77,CCCOCCOCC,[R1]CCCOCCOCC[R2],132.203,132.1150298,1.19,9,0,2,0,6,18.46,C7H16O2,"InChI=1S/C7H16O2/c1-3-5-9-7-6-8-4-2/h3-7H2,1-2H3",MZBACIJSSOHXQA-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.994,18.8,6.036491033,5.575003547,919.4095,2660.7033
182,18.8,99.4,18.8,99.4,Q16539,p38alpha,VHL,,SJF-6690,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-018-08027-7,1092.232,1091.427433,7.57,78,8,14,5,24,228.87,C57H63F2N7O11S,"InChI=1S/C57H63F2N7O11S/c1-34-50(78-33-62-34)36-9-7-35(8-10-36)31-61-52(69)44-28-40(67)32-66(44)53(70)51(56(2,3)4)65-49(68)18-24-75-26-25-74-22-6-23-76-48-30-43-41(29-47(48)73-5)45(17-21-60-43)77-46-16-15-39(27-42(46)59)64-55(72)57(19-20-57)54(71)63-38-13-11-37(58)12-14-38/h7-17,21,27,29-30,33,40,44,51,67H,6,18-20,22-26,28,31-32H2,1-5H3,(H,61,69)(H,63,71)(H,64,72)(H,65,68)/t40-,44+,51-/m1/s1",PCRYOGWRHSLIEZ-XZVMHGATSA-N,71,19,77,CCCOCCOCC,[R1]CCCOCCOCC[R2],132.203,132.1150298,1.19,9,0,2,0,6,18.46,C7H16O2,"InChI=1S/C7H16O2/c1-3-5-9-7-6-8-4-2/h3-7H2,1-2H3",MZBACIJSSOHXQA-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.994,18.8,6.036111527,5.575003547,920.2132,2660.7033
183,210,91,210,91,Q16539,p38alpha,VHL,,SJF-8240,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCCOCCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells after 24 h treatment,,,,,,,5300,Kd was assessed by competition binding assays,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2017.09.010,1106.259,1105.443083,7.93,79,8,14,5,25,228.87,C58H65F2N7O11S,"InChI=1S/C58H65F2N7O11S/c1-35-51(79-34-63-35)37-10-8-36(9-11-37)32-62-53(70)45-29-41(68)33-67(45)54(71)52(57(2,3)4)66-50(69)19-27-76-24-6-23-75-25-7-26-77-49-31-44-42(30-48(49)74-5)46(18-22-61-44)78-47-17-16-40(28-43(47)60)65-56(73)58(20-21-58)55(72)64-39-14-12-38(59)13-15-39/h8-18,22,28,30-31,34,41,45,52,68H,6-7,19-21,23-27,29,32-33H2,1-5H3,(H,62,70)(H,64,72)(H,65,73)(H,66,69)/t41-,45+,52-/m1/s1",SCUZPTNDZHEHLB-ZWUDBOSPSA-N,71,19,78,CCCOCCCOCC,[R1]CCCOCCCOCC[R2],146.23,146.1306798,1.55,10,0,2,0,7,18.46,C8H18O2,"InChI=1S/C8H18O2/c1-3-6-10-8-5-7-9-4-2/h3-8H2,1-2H3",ZFHCEEOJBANLST-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.91,210,5.926473118,5.699942938,1184.4777,1995.5245
183,210,91,210,91,Q16539,p38alpha,VHL,,SJF-8240,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCCOCCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells after 24 h treatment,,,,,,,5300,Kd was assessed by competition binding assays,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2017.09.010,1106.259,1105.443083,7.93,79,8,14,5,25,228.87,C58H65F2N7O11S,"InChI=1S/C58H65F2N7O11S/c1-35-51(79-34-63-35)37-10-8-36(9-11-37)32-62-53(70)45-29-41(68)33-67(45)54(71)52(57(2,3)4)66-50(69)19-27-76-24-6-23-75-25-7-26-77-49-31-44-42(30-48(49)74-5)46(18-22-61-44)78-47-17-16-40(28-43(47)60)65-56(73)58(20-21-58)55(72)64-39-14-12-38(59)13-15-39/h8-18,22,28,30-31,34,41,45,52,68H,6-7,19-21,23-27,29,32-33H2,1-5H3,(H,62,70)(H,64,72)(H,65,73)(H,66,69)/t41-,45+,52-/m1/s1",SCUZPTNDZHEHLB-ZWUDBOSPSA-N,71,19,78,CCCOCCCOCC,[R1]CCCOCCCOCC[R2],146.23,146.1306798,1.55,10,0,2,0,7,18.46,C8H18O2,"InChI=1S/C8H18O2/c1-3-6-10-8-5-7-9-4-2/h3-8H2,1-2H3",ZFHCEEOJBANLST-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.91,210,5.921103166,5.699942938,1199.2144,1995.5245
184,9.5,99.6,9.5,99.6,Q16539,p38alpha,VHL,,SJF-6696,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCCCOCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of p38alpha in MDA-MB-231 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-018-08027-7,1120.286,1119.458733,8.74,80,8,14,5,26,228.87,C59H67F2N7O11S,"InChI=1S/C59H67F2N7O11S/c1-36-52(80-35-64-36)38-12-10-37(11-13-38)32-63-54(71)46-29-42(69)33-68(46)55(72)53(58(2,3)4)67-51(70)34-77-26-7-6-24-76-25-8-9-27-78-50-31-45-43(30-49(50)75-5)47(20-23-62-45)79-48-19-18-41(28-44(48)61)66-57(74)59(21-22-59)56(73)65-40-16-14-39(60)15-17-40/h10-20,23,28,30-31,35,42,46,53,69H,6-9,21-22,24-27,29,32-34H2,1-5H3,(H,63,71)(H,65,73)(H,66,74)(H,67,70)/t42-,46+,53-/m1/s1",GXDYWQXTEYENEU-WFYKIECOSA-N,71,19,79,CCCCOCCCCOC,[R1]CCCCOCCCCOC[R2],160.257,160.1463299,2.44,11,0,2,0,8,18.46,C9H20O2,"InChI=1S/C9H20O2/c1-3-4-8-11-9-6-5-7-10-2/h3-9H2,1-2H3",FBPKXEFBJHBHJN-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,97.35,0.007118644,1,1,1,1,1,0.007118644,0.996,9.5,5.746485354,5.987780634,1792.729,1028.5357
269,20.8,99,20.8,99,Q05397,FAK,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of Fak in PC3 cells after 24 h treatment,,,12.7,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,1040.201,1039.390751,5.62,72,6,15,5,23,226.54,C49H60F3N9O9S2,"InChI=1S/C49H60F3N9O9S2/c1-31-42(71-30-56-31)34-12-10-32(11-13-34)26-54-45(64)40-25-37(62)29-61(40)46(65)43(48(2,3)4)58-41(63)18-19-68-20-21-69-22-23-70-38-16-14-35(15-17-38)57-47-55-28-39(49(50,51)52)44(59-47)53-27-33-8-7-9-36(24-33)60(5)72(6,66)67/h7-17,24,28,30,37,40,43,62H,18-23,25-27,29H2,1-6H3,(H,54,64)(H,58,63)(H2,53,55,57,59)/t37-,40+,43-/m1/s1",DRJLXMYTVYIROA-AKCINUCUSA-N,64,19,11,CCOCCOCC,[R1]CCOCCOCC[R2],118.176,118.0993797,0.66,8,0,2,0,5,18.46,C6H14O2,"InChI=1S/C6H14O2/c1-3-7-5-6-8-4-2/h3-6H2,1-2H3",LZDKZFUFMNSQCJ-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,20.8,6.764470585,5.882321659,172.0004,1311.2284
265,23.2,99,23.2,99,Q05397,FAK,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of Fak in PC3 cells after 24 h treatment,,,10.7,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,982.121,981.3488863,5.86,68,6,14,5,19,217.31,C46H54F3N9O8S2,"InChI=1S/C46H54F3N9O8S2/c1-28-39(67-27-53-28)31-12-10-29(11-13-31)22-51-42(61)37-21-34(59)25-58(37)43(62)40(45(2,3)4)55-38(60)26-65-18-19-66-35-16-14-32(15-17-35)54-44-52-24-36(46(47,48)49)41(56-44)50-23-30-8-7-9-33(20-30)57(5)68(6,63)64/h7-17,20,24,27,34,37,40,59H,18-19,21-23,25-26H2,1-6H3,(H,51,61)(H,55,60)(H2,50,52,54,56)/t34-,37+,40-/m1/s1",SSNVICBSSPQZQX-WPPCIPCFSA-N,64,19,89,CCOC,[R1]CCOC[R2],60.096,60.05751488,0.45,4,0,1,0,1,9.23,C3H8O,"InChI=1S/C3H8O/c1-3-4-2/h3H2,1-2H3",XOBKSJJDNFUZPF-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,23.2,6.403272052,5.844966703,395.119,1429.0035
266,7.6,99,7.6,99,Q05397,FAK,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of Fak in PC3 cells after 24 h treatment,,,14.7,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,996.148,995.3645364,6.22,69,6,14,5,20,217.31,C47H56F3N9O8S2,"InChI=1S/C47H56F3N9O8S2/c1-29-40(68-28-54-29)32-13-11-30(12-14-32)23-52-43(62)38-22-35(60)26-59(38)44(63)41(46(2,3)4)56-39(61)27-66-19-8-20-67-36-17-15-33(16-18-36)55-45-53-25-37(47(48,49)50)42(57-45)51-24-31-9-7-10-34(21-31)58(5)69(6,64)65/h7,9-18,21,25,28,35,38,41,60H,8,19-20,22-24,26-27H2,1-6H3,(H,52,62)(H,56,61)(H2,51,53,55,57)/t35-,38+,41-/m1/s1",SHPXUUGJMCCMIO-LFHXYJAASA-N,64,19,144,CCCOC,[R1]CCCOC[R2],74.123,74.07316494,0.97,5,0,1,0,2,9.23,C4H10O,"InChI=1S/C4H10O/c1-3-4-5-2/h3-4H2,1-2H3",VNKYTQGIUYNRMY-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,7.6,6.673143454,5.69083082,212.2543,2037.8358
267,3,99,3,99,Q05397,FAK,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of Fak in PC3 cells after 24 h treatment,,,6.5,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,996.148,995.3645364,5.76,69,6,14,5,20,217.31,C47H56F3N9O8S2,"InChI=1S/C47H56F3N9O8S2/c1-29-40(68-28-54-29)32-12-10-30(11-13-32)24-52-43(62)38-23-35(60)27-59(38)44(63)41(46(2,3)4)56-39(61)18-19-66-20-21-67-36-16-14-33(15-17-36)55-45-53-26-37(47(48,49)50)42(57-45)51-25-31-8-7-9-34(22-31)58(5)69(6,64)65/h7-17,22,26,28,35,38,41,60H,18-21,23-25,27H2,1-6H3,(H,52,62)(H,56,61)(H2,51,53,55,57)/t35-,38+,41-/m1/s1",MVULIYLBRNHLEE-LFHXYJAASA-N,64,19,13,CCOCC,[R1]CCOCC[R2],74.123,74.07316494,0.81,5,0,1,0,2,9.23,C4H10O,"InChI=1S/C4H10O/c1-3-5-4-2/h3-4H2,1-2H3",RTZKZFJDLAIYFH-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,3,6.486115408,5.793934373,326.5011,1607.1841
268,4,99,4,99,Q05397,FAK,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of Fak in PC3 cells after 24 h treatment,,,14.5,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,1010.175,1009.380186,6.12,70,6,14,5,21,217.31,C48H58F3N9O8S2,"InChI=1S/C48H58F3N9O8S2/c1-30-41(69-29-55-30)33-13-11-31(12-14-33)25-53-44(63)39-24-36(61)28-60(39)45(64)42(47(2,3)4)57-40(62)19-22-67-20-8-21-68-37-17-15-34(16-18-37)56-46-54-27-38(48(49,50)51)43(58-46)52-26-32-9-7-10-35(23-32)59(5)70(6,65)66/h7,9-18,23,27,29,36,39,42,61H,8,19-22,24-26,28H2,1-6H3,(H,53,63)(H,57,62)(H2,52,54,56,58)/t36-,39+,42-/m1/s1",WVWFJWJYLUTFRG-QLMCDVMBSA-N,64,19,145,CCCOCC,[R1]CCCOCC[R2],88.15,88.088815,1.34,6,0,1,0,3,9.23,C5H12O,"InChI=1S/C5H12O/c1-3-5-6-4-2/h3-5H2,1-2H3",NVJUHMXYKCUMQA-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,4,6.574901357,5.964374263,266.1329,1085.4898
270,48.1,91,48.1,91,Q05397,FAK,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOCCOCCOC3=CC=C(NC4=NC=C(C(F)(F)F)C(NCC5=CC=CC(N(C)S(C)(=O)=O)=C5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of Fak in PC3 cells after 24 h treatment,,,6.1,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,1128.307,1127.443181,5.32,78,6,17,5,29,245,C53H68F3N9O11S2,"InChI=1S/C53H68F3N9O11S2/c1-35-46(77-34-60-35)38-12-10-36(11-13-38)30-58-49(68)44-29-41(66)33-65(44)50(69)47(52(2,3)4)62-45(67)18-19-72-20-21-73-22-23-74-24-25-75-26-27-76-42-16-14-39(15-17-42)61-51-59-32-43(53(54,55)56)48(63-51)57-31-37-8-7-9-40(28-37)64(5)78(6,70)71/h7-17,28,32,34,41,44,47,66H,18-27,29-31,33H2,1-6H3,(H,58,68)(H,62,67)(H2,57,59,61,63)/t41-,44+,47-/m1/s1",CVMXJJVQILKJCT-IIWOMYBWSA-N,64,19,12,CCOCCOCCOCCOCC,[R1]CCOCCOCCOCCOCC[R2],206.282,206.1518092,0.37,14,0,4,0,11,36.92,C10H22O4,"InChI=1S/C10H22O4/c1-3-11-5-7-13-9-10-14-8-6-12-4-2/h3-10H2,1-2H3",KIAMPLQEZAMORJ-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,48.1,6.813235285,5.735978953,153.7322,1836.6273
1658,250,90,250/520,90/40,P01116,KRAS G12C,VHL,,LC-2,C=C(F)C(=O)N1CCN(C2=NC(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)=NC3=C2CCN(C2=CC=CC4=CC=CC(Cl)=C24)C3)C[C@@H]1CC#N,Degradation of KRAS G12C in NCI-H23/NCI-H358 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acscentsci.0c00411,1132.805,1131.493121,7.27,80,9,15,3,20,209.69,C59H71ClFN11O7S,"InChI=1S/C59H71ClFN11O7S/c1-37(61)56(76)71-27-26-70(32-42(71)19-22-62)54-45-20-25-69(48-14-7-11-40-10-6-13-46(60)51(40)48)34-47(45)65-58(67-54)79-35-43-12-8-23-68(43)24-9-28-78-29-21-50(74)66-53(59(3,4)5)57(77)72-33-44(73)30-49(72)55(75)63-31-39-15-17-41(18-16-39)52-38(2)64-36-80-52/h6-7,10-11,13-18,36,42-44,49,53,73H,1,8-9,12,19-21,23-35H2,2-5H3,(H,63,75)(H,66,74)/t42-,43-,44+,49-,53+/m0/s1",ZCGQZLKPUVGCBQ-HLMPTVQRSA-N,263,19,145,CCCOCC,[R1]CCCOCC[R2],88.15,88.088815,1.34,6,0,1,0,3,9.23,C5H12O,"InChI=1S/C5H12O/c1-3-5-6-4-2/h3-5H2,1-2H3",NVJUHMXYKCUMQA-UHFFFAOYSA-N,P29323,EPHB2,,O=C1NC2=CC=CC=C2C2=NC(NC3=CC=C(N4CCNCC4)C=C3)=NC=C2N1,,,,,,,,,10.1016/j.cell.2020.10.038,387.447,387.1807583,1.85,29,5,6,4,3,94.21,C21H21N7O,"InChI=1S/C21H21N7O/c29-21-25-17-4-2-1-3-16(17)19-18(26-21)13-23-20(27-19)24-14-5-7-15(8-6-14)28-11-9-22-10-12-28/h1-8,13,22H,9-12H2,(H,23,24,27)(H2,25,26,29)",QUPDTXBHSASKEK-UHFFFAOYSA-N,,118684114,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9,250,5.61463486,5.779071194,2428.6512,1663.14
1658,320,75,590/320/760,80/75/90,P01116,KRAS G12C,VHL,,LC-2,C=C(F)C(=O)N1CCN(C2=NC(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)=NC3=C2CCN(C2=CC=CC4=CC=CC(Cl)=C24)C3)C[C@@H]1CC#N,Degradation of KRAS G12C in NCI-H2030/MIA PaCa-2/SW1573 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3800/2900,Inhibit viability of NCI-H2030/NCI-H23 cells,,,,,,,,,,,,,10.1021/acscentsci.0c00411,1132.805,1131.493121,7.27,80,9,15,3,20,209.69,C59H71ClFN11O7S,"InChI=1S/C59H71ClFN11O7S/c1-37(61)56(76)71-27-26-70(32-42(71)19-22-62)54-45-20-25-69(48-14-7-11-40-10-6-13-46(60)51(40)48)34-47(45)65-58(67-54)79-35-43-12-8-23-68(43)24-9-28-78-29-21-50(74)66-53(59(3,4)5)57(77)72-33-44(73)30-49(72)55(75)63-31-39-15-17-41(18-16-39)52-38(2)64-36-80-52/h6-7,10-11,13-18,36,42-44,49,53,73H,1,8-9,12,19-21,23-35H2,2-5H3,(H,63,75)(H,66,74)/t42-,43-,44+,49-,53+/m0/s1",ZCGQZLKPUVGCBQ-HLMPTVQRSA-N,263,19,145,CCCOCC,[R1]CCCOCC[R2],88.15,88.088815,1.34,6,0,1,0,3,9.23,C5H12O,"InChI=1S/C5H12O/c1-3-5-6-4-2/h3-5H2,1-2H3",NVJUHMXYKCUMQA-UHFFFAOYSA-N,P29323,EPHB2,,O=C1NC2=CC=CC=C2C2=NC(NC3=CC=C(N4CCNCC4)C=C3)=NC=C2N1,,,,,,,,,10.1016/j.cell.2020.10.038,387.447,387.1807583,1.85,29,5,6,4,3,94.21,C21H21N7O,"InChI=1S/C21H21N7O/c29-21-25-17-4-2-1-3-16(17)19-18(26-21)13-23-20(27-19)24-14-5-7-15(8-6-14)28-11-9-22-10-12-28/h1-8,13,22H,9-12H2,(H,23,24,27)(H2,25,26,29)",QUPDTXBHSASKEK-UHFFFAOYSA-N,,118684114,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.75,320,5.61463486,5.779071194,2428.6512,1663.14
1659,640,85,640,85,P01116,KRAS G12C,VHL,,LC-3,C=C(F)C(=O)N1CCN(C2=NC(OC[C@@H]3CCCN3CCC(=O)NCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)=NC3=C2CCN(C2=CC=CC4=CC=CC(Cl)=C24)C3)C[C@@H]1CC#N,Degradation of KRAS G12C in NCI-H2030 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acscentsci.0c00411,1145.804,1144.488369,6.31,81,9,15,4,19,229.56,C59H70ClFN12O7S,"InChI=1S/C59H70ClFN12O7S/c1-36(61)56(78)72-28-27-71(31-41(72)18-22-62)54-44-20-25-70(47-13-7-10-39-9-6-12-45(60)51(39)47)33-46(44)66-58(68-54)80-34-42-11-8-24-69(42)26-21-49(75)63-23-19-50(76)67-53(59(3,4)5)57(79)73-32-43(74)29-48(73)55(77)64-30-38-14-16-40(17-15-38)52-37(2)65-35-81-52/h6-7,9-10,12-17,35,41-43,48,53,74H,1,8,11,18-21,23-34H2,2-5H3,(H,63,75)(H,64,77)(H,67,76)/t41-,42-,43+,48-,53+/m0/s1",QSJKPPVXARILLJ-GYUTUTRISA-N,263,19,358,CCNC(=O)CC,[R1]CCC(=O)NCC[R2],101.149,101.084064,0.38,7,0,1,1,2,29.1,C5H11NO,"InChI=1S/C5H11NO/c1-3-5(7)6-4-2/h3-4H2,1-2H3,(H,6,7)",ABMDIECEEGFXNC-UHFFFAOYSA-N,P29323,EPHB2,,O=C1NC2=CC=CC=C2C2=NC(NC3=CC=C(N4CCNCC4)C=C3)=NC=C2N1,,,,,,,,,10.1016/j.cell.2020.10.038,387.447,387.1807583,1.85,29,5,6,4,3,94.21,C21H21N7O,"InChI=1S/C21H21N7O/c29-21-25-17-4-2-1-3-16(17)19-18(26-21)13-23-20(27-19)24-14-5-7-15(8-6-14)28-11-9-22-10-12-28/h1-8,13,22H,9-12H2,(H,23,24,27)(H2,25,26,29)",QUPDTXBHSASKEK-UHFFFAOYSA-N,,118684114,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,640,5.425865516,5.676563021,3750.8913,2105.8963
1660,880,90,880,90,P01116,KRAS G12C,VHL,,LC-4,C=C(F)C(=O)N1CCN(C2=NC(OC[C@@H]3CCCN3CCCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)=NC3=C2CCN(C2=CC=CC4=CC=CC(Cl)=C24)C3)C[C@@H]1CC#N,Degradation of KRAS G12C in SW1573 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acscentsci.0c00411,1146.832,1145.508771,7.63,81,9,15,3,21,209.69,C60H73ClFN11O7S,"InChI=1S/C60H73ClFN11O7S/c1-38(62)57(77)72-28-27-71(33-43(72)20-23-63)55-46-21-26-70(49-15-9-12-41-11-8-14-47(61)52(41)49)35-48(46)66-59(68-55)80-36-44-13-10-25-69(44)24-6-7-29-79-30-22-51(75)67-54(60(3,4)5)58(78)73-34-45(74)31-50(73)56(76)64-32-40-16-18-42(19-17-40)53-39(2)65-37-81-53/h8-9,11-12,14-19,37,43-45,50,54,74H,1,6-7,10,13,20-22,24-36H2,2-5H3,(H,64,76)(H,67,75)/t43-,44-,45+,50-,54+/m0/s1",ZTFKFELOBVAACZ-JCKBJUPWSA-N,263,19,806,CCCCOCC,[R1]CCCCOCC[R2],102.177,102.1044651,1.7,7,0,1,0,4,9.23,C6H14O,"InChI=1S/C6H14O/c1-3-5-6-7-4-2/h3-6H2,1-2H3",PZHIWRCQKBBTOW-UHFFFAOYSA-N,P29323,EPHB2,,O=C1NC2=CC=CC=C2C2=NC(NC3=CC=C(N4CCNCC4)C=C3)=NC=C2N1,,,,,,,,,10.1016/j.cell.2020.10.038,387.447,387.1807583,1.85,29,5,6,4,3,94.21,C21H21N7O,"InChI=1S/C21H21N7O/c29-21-25-17-4-2-1-3-16(17)19-18(26-21)13-23-20(27-19)24-14-5-7-15(8-6-14)28-11-9-22-10-12-28/h1-8,13,22H,9-12H2,(H,23,24,27)(H2,25,26,29)",QUPDTXBHSASKEK-UHFFFAOYSA-N,,118684114,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9,880,5.634416037,5.790479686,2320.5128,1620.0198
1433,50,71,<=50,>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCC3=CC=C(C4=CC=C(C(=O)N[C@H]5C(C)(C)[C@H](OC6=CC=C(C#N)C(Cl)=C6)C5(C)C)C=C4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR in LNCaP cells after 2-4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00115,973.637,972.401097,9.35,69,7,10,4,16,182.98,C54H61ClN6O7S,"InChI=1S/C54H61ClN6O7S/c1-32-45(69-31-58-32)37-15-11-34(12-16-37)28-57-48(65)43-25-40(62)29-61(43)49(66)46(52(2,3)4)59-44(63)30-67-24-23-33-9-13-35(14-10-33)36-17-19-38(20-18-36)47(64)60-50-53(5,6)51(54(50,7)8)68-41-22-21-39(27-56)42(55)26-41/h9-22,26,31,40,43,46,50-51,62H,23-25,28-30H2,1-8H3,(H,57,65)(H,59,63)(H,60,64)/t40-,43+,46-,50-,51-/m1/s1",GPLDNHBAUYMIMT-XUDCYVGASA-N,38,19,687,COCCC1=CC=CC=C1,[R1]C1=CC=C(C=C1)CCOC[R2],136.194,136.088815,2.03,10,1,1,0,3,9.23,C9H12O,"InChI=1S/C9H12O/c1-10-8-7-9-5-3-2-4-6-9/h2-6H,7-8H2,1H3",CQLYXIUHVFRXLT-UHFFFAOYSA-N,P00533,EGFR,gefitinib,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,,,,,1,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,446.91,446.1520965,4.11,31,4,7,1,8,68.74,C22H24ClFN4O3,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,5447,123631,CHEMBL939,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.465444531,5.853107073,342.4171,1402.4679
151,518,91,518,91,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCC3=CN(CCNC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)N=N3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in A375 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6620000,0.038,18.7,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,995.633,994.3497472,4.49,69,8,16,4,16,223.74,C48H55ClN12O6S2,"InChI=1S/C48H55ClN12O6S2/c1-26-28(3)69-47-40(26)41(31-12-14-33(49)15-13-31)53-36(44-57-55-29(4)61(44)47)19-38(63)50-16-17-59-21-34(56-58-59)23-67-24-39(64)54-43(48(5,6)7)46(66)60-22-35(62)18-37(60)45(65)51-20-30-8-10-32(11-9-30)42-27(2)52-25-68-42/h8-15,21,25,35-37,43,62H,16-20,22-24H2,1-7H3,(H,50,63)(H,51,65)(H,54,64)/t35-,36+,37+,43-/m1/s1",KEXVSUAHVFYWJC-AYWQWSHZSA-N,42,19,61,COCC1=CN(CCN)N=N1,[R1]NCCN1C=C(N=N1)COC[R2],156.189,156.101111,-1.63,11,1,5,1,4,65.96,C6H12N4O,"InChI=1S/C6H12N4O/c1-11-5-6-4-10(3-2-7)9-8-6/h4H,2-3,5,7H2,1H3",XUQZBMLYINPFHS-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.91,518,6.043315745,5.508192656,905.0743,3103.1827
152,726,78,726,78,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCC3=CN(CCNC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)N=N3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in A375 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6340000,0.058,12.2,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,1039.686,1038.375962,4.34,72,8,17,4,19,232.97,C50H59ClN12O7S2,"InChI=1S/C50H59ClN12O7S2/c1-28-30(3)72-49-42(28)43(33-12-14-35(51)15-13-33)55-38(46-59-57-31(4)63(46)49)21-40(65)52-16-17-61-23-36(58-60-61)25-69-18-19-70-26-41(66)56-45(50(5,6)7)48(68)62-24-37(64)20-39(62)47(67)53-22-32-8-10-34(11-9-32)44-29(2)54-27-71-44/h8-15,23,27,37-39,45,64H,16-22,24-26H2,1-7H3,(H,52,65)(H,53,67)(H,56,66)/t37-,38+,39+,45-/m1/s1",LJQXZKRBYGZAEU-DPSJZEHMSA-N,42,19,62,COCCOCC1=CN(CCN)N=N1,[R1]NCCN1C=C(N=N1)COCCOC[R2],200.242,200.1273258,-1.78,14,1,6,1,7,75.19,C8H16N4O2,"InChI=1S/C8H16N4O2/c1-13-4-5-14-7-8-6-12(3-2-9)11-10-8/h6H,2-5,7,9H2,1H3",QPYGOKLPMSIQDN-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.78,726,6.291775158,5.453448398,510.7694,3520.0724
153,2260,69,2260,69,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCC3=CN(CCNC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)N=N3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in A375 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9640000,0.25,4.4,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,1083.739,1082.402177,4.19,75,8,18,4,22,242.2,C52H63ClN12O8S2,"InChI=1S/C52H63ClN12O8S2/c1-30-32(3)75-51-44(30)45(35-12-14-37(53)15-13-35)57-40(48-61-59-33(4)65(48)51)23-42(67)54-16-17-63-25-38(60-62-63)27-72-20-18-71-19-21-73-28-43(68)58-47(52(5,6)7)50(70)64-26-39(66)22-41(64)49(69)55-24-34-8-10-36(11-9-34)46-31(2)56-29-74-46/h8-15,25,29,39-41,47,66H,16-24,26-28H2,1-7H3,(H,54,67)(H,55,69)(H,58,68)/t39-,40+,41+,47-/m1/s1",IVAWBGJHAWQINS-XRFVFAKVSA-N,42,19,63,COCCOCCOCC1=CN(CCN)N=N1,[R1]NCCN1C=C(N=N1)COCCOCCOC[R2],244.295,244.1535405,-1.93,17,1,7,1,10,84.42,C10H20N4O3,"InChI=1S/C10H20N4O3/c1-15-4-5-16-6-7-17-9-10-8-14(3-2-11)13-12-10/h8H,2-7,9,11H2,1H3",LDNUXLMZQAVQMX-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.69,2260,5.797036174,5.70317604,1595.7462,1980.724
209,23.1,89,23.1,89,O60885,BRD4,VHL,,A743,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCOCCCOC3=CC=C(NC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in HCT116 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1158/0008-5472.CAN-18-2918,1092.786,1091.41643,7.71,76,8,15,4,22,211.49,C56H66ClN9O8S2,"InChI=1S/C56H66ClN9O8S2/c1-33-35(3)76-55-48(33)49(38-15-17-40(57)18-16-38)61-44(52-64-63-36(4)66(52)55)28-46(68)60-41-19-21-43(22-20-41)74-26-10-25-72-23-8-9-24-73-31-47(69)62-51(56(5,6)7)54(71)65-30-42(67)27-45(65)53(70)58-29-37-11-13-39(14-12-37)50-34(2)59-32-75-50/h11-22,32,42,44-45,51,67H,8-10,23-31H2,1-7H3,(H,58,70)(H,60,68)(H,62,69)/t42-,44+,45+,51-/m1/s1",LIRKMAWQWVEHBG-QEFNCWSLSA-N,42,19,94,COCCCCOCCCOC1=CC=C(N)C=C1,[R1]NC1=CC=C(C=C1)OCCCOCCCCOC[R2],253.342,253.1677936,1.99,18,1,4,1,10,53.71,C14H23NO3,"InChI=1S/C14H23NO3/c1-16-9-2-3-10-17-11-4-12-18-14-7-5-13(15)6-8-14/h5-8H,2-4,9-12,15H2,1H3",SINCTDJNRNXKAO-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.89,23.1,5.652843163,5.853892318,2224.1129,1399.9344
335,40,98,40,98,P25440,BRD2,VHL,,MZ1,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,69,ITC,,,-9.77,-7.76,-2.02,ITC,,,,,,,,,,,,,,,,,,,,,,,27/219,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1002.661,1001.36948,4.96,69,7,15,4,20,211.49,C49H60ClN9O8S2,"InChI=1S/C49H60ClN9O8S2/c1-28-30(3)69-48-41(28)42(33-12-14-35(50)15-13-33)54-37(45-57-56-31(4)59(45)48)23-39(61)51-16-17-65-18-19-66-20-21-67-26-40(62)55-44(49(5,6)7)47(64)58-25-36(60)22-38(58)46(63)52-24-32-8-10-34(11-9-32)43-29(2)53-27-68-43/h8-15,27,36-38,44,60H,16-26H2,1-7H3,(H,51,61)(H,52,63)(H,55,62)/t36-,37+,38+,44-/m1/s1",PTAMRJLIOCHJMQ-PYNGZGNASA-N,42,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,40,6.141275704,5.533759287,722.3111,2925.7736
335,40,98,40,98,P25440,BRD2,VHL,,MZ1,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,69,ITC,,,-9.77,-7.76,-2.02,ITC,,,,,,,,,,,,,,,,,,,,,,,27/219,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1002.661,1001.36948,4.96,69,7,15,4,20,211.49,C49H60ClN9O8S2,"InChI=1S/C49H60ClN9O8S2/c1-28-30(3)69-48-41(28)42(33-12-14-35(50)15-13-33)54-37(45-57-56-31(4)59(45)48)23-39(61)51-16-17-65-18-19-66-20-21-67-26-40(62)55-44(49(5,6)7)47(64)58-25-36(60)22-38(58)46(63)52-24-32-8-10-34(11-9-32)43-29(2)53-27-68-43/h8-15,27,36-38,44,60H,16-26H2,1-7H3,(H,51,61)(H,52,63)(H,55,62)/t36-,37+,38+,44-/m1/s1",PTAMRJLIOCHJMQ-PYNGZGNASA-N,42,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,40,5.938092297,5.533759287,1153.2082,2925.7736
335,40,98,40,98,P25440,BRD2,VHL,,MZ1,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,69,ITC,,,-9.77,-7.76,-2.02,ITC,,,,,,,,,,,,,,,,,,,,,,,27/219,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1002.661,1001.36948,4.96,69,7,15,4,20,211.49,C49H60ClN9O8S2,"InChI=1S/C49H60ClN9O8S2/c1-28-30(3)69-48-41(28)42(33-12-14-35(50)15-13-33)54-37(45-57-56-31(4)59(45)48)23-39(61)51-16-17-65-18-19-66-20-21-67-26-40(62)55-44(49(5,6)7)47(64)58-25-36(60)22-38(58)46(63)52-24-32-8-10-34(11-9-32)43-29(2)53-27-68-43/h8-15,27,36-38,44,60H,16-26H2,1-7H3,(H,51,61)(H,52,63)(H,55,62)/t36-,37+,38+,44-/m1/s1",PTAMRJLIOCHJMQ-PYNGZGNASA-N,42,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,40,5.870422995,5.533759287,1347.6497,2925.7736
336,200,97,200,97,P25440,BRD2,VHL,,MZ2,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,73,ITC,,,-9.75,-8.79,-0.96,ITC,,,,,,,,,,,,,,,,,,,,,,,123/1259,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912; 10.1021/acschembio.5b00216,1046.714,1045.395694,4.82,72,7,16,4,23,220.72,C51H64ClN9O9S2,"InChI=1S/C51H64ClN9O9S2/c1-30-32(3)72-50-43(30)44(35-12-14-37(52)15-13-35)56-39(47-59-58-33(4)61(47)50)25-41(63)53-16-17-67-18-19-68-20-21-69-22-23-70-28-42(64)57-46(51(5,6)7)49(66)60-27-38(62)24-40(60)48(65)54-26-34-8-10-36(11-9-34)45-31(2)55-29-71-45/h8-15,29,38-40,46,62H,16-28H2,1-7H3,(H,53,63)(H,54,65)(H,57,64)/t38-,39+,40+,46-/m1/s1",LSELSHXLKGXPPF-BOBBFQORSA-N,42,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,200,5.946299112,5.49822466,1131.6207,3175.2311
336,200,97,200,97,P25440,BRD2,VHL,,MZ2,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,73,ITC,,,-9.75,-8.79,-0.96,ITC,,,,,,,,,,,,,,,,,,,,,,,123/1259,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912; 10.1021/acschembio.5b00216,1046.714,1045.395694,4.82,72,7,16,4,23,220.72,C51H64ClN9O9S2,"InChI=1S/C51H64ClN9O9S2/c1-30-32(3)72-50-43(30)44(35-12-14-37(52)15-13-35)56-39(47-59-58-33(4)61(47)50)25-41(63)53-16-17-67-18-19-68-20-21-69-22-23-70-28-42(64)57-46(51(5,6)7)49(66)60-27-38(62)24-40(60)48(65)54-26-34-8-10-36(11-9-34)45-31(2)55-29-71-45/h8-15,29,38-40,46,62H,16-28H2,1-7H3,(H,53,63)(H,54,65)(H,57,64)/t38-,39+,40+,46-/m1/s1",LSELSHXLKGXPPF-BOBBFQORSA-N,42,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,200,5.748383961,5.49822466,1784.9088,3175.2311
336,200,97,200,97,P25440,BRD2,VHL,,MZ2,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,73,ITC,,,-9.75,-8.79,-0.96,ITC,,,,,,,,,,,,,,,,,,,,,,,123/1259,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912; 10.1021/acschembio.5b00216,1046.714,1045.395694,4.82,72,7,16,4,23,220.72,C51H64ClN9O9S2,"InChI=1S/C51H64ClN9O9S2/c1-30-32(3)72-50-43(30)44(35-12-14-37(52)15-13-35)56-39(47-59-58-33(4)61(47)50)25-41(63)53-16-17-67-18-19-68-20-21-69-22-23-70-28-42(64)57-46(51(5,6)7)49(66)60-27-38(62)24-40(60)48(65)54-26-34-8-10-36(11-9-34)45-31(2)55-29-71-45/h8-15,29,38-40,46,62H,16-28H2,1-7H3,(H,53,63)(H,54,65)(H,57,64)/t38-,39+,40+,46-/m1/s1",LSELSHXLKGXPPF-BOBBFQORSA-N,42,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,200,6.050510436,5.49822466,890.204,3175.2311
1654,100,96,100/100,96/97,O60885,BRD4,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,17,ITC in BRD4 BD2,,,-10.6,-11.2,-0.65,ITC in BRD4 BD2,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,26,Kd between VHL and MZ4-BRD4 BD2 was tested by ITC,,,-10.4,-5.36,-5.05,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.96,100,6.049392981,5.308008775,892.4975,4920.2959
1654,100,96,100/100,96/97,O60885,BRD4,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,17,ITC in BRD4 BD2,,,-10.6,-11.2,-0.65,ITC in BRD4 BD2,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,26,Kd between VHL and MZ4-BRD4 BD2 was tested by ITC,,,-10.4,-5.36,-5.05,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.96,100,5.897562172,5.308008775,1266.012,4920.2959
1654,100,96,100/100,96/97,O60885,BRD4,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,17,ITC in BRD4 BD2,,,-10.6,-11.2,-0.65,ITC in BRD4 BD2,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,26,Kd between VHL and MZ4-BRD4 BD2 was tested by ITC,,,-10.4,-5.36,-5.05,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.96,100,6.157855544,5.308008775,695.2555,4920.2959
1654,316,97,316,97,Q15059,BRD3,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,,,,,,,,,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.97,316,6.049392981,5.308008775,892.4975,4920.2959
1654,316,97,316,97,Q15059,BRD3,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,,,,,,,,,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.97,316,5.897562172,5.308008775,1266.012,4920.2959
1654,316,97,316,97,Q15059,BRD3,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,,,,,,,,,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.97,316,6.157855544,5.308008775,695.2555,4920.2959
1654,631,93,631,93,P25440,BRD2,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,,,,,,,,,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,631,6.049392981,5.308008775,892.4975,4920.2959
1654,631,93,631,93,P25440,BRD2,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,,,,,,,,,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,631,5.897562172,5.308008775,1266.012,4920.2959
1654,631,93,631,93,P25440,BRD2,VHL,,MZ4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD2 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,147,ITC,,,-9.34,-5.72,-3.61,ITC,,,,,,,,,,,,,,,,,,,,,,,178/1445,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,958.608,957.3432648,5.11,66,7,14,4,17,202.26,C47H56ClN9O7S2,"InChI=1S/C47H56ClN9O7S2/c1-26-28(3)66-46-39(26)40(31-12-14-33(48)15-13-31)52-35(43-55-54-29(4)57(43)46)21-37(59)49-16-17-63-18-19-64-24-38(60)53-42(47(5,6)7)45(62)56-23-34(58)20-36(56)44(61)50-22-30-8-10-32(11-9-30)41-27(2)51-25-65-41/h8-15,25,34-36,42,58H,16-24H2,1-7H3,(H,49,59)(H,50,61)(H,53,60)/t34-,35+,36+,42-/m1/s1",UAQDCZFGBBSHLT-PBSGCNNPSA-N,42,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,631,6.157855544,5.308008775,695.2555,4920.2959
1793,85,98,85,98,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCC3=CC(N)=CC(OCCNC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,208/69,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,135,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1300,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1049.721,1048.385464,6.51,73,8,15,5,18,228.28,C53H61ClN10O7S2,"InChI=1S/C53H61ClN10O7S2/c1-29-31(3)73-52-45(29)46(35-12-14-37(54)15-13-35)59-41(49-62-61-32(4)64(49)52)24-43(66)56-17-19-71-40-21-34(20-38(55)22-40)16-18-70-27-44(67)60-48(53(5,6)7)51(69)63-26-39(65)23-42(63)50(68)57-25-33-8-10-36(11-9-33)47-30(2)58-28-72-47/h8-15,20-22,28,39,41-42,48,65H,16-19,23-27,55H2,1-7H3,(H,56,66)(H,57,68)(H,60,67)/t39-,41+,42+,48-/m1/s1",BVEMTZIKXNJFIM-NMNKMPBPSA-N,42,19,873,COCCC1=CC(N)=CC(OCCN)=C1,[R1]NCCOC1=CC(=CC(=C1)N)CCOC[R2],210.277,210.1368278,0.38,15,1,4,2,6,70.5,C11H18N2O2,"InChI=1S/C11H18N2O2/c1-14-4-2-9-6-10(13)8-11(7-9)15-5-3-12/h6-8H,2-5,12-13H2,1H3",WAOPHHHWVCMEPH-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,85,6.303573113,5.753643982,497.0807,1763.421
1794,280,88,280,88,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COC[C@@H]3CNC[C@H](COCCNC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,12/6.4,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,570,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3800,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1041.742,1040.416764,5.33,72,8,15,5,18,214.29,C52H65ClN10O7S2,"InChI=1S/C52H65ClN10O7S2/c1-29-31(3)72-51-44(29)45(36-12-14-38(53)15-13-36)58-40(48-61-60-32(4)63(48)51)20-42(65)55-16-17-69-25-34-18-35(22-54-21-34)26-70-27-43(66)59-47(52(5,6)7)50(68)62-24-39(64)19-41(62)49(67)56-23-33-8-10-37(11-9-33)46-30(2)57-28-71-46/h8-15,28,34-35,39-41,47,54,64H,16-27H2,1-7H3,(H,55,65)(H,56,67)(H,59,66)/t34-,35+,39-,40+,41+,47-/m1/s1",XYRCFJBQFAIJBP-MFCIJMLGSA-N,42,19,874,COC[C@@H]1CNC[C@H](COCCN)C1,[R1]NCCOC[C@@H]1C[C@@H](CNC1)COC[R2],202.298,202.1681279,-0.79,14,1,4,2,6,56.51,C10H22N2O2,"InChI=1S/C10H22N2O2/c1-13-7-9-4-10(6-12-5-9)8-14-3-2-11/h9-10,12H,2-8,11H2,1H3/t9-,10+/m0/s1",QWLRGHWNIKYJDV-VHSXEESVSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.88,280,6.070551096,5.760842809,850.0587,1734.4317
1797,7.2,99,7.2,99,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCC#CC#CCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,62/24,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,470,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,67,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,962.599,961.3170501,5.71,67,7,13,4,13,193.03,C49H52ClN9O6S2,"InChI=1S/C49H52ClN9O6S2/c1-28-30(3)67-48-41(28)42(33-16-18-35(50)19-17-33)54-37(45-57-56-31(4)59(45)48)23-39(61)51-20-10-8-9-11-21-65-26-40(62)55-44(49(5,6)7)47(64)58-25-36(60)22-38(58)46(63)52-24-32-12-14-34(15-13-32)43-29(2)53-27-66-43/h12-19,27,36-38,44,60H,20-26H2,1-7H3,(H,51,61)(H,52,63)(H,55,62)/t36-,37+,38+,44-/m1/s1",FXEIENSZGMCCEE-PYNGZGNASA-N,42,19,876,COCC#CC#CCN,[R1]NCC#CC#CCOC[R2],123.155,123.0684139,-0.41,9,0,2,1,1,35.25,C7H9NO,"InChI=1S/C7H9NO/c1-9-7-5-3-2-4-6-8/h6-8H2,1H3",FUTGOKPVWKUISE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,7.2,6.093079642,5.774634409,807.087,1680.2178
174,367.8,85.1,367.8,85.1,Q96SW2,CRBN,VHL,,TD-343,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,876.002,875.3523765,2.33,62,6,14,5,19,234.9,C43H53N7O11S,"InChI=1S/C43H53N7O11S/c1-25-36(62-24-46-25)27-10-8-26(9-11-27)21-45-38(54)32-20-28(51)22-49(32)42(58)37(43(2,3)4)47-34(53)23-61-19-18-60-17-16-59-15-14-44-30-7-5-6-29-35(30)41(57)50(40(29)56)31-12-13-33(52)48-39(31)55/h5-11,24,28,31-32,37,44,51H,12-23H2,1-4H3,(H,45,54)(H,47,53)(H,48,52,55)/t28-,31?,32+,37-/m1/s1",JJODRHXPKVBYEY-JPQBYMPPSA-N,50,19,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.851,367.8,5.342704888,5.224414107,4542.5018,5964.6627
1016,2546.1,77.9,2546.1,77.9,Q96SW2,CRBN,VHL,,TD-033,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)NC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,827.961,827.3312471,3.06,59,6,11,5,14,224.28,C42H49N7O9S,"InChI=1S/C42H49N7O9S/c1-23-35(59-22-44-23)25-15-13-24(14-16-25)20-43-37(54)30-19-26(50)21-48(30)41(58)36(42(2,3)4)46-32(52)12-7-5-6-11-31(51)45-28-10-8-9-27-34(28)40(57)49(39(27)56)29-17-18-33(53)47-38(29)55/h8-10,13-16,22,26,29-30,36,50H,5-7,11-12,17-21H2,1-4H3,(H,43,54)(H,45,51)(H,46,52)(H,47,53,55)/t26-,29?,30+,36-/m1/s1",ZBCXOELGHROVDK-FOLICCEFSA-N,50,19,143,CCCCCC=O,[R1]C(=O)CCCCC[R2],100.161,100.088815,1.64,7,0,1,0,4,17.07,C6H12O,"InChI=1S/C6H12O/c1-2-3-4-5-6-7/h6H,2-5H2,1H3",JARKCYVAAOWBJS-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.779,2546.1,5.694599593,5.528405523,2020.2281,2962.0643
1013,100.6,96.9,100.6,96.9,Q96SW2,CRBN,VHL,,TD-156,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,813.978,813.3519826,4.29,58,6,11,5,15,207.21,C42H51N7O8S,"InChI=1S/C42H51N7O8S/c1-24-35(58-23-45-24)26-15-13-25(14-16-26)21-44-37(53)31-20-27(50)22-48(31)41(57)36(42(2,3)4)46-32(51)12-7-5-6-8-19-43-29-11-9-10-28-34(29)40(56)49(39(28)55)30-17-18-33(52)47-38(30)54/h9-11,13-16,23,27,30-31,36,43,50H,5-8,12,17-22H2,1-4H3,(H,44,53)(H,46,51)(H,47,52,54)/t27-,30?,31+,36-/m1/s1",NONAQRYFKJIZQD-AEXNMDALSA-N,50,19,26,CCCCCC,[R1]CCCCCC[R2],86.178,86.10955045,3.47,6,0,0,0,3,0,C6H14,"InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3",VLKZOEOYAKHREP-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.969,100.6,5.662261766,5.708045557,2176.3976,1958.6392
968,200,75,200/230,75/98,Q96SW2,CRBN,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCOCCOCCCCCOCC(=O)NCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HeLa/HEK293 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.bmc.2019.02.048,1061.269,1060.493955,3.67,75,6,16,6,30,273.23,C53H72N8O13S,"InChI=1S/C53H72N8O13S/c1-34-46(75-33-57-34)36-16-14-35(15-17-36)29-56-48(66)41-28-37(62)30-60(41)52(70)47(53(2,3)4)58-44(65)32-74-25-10-6-8-23-72-27-26-71-22-7-5-9-24-73-31-43(64)55-21-20-54-39-13-11-12-38-45(39)51(69)61(50(38)68)40-18-19-42(63)59-49(40)67/h11-17,33,37,40-41,47,54,62H,5-10,18-32H2,1-4H3,(H,55,64)(H,56,66)(H,58,65)(H,59,63,67)/t37-,40?,41+,47-/m1/s1",PEZCAXDTKNFUCR-CTMFSBKBSA-N,50,19,470,CCNC(=O)COCCCCCOCCOCCCCCOC,[R1]CCNC(=O)COCCCCCOCCOCCCCCOC[R2],333.469,333.2515232,1.49,23,0,5,1,18,66.02,C17H35NO5,"InChI=1S/C17H35NO5/c1-3-18-17(19)16-23-13-9-5-8-12-22-15-14-21-11-7-4-6-10-20-2/h3-16H2,1-2H3,(H,18,19)",MVYNEDGDADJOKN-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.75,200,5.670779652,5.814138661,2134.1274,1534.1271
1011,44.5,97.1,44.5,97.1,Q96SW2,CRBN,VHL,,TD-158,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,842.032,841.3832827,5.37,60,6,11,5,17,207.21,C44H55N7O8S,"InChI=1S/C44H55N7O8S/c1-26-37(60-25-47-26)28-17-15-27(16-18-28)23-46-39(55)33-22-29(52)24-50(33)43(59)38(44(2,3)4)48-34(53)14-9-7-5-6-8-10-21-45-31-13-11-12-30-36(31)42(58)51(41(30)57)32-19-20-35(54)49-40(32)56/h11-13,15-18,25,29,32-33,38,45,52H,5-10,14,19-24H2,1-4H3,(H,46,55)(H,48,53)(H,49,54,56)/t29-,32?,33+,38-/m1/s1",UQJOJHWASBETAR-PHPCURKRSA-N,50,19,32,CCCCCCCC,[R1]CCCCCCCC[R2],114.232,114.1408506,4.55,8,0,0,0,5,0,C8H18,"InChI=1S/C8H18/c1-3-5-7-8-6-4-2/h3-8H2,1-2H3",TVMXDCGIABBOFY-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.971,44.5,5.566349327,5.54200087,2714.2552,2870.7748
1012,20.4,99.6,20.4,99.6,Q96SW2,CRBN,VHL,,TD-165,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,870.086,869.4145828,6.46,62,6,11,5,19,207.21,C46H59N7O8S,"InChI=1S/C46H59N7O8S/c1-28-39(62-27-49-28)30-19-17-29(18-20-30)25-48-41(57)35-24-31(54)26-52(35)45(61)40(46(2,3)4)50-36(55)16-11-9-7-5-6-8-10-12-23-47-33-15-13-14-32-38(33)44(60)53(43(32)59)34-21-22-37(56)51-42(34)58/h13-15,17-20,27,31,34-35,40,47,54H,5-12,16,21-26H2,1-4H3,(H,48,57)(H,50,55)(H,51,56,58)/t31-,34?,35+,40-/m1/s1",KSXVXTSIDVRZBR-IINAPWRYSA-N,50,19,40,CCCCCCCCCC,[R1]CCCCCCCCCC[R2],142.286,142.1721507,5.63,10,0,0,0,7,0,C10H22,"InChI=1S/C10H22/c1-3-5-7-9-10-8-6-4-2/h3-10H2,1-2H3",DIOQZVSQGTUSAI-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.996,20.4,5.886170703,5.682200235,1299.6586,2078.738
1014,28.8,98.4,28.8,98.4,Q96SW2,CRBN,VHL,,TD-759,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,927.138,926.4360466,5.8,66,6,12,6,21,236.31,C48H62N8O9S,"InChI=1S/C48H62N8O9S/c1-29-41(66-28-52-29)31-19-17-30(18-20-31)25-51-43(61)36-24-32(57)27-55(36)47(65)42(48(2,3)4)53-37(58)16-11-9-7-5-6-8-10-12-23-49-39(60)26-50-34-15-13-14-33-40(34)46(64)56(45(33)63)35-21-22-38(59)54-44(35)62/h13-15,17-20,28,32,35-36,42,50,57H,5-12,16,21-27H2,1-4H3,(H,49,60)(H,51,61)(H,53,58)(H,54,59,62)/t32-,35?,36+,42-/m1/s1",FWZROUMFDYURRM-FYESNEIGSA-N,50,19,498,CCCCCCCCCCNC(C)=O,[R1]CC(=O)NCCCCCCCCCC[R2],199.338,199.1936144,4.04,14,0,1,1,9,29.1,C12H25NO,"InChI=1S/C12H25NO/c1-3-4-5-6-7-8-9-10-11-13-12(2)14/h3-11H2,1-2H3,(H,13,14)",DXFXMYYJKFIEGI-UHFFFAOYSA-N,P62942,FKBP12,,CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC=CC(N)=C1,100,IC50 of FKBP12 was assessed by fluorescence polarization assay,,,,,,,10.1021/jm201746x,524.658,524.288637,5.27,38,3,7,1,11,108.16,C30H40N2O6,"InChI=1S/C30H40N2O6/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3/t23-,24+/m0/s1",IIDSDBBDZNDWCN-BJKOFHAPSA-N,50388311,35027274,CHEMBL2059026,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.984,28.8,5.778148854,5.847071638,1666.6759,1422.0942
1656,10,99,40/10/126,66/99/86,Q05397,FAK,VHL,,BI-0319,COC1=CC(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in HLF/SNU-398/HUCCT1 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,>25119/7943/6310,Inhibit proliferation of HLF/SNU-398/HUCCT1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01826,1061.15,1060.39761,5.49,75,7,16,5,23,241.76,C52H59F3N8O11S,"InChI=1S/C52H59F3N8O11S/c1-30-44(75-29-59-30)33-11-9-31(10-12-33)25-57-47(68)38-24-35(64)27-63(38)49(69)45(51(2,3)4)61-42(66)28-73-22-21-72-20-19-71-18-17-56-46(67)34-13-15-37(41(23-34)70-5)60-50-58-26-36(52(53,54)55)48(62-50)74-40-8-6-7-32-14-16-39(65)43(32)40/h6-13,15,23,26,29,35,38,45,64H,14,16-22,24-25,27-28H2,1-5H3,(H,56,67)(H,57,68)(H,61,66)(H,58,60,62)/t35-,38+,45-/m1/s1",UVVQLQQNGHYTOL-JIVXZRRKSA-N,262,19,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,10,6.500829107,5.815953763,315.6246,1527.7287
1656,25,85,25/100/79,85/79/87,Q05397,FAK,VHL,,BI-0319,COC1=CC(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in HLE/HuH-7/SNU-423 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10000/3981/6310,Inhibit proliferation of HLE/HuH-7/SNU-423 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01826,1061.15,1060.39761,5.49,75,7,16,5,23,241.76,C52H59F3N8O11S,"InChI=1S/C52H59F3N8O11S/c1-30-44(75-29-59-30)33-11-9-31(10-12-33)25-57-47(68)38-24-35(64)27-63(38)49(69)45(51(2,3)4)61-42(66)28-73-22-21-72-20-19-71-18-17-56-46(67)34-13-15-37(41(23-34)70-5)60-50-58-26-36(52(53,54)55)48(62-50)74-40-8-6-7-32-14-16-39(65)43(32)40/h6-13,15,23,26,29,35,38,45,64H,14,16-22,24-25,27-28H2,1-5H3,(H,56,67)(H,57,68)(H,61,66)(H,58,60,62)/t35-,38+,45-/m1/s1",UVVQLQQNGHYTOL-JIVXZRRKSA-N,262,19,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,25,6.500829107,5.815953763,315.6246,1527.7287
1656,32,98,243/631/32,80/59/98,Q05397,FAK,VHL,,BI-0319,COC1=CC(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in A549/Hep3B2.1-7/SNU-387 cells after 18 h treatment,,,19,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5012/6310,Inhibit proliferation of SNU-387/Hep3B2.1-7 cells,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 2 h,11,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acs.jmedchem.8b01826,1061.15,1060.39761,5.49,75,7,16,5,23,241.76,C52H59F3N8O11S,"InChI=1S/C52H59F3N8O11S/c1-30-44(75-29-59-30)33-11-9-31(10-12-33)25-57-47(68)38-24-35(64)27-63(38)49(69)45(51(2,3)4)61-42(66)28-73-22-21-72-20-19-71-18-17-56-46(67)34-13-15-37(41(23-34)70-5)60-50-58-26-36(52(53,54)55)48(62-50)74-40-8-6-7-32-14-16-39(65)43(32)40/h6-13,15,23,26,29,35,38,45,64H,14,16-22,24-25,27-28H2,1-5H3,(H,56,67)(H,57,68)(H,61,66)(H,58,60,62)/t35-,38+,45-/m1/s1",UVVQLQQNGHYTOL-JIVXZRRKSA-N,262,19,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,32,6.500829107,5.815953763,315.6246,1527.7287
1656,79,79,79/631/126,79/65/87,Q05397,FAK,VHL,,BI-0319,COC1=CC(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in HUH-1/HepG2/SK-Hep-1 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19953/>25119/7943,Inhibit proliferation of HUH-1/HepG2/SK-Hep-1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01826,1061.15,1060.39761,5.49,75,7,16,5,23,241.76,C52H59F3N8O11S,"InChI=1S/C52H59F3N8O11S/c1-30-44(75-29-59-30)33-11-9-31(10-12-33)25-57-47(68)38-24-35(64)27-63(38)49(69)45(51(2,3)4)61-42(66)28-73-22-21-72-20-19-71-18-17-56-46(67)34-13-15-37(41(23-34)70-5)60-50-58-26-36(52(53,54)55)48(62-50)74-40-8-6-7-32-14-16-39(65)43(32)40/h6-13,15,23,26,29,35,38,45,64H,14,16-22,24-25,27-28H2,1-5H3,(H,56,67)(H,57,68)(H,61,66)(H,58,60,62)/t35-,38+,45-/m1/s1",UVVQLQQNGHYTOL-JIVXZRRKSA-N,262,19,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.79,79,6.500829107,5.815953763,315.6246,1527.7287
1783,7.5,98,7.5,98,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C3=CC4=C(C=C3CS(C)(=O)=O)C3=CN(C)C(=O)C5=C3C(=C[NH]5)CN4C3=NC=C(F)C=C3F)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,1.1/1.4,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01846,1102.253,1101.390002,2.66,77,8,16,5,21,256.48,C53H61F2N9O11S2,"InChI=1S/C53H61F2N9O11S2/c1-30-46(76-29-60-30)32-9-7-31(8-10-32)21-59-50(68)42-19-36(65)25-64(42)52(70)47(53(2,3)4)61-43(66)27-75-16-15-74-14-13-73-12-11-56-49(67)37-20-41-38(17-33(37)28-77(6,71)72)39-26-62(5)51(69)45-44(39)34(22-57-45)24-63(41)48-40(55)18-35(54)23-58-48/h7-10,17-18,20,22-23,26,29,36,42,47,57,65H,11-16,19,21,24-25,27-28H2,1-6H3,(H,56,67)(H,59,68)(H,61,66)/t36-,42+,47-/m1/s1",GPZQCKOJSPAJES-KFRCLFBHSA-N,317,19,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,Q06187,BTK,,O=C(O)CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2,81.4,Inhibition of BTK,,,,,,,10.1016/j.ejmech.2021.113820,422.828,422.0781826,4.07,30,4,6,3,7,117.2,C21H15ClN4O4,"InChI=1S/C21H15ClN4O4/c22-16-8-13(30-12-4-2-1-3-5-12)6-7-14(16)19(29)15-9-23-20-18(15)21(26-11-25-20)24-10-17(27)28/h1-9,11H,10H2,(H,27,28)(H2,23,24,25,26)",GTFCZHOGJFHOEX-UHFFFAOYSA-N,,156770693,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,7.5,5.954474622,6.002888144,1110.5174,993.3719
1784,0.095,96,0.095,96,O60885,BRD4,VHL,7KHH,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)C3=CC4=C(C=C3CS(C)(=O)=O)C3=CN(C)C(=O)C5=C3C(=C[NH]5)CN4C3=NC=C(F)C=C3F)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,4.7/4.3,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,613,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.63,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01846,1096.337,1095.452209,6.78,77,8,13,5,21,228.79,C56H67F2N9O8S2,"InChI=1S/C56H67F2N9O8S2/c1-33-49(76-32-63-33)35-18-16-34(17-19-35)25-62-53(71)45-23-39(68)29-67(45)55(73)50(56(2,3)4)64-46(69)15-13-11-9-7-8-10-12-14-20-59-52(70)40-24-44-41(21-36(40)31-77(6,74)75)42-30-65(5)54(72)48-47(42)37(26-60-48)28-66(44)51-43(58)22-38(57)27-61-51/h16-19,21-22,24,26-27,30,32,39,45,50,60,68H,7-15,20,23,25,28-29,31H2,1-6H3,(H,59,70)(H,62,71)(H,64,69)/t39-,45+,50-/m1/s1",VTPSYVSGGUUAFN-GDNJTPAESA-N,317,19,40,CCCCCCCCCC,[R1]CCCCCCCCCC[R2],142.286,142.1721507,5.63,10,0,0,0,7,0,C10H22,"InChI=1S/C10H22/c1-3-5-7-9-10-8-6-4-2/h3-10H2,1-2H3",DIOQZVSQGTUSAI-UHFFFAOYSA-N,Q06187,BTK,,O=C(O)CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2,81.4,Inhibition of BTK,,,,,,,10.1016/j.ejmech.2021.113820,422.828,422.0781826,4.07,30,4,6,3,7,117.2,C21H15ClN4O4,"InChI=1S/C21H15ClN4O4/c22-16-8-13(30-12-4-2-1-3-5-12)6-7-14(16)19(29)15-9-23-20-18(15)21(26-11-25-20)24-10-17(27)28/h1-9,11H,10H2,(H,27,28)(H2,23,24,25,26)",GTFCZHOGJFHOEX-UHFFFAOYSA-N,,156770693,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.96,0.095,6.083159703,6.064663639,825.7342,861.6608
1787,2.1,98,2.1,98,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCC3=CC(N)=CC(OCCNC(=O)C4=CC5=C(C=C4CS(C)(=O)=O)C4=CN(C)C(=O)C6=C4C(=C[NH]6)CN5C4=NC=C(F)C=C4F)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in EOL-1 cells 4 h treatment,,,7.2/8.1,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,91,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01846,1149.313,1148.405987,4.2,81,9,16,6,19,273.27,C57H62F2N10O10S2,"InChI=1S/C57H62F2N10O10S2/c1-31-50(80-30-65-31)34-9-7-32(8-10-34)22-64-54(73)46-20-39(70)26-69(46)56(75)51(57(2,3)4)66-47(71)28-78-13-11-33-15-38(60)19-40(16-33)79-14-12-61-53(72)41-21-45-42(17-35(41)29-81(6,76)77)43-27-67(5)55(74)49-48(43)36(23-62-49)25-68(45)52-44(59)18-37(58)24-63-52/h7-10,15-19,21,23-24,27,30,39,46,51,62,70H,11-14,20,22,25-26,28-29,60H2,1-6H3,(H,61,72)(H,64,73)(H,66,71)/t39-,46+,51-/m1/s1",UNADZUGJDDCVKE-RVLLIKLQSA-N,317,19,871,CCOC1=CC(N)=CC(CCOC)=C1,[R1]CCOC1=CC(=CC(=C1)N)CCOC[R2],195.262,195.1259288,1.69,14,1,3,1,5,44.48,C11H17NO2,"InChI=1S/C11H17NO2/c1-3-14-11-7-9(4-5-13-2)6-10(12)8-11/h6-8H,3-5,12H2,1-2H3",COXWDCOKOBYDPU-UHFFFAOYSA-N,Q06187,BTK,,O=C(O)CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2,81.4,Inhibition of BTK,,,,,,,10.1016/j.ejmech.2021.113820,422.828,422.0781826,4.07,30,4,6,3,7,117.2,C21H15ClN4O4,"InChI=1S/C21H15ClN4O4/c22-16-8-13(30-12-4-2-1-3-5-12)6-7-14(16)19(29)15-9-23-20-18(15)21(26-11-25-20)24-10-17(27)28/h1-9,11H,10H2,(H,27,28)(H2,23,24,25,26)",GTFCZHOGJFHOEX-UHFFFAOYSA-N,,156770693,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,2.1,6.585139455,5.952373536,259.9325,1115.903
1788,1.4,99.9,1.4,100,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCC3=CC(O)=CC(OCCNC(=O)C4=CC5=C(C=C4CS(C)(=O)=O)C4=CN(C)C(=O)C6=C4C(=C[NH]6)CN5C4=NC=C(F)C=C4F)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,1.8/1.7,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,229,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01846,1150.297,1149.390002,4.52,81,9,16,6,19,267.48,C57H61F2N9O11S2,"InChI=1S/C57H61F2N9O11S2/c1-31-50(80-30-64-31)34-9-7-32(8-10-34)22-63-54(73)46-20-39(70)26-68(46)56(75)51(57(2,3)4)65-47(71)28-78-13-11-33-15-38(69)19-40(16-33)79-14-12-60-53(72)41-21-45-42(17-35(41)29-81(6,76)77)43-27-66(5)55(74)49-48(43)36(23-61-49)25-67(45)52-44(59)18-37(58)24-62-52/h7-10,15-19,21,23-24,27,30,39,46,51,61,69-70H,11-14,20,22,25-26,28-29H2,1-6H3,(H,60,72)(H,63,73)(H,65,71)/t39-,46+,51-/m1/s1",JQHNOZDZLLPAJF-RVLLIKLQSA-N,317,19,872,CCOC1=CC(O)=CC(CCOC)=C1,[R1]CCOC1=CC(=CC(=C1)O)CCOC[R2],196.246,196.1099444,2.02,14,1,3,1,5,38.69,C11H16O3,"InChI=1S/C11H16O3/c1-3-14-11-7-9(4-5-13-2)6-10(12)8-11/h6-8,12H,3-5H2,1-2H3",GASBROUVWUECLM-UHFFFAOYSA-N,Q06187,BTK,,O=C(O)CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2,81.4,Inhibition of BTK,,,,,,,10.1016/j.ejmech.2021.113820,422.828,422.0781826,4.07,30,4,6,3,7,117.2,C21H15ClN4O4,"InChI=1S/C21H15ClN4O4/c22-16-8-13(30-12-4-2-1-3-5-12)6-7-14(16)19(29)15-9-23-20-18(15)21(26-11-25-20)24-10-17(27)28/h1-9,11H,10H2,(H,27,28)(H2,23,24,25,26)",GTFCZHOGJFHOEX-UHFFFAOYSA-N,,156770693,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.999,1.4,6.474640327,6.115837648,335.243,765.8829
1649,4.8,76,4.8,76,Q07817,BCL-xL,VHL,6ZHC,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOCCOCCOCCOCC#CC3=CC=C(OCCCC4=C(C(=O)O)N=C(N5CCC6=CC=CC(C(=O)NC7=NC8=CC=CC=C8S7)=C6C5)S4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in THP-1 cells after 24 h treatment,,,0.6,IC50 was tested by HTRF assay,,,,,,,,,,,,,,,190,SPR,,,,,,,,,,,,,,,290,Titrations of PROTAC over an immobilised VCB surface in the presence of BCL-xL (SPR),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.0c00266,1329.631,1328.495612,8.07,93,9,20,5,34,271.66,C68H80N8O14S3,"InChI=1S/C68H80N8O14S3/c1-45-60(91-44-70-45)49-20-16-47(17-21-49)41-69-63(80)55-40-50(77)42-76(55)64(81)61(68(2,3)4)72-58(78)25-29-85-31-33-87-35-37-89-39-38-88-36-34-86-32-30-84-27-8-10-46-18-22-51(23-19-46)90-28-9-15-57-59(65(82)83)73-67(93-57)75-26-24-48-11-7-12-52(53(48)43-75)62(79)74-66-71-54-13-5-6-14-56(54)92-66/h5-7,11-14,16-23,44,50,55,61,77H,9,15,24-43H2,1-4H3,(H,69,80)(H,72,78)(H,82,83)(H,71,74,79)/t50-,55+,61-/m1/s1",LOJJAKUNUJJOKC-MXEISZGISA-N,260,19,105,CCOCCOCCOCCOCCOCCOC,[R1]COCCOCCOCCOCCOCCOCC[R2],280.361,280.1885886,-0.29,19,0,6,0,16,55.38,C13H28O6,"InChI=1S/C13H28O6/c1-3-15-6-7-17-10-11-19-13-12-18-9-8-16-5-4-14-2/h3-13H2,1-2H3",PJXDGFJDVVVXCY-UHFFFAOYSA-N,P00519,ABL1,GNF-2,NC(=O)C1=CC=CC(C2=CC(NC3=CC=C(OC(F)(F)F)C=C3)=NC=N2)=C1,9,Inhibition of recombinant human c-ABL SH3/SH2/SH1 domain,,,,,,,10.1021/acs.jmedchem.8b01040,374.322,374.0990603,3.8,27,3,5,2,5,90.13,C18H13F3N4O2,"InChI=1S/C18H13F3N4O2/c19-18(20,21)27-14-6-4-13(5-7-14)25-16-9-15(23-10-24-16)11-2-1-3-12(8-11)17(22)26/h1-10H,(H2,22,26)(H,23,24,25)",WEVYNIUIFUYDGI-UHFFFAOYSA-N,50325999,5311510,CHEMBL483847,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.76,4.8,6.284533319,5.620971183,519.3578,2393.4746
1652,8,98,08 25,98/95,O60885,BRD4,VHL,,MZP-54,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,4,Kd of BRD4 BD2 was tested by ITC,,,-11.5,-9.74,-1.73,ITC in BRD4 BD2,,,,,,,,,105,ITC,,,-9.52,-6.18,-3.34,ITC,,,,,,,,,228,Kd between VHL and the complex of protac and BRD4 BD2 was tested by ITC,,,-9.06,-6.9,-2.16,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,49/269,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1036.693,1035.433125,6.56,73,7,12,5,21,200.76,C55H66ClN7O9S,"InChI=1S/C55H66ClN7O9S/c1-34-27-46(60-43-18-16-42(56)17-19-43)45-28-41(15-20-47(45)63(34)36(3)64)38-11-13-40(14-12-38)52(67)57-21-22-70-23-24-71-25-26-72-32-49(66)61-51(55(4,5)6)54(69)62-31-44(65)29-48(62)53(68)58-30-37-7-9-39(10-8-37)50-35(2)59-33-73-50/h7-20,28,33-34,44,46,48,51,60,65H,21-27,29-32H2,1-6H3,(H,57,67)(H,58,68)(H,61,66)/t34-,44+,46+,48-,51+/m0/s1",FYSWLIFIYIVHPI-DDWISSAJSA-N,261,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,8,5.803786636,5.469622456,1571.1345,3391.3885
1652,8,98,08 25,98/95,O60885,BRD4,VHL,,MZP-54,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,4,Kd of BRD4 BD2 was tested by ITC,,,-11.5,-9.74,-1.73,ITC in BRD4 BD2,,,,,,,,,105,ITC,,,-9.52,-6.18,-3.34,ITC,,,,,,,,,228,Kd between VHL and the complex of protac and BRD4 BD2 was tested by ITC,,,-9.06,-6.9,-2.16,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,49/269,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1036.693,1035.433125,6.56,73,7,12,5,21,200.76,C55H66ClN7O9S,"InChI=1S/C55H66ClN7O9S/c1-34-27-46(60-43-18-16-42(56)17-19-43)45-28-41(15-20-47(45)63(34)36(3)64)38-11-13-40(14-12-38)52(67)57-21-22-70-23-24-71-25-26-72-32-49(66)61-51(55(4,5)6)54(69)62-31-44(65)29-48(62)53(68)58-30-37-7-9-39(10-8-37)50-35(2)59-33-73-50/h7-20,28,33-34,44,46,48,51,60,65H,21-27,29-32H2,1-6H3,(H,57,67)(H,58,68)(H,61,66)/t34-,44+,46+,48-,51+/m0/s1",FYSWLIFIYIVHPI-DDWISSAJSA-N,261,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,8,5.842827032,5.469622456,1436.0613,3391.3885
1652,50,91,50,91,Q15059,BRD3,VHL,,MZP-54,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,105,ITC,,,-9.52,-6.18,-3.34,ITC,,,,,,,,,,,,,,,,,,,,,,,49/269,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1036.693,1035.433125,6.56,73,7,12,5,21,200.76,C55H66ClN7O9S,"InChI=1S/C55H66ClN7O9S/c1-34-27-46(60-43-18-16-42(56)17-19-43)45-28-41(15-20-47(45)63(34)36(3)64)38-11-13-40(14-12-38)52(67)57-21-22-70-23-24-71-25-26-72-32-49(66)61-51(55(4,5)6)54(69)62-31-44(65)29-48(62)53(68)58-30-37-7-9-39(10-8-37)50-35(2)59-33-73-50/h7-20,28,33-34,44,46,48,51,60,65H,21-27,29-32H2,1-6H3,(H,57,67)(H,58,68)(H,61,66)/t34-,44+,46+,48-,51+/m0/s1",FYSWLIFIYIVHPI-DDWISSAJSA-N,261,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.91,50,5.803786636,5.469622456,1571.1345,3391.3885
1652,50,91,50,91,Q15059,BRD3,VHL,,MZP-54,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,105,ITC,,,-9.52,-6.18,-3.34,ITC,,,,,,,,,,,,,,,,,,,,,,,49/269,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1036.693,1035.433125,6.56,73,7,12,5,21,200.76,C55H66ClN7O9S,"InChI=1S/C55H66ClN7O9S/c1-34-27-46(60-43-18-16-42(56)17-19-43)45-28-41(15-20-47(45)63(34)36(3)64)38-11-13-40(14-12-38)52(67)57-21-22-70-23-24-71-25-26-72-32-49(66)61-51(55(4,5)6)54(69)62-31-44(65)29-48(62)53(68)58-30-37-7-9-39(10-8-37)50-35(2)59-33-73-50/h7-20,28,33-34,44,46,48,51,60,65H,21-27,29-32H2,1-6H3,(H,57,67)(H,58,68)(H,61,66)/t34-,44+,46+,48-,51+/m0/s1",FYSWLIFIYIVHPI-DDWISSAJSA-N,261,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.91,50,5.842827032,5.469622456,1436.0613,3391.3885
1653,8,95,8/32,95/93,O60885,BRD4,VHL,,MZP-55,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,Aug-39,Kd of BRD4 BD1/2 was tested by ITC,,,0.927927928,1.101851852,1.6/-0.33,ITC in BRD4 BD1/2,,,,,,,,,109,ITC,,,-9.5,-8.01,-1.5,ITC,,,,,,,,,221/183,Kd between VHL and the complex of protac and BRD4 BD1/2 was tested by ITC,,,0.990217391,0.32585752,4.092592593,ITC between VHL and BRD4 BD1/2:PROTAC,,,,,,,83/427,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1080.746,1079.45934,6.41,76,7,13,5,24,209.99,C57H70ClN7O10S,"InChI=1S/C57H70ClN7O10S/c1-36-29-48(62-45-18-16-44(58)17-19-45)47-30-43(15-20-49(47)65(36)38(3)66)40-11-13-42(14-12-40)54(69)59-21-22-72-23-24-73-25-26-74-27-28-75-34-51(68)63-53(57(4,5)6)56(71)64-33-46(67)31-50(64)55(70)60-32-39-7-9-41(10-8-39)52-37(2)61-35-76-52/h7-20,30,35-36,46,48,50,53,62,67H,21-29,31-34H2,1-6H3,(H,59,69)(H,60,70)(H,63,68)/t36-,46+,48+,50-,53+/m0/s1",UHWNJFZTYJNBAN-HYXXSBGTSA-N,261,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,8,5.671306368,5.137850627,2131.5407,7280.3016
1653,8,95,8/32,95/93,O60885,BRD4,VHL,,MZP-55,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,Aug-39,Kd of BRD4 BD1/2 was tested by ITC,,,0.927927928,1.101851852,1.6/-0.33,ITC in BRD4 BD1/2,,,,,,,,,109,ITC,,,-9.5,-8.01,-1.5,ITC,,,,,,,,,221/183,Kd between VHL and the complex of protac and BRD4 BD1/2 was tested by ITC,,,0.990217391,0.32585752,4.092592593,ITC between VHL and BRD4 BD1/2:PROTAC,,,,,,,83/427,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1080.746,1079.45934,6.41,76,7,13,5,24,209.99,C57H70ClN7O10S,"InChI=1S/C57H70ClN7O10S/c1-36-29-48(62-45-18-16-44(58)17-19-45)47-30-43(15-20-49(47)65(36)38(3)66)40-11-13-42(14-12-40)54(69)59-21-22-72-23-24-73-25-26-74-27-28-75-34-51(68)63-53(57(4,5)6)56(71)64-33-46(67)31-50(64)55(70)60-32-39-7-9-41(10-8-39)52-37(2)61-35-76-52/h7-20,30,35-36,46,48,50,53,62,67H,21-29,31-34H2,1-6H3,(H,59,69)(H,60,70)(H,63,68)/t36-,46+,48+,50-,53+/m0/s1",UHWNJFZTYJNBAN-HYXXSBGTSA-N,261,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,8,5.758157021,5.137850627,1745.1911,7280.3016
1653,20,92,20,92,Q15059,BRD3,VHL,,MZP-55,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,Nov-39,Kd of BRD3 BD1/2 was tested by ITC,,,0.926605505,0.956834532,3.2/3,ITC in BRD3 BD1/2,,,,,,,,,109,ITC,,,-9.5,-8.01,-1.5,ITC,,,,,,,,,152/434,Kd between VHL and the complex of protac and BRD3 BD1/2 was tested by ITC,,,1.068886338,0.563437926,3.781021898,ITC between VHL and BRD3 BD1/2:PROTAC,,,,,,,83/427,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1080.746,1079.45934,6.41,76,7,13,5,24,209.99,C57H70ClN7O10S,"InChI=1S/C57H70ClN7O10S/c1-36-29-48(62-45-18-16-44(58)17-19-45)47-30-43(15-20-49(47)65(36)38(3)66)40-11-13-42(14-12-40)54(69)59-21-22-72-23-24-73-25-26-74-27-28-75-34-51(68)63-53(57(4,5)6)56(71)64-33-46(67)31-50(64)55(70)60-32-39-7-9-41(10-8-39)52-37(2)61-35-76-52/h7-20,30,35-36,46,48,50,53,62,67H,21-29,31-34H2,1-6H3,(H,59,69)(H,60,70)(H,63,68)/t36-,46+,48+,50-,53+/m0/s1",UHWNJFZTYJNBAN-HYXXSBGTSA-N,261,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.92,20,5.671306368,5.137850627,2131.5407,7280.3016
1653,20,92,20,92,Q15059,BRD3,VHL,,MZP-55,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,Nov-39,Kd of BRD3 BD1/2 was tested by ITC,,,0.926605505,0.956834532,3.2/3,ITC in BRD3 BD1/2,,,,,,,,,109,ITC,,,-9.5,-8.01,-1.5,ITC,,,,,,,,,152/434,Kd between VHL and the complex of protac and BRD3 BD1/2 was tested by ITC,,,1.068886338,0.563437926,3.781021898,ITC between VHL and BRD3 BD1/2:PROTAC,,,,,,,83/427,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,1080.746,1079.45934,6.41,76,7,13,5,24,209.99,C57H70ClN7O10S,"InChI=1S/C57H70ClN7O10S/c1-36-29-48(62-45-18-16-44(58)17-19-45)47-30-43(15-20-49(47)65(36)38(3)66)40-11-13-42(14-12-40)54(69)59-21-22-72-23-24-73-25-26-74-27-28-75-34-51(68)63-53(57(4,5)6)56(71)64-33-46(67)31-50(64)55(70)60-32-39-7-9-41(10-8-39)52-37(2)61-35-76-52/h7-20,30,35-36,46,48,50,53,62,67H,21-29,31-34H2,1-6H3,(H,59,69)(H,60,70)(H,63,68)/t36-,46+,48+,50-,53+/m0/s1",UHWNJFZTYJNBAN-HYXXSBGTSA-N,261,19,189,COCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOC[R2],207.27,207.1470582,-1.3,14,0,5,1,11,62.94,C9H21NO4,"InChI=1S/C9H21NO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-10H2,1H3",DQTQYVYXIOQYGN-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.92,20,5.758157021,5.137850627,1745.1911,7280.3016
1651,126,94,126/200,94/78,O60885,BRD4,VHL,,MZP-61,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,3,Kd of BRD4 BD2 was tested by ITC,,,-11.7,-10,-1.71,ITC in BRD4 BD2,,,,,,,,,116,ITC,,,-9.46,-4.07,-5.39,ITC,,,,,,,,,781,Kd between VHL and the complex of protac and BRD4 BD2 was tested by ITC,,,-8.33,-7.02,-1.31,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,575/676,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,992.64,991.4069106,6.71,70,7,11,5,18,191.53,C53H62ClN7O8S,"InChI=1S/C53H62ClN7O8S/c1-32-25-44(58-41-18-16-40(54)17-19-41)43-26-39(15-20-45(43)61(32)34(3)62)36-11-13-38(14-12-36)50(65)55-21-22-68-23-24-69-30-47(64)59-49(53(4,5)6)52(67)60-29-42(63)27-46(60)51(66)56-28-35-7-9-37(10-8-35)48-33(2)57-31-70-48/h7-20,26,31-32,42,44,46,49,58,63H,21-25,27-30H2,1-6H3,(H,55,65)(H,56,66)(H,59,64)/t32-,42+,44+,46-,49+/m0/s1",AIFXAXRMMBWMAG-OVLUFEKXSA-N,261,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.94,126,5.277417207,5.416345758,5279.3784,3834.0188
1651,126,94,126/200,94/78,O60885,BRD4,VHL,,MZP-61,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,3,Kd of BRD4 BD2 was tested by ITC,,,-11.7,-10,-1.71,ITC in BRD4 BD2,,,,,,,,,116,ITC,,,-9.46,-4.07,-5.39,ITC,,,,,,,,,781,Kd between VHL and the complex of protac and BRD4 BD2 was tested by ITC,,,-8.33,-7.02,-1.31,ITC between VHL and BRD4 BD2:PROTAC,,,,,,,575/676,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,992.64,991.4069106,6.71,70,7,11,5,18,191.53,C53H62ClN7O8S,"InChI=1S/C53H62ClN7O8S/c1-32-25-44(58-41-18-16-40(54)17-19-41)43-26-39(15-20-45(43)61(32)34(3)62)36-11-13-38(14-12-36)50(65)55-21-22-68-23-24-69-30-47(64)59-49(53(4,5)6)52(67)60-29-42(63)27-46(60)51(66)56-28-35-7-9-37(10-8-35)48-33(2)57-31-70-48/h7-20,26,31-32,42,44,46,49,58,63H,21-25,27-30H2,1-6H3,(H,55,65)(H,56,66)(H,59,64)/t32-,42+,44+,46-,49+/m0/s1",AIFXAXRMMBWMAG-OVLUFEKXSA-N,261,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.94,126,5.5292049,5.416345758,2956.6172,3834.0188
1651,158,74,158,74,Q15059,BRD3,VHL,,MZP-61,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,116,ITC,,,-9.46,-4.07,-5.39,ITC,,,,,,,,,,,,,,,,,,,,,,,575/676,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,992.64,991.4069106,6.71,70,7,11,5,18,191.53,C53H62ClN7O8S,"InChI=1S/C53H62ClN7O8S/c1-32-25-44(58-41-18-16-40(54)17-19-41)43-26-39(15-20-45(43)61(32)34(3)62)36-11-13-38(14-12-36)50(65)55-21-22-68-23-24-69-30-47(64)59-49(53(4,5)6)52(67)60-29-42(63)27-46(60)51(66)56-28-35-7-9-37(10-8-35)48-33(2)57-31-70-48/h7-20,26,31-32,42,44,46,49,58,63H,21-25,27-30H2,1-6H3,(H,55,65)(H,56,66)(H,59,64)/t32-,42+,44+,46-,49+/m0/s1",AIFXAXRMMBWMAG-OVLUFEKXSA-N,261,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.74,158,5.277417207,5.416345758,5279.3784,3834.0188
1651,158,74,158,74,Q15059,BRD3,VHL,,MZP-61,CC(=O)N1C2=CC=C(C3=CC=C(C(=O)NCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCC4=CC=C(C5=C(C)N=CS5)C=C4)C(C)(C)C)C=C3)C=C2[C@H](NC2=CC=C(Cl)C=C2)C[C@@H]1C,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,116,ITC,,,-9.46,-4.07,-5.39,ITC,,,,,,,,,,,,,,,,,,,,,,,575/676,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,992.64,991.4069106,6.71,70,7,11,5,18,191.53,C53H62ClN7O8S,"InChI=1S/C53H62ClN7O8S/c1-32-25-44(58-41-18-16-40(54)17-19-41)43-26-39(15-20-45(43)61(32)34(3)62)36-11-13-38(14-12-36)50(65)55-21-22-68-23-24-69-30-47(64)59-49(53(4,5)6)52(67)60-29-42(63)27-46(60)51(66)56-28-35-7-9-37(10-8-35)48-33(2)57-31-70-48/h7-20,26,31-32,42,44,46,49,58,63H,21-25,27-30H2,1-6H3,(H,55,65)(H,56,66)(H,59,64)/t32-,42+,44+,46-,49+/m0/s1",AIFXAXRMMBWMAG-OVLUFEKXSA-N,261,19,804,COCCOCCN,[R1]NCCOCCOC[R2],119.164,119.0946287,-1.01,8,0,3,1,5,44.48,C5H13NO2,"InChI=1S/C5H13NO2/c1-7-4-5-8-3-2-6/h2-6H2,1H3",QWCGXANSAOXRFE-UHFFFAOYSA-N,P24941,CDK2,J2,CC1=C(C(=O)N2N=C(NC3=CC=C(S(N)(=O)=O)C=C3)N=C2N)SC=C1,0.4,IC50 was assessed by RET Kinase Enzymatic Assay,,,,,,,10.1021/jm050267e,378.439,378.0568803,2.57,25,3,9,3,4,145.99,C14H14N6O3S2,"InChI=1S/C14H14N6O3S2/c1-8-6-7-24-11(8)12(21)20-13(15)18-14(19-20)17-9-2-4-10(5-3-9)25(16,22)23/h2-7H,1H3,(H2,16,22,23)(H3,15,17,18,19)",KQWTXAWKBUUOMU-UHFFFAOYSA-N,6870,5330804,CHEMBL363130,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,47.09,0.0147165,1,1,1,1,1,0.0147165,0.74,158,5.5292049,5.416345758,2956.6172,3834.0188
1790,930,79,930,79,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(C#CCN)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,60/22,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,610,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2600,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1021.28,1020.435001,3.59,72,7,16,5,20,237.51,C52H64N10O8S2,"InChI=1S/C52H64N10O8S2/c1-31-33(3)72-51-44(31)45(37-14-10-35(11-15-37)9-8-18-53)57-40(48-60-59-34(4)62(48)51)26-42(64)54-19-20-68-21-22-69-23-24-70-29-43(65)58-47(52(5,6)7)50(67)61-28-39(63)25-41(61)49(66)55-27-36-12-16-38(17-13-36)46-32(2)56-30-71-46/h10-17,30,39-41,47,63H,18-29,53H2,1-7H3,(H,54,64)(H,55,66)(H,58,65)/t39-,40+,41+,47-/m1/s1",RJYPXJLNNMXFMD-XRFVFAKVSA-N,324,19,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,P11362,FGFR1,FIIN-2,C=CC(=O)NC1=CC=C(CN2C(=O)N(C3=CC(OC)=CC(OC)=C3)CC3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=C4)N=C32)C=C1,1,Inhibition of FGFR1,,,,,,,10.1016/j.ejmech.2016.11.052,634.741,634.3016017,4.05,47,6,9,2,10,115.4,C35H38N8O4,"InChI=1S/C35H38N8O4/c1-5-32(44)37-26-8-6-24(7-9-26)22-43-33-25(23-42(35(43)45)29-18-30(46-3)20-31(19-29)47-4)21-36-34(39-33)38-27-10-12-28(13-11-27)41-16-14-40(2)15-17-41/h5-13,18-21H,1,14-17,22-23H2,2-4H3,(H,37,44)(H,36,38,39)",DVBPRWJMHURKHP-UHFFFAOYSA-N,50232829,91825767,CHEMBL4065323,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.79,930,5.747318449,5.393736956,1789.2934,4038.8995
256,15,76,15,76,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR in VCaP cells after 20 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,0.35,Compounds were administered at 10000 nM and incubated for 2 h,0.24,Compounds were administered at 10000 nM and incubated for 2 h,10.1038/s42003-018-0105-8; 10.1021/acsmedchemlett.0c00194,1020.21,1019.389689,7.45,71,6,12,3,21,186.66,C51H60F3N7O8S2,"InChI=1S/C51H60F3N7O8S2/c1-32-43(71-31-57-32)34-13-11-33(12-14-34)28-56-45(64)41-26-38(62)29-59(41)46(65)44(49(2,3)4)58-42(63)30-68-23-10-22-67-21-8-7-9-24-69-39-19-17-36(18-20-39)61-48(70)60(47(66)50(61,5)6)37-16-15-35(27-55)40(25-37)51(52,53)54/h11-20,25,31,38,41,44,62H,7-10,21-24,26,28-30H2,1-6H3,(H,56,64)(H,58,63)/t38-,41+,44-/m1/s1",MTZBLTXMAXNSIO-UMWCMSNQSA-N,33,19,139,COCCCOCCCCCO,[R1]OCCCCCOCCCOC[R2],176.256,176.1412445,0.68,12,0,3,1,9,38.69,C9H20O3,"InChI=1S/C9H20O3/c1-11-7-5-9-12-8-4-2-3-6-10/h10H,2-9H2,1H3",XPPFZKCGEIHABQ-UHFFFAOYSA-N,Q06187,BTK,Spebrutinib,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(OCCOC)C=C3)=NC=C2F)=C1,0.72,IC50 of BTK was assessed by ADP-Glo luminescence assay,,,,,,,10.1016/j.ejmech.2016.11.047,423.448,423.1706678,3.64,31,3,7,3,10,97.4,C22H22FN5O3,"InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)",KXBDTLQSDKGAEB-UHFFFAOYSA-N,50161162,59174488,CHEMBL3301625,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.76,15,6.34996756,5.605449579,446.717,2480.5639
257,5,98,5,98,P10275,AR,VHL,,ARCC-4,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCOC3=CC=C(C4=CC=C(N5C(=S)N(C6=CC=C(C#N)C(C(F)(F)F)=C6)C(=O)C5(C)C)C=C4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR in VCaP cells after 20 h treatment,,,36,Inhibition of AR by AR radioligand binding assays,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,150,Inhibit proliferation of VCaP cells,,,,,,,,,,,,,,,10.1038/s42003-018-0105-8,1024.201,1023.363474,8.51,72,7,11,3,17,177.43,C53H56F3N7O7S2,"InChI=1S/C53H56F3N7O7S2/c1-32-45(72-31-59-32)36-11-9-33(10-12-36)28-58-47(66)43-26-40(64)29-61(43)48(67)46(51(2,3)4)60-44(65)30-69-23-7-8-24-70-41-21-16-35(17-22-41)34-13-18-38(19-14-34)63-50(71)62(49(68)52(63,5)6)39-20-15-37(27-57)42(25-39)53(54,55)56/h9-22,25,31,40,43,46,64H,7-8,23-24,26,28-30H2,1-6H3,(H,58,66)(H,60,65)/t40-,43+,46-/m1/s1",DUPAJELXESPTNF-PPZGWQTASA-N,33,19,140,COCCCCOC1=CC=CC=C1,[R1]C1=CC=C(C=C1)OCCCCOC[R2],180.247,180.1150298,2.46,13,1,2,0,6,18.46,C11H16O2,"InChI=1S/C11H16O2/c1-12-9-5-6-10-13-11-7-3-2-4-8-11/h2-4,7-8H,5-6,9-10H2,1H3",JZDHXBGNBZJRFK-UHFFFAOYSA-N,Q06187,BTK,Spebrutinib,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(OCCOC)C=C3)=NC=C2F)=C1,0.72,IC50 of BTK was assessed by ADP-Glo luminescence assay,,,,,,,10.1016/j.ejmech.2016.11.047,423.448,423.1706678,3.64,31,3,7,3,10,97.4,C22H22FN5O3,"InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)",KXBDTLQSDKGAEB-UHFFFAOYSA-N,50161162,59174488,CHEMBL3301625,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,5,6.6514606,5.847877526,223.1205,1419.4578
1430,501,70,<=501,51-70,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCN3CCC(C4=CC=C(N5C(=S)N(C6=CC=C(C#N)C(C(F)(F)F)=C6)C(=O)C5(C)C)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of AR in LNCaP cells after 2-4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00115,1045.264,1044.421323,6.98,73,7,12,3,18,180.67,C53H63F3N8O7S2,"InChI=1S/C53H63F3N8O7S2/c1-33-45(73-32-59-33)37-10-8-34(9-11-37)29-58-47(67)43-27-41(65)30-62(43)48(68)46(51(2,3)4)60-44(66)31-71-24-7-23-70-25-22-61-20-18-36(19-21-61)35-12-15-39(16-13-35)64-50(72)63(49(69)52(64,5)6)40-17-14-38(28-57)42(26-40)53(54,55)56/h8-17,26,32,36,41,43,46,65H,7,18-25,27,29-31H2,1-6H3,(H,58,67)(H,60,66)/t41-,43+,46-/m1/s1",FDBSHOXCSNLRGD-LASKKICZSA-N,33,19,684,COCCCOCCN1CCCCC1,[R1]C1CCN(CC1)CCOCCCOC[R2],201.31,201.172879,1.17,14,1,3,0,7,21.7,C11H23NO2,"InChI=1S/C11H23NO2/c1-13-9-5-10-14-11-8-12-6-3-2-4-7-12/h2-11H2,1H3",GJFTZLWOCFLINT-UHFFFAOYSA-N,Q06187,BTK,Spebrutinib,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(OCCOC)C=C3)=NC=C2F)=C1,0.72,IC50 of BTK was assessed by ADP-Glo luminescence assay,,,,,,,10.1016/j.ejmech.2016.11.047,423.448,423.1706678,3.64,31,3,7,3,10,97.4,C22H22FN5O3,"InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)",KXBDTLQSDKGAEB-UHFFFAOYSA-N,50161162,59174488,CHEMBL3301625,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,501,6.167285904,5.69241917,680.3213,2030.3964
1590,50,71,<=50/<=50,>=71/>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCOC3=CC=C(C4=CC=C(N5C(=S)N(C6=CC=C(C#N)C(C(F)(F)F)=C6)C(=O)C5(C)C)C=C4)C=C3)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,1082.281,1081.405339,8.72,76,7,12,3,21,186.66,C56H62F3N7O8S2,"InChI=1S/C56H62F3N7O8S2/c1-35-48(76-34-62-35)39-12-10-36(11-13-39)31-61-50(69)46-29-43(67)32-64(46)51(70)49(54(2,3)4)63-47(68)33-73-26-9-25-72-24-7-8-27-74-44-22-17-38(18-23-44)37-14-19-41(20-15-37)66-53(75)65(52(71)55(66,5)6)42-21-16-40(30-60)45(28-42)56(57,58)59/h10-23,28,34,43,46,49,67H,7-9,24-27,29,31-33H2,1-6H3,(H,61,69)(H,63,68)/t43-,46+,49-/m1/s1",IACCNUDTPQOEHL-YWIAGSDQSA-N,33,19,778,COCCCOCCCCOC1=CC=CC=C1,[R1]C1=CC=C(C=C1)OCCCCOCCCOC[R2],238.327,238.1568946,2.67,17,1,3,0,10,27.69,C14H22O3,"InChI=1S/C14H22O3/c1-15-10-7-12-16-11-5-6-13-17-14-8-3-2-4-9-14/h2-4,8-9H,5-7,10-13H2,1H3",LIGUZNOMUTYXPY-UHFFFAOYSA-N,Q06187,BTK,Spebrutinib,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(OCCOC)C=C3)=NC=C2F)=C1,0.72,IC50 of BTK was assessed by ADP-Glo luminescence assay,,,,,,,10.1016/j.ejmech.2016.11.047,423.448,423.1706678,3.64,31,3,7,3,10,97.4,C22H22FN5O3,"InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)",KXBDTLQSDKGAEB-UHFFFAOYSA-N,50161162,59174488,CHEMBL3301625,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.493454615,5.626316554,321.0298,2364.1958
1587,50,71,<=50/<=50,>=71/>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3F)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,1024.173,1023.364617,7.19,71,6,12,3,20,186.66,C50H57F4N7O8S2,"InChI=1S/C50H57F4N7O8S2/c1-30-42(71-29-57-30)32-12-10-31(11-13-32)26-56-44(64)39-24-36(62)27-59(39)45(65)43(48(2,3)4)58-41(63)28-68-20-9-19-67-18-7-8-21-69-40-17-16-35(23-38(40)51)61-47(70)60(46(66)49(61,5)6)34-15-14-33(25-55)37(22-34)50(52,53)54/h10-17,22-23,29,36,39,43,62H,7-9,18-21,24,26-28H2,1-6H3,(H,56,64)(H,58,63)/t36-,39+,43-/m1/s1",HVIFXYXSTAVNJM-IPQHXDNUSA-N,34,19,767,COCCCOCCCCO,[R1]OCCCCOCCCOC[R2],162.229,162.1255944,0.32,11,0,3,1,8,38.69,C8H18O3,"InChI=1S/C8H18O3/c1-10-6-4-8-11-7-3-2-5-9/h9H,2-8H2,1H3",GBDXTMUABRNWDV-UHFFFAOYSA-N,P41182,BCL6,,CC(C)CCC(=O)N1CCN2C3=NC=C(Cl)C(=N3)NC3=CC4=C(C(=C3)OCCOC[C@H]2C1)N(C)C(=O)CC4,63,IC50 of BCL6 was assessed by a time resolved fluorescence resonance energy transfer assay,,,,,,,10.1021/acschembio.8b00698,543.068,542.2408313,3.05,38,5,8,1,3,100.13,C27H35ClN6O4,"InChI=1S/C27H35ClN6O4/c1-17(2)4-6-24(36)33-8-9-34-20(15-33)16-37-10-11-38-22-13-19(30-26-21(28)14-29-27(34)31-26)12-18-5-7-23(35)32(3)25(18)22/h12-14,17,20H,4-11,15-16H2,1-3H3,(H,29,30,31)/t20-/m1/s1",GPOLUVUMJCGZBW-HXUWFJFHSA-N,,,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.781718553,5.913490884,165.3033,1220.4194
333,100,86,100,86,P11474,ERRalpha,VHL,,,COC1=CC(/C=C2\SC(=O)N(CCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)C2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,Degradation of ERRalpha in MCF-7 cells after 8 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/nchembio.1858,949.043,948.2798037,6.35,66,6,13,3,16,200.49,C46H47F3N6O9S2,"InChI=1S/C46H47F3N6O9S2/c1-26-39(65-25-52-26)30-10-6-27(7-11-30)23-51-41(58)33-21-31(56)24-55(33)43(60)40(45(2,3)4)53-38(57)14-16-63-17-15-54-42(59)37(66-44(54)61)20-28-8-13-35(36(19-28)62-5)64-34-12-9-29(22-50)18-32(34)46(47,48)49/h6-13,18-20,25,31,33,40,56H,14-17,21,23-24H2,1-5H3,(H,51,58)(H,53,57)/b37-20-/t31-,33+,40-/m1/s1",IIJORMBEWMYDEN-FRKKMCEPSA-N,84,19,13,CCOCC,[R1]CCOCC[R2],74.123,74.07316494,0.81,5,0,1,0,2,9.23,C4H10O,"InChI=1S/C4H10O/c1-3-5-4-2/h3-4H2,1-2H3",RTZKZFJDLAIYFH-UHFFFAOYSA-N,Q07817,BCL-xL,,O=C(NC1=NC2=CC=CC=C2S1)C1=CC=CC2=C1CN(C1=NC(C(=O)O)=C(CCCOC3=CC=C(C#CCN4CCNCC4)C=C3F)S1)CC2,,,,,,,0.001,Ki was determined by AlphaScreen competitive binding assay,10.1039/c9cc07217a,710.857,710.2145238,4.14,50,7,10,3,10,119.92,C37H35FN6O4S2,"InChI=1S/C37H35FN6O4S2/c38-28-22-24(6-4-17-43-19-15-39-16-20-43)12-13-30(28)48-21-5-11-32-33(35(46)47)41-37(50-32)44-18-14-25-7-3-8-26(27(25)23-44)34(45)42-36-40-29-9-1-2-10-31(29)49-36/h1-3,7-10,12-13,22,39H,5,11,14-21,23H2,(H,46,47)(H,40,42,45)",GYVGTEWZTVGKGM-UHFFFAOYSA-N,,132020374,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.86,100,6.907427157,5.520585106,123.7579,3015.8858
275,39.2,97.6,39.2/736.2,97.6/68.8,P00533,EGFR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOC3=CC=C(C4=CC=C5N=CN=C(NC6=CC=C(OCC7=CC=CC(F)=C7)C(Cl)=C6)C5=C4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of WT/Exon 20 Ins EGFR in OVCAR8/HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,102,Inhibit proliferation of SKBr3 cells,,,,,,,,,,,,,,,10.1016/j.chembiol.2017.09.009,1030.62,1029.366189,9.03,73,8,13,4,21,186.36,C55H57ClFN7O8S,"InChI=1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1",ZSCOIFSUFMYZEZ-YSWDPXALSA-N,67,19,1,CCOCCOC,[R1]CCOCCOC[R2],104.149,104.0837296,0.3,7,0,2,0,4,18.46,C5H12O2,"InChI=1S/C5H12O2/c1-3-7-5-4-6-2/h3-5H2,1-2H3",CAQYAZNFWDDMIT-UHFFFAOYSA-N,Q9UM73,ALK,TAE684,COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,0.1,IC50 of ALK was assessed by TR-FRET ALK activity assay,,,,,,,10.1021/acs.jmedchem.7b01655,614.216,613.2601868,5.67,42,5,10,2,9,102.93,C30H40ClN7O3S,"InChI=1S/C30H40ClN7O3S/c1-21(2)42(39,40)28-8-6-5-7-26(28)33-29-24(31)20-32-30(35-29)34-25-10-9-23(19-27(25)41-4)37-13-11-22(12-14-37)38-17-15-36(3)16-18-38/h5-10,19-22H,11-18H2,1-4H3,(H2,32,33,34,35)",QQWUGDVOUVUTOY-UHFFFAOYSA-N,50242742,16038120,CHEMBL509032,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.976,39.2,6.10096221,6.136059878,792.5703,731.0383
1373,136,88,136,88,Q06187,BTK,VHL,,,C=CC(=O)N1C[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C[C@H]1C(=O)OCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of BTK in K562 cells after 18 h treatment,,,39,IC50 was tested by the HTRF KinEase assays,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/c9cc08238g,1029.19,1028.421459,4.99,74,8,17,4,20,255.55,C53H60N10O10S,"InChI=1S/C53H60N10O10S/c1-6-43(66)61-27-36(63-49-44(48(54)56-30-57-49)45(60-63)34-16-18-39(19-17-34)73-38-10-8-7-9-11-38)24-41(61)52(69)72-23-22-70-20-21-71-29-42(65)59-47(53(3,4)5)51(68)62-28-37(64)25-40(62)50(67)55-26-33-12-14-35(15-13-33)46-32(2)58-31-74-46/h6-19,30-31,36-37,40-41,47,64H,1,20-29H2,2-5H3,(H,55,67)(H,59,65)(H2,54,56,57)/t36-,37+,40-,41-,47+/m0/s1",JQIURFOHEWHROK-WNKYWPOYSA-N,208,19,1,CCOCCOC,[R1]CCOCCOC[R2],104.149,104.0837296,0.3,7,0,2,0,4,18.46,C5H12O2,"InChI=1S/C5H12O2/c1-3-7-5-4-6-2/h3-5H2,1-2H3",CAQYAZNFWDDMIT-UHFFFAOYSA-N,P51451,BLK,XMD8-87,COC1=CC(N2CCN(C)CC2)=CC=C1NC1=NC=C2NC(=O)C3=CC=CC=C3N(C)C2=N1,,,,,,,,,10.1016/j.cell.2020.10.038,445.527,445.2226231,2.91,33,5,8,2,4,85.86,C24H27N7O2,"InChI=1S/C24H27N7O2/c1-29-10-12-31(13-11-29)16-8-9-18(21(14-16)33-3)27-24-25-15-19-22(28-24)30(2)20-7-5-4-6-17(20)23(32)26-19/h4-9,14-15H,10-13H2,1-3H3,(H,26,32)(H,25,27,28)",LGLHCXISMKHLIK-UHFFFAOYSA-N,50337126,53322923,CHEMBL1672987,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.88,136,6.108689917,5.437322763,778.5923,3653.2319
1373,136,88,136,88,Q06187,BTK,VHL,,,C=CC(=O)N1C[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C[C@H]1C(=O)OCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of BTK in K562 cells after 18 h treatment,,,39,IC50 was tested by the HTRF KinEase assays,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/c9cc08238g,1029.19,1028.421459,4.99,74,8,17,4,20,255.55,C53H60N10O10S,"InChI=1S/C53H60N10O10S/c1-6-43(66)61-27-36(63-49-44(48(54)56-30-57-49)45(60-63)34-16-18-39(19-17-34)73-38-10-8-7-9-11-38)24-41(61)52(69)72-23-22-70-20-21-71-29-42(65)59-47(53(3,4)5)51(68)62-28-37(64)25-40(62)50(67)55-26-33-12-14-35(15-13-33)46-32(2)58-31-74-46/h6-19,30-31,36-37,40-41,47,64H,1,20-29H2,2-5H3,(H,55,67)(H,59,65)(H2,54,56,57)/t36-,37+,40-,41-,47+/m0/s1",JQIURFOHEWHROK-WNKYWPOYSA-N,208,19,1,CCOCCOC,[R1]CCOCCOC[R2],104.149,104.0837296,0.3,7,0,2,0,4,18.46,C5H12O2,"InChI=1S/C5H12O2/c1-3-7-5-4-6-2/h3-5H2,1-2H3",CAQYAZNFWDDMIT-UHFFFAOYSA-N,P51451,BLK,XMD8-87,COC1=CC(N2CCN(C)CC2)=CC=C1NC1=NC=C2NC(=O)C3=CC=CC=C3N(C)C2=N1,,,,,,,,,10.1016/j.cell.2020.10.038,445.527,445.2226231,2.91,33,5,8,2,4,85.86,C24H27N7O2,"InChI=1S/C24H27N7O2/c1-29-10-12-31(13-11-29)16-8-9-18(21(14-16)33-3)27-24-25-15-19-22(28-24)30(2)20-7-5-4-6-17(20)23(32)26-19/h4-9,14-15H,10-13H2,1-3H3,(H,26,32)(H,25,27,28)",LGLHCXISMKHLIK-UHFFFAOYSA-N,50337126,53322923,CHEMBL1672987,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.88,136,6.243220539,5.437322763,571.1885,3653.2319
1373,220,75,220,75,P51451,BLK,VHL,,,C=CC(=O)N1C[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C[C@H]1C(=O)OCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of BLK in Ramos cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/c9cc08238g,1029.19,1028.421459,4.99,74,8,17,4,20,255.55,C53H60N10O10S,"InChI=1S/C53H60N10O10S/c1-6-43(66)61-27-36(63-49-44(48(54)56-30-57-49)45(60-63)34-16-18-39(19-17-34)73-38-10-8-7-9-11-38)24-41(61)52(69)72-23-22-70-20-21-71-29-42(65)59-47(53(3,4)5)51(68)62-28-37(64)25-40(62)50(67)55-26-33-12-14-35(15-13-33)46-32(2)58-31-74-46/h6-19,30-31,36-37,40-41,47,64H,1,20-29H2,2-5H3,(H,55,67)(H,59,65)(H2,54,56,57)/t36-,37+,40-,41-,47+/m0/s1",JQIURFOHEWHROK-WNKYWPOYSA-N,208,19,1,CCOCCOC,[R1]CCOCCOC[R2],104.149,104.0837296,0.3,7,0,2,0,4,18.46,C5H12O2,"InChI=1S/C5H12O2/c1-3-7-5-4-6-2/h3-5H2,1-2H3",CAQYAZNFWDDMIT-UHFFFAOYSA-N,P51451,BLK,XMD8-87,COC1=CC(N2CCN(C)CC2)=CC=C1NC1=NC=C2NC(=O)C3=CC=CC=C3N(C)C2=N1,,,,,,,,,10.1016/j.cell.2020.10.038,445.527,445.2226231,2.91,33,5,8,2,4,85.86,C24H27N7O2,"InChI=1S/C24H27N7O2/c1-29-10-12-31(13-11-29)16-8-9-18(21(14-16)33-3)27-24-25-15-19-22(28-24)30(2)20-7-5-4-6-17(20)23(32)26-19/h4-9,14-15H,10-13H2,1-3H3,(H,26,32)(H,25,27,28)",LGLHCXISMKHLIK-UHFFFAOYSA-N,50337126,53322923,CHEMBL1672987,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.75,220,6.108689917,5.437322763,778.5923,3653.2319
1373,220,75,220,75,P51451,BLK,VHL,,,C=CC(=O)N1C[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C[C@H]1C(=O)OCCOCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of BLK in Ramos cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/c9cc08238g,1029.19,1028.421459,4.99,74,8,17,4,20,255.55,C53H60N10O10S,"InChI=1S/C53H60N10O10S/c1-6-43(66)61-27-36(63-49-44(48(54)56-30-57-49)45(60-63)34-16-18-39(19-17-34)73-38-10-8-7-9-11-38)24-41(61)52(69)72-23-22-70-20-21-71-29-42(65)59-47(53(3,4)5)51(68)62-28-37(64)25-40(62)50(67)55-26-33-12-14-35(15-13-33)46-32(2)58-31-74-46/h6-19,30-31,36-37,40-41,47,64H,1,20-29H2,2-5H3,(H,55,67)(H,59,65)(H2,54,56,57)/t36-,37+,40-,41-,47+/m0/s1",JQIURFOHEWHROK-WNKYWPOYSA-N,208,19,1,CCOCCOC,[R1]CCOCCOC[R2],104.149,104.0837296,0.3,7,0,2,0,4,18.46,C5H12O2,"InChI=1S/C5H12O2/c1-3-7-5-4-6-2/h3-5H2,1-2H3",CAQYAZNFWDDMIT-UHFFFAOYSA-N,P51451,BLK,XMD8-87,COC1=CC(N2CCN(C)CC2)=CC=C1NC1=NC=C2NC(=O)C3=CC=CC=C3N(C)C2=N1,,,,,,,,,10.1016/j.cell.2020.10.038,445.527,445.2226231,2.91,33,5,8,2,4,85.86,C24H27N7O2,"InChI=1S/C24H27N7O2/c1-29-10-12-31(13-11-29)16-8-9-18(21(14-16)33-3)27-24-25-15-19-22(28-24)30(2)20-7-5-4-6-17(20)23(32)26-19/h4-9,14-15H,10-13H2,1-3H3,(H,26,32)(H,25,27,28)",LGLHCXISMKHLIK-UHFFFAOYSA-N,50337126,53322923,CHEMBL1672987,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.75,220,6.243220539,5.437322763,571.1885,3653.2319
276,11.7,98.9,11.7/22.3,98.9/96.6,P00533,EGFR,VHL,,,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCCCOCCOCCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,Degradation of Exon 19 del/L858R EGFR in HCC827/H3255 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2017.09.009,934.532,933.3661887,6.88,65,6,13,4,22,186.36,C47H57ClFN7O8S,"InChI=1S/C47H57ClFN7O8S/c1-29-42(65-28-53-29)31-11-9-30(10-12-31)25-50-45(59)38-22-33(57)26-56(38)46(60)43(47(2,3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14,21,23-24,27-28,33,38,43,57H,6-8,15-20,22,25-26H2,1-5H3,(H,50,59)(H,55,58)(H,51,52,54)/t33-,38+,43-/m1/s1",NICKHWYZMNLEPJ-TZSMONEZSA-N,69,19,149,CCCCCOCCOCC,[R1]CCCCCOCCOCC[R2],160.257,160.1463299,2.09,11,0,2,0,8,18.46,C9H20O2,"InChI=1S/C9H20O2/c1-3-5-6-7-11-9-8-10-4-2/h3-9H2,1-2H3",UOECJVYWINLCEV-UHFFFAOYSA-N,P00533,EGFR,B30,CN(C)C1CCN(C2=CC=C(NC3=CC4=C(N5CCC(CO)CC5)N=C(NC5=CC=C(F)C=C5)N=C4C=N3)N=C2)CC1,10.4/1.1/7.2/34,IC50 of EGFR WT/L858R(L858R/T790M/C797S)/(L858R/T790M) was assessed by Kinase-Glo Plus luminescence kinase assay kit,,,,,,,10.1016/j.ejmech.2018.02.051,571.705,571.3183351,4.82,42,6,10,3,8,105.57,C31H38FN9O,"InChI=1S/C31H38FN9O/c1-39(2)24-11-15-40(16-12-24)25-7-8-28(33-18-25)37-29-17-26-27(19-34-29)36-31(35-23-5-3-22(32)4-6-23)38-30(26)41-13-9-21(20-42)10-14-41/h3-8,17-19,21,24,42H,9-16,20H2,1-2H3,(H,33,34,37)(H,35,36,38)",DXOUQSZKEPSXBC-UHFFFAOYSA-N,50458062,134817166,CHEMBL4209019,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.989,11.7,6.613493487,5.733960373,243.5042,1845.1838
277,215.8,79.1,215.8,79.1,P00533,EGFR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCOCCCCOCCCCOC3=CC4=NC=NC(NC5=CC=C(F)C(Cl)=C5)=C4C=C3NC(=O)/C=C/CN(C)C)C(C)(C)C)C=C2)SC=N1,"Degradation of L858R, T790M EGFR in H1975 cells after 24 h treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2017.09.009,1086.773,1085.497537,7.81,76,6,14,5,29,209.47,C56H73ClFN9O8S,"InChI=1S/C56H73ClFN9O8S/c1-37-51(76-36-62-37)39-19-17-38(18-20-39)33-59-54(71)47-30-41(68)34-67(47)55(72)52(56(2,3)4)65-50(70)15-8-7-9-24-73-25-10-11-26-74-27-12-13-28-75-48-32-45-42(31-46(48)64-49(69)16-14-23-66(5)6)53(61-35-60-45)63-40-21-22-44(58)43(57)29-40/h14,16-22,29,31-32,35-36,41,47,52,68H,7-13,15,23-28,30,33-34H2,1-6H3,(H,59,71)(H,64,69)(H,65,70)(H,60,61,63)/b16-14+/t41-,47+,52-/m1/s1",BXHBYEPLXDQKAT-JYCNGAFSSA-N,70,19,150,CCCCCOCCCCOCCCC,[R1]CCCCOCCCCOCCCCC[R2],216.365,216.2089301,3.69,15,0,2,0,12,18.46,C13H28O2,"InChI=1S/C13H28O2/c1-3-5-7-11-15-13-9-8-12-14-10-6-4-2/h3-13H2,1-2H3",BEGITWDDPUIZSL-UHFFFAOYSA-N,P00533,EGFR,XTF-262,C=CC(=O)NC1=CC=CC(N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=C4OC)N=C32)=C1,240,IC50 was assessed by ELISA,,,48,Kd was assessed by DiscoveRx,,,10.1039/C5MD00208G,525.613,525.2488379,3.15,39,5,9,2,7,104.62,C29H31N7O3,"InChI=1S/C29H31N7O3/c1-5-26(37)31-20-7-6-8-22(16-20)36-27(38)15-19(2)23-18-30-29(33-28(23)36)32-24-10-9-21(17-25(24)39-4)35-13-11-34(3)12-14-35/h5-10,15-18H,1,11-14H2,2-4H3,(H,31,37)(H,30,32,33)",VJQPNQROUWVJQN-UHFFFAOYSA-N,50131841,72201501,CHEMBL3633143,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.791,215.8,6.158990433,5.774156593,693.4411,1682.0675
334,1.4,95,1.4,95,O43353,RIPK2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOC3=CC4=NC=CC(NC5=CC=C6SC=NC6=C5)=C4C=C3S(=O)(=O)C(C)(C)C)C(C)(C)C)C=C2)SC=N1,Degradation of RIPK2 in THP-1 cells after 16 h treatment,,,,,,,,,,,,,,,,,,,656,Inhibition of VHL by competition binding assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/nchembio.1858,1060.331,1059.390419,5.91,73,7,17,4,24,229.73,C52H65N7O11S3,"InChI=1S/C52H65N7O11S3/c1-33-47(72-31-55-33)35-10-8-34(9-11-35)28-54-49(62)42-25-37(60)29-59(42)50(63)48(51(2,3)4)58-46(61)30-69-21-20-67-17-16-66-18-19-68-22-23-70-43-27-40-38(26-45(43)73(64,65)52(5,6)7)39(14-15-53-40)57-36-12-13-44-41(24-36)56-32-71-44/h8-15,24,26-27,31-32,37,42,48,60H,16-23,25,28-30H2,1-7H3,(H,53,57)(H,54,62)(H,58,61)/t37-,42+,48-/m1/s1",RIEGJNXDHULIKM-GPPJZCFZSA-N,85,19,2,CCOCCOCCOCCOC,[R1]CCOCCOCCOCCOC[R2],192.255,192.1361591,0,13,0,4,0,10,36.92,C9H20O4,"InChI=1S/C9H20O4/c1-3-11-6-7-13-9-8-12-5-4-10-2/h3-9H2,1-2H3",JRRDISHSXWGFRF-UHFFFAOYSA-N,Q9UBN7,HDAC6,Nexturastat A,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=CC=C1,5.02,IC50 of HDAC6,,,,,,,10.1021/jm301098e,341.411,341.1739416,2.64,25,2,3,3,7,81.67,C19H23N3O3,"InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)",JZWXMCPARMXZQV-UHFFFAOYSA-N,50398716,71462653,CHEMBL2179618,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,1.4,6.01145175,5.312451051,973.976,4870.2241
1996,3.54,74.8,3.54,74.8,P00533,EGFR e19d,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR del19 in HCC827 cells after 48 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.76,Inhibit proliferation of HCC827 (EGFRdel19) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2020.112781,1009.339,1008.55202,9.08,73,9,14,5,20,185.77,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N,275,19,27,CCCCCCC,[R1]CCCCCCC[R2],100.205,100.1252005,4.01,7,0,0,0,4,0,C7H16,"InChI=1S/C7H16/c1-3-5-7-6-4-2/h3-7H2,1-2H3",IMNFDUFMRHMDMM-UHFFFAOYSA-N,Q9NYV4,CDK12,,CC(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(N[C@@H]2CCCNC2)=NC=C1Cl,,,,,,,,,10.1038/s41589-021-00765-y,409.943,409.1339237,3.74,27,3,7,3,6,96.01,C18H24ClN5O2S,"InChI=1S/C18H24ClN5O2S/c1-12(2)27(25,26)16-8-4-3-7-15(16)23-17-14(19)11-21-18(24-17)22-13-6-5-9-20-10-13/h3-4,7-8,11-13,20H,5-6,9-10H2,1-2H3,(H2,21,22,23,24)/t13-/m1/s1",FPZZWAVDOQUIAK-CYBMUJFWSA-N,,155235850,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.748,3.54,7.138780305,5.531054468,72.6473,2944.0524
1996,151.2,80.3,151.2,80.3,P00533,EGFR L858R/T790M,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR L858R/T790M in H1975 cells after 48 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,970,Inhibit proliferation of H1975 (EGFR L858R/T790M) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2020.112781,1009.339,1008.55202,9.08,73,9,14,5,20,185.77,C56H72N12O4S,"InChI=1S/C56H72N12O4S/c1-38-49(73-37-59-38)40-22-20-39(21-23-40)34-57-52(71)47-33-45(69)36-67(47)53(72)50(56(2,3)4)63-48(70)19-11-6-5-7-14-28-65-29-31-66(32-30-65)43-26-24-42(25-27-43)60-54-58-35-46-51(64-54)68(44-17-12-13-18-44)55(62-46)61-41-15-9-8-10-16-41/h8-10,15-16,20-27,35,37,44-45,47,50,69H,5-7,11-14,17-19,28-34,36H2,1-4H3,(H,57,71)(H,61,62)(H,63,70)(H,58,60,64)/t45-,47+,50-/m1/s1",OAEOAAWVWTZNON-KHDRDAPVSA-N,275,19,27,CCCCCCC,[R1]CCCCCCC[R2],100.205,100.1252005,4.01,7,0,0,0,4,0,C7H16,"InChI=1S/C7H16/c1-3-5-7-6-4-2/h3-7H2,1-2H3",IMNFDUFMRHMDMM-UHFFFAOYSA-N,Q9NYV4,CDK12,,CC(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(N[C@@H]2CCCNC2)=NC=C1Cl,,,,,,,,,10.1038/s41589-021-00765-y,409.943,409.1339237,3.74,27,3,7,3,6,96.01,C18H24ClN5O2S,"InChI=1S/C18H24ClN5O2S/c1-12(2)27(25,26)16-8-4-3-7-15(16)23-17-14(19)11-21-18(24-17)22-13-6-5-9-20-10-13/h3-4,7-8,11-13,20H,5-6,9-10H2,1-2H3,(H2,21,22,23,24)/t13-/m1/s1",FPZZWAVDOQUIAK-CYBMUJFWSA-N,,155235850,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.803,151.2,7.138780305,5.531054468,72.6473,2944.0524
1995,0.51,80.4,0.51,80.4,P00533,EGFR e19d,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR del19 in HCC827 cells after 48 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.83,Inhibit proliferation of HCC827 (EGFRdel19) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2020.112781,995.312,994.5363697,8.54,72,9,14,5,19,185.77,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N,275,19,26,CCCCCC,[R1]CCCCCC[R2],86.178,86.10955045,3.47,6,0,0,0,3,0,C6H14,"InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3",VLKZOEOYAKHREP-UHFFFAOYSA-N,Q9NYV4,CDK12,,CC(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(N[C@@H]2CCCNC2)=NC=C1Cl,,,,,,,,,10.1038/s41589-021-00765-y,409.943,409.1339237,3.74,27,3,7,3,6,96.01,C18H24ClN5O2S,"InChI=1S/C18H24ClN5O2S/c1-12(2)27(25,26)16-8-4-3-7-15(16)23-17-14(19)11-21-18(24-17)22-13-6-5-9-20-10-13/h3-4,7-8,11-13,20H,5-6,9-10H2,1-2H3,(H2,21,22,23,24)/t13-/m1/s1",FPZZWAVDOQUIAK-CYBMUJFWSA-N,,155235850,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.804,0.51,6.903700406,5.464463474,124.8244,3431.915
1995,126.2,90.3,126.2,90.3,P00533,EGFR L858R/T790M,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=NC=C6N=C(NC7=CC=CC=C7)N(C7CCCC7)C6=N5)C=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR L858R/T790M in H1975 cells after 48 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,203,Inhibit proliferation of H1975 (EGFR L858R/T790M) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2020.112781,995.312,994.5363697,8.54,72,9,14,5,19,185.77,C55H70N12O4S,"InChI=1S/C55H70N12O4S/c1-37-48(72-36-58-37)39-21-19-38(20-22-39)33-56-51(70)46-32-44(68)35-66(46)52(71)49(55(2,3)4)62-47(69)18-10-5-6-13-27-64-28-30-65(31-29-64)42-25-23-41(24-26-42)59-53-57-34-45-50(63-53)67(43-16-11-12-17-43)54(61-45)60-40-14-8-7-9-15-40/h7-9,14-15,19-26,34,36,43-44,46,49,68H,5-6,10-13,16-18,27-33,35H2,1-4H3,(H,56,70)(H,60,61)(H,62,69)(H,57,59,63)/t44-,46+,49-/m1/s1",MCPFQJKJCFMAIH-CRHSMECVSA-N,275,19,26,CCCCCC,[R1]CCCCCC[R2],86.178,86.10955045,3.47,6,0,0,0,3,0,C6H14,"InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3",VLKZOEOYAKHREP-UHFFFAOYSA-N,Q9NYV4,CDK12,,CC(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(N[C@@H]2CCCNC2)=NC=C1Cl,,,,,,,,,10.1038/s41589-021-00765-y,409.943,409.1339237,3.74,27,3,7,3,6,96.01,C18H24ClN5O2S,"InChI=1S/C18H24ClN5O2S/c1-12(2)27(25,26)16-8-4-3-7-15(16)23-17-14(19)11-21-18(24-17)22-13-6-5-9-20-10-13/h3-4,7-8,11-13,20H,5-6,9-10H2,1-2H3,(H2,21,22,23,24)/t13-/m1/s1",FPZZWAVDOQUIAK-CYBMUJFWSA-N,,155235850,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.903,126.2,6.903700406,5.464463474,124.8244,3431.915
567,34.8,98,34.8,98,P00533,EGFR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCN3CCN(C4=CC=C(NC5=CC6=C(N7CCC(CO)CC7)N=C(NC7=CC=C(F)C=C7)N=C6C=N5)N=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR in HCC827 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,220,Inhibit proliferation of HCC827 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2020.112061,1070.354,1069.548412,7.67,77,9,16,6,20,217.2,C57H72FN13O5S,"InChI=1S/C57H72FN13O5S/c1-37-51(77-36-62-37)40-12-10-38(11-13-40)31-61-54(75)47-29-44(73)34-71(47)55(76)52(57(2,3)4)66-50(74)9-7-5-6-8-22-68-25-27-69(28-26-68)43-18-19-48(59-32-43)65-49-30-45-46(33-60-49)64-56(63-42-16-14-41(58)15-17-42)67-53(45)70-23-20-39(35-72)21-24-70/h10-19,30,32-33,36,39,44,47,52,72-73H,5-9,20-29,31,34-35H2,1-4H3,(H,61,75)(H,66,74)(H,59,60,65)(H,63,64,67)/t44-,47+,52-/m1/s1",LCTCXOPSLJEXKE-FEDPBZRBSA-N,106,19,26,CCCCCC,[R1]CCCCCC[R2],86.178,86.10955045,3.47,6,0,0,0,3,0,C6H14,"InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3",VLKZOEOYAKHREP-UHFFFAOYSA-N,,BCR-ABL,GNF-5,O=C(NCCO)C1=CC=CC(C2=CC(NC3=CC=C(OC(F)(F)F)C=C3)=NC=N2)=C1,,,430,Inhibition of Bcr-Abl in mouse BA/F3 cells,,,,,10.1021/jm100555f,418.375,418.1252751,3.51,30,3,6,3,7,96.37,C20H17F3N4O3,"InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-6-4-15(5-7-16)27-18-11-17(25-12-26-18)13-2-1-3-14(10-13)19(29)24-8-9-28/h1-7,10-12,28H,8-9H2,(H,24,29)(H,25,26,27)",IIQUYGWWHIHOCF-UHFFFAOYSA-N,50328152,44129660,CHEMBL1257423,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,34.8,6.700730948,5.452925798,199.1907,3524.3108
2424,640,59,640,59,O15379,HDAC3,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,140,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.9,0.011017488,1,1,1,1,1,0.011017488,0.59,640,6.717337765,5.615407386,191.7177,2424.3349
2424,640,59,640,59,O15379,HDAC3,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,140,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.9,0.011017488,1,1,1,1,1,0.011017488,0.59,640,6.783614112,5.615407386,164.5833,2424.3349
2424,640,59,640,59,O15379,HDAC3,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,140,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.9,0.011017488,1,1,1,1,1,0.011017488,0.59,640,7.460291639,5.615407386,34.6504,2424.3349
2424,910,74,910,74,Q13547,HDAC1,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,220,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,18.57,0.037318255,1,1,1,1,1,0.037318255,0.74,910,6.717337765,5.615407386,191.7177,2424.3349
2424,910,74,910,74,Q13547,HDAC1,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,220,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,18.57,0.037318255,1,1,1,1,1,0.037318255,0.74,910,6.783614112,5.615407386,164.5833,2424.3349
2424,910,74,910,74,Q13547,HDAC1,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,220,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,18.57,0.037318255,1,1,1,1,1,0.037318255,0.74,910,7.460291639,5.615407386,34.6504,2424.3349
2424,4190,56,4190,56,Q92769,HDAC2,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC2 in HCT116 cells after 24 h treatment,,,360,IC50 of HDAC2-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.56,4190,6.717337765,5.615407386,191.7177,2424.3349
2424,4190,56,4190,56,Q92769,HDAC2,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC2 in HCT116 cells after 24 h treatment,,,360,IC50 of HDAC2-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.56,4190,6.783614112,5.615407386,164.5833,2424.3349
2424,4190,56,4190,56,Q92769,HDAC2,VHL,,JPS014,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC2 in HCT116 cells after 24 h treatment,,,360,IC50 of HDAC2-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,854.087,853.4196682,5.85,61,5,10,6,20,205.08,C46H59N7O7S,"InChI=1S/C46H59N7O7S/c1-30-41(61-29-49-30)32-18-16-31(17-19-32)26-48-44(58)38-25-35(54)27-53(38)45(59)42(46(2,3)4)52-39(55)15-9-7-5-6-8-12-24-60-28-40(56)50-34-22-20-33(21-23-34)43(57)51-37-14-11-10-13-36(37)47/h10-11,13-14,16-23,29,35,38,42,54H,5-9,12,15,24-28,47H2,1-4H3,(H,48,58)(H,50,56)(H,51,57)(H,52,55)/t35-,38+,42-/m1/s1",QANLZMZKZIPVPD-DRTKLYQKSA-N,129,19,1166,CCCCCCCCOC,[R1]COCCCCCCCC[R2],144.258,144.1514153,3.5,10,0,1,0,7,9.23,C9H20O,"InChI=1S/C9H20O/c1-3-4-5-6-7-8-9-10-2/h3-9H2,1-2H3",RIAWWRJHTAZJSU-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.56,4190,7.460291639,5.615407386,34.6504,2424.3349
2426,530,66,530,66,O15379,HDAC3,VHL,,JPS016,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,380,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,898.14,897.445883,6.16,64,5,11,6,23,214.31,C48H63N7O8S,"InChI=1S/C48H63N7O8S/c1-32-43(64-31-51-32)34-18-16-33(17-19-34)27-50-46(60)40-26-37(56)28-55(40)47(61)44(48(2,3)4)54-42(58)30-63-25-13-9-7-5-6-8-12-24-62-29-41(57)52-36-22-20-35(21-23-36)45(59)53-39-15-11-10-14-38(39)49/h10-11,14-23,31,37,40,44,56H,5-9,12-13,24-30,49H2,1-4H3,(H,50,60)(H,52,57)(H,53,59)(H,54,58)/t37-,40+,44-/m1/s1",BOXZMOCGSKLDAH-OUZJXKGJSA-N,129,19,1168,COCCCCCCCCCOC,[R1]COCCCCCCCCCOC[R2],188.311,188.17763,2.98,13,0,2,0,10,18.46,C11H24O2,"InChI=1S/C11H24O2/c1-12-10-8-6-4-3-5-7-9-11-13-2/h3-11H2,1-2H3",GXGHXTUSAJHVBB-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.9,0.011017488,1,1,1,1,1,0.011017488,0.66,530,6.48936793,5.425379405,324.065,3755.0921
2426,530,66,530,66,O15379,HDAC3,VHL,,JPS016,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,380,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,898.14,897.445883,6.16,64,5,11,6,23,214.31,C48H63N7O8S,"InChI=1S/C48H63N7O8S/c1-32-43(64-31-51-32)34-18-16-33(17-19-34)27-50-46(60)40-26-37(56)28-55(40)47(61)44(48(2,3)4)54-42(58)30-63-25-13-9-7-5-6-8-12-24-62-29-41(57)52-36-22-20-35(21-23-36)45(59)53-39-15-11-10-14-38(39)49/h10-11,14-23,31,37,40,44,56H,5-9,12-13,24-30,49H2,1-4H3,(H,50,60)(H,52,57)(H,53,59)(H,54,58)/t37-,40+,44-/m1/s1",BOXZMOCGSKLDAH-OUZJXKGJSA-N,129,19,1168,COCCCCCCCCCOC,[R1]COCCCCCCCCCOC[R2],188.311,188.17763,2.98,13,0,2,0,10,18.46,C11H24O2,"InChI=1S/C11H24O2/c1-12-10-8-6-4-3-5-7-9-11-13-2/h3-11H2,1-2H3",GXGHXTUSAJHVBB-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.9,0.011017488,1,1,1,1,1,0.011017488,0.66,530,6.714082844,5.425379405,193.16,3755.0921
2426,550,77,550,77,Q13547,HDAC1,VHL,,JPS016,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,570,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,898.14,897.445883,6.16,64,5,11,6,23,214.31,C48H63N7O8S,"InChI=1S/C48H63N7O8S/c1-32-43(64-31-51-32)34-18-16-33(17-19-34)27-50-46(60)40-26-37(56)28-55(40)47(61)44(48(2,3)4)54-42(58)30-63-25-13-9-7-5-6-8-12-24-62-29-41(57)52-36-22-20-35(21-23-36)45(59)53-39-15-11-10-14-38(39)49/h10-11,14-23,31,37,40,44,56H,5-9,12-13,24-30,49H2,1-4H3,(H,50,60)(H,52,57)(H,53,59)(H,54,58)/t37-,40+,44-/m1/s1",BOXZMOCGSKLDAH-OUZJXKGJSA-N,129,19,1168,COCCCCCCCCCOC,[R1]COCCCCCCCCCOC[R2],188.311,188.17763,2.98,13,0,2,0,10,18.46,C11H24O2,"InChI=1S/C11H24O2/c1-12-10-8-6-4-3-5-7-9-11-13-2/h3-11H2,1-2H3",GXGHXTUSAJHVBB-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,18.57,0.037318255,1,1,1,1,1,0.037318255,0.77,550,6.48936793,5.425379405,324.065,3755.0921
2426,550,77,550,77,Q13547,HDAC1,VHL,,JPS016,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCCCCCOCC(=O)NC3=CC=C(C(=O)NC4=CC=CC=C4N)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,570,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,898.14,897.445883,6.16,64,5,11,6,23,214.31,C48H63N7O8S,"InChI=1S/C48H63N7O8S/c1-32-43(64-31-51-32)34-18-16-33(17-19-34)27-50-46(60)40-26-37(56)28-55(40)47(61)44(48(2,3)4)54-42(58)30-63-25-13-9-7-5-6-8-12-24-62-29-41(57)52-36-22-20-35(21-23-36)45(59)53-39-15-11-10-14-38(39)49/h10-11,14-23,31,37,40,44,56H,5-9,12-13,24-30,49H2,1-4H3,(H,50,60)(H,52,57)(H,53,59)(H,54,58)/t37-,40+,44-/m1/s1",BOXZMOCGSKLDAH-OUZJXKGJSA-N,129,19,1168,COCCCCCCCCCOC,[R1]COCCCCCCCCCOC[R2],188.311,188.17763,2.98,13,0,2,0,10,18.46,C11H24O2,"InChI=1S/C11H24O2/c1-12-10-8-6-4-3-5-7-9-11-13-2/h3-11H2,1-2H3",GXGHXTUSAJHVBB-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,18.57,0.037318255,1,1,1,1,1,0.037318255,0.77,550,6.714082844,5.425379405,193.16,3755.0921
1181,4.3,57,7.1/4.3,90/57,Q9UBN7,HDAC6,VHL,,,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=C(OCCCCCCCCCCCN2C=C(CCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)N=N2)C=C1,Degradation of HDAC6 in MM1S/Mouse 4935 cells after 4/6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00046,1091.434,1090.603781,9.17,78,6,13,6,31,233.24,C59H82N10O8S,"InChI=1S/C59H82N10O8S/c1-6-7-33-67(38-44-23-27-46(28-24-44)55(72)65-76)58(75)62-47-29-31-50(32-30-47)77-35-18-14-12-10-8-9-11-13-17-34-68-39-48(64-66-68)19-15-16-20-52(71)63-54(59(3,4)5)57(74)69-40-49(70)36-51(69)56(73)60-37-43-21-25-45(26-22-43)53-42(2)61-41-78-53/h21-32,39,41,49,51,54,70,76H,6-20,33-38,40H2,1-5H3,(H,60,73)(H,62,75)(H,63,71)(H,65,72)/t49-,51+,54-/m1/s1",QLLXPSZTCLBVQY-UFUXGVROSA-N,127,19,587,CCCCC1=CN(CCCCCCCCCCCO)N=N1,[R1]OCCCCCCCCCCCN1C=C(N=N1)CCCC[R2],295.471,295.2623627,4.81,21,1,4,1,14,50.94,C17H33N3O,"InChI=1S/C17H33N3O/c1-2-3-13-17-16-20(19-18-17)14-11-9-7-5-4-6-8-10-12-15-21/h16,21H,2-15H2,1H3",LSFLKGDYYTXSAV-UHFFFAOYSA-N,P42858,Htt,,COC1=CC=C2N=C(/N=N/C3=CC=C(N(C)C)C=C3)SC2=C1,,,,,,,,,10.1002/anie.201706529,312.398,312.1044821,4.58,22,3,6,0,4,50.08,C16H16N4OS,"InChI=1S/C16H16N4OS/c1-20(2)12-6-4-11(5-7-12)18-19-16-17-14-9-8-13(21-3)10-15(14)22-16/h4-10H,1-3H3/b19-18+",AVPFTROGVGTTEC-VHEBQXMUSA-N,50363719,77390,CHEMBL1378812,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.33,0.011118242,1,1,1,1,1,0.011118242,0.57,4.3,6.852926474,5.771757312,140.3051,1691.3858
1182,11,89,11,89,Q9UBN7,HDAC6,VHL,,,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=C(OCCCCCCCCCCCCN2C=C(CCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)N=N2)C=C1,Degradation of HDAC6 in MM1S cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00046,1105.461,1104.619431,9.72,79,6,13,6,32,233.24,C60H84N10O8S,"InChI=1S/C60H84N10O8S/c1-6-7-34-68(39-45-24-28-47(29-25-45)56(73)66-77)59(76)63-48-30-32-51(33-31-48)78-36-19-15-13-11-9-8-10-12-14-18-35-69-40-49(65-67-69)20-16-17-21-53(72)64-55(60(3,4)5)58(75)70-41-50(71)37-52(70)57(74)61-38-44-22-26-46(27-23-44)54-43(2)62-42-79-54/h22-33,40,42,50,52,55,71,77H,6-21,34-39,41H2,1-5H3,(H,61,74)(H,63,76)(H,64,72)(H,66,73)/t50-,52+,55-/m1/s1",TXQZPPRNSVBETP-MXXGPWJYSA-N,127,19,588,CCCCC1=CN(CCCCCCCCCCCCO)N=N1,[R1]OCCCCCCCCCCCCN1C=C(N=N1)CCCC[R2],309.498,309.2780127,5.35,22,1,4,1,15,50.94,C18H35N3O,"InChI=1S/C18H35N3O/c1-2-3-14-18-17-21(20-19-18)15-12-10-8-6-4-5-7-9-11-13-16-22/h17,22H,2-16H2,1H3",QOFRJYTZYRGQMG-UHFFFAOYSA-N,P42858,Htt,,COC1=CC=C2N=C(/N=N/C3=CC=C(N(C)C)C=C3)SC2=C1,,,,,,,,,10.1002/anie.201706529,312.398,312.1044821,4.58,22,3,6,0,4,50.08,C16H16N4OS,"InChI=1S/C16H16N4OS/c1-20(2)12-6-4-11(5-7-12)18-19-16-17-14-9-8-13(21-3)10-15(14)22-16/h4-10H,1-3H3/b19-18+",AVPFTROGVGTTEC-VHEBQXMUSA-N,50363719,77390,CHEMBL1378812,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,62.33,0.011118242,1,1,1,1,1,0.011118242,0.89,11,6.96917796,5.859277043,107.3549,1382.6841
937,300,75,300/670,75/96,Q15910,EZH2,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in HeLa/DB cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.75,300,6.396078947,5.92084381,401.7178,1199.9308
937,300,75,300/670,75/96,Q15910,EZH2,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in HeLa/DB cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.75,300,6.395580787,5.92084381,402.1788,1199.9308
937,300,75,300/670,75/96,Q15910,EZH2,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in HeLa/DB cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.75,300,6.735067223,5.92084381,184.0487,1199.9308
937,590,82,(n/a)/590,22/82,Q15022,SUZ12,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SUZ12 in HeLa/DB cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,22.27,0.031118096,1,1,1,1,1,0.031118096,0.82,590,6.396078947,5.92084381,401.7178,1199.9308
937,590,82,(n/a)/590,22/82,Q15022,SUZ12,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SUZ12 in HeLa/DB cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,22.27,0.031118096,1,1,1,1,1,0.031118096,0.82,590,6.395580787,5.92084381,402.1788,1199.9308
937,590,82,(n/a)/590,22/82,Q15022,SUZ12,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SUZ12 in HeLa/DB cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,22.27,0.031118096,1,1,1,1,1,0.031118096,0.82,590,6.735067223,5.92084381,184.0487,1199.9308
937,610,94,610,94,O75530,EED,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in DB cells after 24h treatment,90,% EED protein degradation in DB cells at 3000 nM for 24h treatment,49.3,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,610,6.396078947,5.92084381,401.7178,1199.9308
937,610,94,610,94,O75530,EED,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in DB cells after 24h treatment,90,% EED protein degradation in DB cells at 3000 nM for 24h treatment,49.3,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,610,6.395580787,5.92084381,402.1788,1199.9308
937,610,94,610,94,O75530,EED,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in DB cells after 24h treatment,90,% EED protein degradation in DB cells at 3000 nM for 24h treatment,49.3,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,610,6.735067223,5.92084381,184.0487,1199.9308
937,610,94,790/610,92/94,O75530,EED,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in HeLa/DB cells after 24 h treatment,,,247,IC50 of EED was tested by the TR-FRET assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,610,6.396078947,5.92084381,401.7178,1199.9308
937,610,94,790/610,92/94,O75530,EED,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in HeLa/DB cells after 24 h treatment,,,247,IC50 of EED was tested by the TR-FRET assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,610,6.395580787,5.92084381,402.1788,1199.9308
937,610,94,790/610,92/94,O75530,EED,VHL,,UNC6852,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in HeLa/DB cells after 24 h treatment,,,247,IC50 of EED was tested by the TR-FRET assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3400/410,Inhibit proliferation of DB/Pfeiffer cells,,,,,,,,,,,,,10.1016/j.chembiol.2019.11.006,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,610,6.735067223,5.92084381,184.0487,1199.9308
937,670,96,670,96,Q15910,EZH2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in DB cells after 24h treatment,53,% EZH2 protein degradation in DB cells at 3000 nM for 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.96,670,6.396078947,5.92084381,401.7178,1199.9308
937,670,96,670,96,Q15910,EZH2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in DB cells after 24h treatment,53,% EZH2 protein degradation in DB cells at 3000 nM for 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.96,670,6.395580787,5.92084381,402.1788,1199.9308
937,670,96,670,96,Q15910,EZH2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCNC(=O)C3=CC=C(C4=CN=C(NCC5=CC=CO5)N5C=NN=C45)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in DB cells after 24h treatment,53,% EZH2 protein degradation in DB cells at 3000 nM for 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,832.988,832.3479003,4.72,60,7,13,5,15,208.98,C43H48N10O6S,"InChI=1S/C43H48N10O6S/c1-26-36(60-25-48-26)29-11-9-27(10-12-29)20-45-40(57)34-19-31(54)23-52(34)41(58)37(43(2,3)4)50-35(55)8-5-17-44-39(56)30-15-13-28(14-16-30)33-22-47-42(53-24-49-51-38(33)53)46-21-32-7-6-18-59-32/h6-7,9-16,18,22,24-25,31,34,37,54H,5,8,17,19-21,23H2,1-4H3,(H,44,56)(H,45,57)(H,46,47)(H,50,55)/t31-,34+,37-/m1/s1",PPNNFXIBKLCMTI-WXEAQWFJSA-N,148,19,446,CCCNC=O,[R1]C(=O)NCCC[R2],87.122,87.06841391,1.04,6,0,1,1,3,29.1,C4H9NO,"InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)",SUUDTPGCUKBECW-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.96,670,6.735067223,5.92084381,184.0487,1199.9308
4266,111,84,111,84,O75530,EED,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)[C@H]3C[C@@H](NC(=O)C4=CC=C(C5=CN=C(NCC6=CC=CO6)N6C=NN=C56)C=C4)C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in DB cells after 24h treatment,,,47,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,844.999,844.3479003,4.95,61,8,13,5,13,208.98,C44H48N10O6S,"InChI=1S/C44H48N10O6S/c1-25-36(61-24-48-25)28-9-7-26(8-10-28)19-45-41(58)35-18-32(55)22-53(35)42(59)37(44(2,3)4)51-40(57)30-16-31(17-30)50-39(56)29-13-11-27(12-14-29)34-21-47-43(54-23-49-52-38(34)54)46-20-33-6-5-15-60-33/h5-15,21,23-24,30-32,35,37,55H,16-20,22H2,1-4H3,(H,45,58)(H,46,47)(H,50,56)(H,51,57)/t30-,31+,32-,35+,37-/m1/s1",ARONHQOAKYUHEE-AOBTXCIISA-N,148,19,1998,O=CNC1CCC1,[R1]CC(=O)N[C@H]1C[C@H](C1)C[R2],99.133,99.06841391,1.05,7,1,1,1,2,29.1,C5H9NO,"InChI=1S/C5H9NO/c7-4-6-5-2-1-3-5/h4-5H,1-3H2,(H,6,7)",MFXUSQSDQJBLBN-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.84,111,6.267651474,5.721305791,539.9438,1899.7402
4266,111,84,111,84,O75530,EED,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)[C@H]3C[C@@H](NC(=O)C4=CC=C(C5=CN=C(NCC6=CC=CO6)N6C=NN=C56)C=C4)C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in DB cells after 24h treatment,,,47,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,844.999,844.3479003,4.95,61,8,13,5,13,208.98,C44H48N10O6S,"InChI=1S/C44H48N10O6S/c1-25-36(61-24-48-25)28-9-7-26(8-10-28)19-45-41(58)35-18-32(55)22-53(35)42(59)37(44(2,3)4)51-40(57)30-16-31(17-30)50-39(56)29-13-11-27(12-14-29)34-21-47-43(54-23-49-52-38(34)54)46-20-33-6-5-15-60-33/h5-15,21,23-24,30-32,35,37,55H,16-20,22H2,1-4H3,(H,45,58)(H,46,47)(H,50,56)(H,51,57)/t30-,31+,32-,35+,37-/m1/s1",ARONHQOAKYUHEE-AOBTXCIISA-N,148,19,1998,O=CNC1CCC1,[R1]CC(=O)N[C@H]1C[C@H](C1)C[R2],99.133,99.06841391,1.05,7,1,1,1,2,29.1,C5H9NO,"InChI=1S/C5H9NO/c7-4-6-5-2-1-3-5/h4-5H,1-3H2,(H,6,7)",MFXUSQSDQJBLBN-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.84,111,6.267697732,5.721305791,539.8863,1899.7402
4266,275,86,275,86,Q15910,EZH2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)[C@H]3C[C@@H](NC(=O)C4=CC=C(C5=CN=C(NCC6=CC=CO6)N6C=NN=C56)C=C4)C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in DB cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,844.999,844.3479003,4.95,61,8,13,5,13,208.98,C44H48N10O6S,"InChI=1S/C44H48N10O6S/c1-25-36(61-24-48-25)28-9-7-26(8-10-28)19-45-41(58)35-18-32(55)22-53(35)42(59)37(44(2,3)4)51-40(57)30-16-31(17-30)50-39(56)29-13-11-27(12-14-29)34-21-47-43(54-23-49-52-38(34)54)46-20-33-6-5-15-60-33/h5-15,21,23-24,30-32,35,37,55H,16-20,22H2,1-4H3,(H,45,58)(H,46,47)(H,50,56)(H,51,57)/t30-,31+,32-,35+,37-/m1/s1",ARONHQOAKYUHEE-AOBTXCIISA-N,148,19,1998,O=CNC1CCC1,[R1]CC(=O)N[C@H]1C[C@H](C1)C[R2],99.133,99.06841391,1.05,7,1,1,1,2,29.1,C5H9NO,"InChI=1S/C5H9NO/c7-4-6-5-2-1-3-5/h4-5H,1-3H2,(H,6,7)",MFXUSQSDQJBLBN-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.86,275,6.267651474,5.721305791,539.9438,1899.7402
4266,275,86,275,86,Q15910,EZH2,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)[C@H]3C[C@@H](NC(=O)C4=CC=C(C5=CN=C(NCC6=CC=CO6)N6C=NN=C56)C=C4)C3)C(C)(C)C)C=C2)SC=N1,Degradation of EZH2 in DB cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,844.999,844.3479003,4.95,61,8,13,5,13,208.98,C44H48N10O6S,"InChI=1S/C44H48N10O6S/c1-25-36(61-24-48-25)28-9-7-26(8-10-28)19-45-41(58)35-18-32(55)22-53(35)42(59)37(44(2,3)4)51-40(57)30-16-31(17-30)50-39(56)29-13-11-27(12-14-29)34-21-47-43(54-23-49-52-38(34)54)46-20-33-6-5-15-60-33/h5-15,21,23-24,30-32,35,37,55H,16-20,22H2,1-4H3,(H,45,58)(H,46,47)(H,50,56)(H,51,57)/t30-,31+,32-,35+,37-/m1/s1",ARONHQOAKYUHEE-AOBTXCIISA-N,148,19,1998,O=CNC1CCC1,[R1]CC(=O)N[C@H]1C[C@H](C1)C[R2],99.133,99.06841391,1.05,7,1,1,1,2,29.1,C5H9NO,"InChI=1S/C5H9NO/c7-4-6-5-2-1-3-5/h4-5H,1-3H2,(H,6,7)",MFXUSQSDQJBLBN-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,79.49,0.008718078,1,1,1,1,1,0.008718078,0.86,275,6.267697732,5.721305791,539.8863,1899.7402
4267,67,64,67,64,O75530,EED,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)[C@H]3C[C@H](NC(=O)C4=CC=C(C5=CN=C(NCC6=CC=CO6)N6C=NN=C56)C=C4)C3)C(C)(C)C)C=C2)SC=N1,Degradation of EED in DB cells after 24h treatment,,,33,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.2c00804,844.999,844.3479003,4.95,61,8,13,5,13,208.98,C44H48N10O6S,"InChI=1S/C44H48N10O6S/c1-25-36(61-24-48-25)28-9-7-26(8-10-28)19-45-41(58)35-18-32(55)22-53(35)42(59)37(44(2,3)4)51-40(57)30-16-31(17-30)50-39(56)29-13-11-27(12-14-29)34-21-47-43(54-23-49-52-38(34)54)46-20-33-6-5-15-60-33/h5-15,21,23-24,30-32,35,37,55H,16-20,22H2,1-4H3,(H,45,58)(H,46,47)(H,50,56)(H,51,57)/t30-,31-,32-,35+,37-/m1/s1",ARONHQOAKYUHEE-RQQRUTLXSA-N,148,19,1999,O=CNC1CCC1,[R1]C(=O)N[C@H]1C[C@@H](C1)[R2],99.133,99.06841391,1.05,7,1,1,1,2,29.1,C5H9NO,"InChI=1S/C5H9NO/c7-4-6-5-2-1-3-5/h4-5H,1-3H2,(H,6,7)",MFXUSQSDQJBLBN-UHFFFAOYSA-N,,Tubulin,combretastatin A-4,COC1=CC=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,1200,Inhibition of tubulin polymerization,,,,,,,10.1021/jm0205797,316.353,316.1310737,3.72,23,2,5,1,6,57.15,C18H20O5,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-",HVXBOLULGPECHP-WAYWQWQTSA-N,50005480,5351344,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.64,67,6.191176439,5.916112692,643.9076,1213.074
1015,367.7,82,367.7,82,Q96SW2,CRBN,VHL,,TD-760,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)COC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C(C)(C)C)C=C2)SC=N1,Degradation of CRBN in HEK293T cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41598-019-56177-5,928.122,927.4200622,5.24,66,6,12,5,21,233.51,C48H61N7O10S,"InChI=1S/C48H61N7O10S/c1-29-41(66-28-51-29)31-19-17-30(18-20-31)25-50-43(60)35-24-32(56)26-54(35)47(64)42(48(2,3)4)52-37(57)16-11-9-7-5-6-8-10-12-23-49-39(59)27-65-36-15-13-14-33-40(36)46(63)55(45(33)62)34-21-22-38(58)53-44(34)61/h13-15,17-20,28,32,34-35,42,56H,5-12,16,21-27H2,1-4H3,(H,49,59)(H,50,60)(H,52,57)(H,53,58,61)/t32-,34?,35+,42-/m1/s1",NANCWGWHLCCPLL-MSVILSSVSA-N,75,19,499,CCCCCCCCCCNC(=O)CO,[R1]OCC(=O)NCCCCCCCCCC[R2],215.337,215.188529,3.39,15,0,2,2,10,49.33,C12H25NO2,"InChI=1S/C12H25NO2/c1-2-3-4-5-6-7-8-9-10-13-12(15)11-14/h14H,2-11H2,1H3,(H,13,15)",AOLDPOOTBNCOFB-UHFFFAOYSA-N,Q16678,CYP1B1,,COC1=CC=C(OC)C2=C1C(OC)=CC1=C2OC(C2=CC=CC=C2)=CC1=O,1.4,IC50 of CYP1B1 was determined by the standard EROD assay,,,,,,,10.1016/j.ejmech.2019.112028,362.381,362.1154237,4.34,27,4,5,0,4,57.9,C22H18O5,"InChI=1S/C22H18O5/c1-24-16-9-10-17(25-2)21-20(16)19(26-3)11-14-15(23)12-18(27-22(14)21)13-7-5-4-6-8-13/h4-12H,1-3H3",RWKCNXGHHHVDGY-UHFFFAOYSA-N,50081709,118735488,CHEMBL3422257,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.82,367.7,5.636065554,5.751273596,2311.7158,1773.0721
1429,50,71,<=50/<=50,>=71/51-70,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCCOC3=CC=C(N4C(=O)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR in LNCaP/VCaP cells after 2-4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00115,1004.142,1003.412532,6.85,71,6,12,3,21,203.73,C51H60F3N7O9S,"InChI=1S/C51H60F3N7O9S/c1-32-43(71-31-57-32)34-13-11-33(12-14-34)28-56-45(64)41-26-38(62)29-59(41)46(65)44(49(2,3)4)58-42(63)30-69-23-10-22-68-21-8-7-9-24-70-39-19-17-36(18-20-39)61-48(67)60(47(66)50(61,5)6)37-16-15-35(27-55)40(25-37)51(52,53)54/h11-20,25,31,38,41,44,62H,7-10,21-24,26,28-30H2,1-6H3,(H,56,64)(H,58,63)/t38-,41+,44-/m1/s1",JAJUSXSEHHKCEK-UMWCMSNQSA-N,253,19,683,CCCCCOCCCOC,[R1]CCCCCOCCCOC[R2],160.257,160.1463299,2.08,11,0,2,0,8,18.46,C9H20O2,"InChI=1S/C9H20O2/c1-3-4-5-8-11-9-6-7-10-2/h3-9H2,1-2H3",SRNPGWZFBBKXEF-UHFFFAOYSA-N,Q13153,PAK1,NVS-PAK1-1,CC(C)NC(=O)N1CC[C@H](NC2=NC3=CC(F)=CC=C3N(CC(F)F)C3=CC=C(Cl)C=C23)C1,5.2,Inhibition of wild type dephosphorylated form of PAK1,,,7,Kd was assessed by qPCR analysis,,,10.1021/acsmedchemlett.5b00102,479.934,479.1699728,4.5,33,4,4,2,4,59.97,C23H25ClF3N5O,"InChI=1S/C23H25ClF3N5O/c1-13(2)28-23(33)31-8-7-16(11-31)29-22-17-9-14(24)3-5-19(17)32(12-21(26)27)20-6-4-15(25)10-18(20)30-22/h3-6,9-10,13,16,21H,7-8,11-12H2,1-2H3,(H,28,33)(H,29,30)/t16-/m0/s1",OINGHOPGNMYCAB-INIZCTEOSA-N,50112348,137125241,CHEMBL3609372,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.314080079,5.602302658,485.199,2498.6035
1584,50,71,<=50/<=50,>=71/51-70,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCCOC3=CC=C(N4C(=S)N(C5=CN=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,1021.198,1020.384938,6.71,71,6,13,3,21,199.55,C50H59F3N8O8S2,"InChI=1S/C50H59F3N8O8S2/c1-31-42(71-30-57-31)33-13-11-32(12-14-33)26-56-44(64)40-24-36(62)28-59(40)45(65)43(48(2,3)4)58-41(63)29-68-21-10-20-67-19-8-7-9-22-69-37-17-15-34(16-18-37)61-47(70)60(46(66)49(61,5)6)35-23-38(50(51,52)53)39(25-54)55-27-35/h11-18,23,27,30,36,40,43,62H,7-10,19-22,24,26,28-29H2,1-6H3,(H,56,64)(H,58,63)/t36-,40+,43-/m1/s1",SGTVGCRQPJCKNZ-QIWIAYTASA-N,251,19,683,CCCCCOCCCOC,[R1]CCCCCOCCCOC[R2],160.257,160.1463299,2.08,11,0,2,0,8,18.46,C9H20O2,"InChI=1S/C9H20O2/c1-3-4-5-8-11-9-6-7-10-2/h3-9H2,1-2H3",SRNPGWZFBBKXEF-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,CCOC1=CC2=C(C=C1NC(=O)C1=CC=CC(C(F)(F)F)=N1)N(C)C(CCC(C)(C)C(=O)OC)=N2,70,IC50 was assessed by Z'-Lyte kinase assay,,,,,,,10.1021/acsmedchemlett.0c00474,492.498,492.19844,4.2,35,3,7,1,8,95.34,C24H27F3N4O4,"InChI=1S/C24H27F3N4O4/c1-6-35-18-13-15-17(31(4)20(29-15)10-11-23(2,3)22(33)34-5)12-16(18)30-21(32)14-8-7-9-19(28-14)24(25,26)27/h7-9,12-13H,6,10-11H2,1-5H3,(H,30,32)",HZWJTPQMGLFQCE-UHFFFAOYSA-N,,,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.875685587,5.851924406,133.1418,1406.2923
1588,50,71,<=50/<=50,>=71/>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCOC3=CC=C(N4C(=S)N(C5=CN=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,1007.171,1006.369287,6.35,70,6,13,3,20,199.55,C49H57F3N8O8S2,"InChI=1S/C49H57F3N8O8S2/c1-30-41(70-29-56-30)32-12-10-31(11-13-32)25-55-43(63)39-23-35(61)27-58(39)44(64)42(47(2,3)4)57-40(62)28-67-20-9-19-66-18-7-8-21-68-36-16-14-33(15-17-36)60-46(69)59(45(65)48(60,5)6)34-22-37(49(50,51)52)38(24-53)54-26-34/h10-17,22,26,29,35,39,42,61H,7-9,18-21,23,25,27-28H2,1-6H3,(H,55,63)(H,57,62)/t35-,39+,42-/m1/s1",QRYUVTSBJUTMOL-DCFQOXSYSA-N,251,19,777,CCCCOCCCOC,[R1]CCCCOCCCOC[R2],146.23,146.1306798,1.54,10,0,2,0,7,18.46,C8H18O2,"InChI=1S/C8H18O2/c1-3-4-7-10-8-5-6-9-2/h3-8H2,1-2H3",SYQZZZDASGVPDV-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,CCOC1=CC2=C(C=C1NC(=O)C1=CC=CC(C(F)(F)F)=N1)N(C)C(CCC(C)(C)C(=O)OC)=N2,70,IC50 was assessed by Z'-Lyte kinase assay,,,,,,,10.1021/acsmedchemlett.0c00474,492.498,492.19844,4.2,35,3,7,1,8,95.34,C24H27F3N4O4,"InChI=1S/C24H27F3N4O4/c1-6-35-18-13-15-17(31(4)20(29-15)10-11-23(2,3)22(33)34-5)12-16(18)30-21(32)14-8-7-9-19(28-14)24(25,26)27/h7-9,12-13H,6,10-11H2,1-5H3,(H,30,32)",HZWJTPQMGLFQCE-UHFFFAOYSA-N,,,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.879959349,5.864554029,131.838,1365.9851
1589,50,71,<=50/<=50,>=71/>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(Cl)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,972.631,971.3476815,6.83,67,6,12,3,20,186.66,C49H58ClN7O8S2,"InChI=1S/C49H58ClN7O8S2/c1-31-42(67-30-53-31)33-12-10-32(11-13-33)27-52-44(60)40-25-37(58)28-55(40)45(61)43(48(2,3)4)54-41(59)29-64-22-9-21-63-20-7-8-23-65-38-18-16-35(17-19-38)57-47(66)56(46(62)49(57,5)6)36-15-14-34(26-51)39(50)24-36/h10-19,24,30,37,40,43,58H,7-9,20-23,25,27-29H2,1-6H3,(H,52,60)(H,54,59)/t37-,40+,43-/m1/s1",HTGWWWOBPGTSLC-AKCINUCUSA-N,252,19,777,CCCCOCCCOC,[R1]CCCCOCCCOC[R2],146.23,146.1306798,1.54,10,0,2,0,7,18.46,C8H18O2,"InChI=1S/C8H18O2/c1-3-4-7-10-8-5-6-9-2/h3-8H2,1-2H3",SYQZZZDASGVPDV-UHFFFAOYSA-N,Q8IXJ6,SIRT2,TM,CCCCCCCCCCCCCC(=S)NCCCC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=CC=C1,93/370,Inhibit SIRT2 deacetylase/defatty-acylase,,,,,,,10.1021/acsmedchemlett.0c00423,581.867,581.3651135,9.61,41,2,4,3,22,79.46,C34H51N3O3S,"InChI=1S/C34H51N3O3S/c1-2-3-4-5-6-7-8-9-10-11-18-26-32(41)35-27-20-19-25-31(33(38)36-30-23-16-13-17-24-30)37-34(39)40-28-29-21-14-12-15-22-29/h12-17,21-24,31H,2-11,18-20,25-28H2,1H3,(H,35,41)(H,36,38)(H,37,39)/t31-/m0/s1",CJQGLLUJIVNREL-HKBQPEDESA-N,50276140,126843233,CHEMBL4129995,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.519345688,5.63130351,302.4505,2337.2033
1795,87,99.9,87,100,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCC3=CC(N)=CC(CCOCCOCC#CC4=CC=C(C5=N[C@@H](CC6=NC=CS6)C6=NN=C(C)N6C6=C5C(C)=C(C)S6)C=C4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,55/40,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,440,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,480,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1107.442,1106.432893,7.89,78,9,16,4,19,212.07,C59H66N10O6S3,"InChI=1S/C59H66N10O6S3/c1-35-37(3)78-58-51(35)52(64-47(31-50-61-21-26-76-50)55-67-66-38(4)69(55)58)43-15-10-39(11-16-43)9-8-22-74-24-25-75-23-20-42-27-41(28-45(60)29-42)14-19-49(71)65-54(59(5,6)7)57(73)68-33-46(70)30-48(68)56(72)62-32-40-12-17-44(18-13-40)53-36(2)63-34-77-53/h10-13,15-18,21,26-29,34,46-48,54,70H,14,19-20,22-25,30-33,60H2,1-7H3,(H,62,72)(H,65,71)/t46-,47+,48+,54-/m1/s1",MXYBZGJJYHQKSU-OSCONUCQSA-N,286,19,875,C#CCOCCOCCC1=CC(N)=CC(CC)=C1,[R1]C#CCOCCOCCC1=CC(=CC(=C1)CC[R2])N,247.338,247.1572289,2.12,18,1,3,1,8,44.48,C15H21NO2,"InChI=1S/C15H21NO2/c1-3-6-17-8-9-18-7-5-14-10-13(4-2)11-15(16)12-14/h1,10-12H,4-9,16H2,2H3",SVPJJVOCPCNJHP-UHFFFAOYSA-N,P50750,CDK9,,CC(C)C1=C2N=C(OC3CCN(C)CC3)N=C(NCC3=CC=CC=C3)N2N=C1,3070,Inhibit growth of MDA-MB-468 cells,,,,,,,10.1021/acs.jmedchem.1c01350,380.496,380.2324595,3.93,28,4,7,1,6,67.58,C21H28N6O,"InChI=1S/C21H28N6O/c1-15(2)18-14-23-27-19(18)24-21(28-17-9-11-26(3)12-10-17)25-20(27)22-13-16-7-5-4-6-8-16/h4-8,14-15,17H,9-13H2,1-3H3,(H,22,24,25)",BWJDMRPMFRWAOP-UHFFFAOYSA-N,,89789681,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.999,87,5.747846691,5.736629713,1787.1183,1833.8774
1796,6500,99.9,6500,100,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCC3=CC(N)=CC(CCOCCOCC#CC4=CC=C(C5=N[C@@H](CC(=O)NCCS(=O)(=O)O)C6=NN=C(C)N6C6=C5C(C)=C(C)S6)C=C4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,18/13,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11000,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1175.47,1174.443851,5,82,8,17,6,22,282.65,C59H70N10O10S3,"InChI=1S/C59H70N10O10S3/c1-35-37(3)81-58-51(35)52(64-47(55-67-66-38(4)69(55)58)31-50(72)61-21-26-82(75,76)77)43-15-10-39(11-16-43)9-8-22-78-24-25-79-23-20-42-27-41(28-45(60)29-42)14-19-49(71)65-54(59(5,6)7)57(74)68-33-46(70)30-48(68)56(73)62-32-40-12-17-44(18-13-40)53-36(2)63-34-80-53/h10-13,15-18,27-29,34,46-48,54,70H,14,19-26,30-33,60H2,1-7H3,(H,61,72)(H,62,73)(H,65,71)(H,75,76,77)/t46-,47+,48+,54-/m1/s1",JSCBAQVBPQZYHJ-OSCONUCQSA-N,287,19,875,C#CCOCCOCCC1=CC(N)=CC(CC)=C1,[R1]C#CCOCCOCCC1=CC(=CC(=C1)CC[R2])N,247.338,247.1572289,2.12,18,1,3,1,8,44.48,C15H21NO2,"InChI=1S/C15H21NO2/c1-3-6-17-8-9-18-7-5-14-10-13(4-2)11-15(16)12-14/h1,10-12H,4-9,16H2,2H3",SVPJJVOCPCNJHP-UHFFFAOYSA-N,P10275,AR,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=CC=C3)CC2)C=C1Cl,,,,,,,,,,354.837,354.1135055,4.55,25,3,3,1,4,62.12,C20H19ClN2O2,"InChI=1S/C20H19ClN2O2/c21-19-12-18(9-6-15(19)13-22)25-17-10-7-16(8-11-17)23-20(24)14-4-2-1-3-5-14/h1-6,9,12,16-17H,7-8,10-11H2,(H,23,24)/t16-,17-",CHIRYVXGOIAKBG-QAQDUYKDSA-N,,155218484,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,32.66,0.021218616,1,1,1,1,1,0.021218616,0.999,6500,5.70939559,5.484707868,1952.5601,3275.6096
2073,6.8,95,6.8,95,P15056,BRAF V600E,VHL,,SJF-0628,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=C[NH]C3=NC=C(C4=CC=C(N5CCN(CC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)C=C23)=C1F,Degradation of BRAF V600E in SK-MEL-28 cells,,,1.87/24.4,IC50 was assessed by radio labeled kinase assay/Elisa Kinase inhibition Assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37/218,Inhibit growth of SK-MEL-28/SK-MEL-239 C4 cells,,,,,,,,,,,,,10.1038/s41467-021-21159-7,1010.203,1009.379044,6.39,71,8,12,5,16,210.03,C51H57F2N9O7S2,"InChI=1S/C51H57F2N9O7S2/c1-6-21-71(68,69)59-40-16-15-39(52)43(44(40)53)45(65)38-26-55-48-37(38)22-34(25-54-48)32-11-13-35(14-12-32)61-19-17-60(18-20-61)28-42(64)58-47(51(3,4)5)50(67)62-27-36(63)23-41(62)49(66)56-24-31-7-9-33(10-8-31)46-30(2)57-29-70-46/h7-16,22,25-26,29,36,41,47,59,63H,6,17-21,23-24,27-28H2,1-5H3,(H,54,55)(H,56,66)(H,58,64)/t36-,41+,47-/m1/s1",MBCAVOCJJAQHHT-FGUOTCRGSA-N,171,19,1012,CN1CCNCC1,[R1]N1CCN(CC1)C[R2],100.165,100.1000484,-0.39,7,1,2,1,0,15.27,C5H12N2,"InChI=1S/C5H12N2/c1-7-4-2-6-3-5-7/h6H,2-5H2,1H3",PVOAHINGSUIXLS-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,NC(=O)C1=NN(C2=CC=C(C(=O)O)C=C2)C=C1NC(=O)C1=COC(C2=CC=NC=C2)=N1,,,,,,,,,,418.369,418.1025675,1.35,31,4,8,3,6,166.23,C20H14N6O5,"InChI=1S/C20H14N6O5/c21-17(27)16-14(9-26(25-16)13-3-1-12(2-4-13)20(29)30)23-18(28)15-10-31-19(24-15)11-5-7-22-8-6-11/h1-10H,(H2,21,27)(H,23,28)(H,29,30)",HSZVOHYCNGRTDZ-UHFFFAOYSA-N,,138694550,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,6.8,6.231824164,5.85765547,586.3755,1387.8564
2073,15,95,15,95,P15056,BRAF G469A,VHL,,SJF-0628,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=C[NH]C3=NC=C(C4=CC=C(N5CCN(CC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)C=C23)=C1F,Degradation of BRAF G469A in SK-MEL-246 cells,,,0.98,IC50 was assessed by radio labeled kinase assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45,Inhibit growth of SK-MEL-246 cells,,,,,,,,,,,,,10.1038/s41467-021-21159-7,1010.203,1009.379044,6.39,71,8,12,5,16,210.03,C51H57F2N9O7S2,"InChI=1S/C51H57F2N9O7S2/c1-6-21-71(68,69)59-40-16-15-39(52)43(44(40)53)45(65)38-26-55-48-37(38)22-34(25-54-48)32-11-13-35(14-12-32)61-19-17-60(18-20-61)28-42(64)58-47(51(3,4)5)50(67)62-27-36(63)23-41(62)49(66)56-24-31-7-9-33(10-8-31)46-30(2)57-29-70-46/h7-16,22,25-26,29,36,41,47,59,63H,6,17-21,23-24,27-28H2,1-5H3,(H,54,55)(H,56,66)(H,58,64)/t36-,41+,47-/m1/s1",MBCAVOCJJAQHHT-FGUOTCRGSA-N,171,19,1012,CN1CCNCC1,[R1]N1CCN(CC1)C[R2],100.165,100.1000484,-0.39,7,1,2,1,0,15.27,C5H12N2,"InChI=1S/C5H12N2/c1-7-4-2-6-3-5-7/h6H,2-5H2,1H3",PVOAHINGSUIXLS-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,NC(=O)C1=NN(C2=CC=C(C(=O)O)C=C2)C=C1NC(=O)C1=COC(C2=CC=NC=C2)=N1,,,,,,,,,,418.369,418.1025675,1.35,31,4,8,3,6,166.23,C20H14N6O5,"InChI=1S/C20H14N6O5/c21-17(27)16-14(9-26(25-16)13-3-1-12(2-4-13)20(29)30)23-18(28)15-10-31-19(24-15)11-5-7-22-8-6-11/h1-10H,(H2,21,27)(H,23,28)(H,29,30)",HSZVOHYCNGRTDZ-UHFFFAOYSA-N,,138694550,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,15,6.231824164,5.85765547,586.3755,1387.8564
2073,23,80,29/23,80/90,P15056,BRAF G466V,VHL,,SJF-0628,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=C[NH]C3=NC=C(C4=CC=C(N5CCN(CC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCC6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)C=C23)=C1F,Degradation of BRAF G466V in H1666/CAL-12T cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-21159-7,1010.203,1009.379044,6.39,71,8,12,5,16,210.03,C51H57F2N9O7S2,"InChI=1S/C51H57F2N9O7S2/c1-6-21-71(68,69)59-40-16-15-39(52)43(44(40)53)45(65)38-26-55-48-37(38)22-34(25-54-48)32-11-13-35(14-12-32)61-19-17-60(18-20-61)28-42(64)58-47(51(3,4)5)50(67)62-27-36(63)23-41(62)49(66)56-24-31-7-9-33(10-8-31)46-30(2)57-29-70-46/h7-16,22,25-26,29,36,41,47,59,63H,6,17-21,23-24,27-28H2,1-5H3,(H,54,55)(H,56,66)(H,58,64)/t36-,41+,47-/m1/s1",MBCAVOCJJAQHHT-FGUOTCRGSA-N,171,19,1012,CN1CCNCC1,[R1]N1CCN(CC1)C[R2],100.165,100.1000484,-0.39,7,1,2,1,0,15.27,C5H12N2,"InChI=1S/C5H12N2/c1-7-4-2-6-3-5-7/h6H,2-5H2,1H3",PVOAHINGSUIXLS-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,NC(=O)C1=NN(C2=CC=C(C(=O)O)C=C2)C=C1NC(=O)C1=COC(C2=CC=NC=C2)=N1,,,,,,,,,,418.369,418.1025675,1.35,31,4,8,3,6,166.23,C20H14N6O5,"InChI=1S/C20H14N6O5/c21-17(27)16-14(9-26(25-16)13-3-1-12(2-4-13)20(29)30)23-18(28)15-10-31-19(24-15)11-5-7-22-8-6-11/h1-10H,(H2,21,27)(H,23,28)(H,29,30)",HSZVOHYCNGRTDZ-UHFFFAOYSA-N,,138694550,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.8,23,6.231824164,5.85765547,586.3755,1387.8564
2411,7.95,98,7.95,98,P00533,EGFR e19d,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR del19 in HCC-827 cells after 72 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36,Inhibit proliferation of HCC-827 (EGFRdel19) cells,,,,,,,,,,,,,,,10.1016/j.bioorg.2022.105605,1091.756,1090.477805,7.83,77,8,15,5,23,221.72,C56H68ClFN12O6S,"InChI=1S/C56H68ClFN12O6S/c1-36-51(77-35-62-36)38-18-16-37(17-19-38)30-59-54(74)47-27-41(71)32-70(47)55(75)52(56(2,3)4)65-50(73)14-9-6-5-7-12-25-69-31-40(66-67-69)33-76-48-29-45-42(53(61-34-60-45)63-39-20-21-44(58)43(57)26-39)28-46(48)64-49(72)15-13-24-68-22-10-8-11-23-68/h13,15-21,26,28-29,31,34-35,41,47,52,71H,5-12,14,22-25,27,30,32-33H2,1-4H3,(H,59,74)(H,64,72)(H,65,73)(H,60,61,63)/b15-13+/t41-,47+,52-/m1/s1",BUDQKNIUFHYJQZ-ABSCMPNGSA-N,372,19,1157,CCCCCCCN1C=C(C)N=N1,[R1]CC1=CN(N=N1)CCCCCCC[R2],181.283,181.1578976,2.9,13,1,3,0,6,30.71,C10H19N3,"InChI=1S/C10H19N3/c1-3-4-5-6-7-8-13-9-10(2)11-12-13/h9H,3-8H2,1-2H3",UUMUOZRKBCQOFS-UHFFFAOYSA-N,Q13164,ERK5,,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C2C(=N1)N(C)C1=CC=CC=C1C(=O)N2C,230,Inhibition of EGF-induced BMK1 autophosphorylation in human HeLa cells by SDS-PAGE analysis,,,,,,,10.1021/ml100304b,445.527,445.2226231,2.63,33,5,8,2,4,85.86,C24H27N7O2,"InChI=1S/C24H27N7O2/c1-29-19-7-5-4-6-17(19)23(32)30(2)20-15-26-24(28-22(20)29)27-18-9-8-16(14-21(18)33-3)31-12-10-25-11-13-31/h4-9,14-15,25H,10-13H2,1-3H3,(H,26,27,28)",HGHFBVBNHYJNHK-UHFFFAOYSA-N,50337130,53321707,CHEMBL1673042,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,7.95,7.114403131,6.058124895,76.8417,874.7322
2414,3.57,91,3.57,91,P00533,EGFR e19d,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCN3C=C(COC4=CC5=NC=NC(NC6=CC=C(F)C(Cl)=C6)=C5C=C4NC(=O)/C=C/CN4CCCCC4)N=N3)C(C)(C)C)C=C2)SC=N1,Degradation of EGFR del19 in HCC-827 cells after 72 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6,Inhibit proliferation of HCC-827 (EGFRdel19) cells,,,,,,,,,,,,,,,10.1016/j.bioorg.2022.105605,1133.837,1132.524755,9.46,80,8,15,5,26,221.72,C59H74ClFN12O6S,"InChI=1S/C59H74ClFN12O6S/c1-39-54(80-38-65-39)41-21-19-40(20-22-41)33-62-57(77)50-30-44(74)35-73(50)58(78)55(59(2,3)4)68-53(76)17-12-9-7-5-6-8-10-15-28-72-34-43(69-70-72)36-79-51-32-48-45(56(64-37-63-48)66-42-23-24-47(61)46(60)29-42)31-49(51)67-52(75)18-16-27-71-25-13-11-14-26-71/h16,18-24,29,31-32,34,37-38,44,50,55,74H,5-15,17,25-28,30,33,35-36H2,1-4H3,(H,62,77)(H,67,75)(H,68,76)(H,63,64,66)/b18-16+/t44-,50+,55-/m1/s1",RBUUUIFZYMVDPT-DLMBMICPSA-N,372,19,1160,CCCCCCCCCCN1C=C(C)N=N1,[R1]CC1=CN(N=N1)CCCCCCCCCC[R2],223.364,223.2048478,4.52,16,1,3,0,9,30.71,C13H25N3,"InChI=1S/C13H25N3/c1-3-4-5-6-7-8-9-10-11-16-12-13(2)14-15-16/h12H,3-11H2,1-2H3",OGKDLUIQGXUWQA-UHFFFAOYSA-N,Q13164,ERK5,,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C2C(=N1)N(C)C1=CC=CC=C1C(=O)N2C,230,Inhibition of EGF-induced BMK1 autophosphorylation in human HeLa cells by SDS-PAGE analysis,,,,,,,10.1021/ml100304b,445.527,445.2226231,2.63,33,5,8,2,4,85.86,C24H27N7O2,"InChI=1S/C24H27N7O2/c1-29-19-7-5-4-6-17(19)23(32)30(2)20-15-26-24(28-22(20)29)27-18-9-8-16(14-21(18)33-3)31-12-10-25-11-13-31/h4-9,14-15,25H,10-13H2,1-3H3,(H,26,27,28)",HGHFBVBNHYJNHK-UHFFFAOYSA-N,50337130,53321707,CHEMBL1673042,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,3.57,7.117037529,5.896152644,76.377,1270.1276
3149,120,76,120,76,P04035,HMGCR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)O[C@H]3C[C@@H](C)C=C4C=C[C@H](C)[C@H](CCC(O)C[C@@H](O)CC(=O)O)[C@H]43)C(C)(C)C)C=C2)SC=N1,Degradation of HMGCR in HepG2 cells after 16 h treatment,,,250,Inhibition of HMGCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18.22,Caco-2 A2B assay,,,10.1016/j.apsb.2020.11.001,978.307,977.5547647,7.73,69,5,11,7,25,227.72,C53H79N5O10S,"InChI=1S/C53H79N5O10S/c1-33-25-38-19-16-34(2)42(23-22-39(59)27-40(60)29-46(63)64)47(38)44(26-33)68-52(67)54-24-14-12-10-8-7-9-11-13-15-45(62)57-49(53(4,5)6)51(66)58-31-41(61)28-43(58)50(65)55-30-36-17-20-37(21-18-36)48-35(3)56-32-69-48/h16-21,25,32-34,39-44,47,49,59-61H,7-15,22-24,26-31H2,1-6H3,(H,54,67)(H,55,65)(H,57,62)(H,63,64)/t33-,34-,39?,40+,41+,42-,43-,44-,47-,49+/m0/s1",YASBQIQZXTUKLR-SHAIEYSUSA-N,523,19,1191,CCCCCCCCCCN,[R1]NCCCCCCCCCC[R2],157.301,157.1830497,3.79,11,0,1,1,8,26.02,C10H23N,"InChI=1S/C10H23N/c1-2-3-4-5-6-7-8-9-10-11/h2-11H2,1H3",MHZGKXUYDGKKIU-UHFFFAOYSA-N,Q93009,USP7,XL188,C[C@H](CC(=O)N1CCC(O)(CN2C=NC3=CC(NC(=O)CCN4CCN(C)CC4)=CC=C3C2=O)CC1)C1=CC=CC=C1,,,,,,,,,10.1016/j.chembiol.2017.09.003,574.726,574.3267538,1.25,42,5,8,2,9,111.01,C32H42N6O4,"InChI=1S/C32H42N6O4/c1-24(25-6-4-3-5-7-25)20-30(40)37-14-11-32(42,12-15-37)22-38-23-33-28-21-26(8-9-27(28)31(38)41)34-29(39)10-13-36-18-16-35(2)17-19-36/h3-9,21,23-24,42H,10-20,22H2,1-2H3,(H,34,39)/t24-/m1/s1",QLBYDWATOPNXBG-XMMPIXPASA-N,50514122,131953451,CHEMBL4548694,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.76,120,7.368586278,5.626272727,42.797,2364.4344
3065,16,95,16,95,P51617,IRAK1,VHL,,,COC1=CC(N2CCC(OCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC(=O)C1=CC=CC(C2=CC=N[NH]2)=N1,Degradation of IRAK1 in HEK293T cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.1c00244,864.042,863.378866,4.63,62,7,12,5,14,204,C45H53N9O7S,"InChI=1S/C45H53N9O7S/c1-27-40(62-26-47-27)29-11-9-28(10-12-29)23-46-43(58)37-22-31(55)24-54(37)44(59)41(45(2,3)4)51-39(56)25-61-32-16-19-53(20-17-32)30-13-14-35(38(21-30)60-5)50-42(57)36-8-6-7-33(49-36)34-15-18-48-52-34/h6-15,18,21,26,31-32,37,41,55H,16-17,19-20,22-25H2,1-5H3,(H,46,58)(H,48,52)(H,50,57)(H,51,56)/t31-,37+,41-/m1/s1",PWCLOPMRUGHLET-SPVIJIGUSA-N,497,19,1391,CO,[R1]OC[R2],32.042,32.02621475,-0.46,2,0,1,1,0,20.23,CH4O,"InChI=1S/CH4O/c1-2/h2H,1H3",OKKJLVBELUTLKV-UHFFFAOYSA-N,P98170,XIAP,,CN[C@@H](C)C(=O)N[C@H](C(=O)N1CC2=CC(O)=CC=C2C[C@H]1C(=O)N[C@@H]1CCCC2=CC=CC=C21)C(C)(C)C,,,,,,,,,10.1016/j.ejmech.2022.114910,520.674,520.3049558,3.66,38,4,5,4,6,110.77,C30H40N4O4,"InChI=1S/C30H40N4O4/c1-18(31-5)27(36)33-26(30(2,3)4)29(38)34-17-21-15-22(35)14-13-20(21)16-25(34)28(37)32-24-12-8-10-19-9-6-7-11-23(19)24/h6-7,9,11,13-15,18,24-26,31,35H,8,10,12,16-17H2,1-5H3,(H,32,37)(H,33,36)/t18-,24+,25-,26+/m0/s1",HIBPHKLMOULUBF-YSQWDHOWSA-N,,170249997,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,16,6.272983442,5.429960011,533.3552,3715.6944
3067,16,97,16,97,P51617,IRAK1,VHL,,,COC1=CC(N2CCN(C(=O)OCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC(=O)C1=CC=CC(C2=CC=N[NH]2)=N1,Degradation of IRAK1 in HEK293T cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.1c00244,893.04,892.3690296,3.9,64,7,13,5,13,224.31,C45H52N10O8S,"InChI=1S/C45H52N10O8S/c1-27-39(64-26-47-27)29-11-9-28(10-12-29)23-46-42(59)36-22-31(56)24-55(36)43(60)40(45(2,3)4)51-38(57)25-63-44(61)54-19-17-53(18-20-54)30-13-14-34(37(21-30)62-5)50-41(58)35-8-6-7-32(49-35)33-15-16-48-52-33/h6-16,21,26,31,36,40,56H,17-20,22-25H2,1-5H3,(H,46,59)(H,48,52)(H,50,58)(H,51,57)/t31-,36+,40-/m1/s1",GGEHXEZNDKXJIX-OXGRJUKFSA-N,498,19,1405,COC=O,[R1]C(=O)OC[R2],60.052,60.02112937,0.13,4,0,2,0,1,26.3,C2H4O2,"InChI=1S/C2H4O2/c1-4-2-3/h2H,1H3",TZIHFWKZFHZASV-UHFFFAOYSA-N,Q9ULX9,MAFF,Lathyrol,C=C1CC[C@H]2[C@@H](/C=C(\C)C(=O)[C@@]3(O)C[C@H](C)[C@H](O)[C@@H]3[C@H]1O)C2(C)C,,,,,20900/15500,MST/SPR,,,10.1021/acs.jnatprod.8b00600,334.456,334.2144094,2.18,24,3,4,3,0,77.76,C20H30O4,"InChI=1S/C20H30O4/c1-10-6-7-13-14(19(13,4)5)8-11(2)18(23)20(24)9-12(3)17(22)15(20)16(10)21/h8,12-17,21-22,24H,1,6-7,9H2,2-5H3/b11-8+/t12-,13-,14+,15-,16-,17-,20+/m0/s1",SDBITTRHSROXCY-SVSKDHLKSA-N,,15479845,CHEMBL3426445,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,16,6.336325742,5.341215184,460.9717,4558.1101
3245,260,71,260,71,P61964,WDR5,VHL,7JTO,MS33,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCC(=O)NCCN3CCN(CC4=CC=CC(C5=CC=C(N6CCN(C)CC6)C(NC(=O)C6=C[NH]C(=O)C=C6C(F)(F)F)=C5)=C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of WDR5 in MV4;11 cells after 18 h treatment,,,,,,,120,ITC,,,,,,,,,,,,,,,870,ITC,,,,,,,,,,,,,,,520,Kd between VHL and the complex of protac and WDR5 was tested by ITC,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1126/scitranslmed.abj1578,1208.507,1207.6228,7.09,86,8,13,6,25,215.65,C64H84F3N11O7S,"InChI=1S/C64H84F3N11O7S/c1-43-58(86-42-71-43)46-20-18-44(19-21-46)38-70-61(84)54-36-49(79)41-78(54)62(85)59(63(2,3)4)73-56(81)17-12-10-8-6-7-9-11-16-55(80)68-24-25-75-28-30-76(31-29-75)40-45-14-13-15-47(34-45)48-22-23-53(77-32-26-74(5)27-33-77)52(35-48)72-60(83)50-39-69-57(82)37-51(50)64(65,66)67/h13-15,18-23,34-35,37,39,42,49,54,59,79H,6-12,16-17,24-33,36,38,40-41H2,1-5H3,(H,68,80)(H,69,82)(H,70,84)(H,72,83)(H,73,81)/t49-,54+,59-/m1/s1",GLYGYEQLMMPSAW-QWQPEEPRSA-N,531,19,1496,CCCCCCCCCC(=O)NCC,[R1]CCNC(=O)CCCCCCCCC[R2],199.338,199.1936144,3.98,14,0,1,1,9,29.1,C12H25NO,"InChI=1S/C12H25NO/c1-3-5-6-7-8-9-10-11-12(14)13-4-2/h3-11H2,1-2H3,(H,13,14)",VXUAXBGDCYWTME-UHFFFAOYSA-N,Q15910,EZH2,,CC1=CC(C)=C(CNC(=O)C2=CC(C3=CC=C(N4CCNCC4)N=C3)=CC3=C2C=NN3C(C)C)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2022.114462,499.619,499.2695733,2.54,37,5,7,3,6,107.94,C28H33N7O2,"InChI=1S/C28H33N7O2/c1-17(2)35-25-13-21(20-5-6-26(30-14-20)34-9-7-29-8-10-34)12-22(24(25)16-32-35)27(36)31-15-23-18(3)11-19(4)33-28(23)37/h5-6,11-14,16-17,29H,7-10,15H2,1-4H3,(H,31,36)(H,33,37)",VYFBRDJIRRTWMS-UHFFFAOYSA-N,,54596558,CHEMBL5179558,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,67.82,0.010218225,1,1,1,1,1,0.010218225,0.71,260,6.380108057,5.517466651,416.7657,3037.6193
3254,92,73,92,73,P61964,WDR5,VHL,,MS132,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CNC(=O)C3=CC=C(F)C(C4=CC=C(N5C[C@H](C)N(C)[C@H](C)C5)C(NC(=O)C5=C[NH]C(=O)C=C5C(F)(F)F)=C4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of WDR5 in MIA PaCa-2 cells after 18 h treatment,,,,,,,122,ITC,,,,,,,,,,,,,,,534,ITC,,,,,,,,,,,,,,,232,ITC,,,,,,,,,,,,,,,5700/4000/9200,Inhibit proliferation of MIA PaCa-2/BxPC-3/HPAF-II cells,,,,,,,,,,,10.1021/acs.jmedchem.3c01521,1016.132,1015.403779,5.11,72,7,11,6,13,209.17,C51H57F4N9O7S,"InChI=1S/C51H57F4N9O7S/c1-27-23-63(24-28(2)62(27)7)40-15-13-32(17-39(40)60-47(69)36-21-56-42(66)19-37(36)51(53,54)55)35-16-33(12-14-38(35)52)46(68)58-22-43(67)61-45(50(4,5)6)49(71)64-25-34(65)18-41(64)48(70)57-20-30-8-10-31(11-9-30)44-29(3)59-26-72-44/h8-17,19,21,26-28,34,41,45,65H,18,20,22-25H2,1-7H3,(H,56,66)(H,57,70)(H,58,68)(H,60,69)(H,61,67)/t27-,28+,34-,41+,45-/m1/s1",OJCYPKZNPSJLGY-KQNJQULYSA-N,535,19,1497,CNC=O,[R1]C(=O)NC[R2],59.068,59.03711378,0.14,4,0,1,1,1,29.1,C2H5NO,"InChI=1S/C2H5NO/c1-3-2-4/h2H,1H3,(H,3,4)",ATHHXGZTWNVVOU-UHFFFAOYSA-N,P15056,BRAF V600E,PLX8394-L,O=C(C1=C(F)C=CC(NS(=O)(=O)N2CC[C@@H](F)C2)=C1F)C1=C[NH]C2=NC=C(C3=CN=C(N4CCNCC4)N=C3)C=C12,,,,,,,,,10.1038/s41591-018-0274-5,586.6,586.1722423,1.98,41,6,8,3,7,136.21,C26H25F3N8O3S,"InChI=1S/C26H25F3N8O3S/c27-17-3-6-37(14-17)41(39,40)35-21-2-1-20(28)22(23(21)29)24(38)19-13-32-25-18(19)9-15(10-31-25)16-11-33-26(34-12-16)36-7-4-30-5-8-36/h1-2,9-13,17,30,35H,3-8,14H2,(H,31,32)/t17-/m1/s1",DHKOCXOHXNSNBX-QGZVFWFLSA-N,,,,19VHL,19,P40337,VHL,,C#CC1=CC=C([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(C)=O)C(C)(C)C)C=C1,879,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,413.518,413.2314565,1.86,30,2,4,3,5,98.74,C23H31N3O4,"InChI=1S/C23H31N3O4/c1-7-16-8-10-17(11-9-16)14(2)24-21(29)19-12-18(28)13-26(19)22(30)20(23(4,5)6)25-15(3)27/h1,8-11,14,18-20,28H,12-13H2,2-6H3,(H,24,29)(H,25,27)/t14-,18+,19-,20+/m0/s1",WHTWICJCWCIKHM-WEFJBSGNSA-N,,153633215,CHEMBL4585902,67.82,0.010218225,1,1,1,1,1,0.010218225,0.73,92,6.943294916,6.100975706,113.9476,792.5457
285,27,91,27,91,O15264,p38delta,CRBN,,SJF-8242,COC1=CC2=C(OC3=CC=C(NC(=O)C4(C(=O)NC5=CC=C(F)C=C5)CC4)C=C3F)C=CN=C2C=C1OCCCOCCCOCCC(=O)NCCOC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of p38delta in MDA-MB-231 cells after 24 h treatment,,,,,,,2000,Kd was assessed by competition binding assays,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2017.09.010,992.986,992.3403921,5.03,72,8,14,4,24,239.12,C51H50F2N6O13,"InChI=1S/C51H50F2N6O13/c1-67-41-28-34-36(54-19-15-38(34)72-39-13-11-32(27-35(39)53)57-50(66)51(17-18-51)49(65)56-31-9-7-30(52)8-10-31)29-42(41)70-24-4-23-68-21-3-22-69-25-16-43(60)55-20-26-71-40-6-2-5-33-45(40)48(64)59(47(33)63)37-12-14-44(61)58-46(37)62/h2,5-11,13,15,19,27-29,37H,3-4,12,14,16-18,20-26H2,1H3,(H,55,60)(H,56,65)(H,57,66)(H,58,61,62)",ZAJXSUNUSHEGCB-UHFFFAOYSA-N,71,3,155,CCCOCCCOCCC(=O)NCCO,[R1]CCCOCCCOCCC(=O)NCCO[R2],233.308,233.1627082,-0.25,16,0,4,2,11,67.79,C11H23NO4,"InChI=1S/C11H23NO4/c1-2-7-15-8-3-9-16-10-4-11(14)12-5-6-13/h13H,2-10H2,1H3,(H,12,14)",NCLTXMWFZMRLQT-UHFFFAOYSA-N,P24941,CDK2,AT-7519,O=C(NC1CCNCC1)C1=C(NC(=O)C2=C(Cl)C=CC=C2Cl)C=N[NH]1,,,,,30,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,382.251,381.0759301,2.59,25,3,4,4,4,98.91,C16H17Cl2N5O2,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,11338033,CHEMBL445813,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,27,6.485421613,6.841306544,327.0231,144.1098
271,8.2,98,8.2,98,Q05397,FAK,CRBN,,,CN(C1=CC=CC(CNC2=NC(NC3=CC=C(OCCCOCCC(=O)NCCOC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2C(F)(F)F)=C1)S(C)(=O)=O,Degradation of Fak in PC3 cells after 24 h treatment,,,11.3,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,896.902,896.2774952,3.22,63,6,14,4,20,227.56,C41H43F3N8O10S,"InChI=1S/C41H43F3N8O10S/c1-51(63(2,58)59)27-7-3-6-25(22-27)23-46-36-30(41(42,43)44)24-47-40(50-36)48-26-10-12-28(13-11-26)61-19-5-18-60-20-16-33(53)45-17-21-62-32-9-4-8-29-35(32)39(57)52(38(29)56)31-14-15-34(54)49-37(31)55/h3-4,6-13,22,24,31H,5,14-21,23H2,1-2H3,(H,45,53)(H,49,54,55)(H2,46,47,48,50)",ATTMBNXPUWOYNQ-UHFFFAOYSA-N,64,3,146,CCCOCCC(=O)NCCO,[R1]CCCOCCC(=O)NCCO[R2],175.228,175.1208434,-0.46,12,0,3,2,7,58.56,C8H17NO3,"InChI=1S/C8H17NO3/c1-2-6-12-7-3-8(11)9-4-5-10/h10H,2-7H2,1H3,(H,9,11)",ZWZRKLRMHPVSCL-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,8.2,7.451355532,7.166869062,35.3708,68.0975
272,26.7,99,26.7,99,Q05397,FAK,CRBN,,,CN(C1=CC=CC(CNC2=NC(NC3=CC=C(OCCOCCOCCC(=O)NCCOC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2C(F)(F)F)=C1)S(C)(=O)=O,Degradation of Fak in PC3 cells after 24 h treatment,,,4.7,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,926.928,926.2880599,2.72,65,6,15,4,22,236.79,C42H45F3N8O11S,"InChI=1S/C42H45F3N8O11S/c1-52(65(2,59)60)28-6-3-5-26(23-28)24-47-37-31(42(43,44)45)25-48-41(51-37)49-27-9-11-29(12-10-27)63-22-21-62-20-19-61-17-15-34(54)46-16-18-64-33-8-4-7-30-36(33)40(58)53(39(30)57)32-13-14-35(55)50-38(32)56/h3-12,23,25,32H,13-22,24H2,1-2H3,(H,46,54)(H,50,55,56)(H2,47,48,49,51)",RKQPBRYWQQLESB-UHFFFAOYSA-N,64,3,147,CCOCCOCCC(=O)NCCO,[R1]CCOCCOCCC(=O)NCCO[R2],205.254,205.1314081,-1.14,14,0,4,2,9,67.79,C9H19NO4,"InChI=1S/C9H19NO4/c1-2-13-7-8-14-6-3-9(12)10-4-5-11/h11H,2-8H2,1H3,(H,10,12)",CGZNNRDCSGZCCN-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,26.7,7.25063992,6.955628171,56.1513,110.7572
273,10,87,<10,87,Q05397,FAK,CRBN,,,CN(C1=CC=CC(CNC2=NC(NC3=CC=C(OCCOCCOCCOCCOCCC(=O)NCCOC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C=C3)=NC=C2C(F)(F)F)=C1)S(C)(=O)=O,Degradation of Fak in PC3 cells after 24 h treatment,,,9.7,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.8b08008,1015.034,1014.340489,2.42,71,6,17,4,28,255.25,C46H53F3N8O13S,"InChI=1S/C46H53F3N8O13S/c1-56(71(2,63)64)32-6-3-5-30(27-32)28-51-41-35(46(47,48)49)29-52-45(55-41)53-31-9-11-33(12-10-31)69-26-25-68-24-23-67-22-21-66-20-19-65-17-15-38(58)50-16-18-70-37-8-4-7-34-40(37)44(62)57(43(34)61)36-13-14-39(59)54-42(36)60/h3-12,27,29,36H,13-26,28H2,1-2H3,(H,50,58)(H,54,59,60)(H2,51,52,53,55)",QZQNVCJSORWNHR-UHFFFAOYSA-N,64,3,148,CCOCCOCCOCCOCCC(=O)NCCO,[R1]CCOCCOCCOCCOCCC(=O)NCCO[R2],293.36,293.1838376,-1.43,20,0,6,2,15,86.25,C13H27NO6,"InChI=1S/C13H27NO6/c1-2-17-7-8-19-11-12-20-10-9-18-6-3-13(16)14-4-5-15/h15H,2-12H2,1H3,(H,14,16)",SESQQSBFFNCJEC-UHFFFAOYSA-N,Q9UM73,ALK,Brigatinib A,COC1=CC(N2CCNCC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1,1.6,Inhibit proliferation of SR cells,,,,,,,10.1016/j.ejmech.2020.112190,486.944,486.1699884,3.59,33,4,8,3,7,91.41,C23H28ClN6O2P,"InChI=1S/C23H28ClN6O2P/c1-32-20-14-16(30-12-10-25-11-13-30)8-9-18(20)28-23-26-15-17(24)22(29-23)27-19-6-4-5-7-21(19)33(2,3)31/h4-9,14-15,25H,10-13H2,1-3H3,(H2,26,27,28,29)",YVXLIHUPXSTEHG-UHFFFAOYSA-N,,68165331,CHEMBL4745797,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.87,10,7.163554841,6.7323787,68.6191,185.1916
339,6,97,6,97,O60885,BRD4,CRBN,6BOY,dBET6,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCCCCCNC(=O)COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in HEK293T cells after 3 h treatment,,,,,,,46,Kd of BRD4 BD1 was assessed by FP,,,,,,,,,,,,,,,264,FP,,,,,,,,,,,,,,,33,Kd was tested by AlphaLISA assay,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.1c00376,841.391,840.2820445,5.02,59,7,12,3,16,194.05,C42H45ClN8O7S,"InChI=1S/C42H45ClN8O7S/c1-23-24(2)59-42-35(23)37(26-13-15-27(43)16-14-26)46-29(38-49-48-25(3)50(38)42)21-33(53)44-19-8-6-4-5-7-9-20-45-34(54)22-58-31-12-10-11-28-36(31)41(57)51(40(28)56)30-17-18-32(52)47-39(30)55/h10-16,29-30H,4-9,17-22H2,1-3H3,(H,44,53)(H,45,54)(H,47,52,55)/t29-,30?/m0/s1",JGQPZPLJOBHHBK-UFXYQILXSA-N,42,3,191,NCCCCCCCCNC(=O)CO,[R1]NCCCCCCCCNC(=O)CO[R2],202.298,202.1681279,0.46,14,0,3,3,9,75.35,C10H22N2O2,"InChI=1S/C10H22N2O2/c11-7-5-3-1-2-4-6-8-12-10(14)9-13/h13H,1-9,11H2,(H,12,14)",YRHIKLITYIBTQJ-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.97,6,6.721677265,6.511927935,189.8116,307.6607
339,10,95,10/50,,O60885,BRD4,CRBN,6BOY,dBET6,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCCCCCNC(=O)COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 BD1/2 assessed by EGFP/mCherry reporter assay,,,,,,,,,,,,,,,,,,,800,Inhibition of CRBN by competition binding assay,,,,,,,,,,,,,,,1800/4100,Inhibition of CRBN in the presence of BRD4 BD1/2 by competition binding assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-018-0055-y,841.391,840.2820445,5.02,59,7,12,3,16,194.05,C42H45ClN8O7S,"InChI=1S/C42H45ClN8O7S/c1-23-24(2)59-42-35(23)37(26-13-15-27(43)16-14-26)46-29(38-49-48-25(3)50(38)42)21-33(53)44-19-8-6-4-5-7-9-20-45-34(54)22-58-31-12-10-11-28-36(31)41(57)51(40(28)56)30-17-18-32(52)47-39(30)55/h10-16,29-30H,4-9,17-22H2,1-3H3,(H,44,53)(H,45,54)(H,47,52,55)/t29-,30?/m0/s1",JGQPZPLJOBHHBK-UFXYQILXSA-N,42,3,191,NCCCCCCCCNC(=O)CO,[R1]NCCCCCCCCNC(=O)CO[R2],202.298,202.1681279,0.46,14,0,3,3,9,75.35,C10H22N2O2,"InChI=1S/C10H22N2O2/c11-7-5-3-1-2-4-6-8-12-10(14)9-13/h13H,1-9,11H2,(H,12,14)",YRHIKLITYIBTQJ-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,10,6.721677265,6.511927935,189.8116,307.6607
4868,97.1,88,97.1,88,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC(=O)NCCCOC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,771.256,770.2037941,2.87,54,7,12,3,11,194.05,C37H35ClN8O7S,"InChI=1S/C37H35ClN8O7S/c1-18-19(2)54-37-30(18)32(21-8-10-22(38)11-9-21)41-24(33-44-43-20(3)45(33)37)16-28(48)40-17-29(49)39-14-5-15-53-26-7-4-6-23-31(26)36(52)46(35(23)51)25-12-13-27(47)42-34(25)50/h4,6-11,24-25H,5,12-17H2,1-3H3,(H,39,49)(H,40,48)(H,42,47,50)/t24-,25?/m0/s1",FZPFOKCSBXRUCY-SKCDSABHSA-N,42,3,2210,NCC(=O)NCCCO,[R1]NCC(=O)NCCCO[R2],132.163,132.0898776,-1.7,9,0,3,3,4,75.35,C5H12N2O2,"InChI=1S/C5H12N2O2/c6-4-5(9)7-2-1-3-8/h8H,1-4,6H2,(H,7,9)",PIMLXADKMANMOY-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.88,97.1,7.365915382,5.853910115,43.0611,1399.877
4869,134,79,134,79,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC(=O)NCCCCOC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,785.283,784.2194442,3.22,55,7,12,3,12,194.05,C38H37ClN8O7S,"InChI=1S/C38H37ClN8O7S/c1-19-20(2)55-38-31(19)33(22-9-11-23(39)12-10-22)42-25(34-45-44-21(3)46(34)38)17-29(49)41-18-30(50)40-15-4-5-16-54-27-8-6-7-24-32(27)37(53)47(36(24)52)26-13-14-28(48)43-35(26)51/h6-12,25-26H,4-5,13-18H2,1-3H3,(H,40,50)(H,41,49)(H,43,48,51)/t25-,26?/m0/s1",DZBLWYQPZXUQGG-PMCHYTPCSA-N,42,3,2211,NCC(=O)NCCCCO,[R1]NCC(=O)NCCCCO[R2],146.19,146.1055277,-1.34,10,0,3,3,5,75.35,C6H14N2O2,"InChI=1S/C6H14N2O2/c7-5-6(10)8-3-1-2-4-9/h9H,1-5,7H2,(H,8,10)",DFMZIUNIBJFWBP-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.79,134,7.098126541,6.123089567,79.7762,753.2002
4870,184,86,184,86,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC(=O)NCCCCCOC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,799.31,798.2350943,3.58,56,7,12,3,13,194.05,C39H39ClN8O7S,"InChI=1S/C39H39ClN8O7S/c1-20-21(2)56-39-32(20)34(23-10-12-24(40)13-11-23)43-26(35-46-45-22(3)47(35)39)18-30(50)42-19-31(51)41-16-5-4-6-17-55-28-9-7-8-25-33(28)38(54)48(37(25)53)27-14-15-29(49)44-36(27)52/h7-13,26-27H,4-6,14-19H2,1-3H3,(H,41,51)(H,42,50)(H,44,49,52)/t26-,27?/m0/s1",ILDJWQYNDNRRFS-QBHOUYDASA-N,42,3,2212,NCC(=O)NCCCCCO,[R1]NCC(=O)NCCCCCO[R2],160.217,160.1211778,-0.98,11,0,3,3,6,75.35,C7H16N2O2,"InChI=1S/C7H16N2O2/c8-6-7(11)9-4-2-1-3-5-10/h10H,1-6,8H2,(H,9,11)",CURKCVIQEBIACY-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.86,184,6.871469248,6.022176762,134.4407,950.218
4873,239,81,239,81,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)N1CCN(CC(=O)NCCCOC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,840.363,839.2616434,2.86,59,8,13,2,11,188.5,C41H42ClN9O7S,"InChI=1S/C41H42ClN9O7S/c1-22-23(2)59-41-34(22)36(25-8-10-26(42)11-9-25)44-28(37-47-46-24(3)50(37)41)20-33(54)49-17-15-48(16-18-49)21-32(53)43-14-5-19-58-30-7-4-6-27-35(30)40(57)51(39(27)56)29-12-13-31(52)45-38(29)55/h4,6-11,28-29H,5,12-21H2,1-3H3,(H,43,53)(H,45,52,55)/t28-,29?/m0/s1",ITDXUECDKFMKGU-XLTVJXRZSA-N,42,3,2215,O=C(CN1CCNCC1)NCCCO,[R1]N1CCN(CC1)CC(=O)NCCCO[R2],201.27,201.1477268,-1.37,14,1,4,3,5,64.6,C9H19N3O2,"InChI=1S/C9H19N3O2/c13-7-1-2-11-9(14)8-12-5-3-10-4-6-12/h10,13H,1-8H2,(H,11,14)",QOKXUFARWLTLHE-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.81,239,7.185216147,6.126522026,65.2806,747.2707
4874,89.9,78,89.9,78,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)N1CCN(CC(=O)NCCCCOC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,854.39,853.2772934,3.22,60,8,13,2,12,188.5,C42H44ClN9O7S,"InChI=1S/C42H44ClN9O7S/c1-23-24(2)60-42-35(23)37(26-9-11-27(43)12-10-26)45-29(38-48-47-25(3)51(38)42)21-34(55)50-18-16-49(17-19-50)22-33(54)44-15-4-5-20-59-31-8-6-7-28-36(31)41(58)52(40(28)57)30-13-14-32(53)46-39(30)56/h6-12,29-30H,4-5,13-22H2,1-3H3,(H,44,54)(H,46,53,56)/t29-,30?/m0/s1",LAECKGLWOSIZEO-UFXYQILXSA-N,42,3,2216,O=C(CN1CCNCC1)NCCCCO,[R1]N1CCN(CC1)CC(=O)NCCCCO[R2],215.297,215.1633769,-1.02,15,1,4,3,6,64.6,C10H21N3O2,"InChI=1S/C10H21N3O2/c14-8-2-1-3-12-10(15)9-13-6-4-11-5-7-13/h11,14H,1-9H2,(H,12,15)",CKQXJPOPFPHMEV-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.78,89.9,6.918620458,6.049974482,120.609,891.3033
4875,60,94,60,94,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)N1CCN(CC(=O)NCCCCCOC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,868.417,867.2929435,3.57,61,8,13,2,13,188.5,C43H46ClN9O7S,"InChI=1S/C43H46ClN9O7S/c1-24-25(2)61-43-36(24)38(27-10-12-28(44)13-11-27)46-30(39-49-48-26(3)52(39)43)22-35(56)51-19-17-50(18-20-51)23-34(55)45-16-5-4-6-21-60-32-9-7-8-29-37(32)42(59)53(41(29)58)31-14-15-33(54)47-40(31)57/h7-13,30-31H,4-6,14-23H2,1-3H3,(H,45,55)(H,47,54,57)/t30-,31?/m0/s1",SDWUURRMSCHVOR-FSRLHOSWSA-N,42,3,2217,O=C(CN1CCNCC1)NCCCCCO,[R1]N1CCN(CC1)CC(=O)NCCCCCO[R2],229.324,229.179027,-0.66,16,1,4,3,7,64.6,C11H23N3O2,"InChI=1S/C11H23N3O2/c15-9-3-1-2-4-13-11(16)10-14-7-5-12-6-8-14/h12,15H,1-10H2,(H,13,16)",CUEAANJCBWIKAF-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.94,60,6.924627388,6.126826479,118.9522,746.7471
4878,62,86,62,86,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)OCC(=O)NCCCCOC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in MDA-MB-231 cells after 8h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01218,786.267,785.2034598,3.8,55,7,13,2,12,191.25,C38H36ClN7O8S,"InChI=1S/C38H36ClN7O8S/c1-19-20(2)55-38-31(19)33(22-9-11-23(39)12-10-22)41-25(34-44-43-21(3)45(34)38)17-30(49)54-18-29(48)40-15-4-5-16-53-27-8-6-7-24-32(27)37(52)46(36(24)51)26-13-14-28(47)42-35(26)50/h6-12,25-26H,4-5,13-18H2,1-3H3,(H,40,48)(H,42,47,50)/t25-,26?/m0/s1",PLVCAPPHMNXCHP-PMCHYTPCSA-N,42,3,2220,O=C(CO)NCCCCO,[R1]OCC(=O)NCCCCO[R2],147.174,147.0895433,-1.08,10,0,3,3,5,69.56,C6H13NO3,"InChI=1S/C6H13NO3/c8-4-2-1-3-7-6(10)5-9/h8-9H,1-5H2,(H,7,10)",CWSYIPMVNYAKIY-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.86,62,7.321941597,6.204758742,47.6495,624.0814
3743,0.1,98,0.1,98,O60885,BRD4,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.1,7.071644549,6.616047135,84.7921,242.0766
3743,0.1,98,0.1,98,O60885,BRD4,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.1,6.567727922,6.616047135,270.5653,242.0766
3743,0.1,98,0.1,98,O60885,BRD4,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.1,7.616367547,6.616047135,24.1898,242.0766
3743,0.3,97,0.3,97,P25440,BRD2,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,0.3,7.071644549,6.616047135,84.7921,242.0766
3743,0.3,97,0.3,97,P25440,BRD2,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,0.3,6.567727922,6.616047135,270.5653,242.0766
3743,0.3,97,0.3,97,P25440,BRD2,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,0.3,7.616367547,6.616047135,24.1898,242.0766
3743,0.4,98,0.4,98,Q15059,BRD3,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD3 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,47.09,0.0147165,1,1,1,1,1,0.0147165,0.98,0.4,7.071644549,6.616047135,84.7921,242.0766
3743,0.4,98,0.4,98,Q15059,BRD3,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD3 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,47.09,0.0147165,1,1,1,1,1,0.0147165,0.98,0.4,6.567727922,6.616047135,270.5653,242.0766
3743,0.4,98,0.4,98,Q15059,BRD3,CRBN,,BD-7102,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CC5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD3 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,712.792,712.2216371,3.03,52,9,12,1,6,144.55,C38H32N8O5S,"InChI=1S/C38H32N8O5S/c1-22-41-42-32-21-51-20-28-27(14-23-6-3-2-4-7-23)31(52-38(28)45(22)32)12-10-24-15-39-44(18-24)19-25-16-43(17-25)29-9-5-8-26-34(29)37(50)46(36(26)49)30-11-13-33(47)40-35(30)48/h2-9,15,18,25,30H,11,13-14,16-17,19-21H2,1H3,(H,40,47,48)",YINXRHBANVHQMY-UHFFFAOYSA-N,46,3,1664,CC1CNC1,[R1]CC1CN(C1)[R2],71.123,71.07349929,0.36,5,1,1,1,0,12.03,C4H9N,"InChI=1S/C4H9N/c1-4-2-5-3-4/h4-5H,2-3H2,1H3",HTHMVKNHGOVITA-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,47.09,0.0147165,1,1,1,1,1,0.0147165,0.98,0.4,7.616367547,6.616047135,24.1898,242.0766
3744,0.4,98,0.4,98,O60885,BRD4,CRBN,,BD-7163,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CCN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,726.819,726.2372872,3.52,53,9,12,1,5,144.55,C39H34N8O5S,"InChI=1S/C39H34N8O5S/c1-23-42-43-33-22-52-21-29-28(18-24-6-3-2-4-7-24)32(53-39(29)46(23)33)12-10-25-19-40-45(20-25)26-14-16-44(17-15-26)30-9-5-8-27-35(30)38(51)47(37(27)50)31-11-13-34(48)41-36(31)49/h2-9,19-20,26,31H,11,13-18,21-22H2,1H3,(H,41,48,49)",LBOQQOZSFDCXGL-UHFFFAOYSA-N,46,3,202,C1CCNCC1,[R1]C1CCN(CC1)[R2],85.15,85.08914935,0.64,6,1,1,1,0,12.03,C5H11N,"InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2",NQRYJNQNLNOLGT-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.4,6.515181881,6.818216922,305.3642,151.9788
3744,0.4,98,0.4,98,O60885,BRD4,CRBN,,BD-7163,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CCN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,726.819,726.2372872,3.52,53,9,12,1,5,144.55,C39H34N8O5S,"InChI=1S/C39H34N8O5S/c1-23-42-43-33-22-52-21-29-28(18-24-6-3-2-4-7-24)32(53-39(29)46(23)33)12-10-25-19-40-45(20-25)26-14-16-44(17-15-26)30-9-5-8-27-35(30)38(51)47(37(27)50)31-11-13-34(48)41-36(31)49/h2-9,19-20,26,31H,11,13-18,21-22H2,1H3,(H,41,48,49)",LBOQQOZSFDCXGL-UHFFFAOYSA-N,46,3,202,C1CCNCC1,[R1]C1CCN(CC1)[R2],85.15,85.08914935,0.64,6,1,1,1,0,12.03,C5H11N,"InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2",NQRYJNQNLNOLGT-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.4,6.136355537,6.818216922,730.5408,151.9788
3744,0.4,98,0.4,98,O60885,BRD4,CRBN,,BD-7163,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CCN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,726.819,726.2372872,3.52,53,9,12,1,5,144.55,C39H34N8O5S,"InChI=1S/C39H34N8O5S/c1-23-42-43-33-22-52-21-29-28(18-24-6-3-2-4-7-24)32(53-39(29)46(23)33)12-10-25-19-40-45(20-25)26-14-16-44(17-15-26)30-9-5-8-27-35(30)38(51)47(37(27)50)31-11-13-34(48)41-36(31)49/h2-9,19-20,26,31H,11,13-18,21-22H2,1H3,(H,41,48,49)",LBOQQOZSFDCXGL-UHFFFAOYSA-N,46,3,202,C1CCNCC1,[R1]C1CCN(CC1)[R2],85.15,85.08914935,0.64,6,1,1,1,0,12.03,C5H11N,"InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2",NQRYJNQNLNOLGT-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.4,7.146938689,6.818216922,71.2954,151.9788
3744,50,68,50,68,P25440,BRD2,CRBN,,BD-7163,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CCN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,726.819,726.2372872,3.52,53,9,12,1,5,144.55,C39H34N8O5S,"InChI=1S/C39H34N8O5S/c1-23-42-43-33-22-52-21-29-28(18-24-6-3-2-4-7-24)32(53-39(29)46(23)33)12-10-25-19-40-45(20-25)26-14-16-44(17-15-26)30-9-5-8-27-35(30)38(51)47(37(27)50)31-11-13-34(48)41-36(31)49/h2-9,19-20,26,31H,11,13-18,21-22H2,1H3,(H,41,48,49)",LBOQQOZSFDCXGL-UHFFFAOYSA-N,46,3,202,C1CCNCC1,[R1]C1CCN(CC1)[R2],85.15,85.08914935,0.64,6,1,1,1,0,12.03,C5H11N,"InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2",NQRYJNQNLNOLGT-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.68,50,6.515181881,6.818216922,305.3642,151.9788
3744,50,68,50,68,P25440,BRD2,CRBN,,BD-7163,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CCN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,726.819,726.2372872,3.52,53,9,12,1,5,144.55,C39H34N8O5S,"InChI=1S/C39H34N8O5S/c1-23-42-43-33-22-52-21-29-28(18-24-6-3-2-4-7-24)32(53-39(29)46(23)33)12-10-25-19-40-45(20-25)26-14-16-44(17-15-26)30-9-5-8-27-35(30)38(51)47(37(27)50)31-11-13-34(48)41-36(31)49/h2-9,19-20,26,31H,11,13-18,21-22H2,1H3,(H,41,48,49)",LBOQQOZSFDCXGL-UHFFFAOYSA-N,46,3,202,C1CCNCC1,[R1]C1CCN(CC1)[R2],85.15,85.08914935,0.64,6,1,1,1,0,12.03,C5H11N,"InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2",NQRYJNQNLNOLGT-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.68,50,6.136355537,6.818216922,730.5408,151.9788
3744,50,68,50,68,P25440,BRD2,CRBN,,BD-7163,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CCN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,726.819,726.2372872,3.52,53,9,12,1,5,144.55,C39H34N8O5S,"InChI=1S/C39H34N8O5S/c1-23-42-43-33-22-52-21-29-28(18-24-6-3-2-4-7-24)32(53-39(29)46(23)33)12-10-25-19-40-45(20-25)26-14-16-44(17-15-26)30-9-5-8-27-35(30)38(51)47(37(27)50)31-11-13-34(48)41-36(31)49/h2-9,19-20,26,31H,11,13-18,21-22H2,1H3,(H,41,48,49)",LBOQQOZSFDCXGL-UHFFFAOYSA-N,46,3,202,C1CCNCC1,[R1]C1CCN(CC1)[R2],85.15,85.08914935,0.64,6,1,1,1,0,12.03,C5H11N,"InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2",NQRYJNQNLNOLGT-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.68,50,7.146938689,6.818216922,71.2954,151.9788
3745,0.2,95,3.5/0.2,90/95,O60885,BRD4,CRBN,,BD-7148,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MCF-7/T47D cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-31-20-50-19-27-26(14-22-6-3-2-4-7-22)30(51-37(27)44(21)31)12-10-23-15-38-43(16-23)24-17-42(18-24)28-9-5-8-25-33(28)36(49)45(35(25)48)29-11-13-32(46)39-34(29)47/h2-9,15-16,24,29H,11,13-14,17-20H2,1H3,(H,39,46,47)",JTXHXYXYGGEYBL-UHFFFAOYSA-N,46,3,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.2,7.339625809,6.561924347,45.7482,274.2052
3745,0.2,93,0.9/0.2/3.6,99/93/93,O60885,BRD4,CRBN,,BD-7148,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11/RS4;11/HL60 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-31-20-50-19-27-26(14-22-6-3-2-4-7-22)30(51-37(27)44(21)31)12-10-23-15-38-43(16-23)24-17-42(18-24)28-9-5-8-25-33(28)36(49)45(35(25)48)29-11-13-32(46)39-34(29)47/h2-9,15-16,24,29H,11,13-14,17-20H2,1H3,(H,39,46,47)",JTXHXYXYGGEYBL-UHFFFAOYSA-N,46,3,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.93,0.2,7.339625809,6.561924347,45.7482,274.2052
3745,1,93,13/1.0/5.6,92/93/95,O60885,BRD4,CRBN,,BD-7148,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MOLM13/MDA-MB-231/MDA-MB-453 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-31-20-50-19-27-26(14-22-6-3-2-4-7-22)30(51-37(27)44(21)31)12-10-23-15-38-43(16-23)24-17-42(18-24)28-9-5-8-25-33(28)36(49)45(35(25)48)29-11-13-32(46)39-34(29)47/h2-9,15-16,24,29H,11,13-14,17-20H2,1H3,(H,39,46,47)",JTXHXYXYGGEYBL-UHFFFAOYSA-N,46,3,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.93,1,7.339625809,6.561924347,45.7482,274.2052
3747,0.1,99,0.6/<0.1/0.2,99/99/99,O60885,BRD4,CRBN,,BD-9136,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5(CCN6CCN(C)CC6)CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MDA-MB-453/MCF-7/T47D cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,824.968,824.3216855,2.84,60,10,14,1,8,151.03,C44H44N10O5S,"InChI=1S/C44H44N10O5S/c1-28-47-48-37-25-59-24-33-32(21-29-7-4-3-5-8-29)36(60-43(33)53(28)37)13-11-30-22-45-52(23-30)44(15-16-50-19-17-49(2)18-20-50)26-51(27-44)34-10-6-9-31-39(34)42(58)54(41(31)57)35-12-14-38(55)46-40(35)56/h3-10,22-23,35H,12,14-21,24-27H2,1-2H3,(H,46,55,56)",WNTMFWJFGDGXOH-UHFFFAOYSA-N,46,3,1752,CN1CCN(CCC2CNC2)CC1,[R1]C1(CN(C1)[R2])CCN2CCN(CC2)C,183.299,183.1735477,0.03,13,2,3,1,3,18.51,C10H21N3,"InChI=1S/C10H21N3/c1-12-4-6-13(7-5-12)3-2-10-8-11-9-10/h10-11H,2-9H2,1H3",BZCCKYUASUQBEL-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,0.1,7.283633991,6.798721987,52.0434,158.9564
3747,0.5,99,0.5/0.7/0.5,99/99/95,O60885,BRD4,CRBN,,BD-9136,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5(CCN6CCN(C)CC6)CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in HL60/RS4;11/MDA-MB-231 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,824.968,824.3216855,2.84,60,10,14,1,8,151.03,C44H44N10O5S,"InChI=1S/C44H44N10O5S/c1-28-47-48-37-25-59-24-33-32(21-29-7-4-3-5-8-29)36(60-43(33)53(28)37)13-11-30-22-45-52(23-30)44(15-16-50-19-17-49(2)18-20-50)26-51(27-44)34-10-6-9-31-39(34)42(58)54(41(31)57)35-12-14-38(55)46-40(35)56/h3-10,22-23,35H,12,14-21,24-27H2,1-2H3,(H,46,55,56)",WNTMFWJFGDGXOH-UHFFFAOYSA-N,46,3,1752,CN1CCN(CCC2CNC2)CC1,[R1]C1(CN(C1)[R2])CCN2CCN(CC2)C,183.299,183.1735477,0.03,13,2,3,1,3,18.51,C10H21N3,"InChI=1S/C10H21N3/c1-12-4-6-13(7-5-12)3-2-10-8-11-9-10/h10-11H,2-9H2,1H3",BZCCKYUASUQBEL-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,0.5,7.283633991,6.798721987,52.0434,158.9564
3747,1.2,99,1.2/4.7/1.5,99/96/90,O60885,BRD4,CRBN,,BD-9136,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5(CCN6CCN(C)CC6)CN(C6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11/MV-4-11/MOLM13 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,824.968,824.3216855,2.84,60,10,14,1,8,151.03,C44H44N10O5S,"InChI=1S/C44H44N10O5S/c1-28-47-48-37-25-59-24-33-32(21-29-7-4-3-5-8-29)36(60-43(33)53(28)37)13-11-30-22-45-52(23-30)44(15-16-50-19-17-49(2)18-20-50)26-51(27-44)34-10-6-9-31-39(34)42(58)54(41(31)57)35-12-14-38(55)46-40(35)56/h3-10,22-23,35H,12,14-21,24-27H2,1-2H3,(H,46,55,56)",WNTMFWJFGDGXOH-UHFFFAOYSA-N,46,3,1752,CN1CCN(CCC2CNC2)CC1,[R1]C1(CN(C1)[R2])CCN2CCN(CC2)C,183.299,183.1735477,0.03,13,2,3,1,3,18.51,C10H21N3,"InChI=1S/C10H21N3/c1-12-4-6-13(7-5-12)3-2-10-8-11-9-10/h10-11H,2-9H2,1H3",BZCCKYUASUQBEL-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,1.2,7.283633991,6.798721987,52.0434,158.9564
3562,46.1,95.01,46.1,95.01,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CC2=CC=C(C#CC3CCN(C4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)N=C2)CC1,Degradation of BTK in Ramos cells after 24 h treatment,58.57,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,840.945,840.3496145,4.94,63,10,13,2,8,181.77,C48H44N10O5,"InChI=1S/C48H44N10O5/c49-44-42-43(32-11-15-36(16-12-32)63-35-5-2-1-3-6-35)54-58(45(42)52-29-51-44)34-21-23-55(24-22-34)28-31-10-14-33(50-27-31)13-9-30-19-25-56(26-20-30)38-8-4-7-37-41(38)48(62)57(47(37)61)39-17-18-40(59)53-46(39)60/h1-8,10-12,14-16,27,29-30,34,39H,17-26,28H2,(H2,49,51,52)(H,53,59,60)",QSCOJWKWSHBBPQ-UHFFFAOYSA-N,51,3,1659,CC1=CC=C(C#CC2CCNCC2)N=C1,[R1]CC1=CN=C(C=C1)C#CC2CCN(CC2)[R2],200.285,200.1313485,1.76,15,2,2,1,0,24.92,C13H16N2,"InChI=1S/C13H16N2/c1-11-2-4-13(15-10-11)5-3-12-6-8-14-9-7-12/h2,4,10,12,14H,6-9H2,1H3",OFFLKOQQNZKIFZ-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9501,46.1,7.361447809,7.004332864,43.5063,99.0073
3558,9.37,99.36,9.37/10.34 ,99.36/99.51,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(C(=O)CN2CCN(CC3CCN(C4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)CC2)CC1,Degradation of BTK in Ramos/Mino cells after 24 h treatment,90.96,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,865.996,865.4023784,3.63,64,10,14,2,10,192.43,C47H51N11O6,"InChI=1S/C47H51N11O6/c48-43-41-42(31-9-11-34(12-10-31)64-33-5-2-1-3-6-33)52-58(44(41)50-29-49-43)32-17-21-56(22-18-32)39(60)28-54-25-23-53(24-26-54)27-30-15-19-55(20-16-30)36-8-4-7-35-40(36)47(63)57(46(35)62)37-13-14-38(59)51-45(37)61/h1-12,29-30,32,37H,13-28H2,(H2,48,49,50)(H,51,59,61)",FCQYWOVXHUEFAG-UHFFFAOYSA-N,51,3,1661,O=CCN1CCN(CC2CCNCC2)CC1,[R1]C(=O)CN1CCN(CC1)CC2CCN(CC2)[R2],225.336,225.1841124,-0.08,16,2,4,1,4,35.58,C12H23N3O,"InChI=1S/C12H23N3O/c16-10-9-14-5-7-15(8-6-14)11-12-1-3-13-4-2-12/h10,12-13H,1-9,11H2",ILQSVJSYQRDNRW-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9936,9.37,6.823326694,6.454292103,150.2012,351.3241
3559,7.27,97.56,7.27/9.06,97.56/99.70,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(C(=O)CN2CCN(CC3CN(C4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)C3)CC2)CC1,Degradation of BTK in Ramos/Mino cells after 24 h treatment,67.51,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,837.942,837.3710782,2.91,62,10,14,2,10,192.43,C45H47N11O6,"InChI=1S/C45H47N11O6/c46-41-39-40(29-9-11-32(12-10-29)62-31-5-2-1-3-6-31)50-56(42(39)48-27-47-41)30-15-17-53(18-16-30)37(58)26-52-21-19-51(20-22-52)23-28-24-54(25-28)34-8-4-7-33-38(34)45(61)55(44(33)60)35-13-14-36(57)49-43(35)59/h1-12,27-28,30,35H,13-26H2,(H2,46,47,48)(H,49,57,59)",BZECJEIHNUUQGB-UHFFFAOYSA-N,51,3,1662,O=CCN1CCN(CC2CNC2)CC1,[R1]C(=O)CN1CCN(CC1)CC2CN(C2)[R2],197.282,197.1528122,-0.79,14,2,4,1,4,35.58,C10H19N3O,"InChI=1S/C10H19N3O/c14-6-5-12-1-3-13(4-2-12)9-10-7-11-8-10/h6,10-11H,1-5,7-9H2",DDYLSNUNYAOPJC-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9756,7.27,7.348136199,6.731966145,44.8605,185.3676
2842,20,93.8,20,93.8,Q06187,BTK,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK in JeKo-1 cells after 24 h treatment,86.5/88.6,% BTK degradation in JeKo-1 cells after 24 h treatment at 100/1000 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.7/1760.0,Inhibition of cell proliferation in JeKo-1/BTK C481S Ba/F3 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115403,1024.529,1023.389346,4.65,73,8,16,6,27,262.76,C51H58ClN9O12,"InChI=1S/C51H58ClN9O12/c52-39-29-35(73-34-5-2-1-3-6-34)13-14-36(39)45(63)38-30-55-46-44(38)47(57-31-56-46)58-32-9-11-33(12-10-32)59-51(67)54-18-20-69-22-24-71-26-28-72-27-25-70-23-21-68-19-17-53-40-8-4-7-37-43(40)50(66)61(49(37)65)41-15-16-42(62)60-48(41)64/h1-8,13-14,29-33,41,53H,9-12,15-28H2,(H2,54,59,67)(H,60,62,64)(H2,55,56,57,58)/t32-,33+,41?",OIAOFDRZXBDDRR-HYKUANOISA-N,453,3,1867,NCCOCCOCCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCCOCCOCCN[R2],308.375,308.1947366,-1.54,21,0,7,2,18,101.27,C13H28N2O6,"InChI=1S/C13H28N2O6/c14-1-3-17-5-7-19-9-11-21-12-10-20-8-6-18-4-2-15-13-16/h13H,1-12,14H2,(H,15,16)",MPRWBBVZLVIJGJ-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.938,20,6.587956348,7.164461185,258.252,68.4761
2842,41.9,93,41.9,93,Q06187,BTK,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,56.4,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.7,Inhibit proliferation of TMD8 cells,,,,,,,,,,,<0.53,Caco-2 A2B assay,7.5,Caco-2 B2A assay,10.1016/j.ejmech.2021.113820,1024.529,1023.389346,4.65,73,8,16,6,27,262.76,C51H58ClN9O12,"InChI=1S/C51H58ClN9O12/c52-39-29-35(73-34-5-2-1-3-6-34)13-14-36(39)45(63)38-30-55-46-44(38)47(57-31-56-46)58-32-9-11-33(12-10-32)59-51(67)54-18-20-69-22-24-71-26-28-72-27-25-70-23-21-68-19-17-53-40-8-4-7-37-43(40)50(66)61(49(37)65)41-15-16-42(62)60-48(41)64/h1-8,13-14,29-33,41,53H,9-12,15-28H2,(H2,54,59,67)(H,60,62,64)(H2,55,56,57,58)/t32-,33+,41?",OIAOFDRZXBDDRR-HYKUANOISA-N,453,3,1867,NCCOCCOCCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCCOCCOCCN[R2],308.375,308.1947366,-1.54,21,0,7,2,18,101.27,C13H28N2O6,"InChI=1S/C13H28N2O6/c14-1-3-17-5-7-19-9-11-21-12-10-20-8-6-18-4-2-15-13-16/h13H,1-12,14H2,(H,15,16)",MPRWBBVZLVIJGJ-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,41.9,6.587956348,7.164461185,258.252,68.4761
2842,42.9,90.7,42.9,90.7,Q06187,BTK C481S,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK C481S in TMD8 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,253.5,Inhibit proliferation of TMD8 (BTK C481S) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,1024.529,1023.389346,4.65,73,8,16,6,27,262.76,C51H58ClN9O12,"InChI=1S/C51H58ClN9O12/c52-39-29-35(73-34-5-2-1-3-6-34)13-14-36(39)45(63)38-30-55-46-44(38)47(57-31-56-46)58-32-9-11-33(12-10-32)59-51(67)54-18-20-69-22-24-71-26-28-72-27-25-70-23-21-68-19-17-53-40-8-4-7-37-43(40)50(66)61(49(37)65)41-15-16-42(62)60-48(41)64/h1-8,13-14,29-33,41,53H,9-12,15-28H2,(H2,54,59,67)(H,60,62,64)(H2,55,56,57,58)/t32-,33+,41?",OIAOFDRZXBDDRR-HYKUANOISA-N,453,3,1867,NCCOCCOCCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCCOCCOCCN[R2],308.375,308.1947366,-1.54,21,0,7,2,18,101.27,C13H28N2O6,"InChI=1S/C13H28N2O6/c14-1-3-17-5-7-19-9-11-21-12-10-20-8-6-18-4-2-15-13-16/h13H,1-12,14H2,(H,15,16)",MPRWBBVZLVIJGJ-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.907,42.9,6.587956348,7.164461185,258.252,68.4761
1380,2.2,97,2.2,97,Q06187,BTK,CRBN,,NC-1,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)CCCCCCOCCOCCOCCOCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C1,Degradation of BTK in Mino cells after 24 h treatment,,,16,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.9b13907,947.059,946.4225047,3.81,69,8,16,2,25,228.86,C50H58N8O11,"InChI=1S/C50H58N8O11/c51-46-44-45(34-16-18-37(19-17-34)69-36-11-4-3-5-12-36)55-58(47(44)53-33-52-46)35-10-9-22-56(32-35)42(60)15-6-1-2-7-23-64-24-25-65-26-27-66-28-29-67-30-31-68-40-14-8-13-38-43(40)50(63)57(49(38)62)39-20-21-41(59)54-48(39)61/h3-5,8,11-14,16-19,33,35,39H,1-2,6-7,9-10,15,20-32H2,(H2,51,52,53)(H,54,59,61)/t35-,39?/m1/s1",QSLUWEWRUWTRBT-QQKHLPPFSA-N,217,3,659,CCCCCCOCCOCCOCCOCCO,[R1]CCCCCCOCCOCCOCCOCCO[R2],278.389,278.2093241,1.29,19,0,5,1,16,57.15,C14H30O5,"InChI=1S/C14H30O5/c1-2-3-4-5-7-16-9-11-18-13-14-19-12-10-17-8-6-15/h15H,2-14H2,1H3",VUEUVIPIBVJLCY-UHFFFAOYSA-N,Q9Y616,IRAK3,,CC(=O)N1CCN([C@H]2CC[C@@H](NC3=NC=NN4C=CC(C(C)C)=C34)CC2)CC1,6,LanthaScreen Eu IRAK3 binding displacement assay using an Alexa Fluor conjugate,,,,,,,10.1021/acs.jmedchem.0c01125,384.528,384.2637596,2.5,28,4,6,1,4,65.77,C21H32N6O,"InChI=1S/C21H32N6O/c1-15(2)19-8-9-27-20(19)21(22-14-23-27)24-17-4-6-18(7-5-17)26-12-10-25(11-13-26)16(3)28/h8-9,14-15,17-18H,4-7,10-13H2,1-3H3,(H,22,23,24)/t17-,18+",FQBRQRVXPUQKLG-HDICACEKSA-N,50466824,145979845,CHEMBL4278882,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,2.2,6.236557371,6.910866707,580.0195,122.7816
1381,8.6,91,8.6,91,Q06187,BTK,CRBN,,IR-1,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)/C=C/COCCOCCOCCOCCOCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C1,Degradation of BTK in Mino cells after 24 h treatment,,,2,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.9b13907,947.015,946.3861192,2.37,69,8,17,2,24,238.09,C49H54N8O12,"InChI=1S/C49H54N8O12/c50-45-43-44(33-13-15-36(16-14-33)69-35-8-2-1-3-9-35)54-57(46(43)52-32-51-45)34-7-5-19-55(31-34)41(59)12-6-20-63-21-22-64-23-24-65-25-26-66-27-28-67-29-30-68-39-11-4-10-37-42(39)49(62)56(48(37)61)38-17-18-40(58)53-47(38)60/h1-4,6,8-16,32,34,38H,5,7,17-31H2,(H2,50,51,52)(H,53,58,60)/b12-6+/t34-,38?/m1/s1",AWOLTJZICWTLFS-AHDGVXFFSA-N,216,3,660,COCCOCCOCCOCCOCCO,[R1]COCCOCCOCCOCCOCCO[R2],252.307,252.1572885,-1.2,17,0,6,1,14,66.38,C11H24O6,"InChI=1S/C11H24O6/c1-13-4-5-15-8-9-17-11-10-16-7-6-14-3-2-12/h12H,2-11H2,1H3",SLNYBUIEAMRFSZ-UHFFFAOYSA-N,O00444,PLK4,Rebastinib,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(C)(C)C)=NN3C3=CC=C4N=CC=CC4=C3)C(F)=C2)=CC=N1,,,,,4088,Kd apparent of PLK4,,,10.1126/science.aan4368,553.598,553.223766,4.93,41,5,7,3,6,123.06,C30H28FN7O3,"InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)",WVXNSAVVKYZVOE-UHFFFAOYSA-N,185674,25066467,CHEMBL1738757,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,8.6,6.851942275,6.528402873,140.6234,296.2082
1382,1.9,88,1.9,88,Q06187,BTK,CRBN,,IR-2,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)/C=C/CCCCOCCOCCOCCOCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C1,Degradation of BTK in Mino cells after 24 h treatment,,,14,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.9b13907,945.043,944.4068546,3.69,69,8,16,2,24,228.86,C50H56N8O11,"InChI=1S/C50H56N8O11/c51-46-44-45(34-16-18-37(19-17-34)69-36-11-4-3-5-12-36)55-58(47(44)53-33-52-46)35-10-9-22-56(32-35)42(60)15-6-1-2-7-23-64-24-25-65-26-27-66-28-29-67-30-31-68-40-14-8-13-38-43(40)50(63)57(49(38)62)39-20-21-41(59)54-48(39)61/h3-6,8,11-19,33,35,39H,1-2,7,9-10,20-32H2,(H2,51,52,53)(H,54,59,61)/b15-6+/t35-,39?/m1/s1",ZJJZBBBSQKVNHL-BYBNZYMESA-N,216,3,661,CCCCOCCOCCOCCOCCO,[R1]CCCCOCCOCCOCCOCCO[R2],250.335,250.1780239,0.2,17,0,5,1,14,57.15,C12H26O5,"InChI=1S/C12H26O5/c1-2-3-5-14-7-9-16-11-12-17-10-8-15-6-4-13/h13H,2-12H2,1H3",MXVMODFDROLTFD-UHFFFAOYSA-N,O00444,PLK4,Rebastinib,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(C)(C)C)=NN3C3=CC=C4N=CC=CC4=C3)C(F)=C2)=CC=N1,,,,,4088,Kd apparent of PLK4,,,10.1126/science.aan4368,553.598,553.223766,4.93,41,5,7,3,6,123.06,C30H28FN7O3,"InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)",WVXNSAVVKYZVOE-UHFFFAOYSA-N,185674,25066467,CHEMBL1738757,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.88,1.9,6.431889456,6.835064937,369.9223,146.1959
1383,10,68,10,68,Q06187,BTK,CRBN,,,N#C/C(=C/COCCOCCOCCOCCOCCOC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C1,Degradation of BTK in Mino cells after 24 h treatment,,,12,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.9b13907,972.025,971.3813681,2.3,71,8,18,2,24,261.88,C50H53N9O12,"InChI=1S/C50H53N9O12/c51-30-34(48(62)57-18-5-6-35(31-57)59-46-43(45(52)53-32-54-46)44(56-59)33-11-13-37(14-12-33)71-36-7-2-1-3-8-36)17-19-65-20-21-66-22-23-67-24-25-68-26-27-69-28-29-70-40-10-4-9-38-42(40)50(64)58(49(38)63)39-15-16-41(60)55-47(39)61/h1-4,7-14,17,32,35,39H,5-6,15-16,18-29,31H2,(H2,52,53,54)(H,55,60,61)/b34-17-/t35-,39?/m1/s1",PVBBNEIMTQFCAP-YFDXCGLRSA-N,215,3,660,COCCOCCOCCOCCOCCO,[R1]COCCOCCOCCOCCOCCO[R2],252.307,252.1572885,-1.2,17,0,6,1,14,66.38,C11H24O6,"InChI=1S/C11H24O6/c1-13-4-5-15-8-9-17-11-10-16-7-6-14-3-2-12/h12H,2-11H2,1H3",SLNYBUIEAMRFSZ-UHFFFAOYSA-N,P03372,ER,,C[C@@H]1CC2=C([NH]C3=CC=CC=C23)[C@@H](C2=CN=C(Cl)N=C2)N1CC(C)(C)F,,,,,,,,,,372.875,372.1517026,4.29,26,4,3,1,3,44.81,C20H22ClFN4,"InChI=1S/C20H22ClFN4/c1-12-8-15-14-6-4-5-7-16(14)25-17(15)18(26(12)11-20(2,3)22)13-9-23-19(21)24-10-13/h4-7,9-10,12,18,25H,8,11H2,1-3H3/t12-,18-/m1/s1",COWURNTXICZXOE-KZULUSFZSA-N,,155166674,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.68,10,6.637952137,7.01643132,230.1695,96.2872
1384,35,66,35,66,Q06187,BTK,CRBN,,,N#C/C(=C/CCCCOCCOCCOCCOCCOC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C1,Degradation of BTK in Mino cells after 24 h treatment,,,1,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.9b13907,970.053,969.4021036,3.62,71,8,17,2,24,252.65,C51H55N9O11,"InChI=1S/C51H55N9O11/c52-31-35(49(63)58-21-8-10-36(32-58)60-47-44(46(53)54-33-55-47)45(57-60)34-15-17-38(18-16-34)71-37-11-4-1-5-12-37)9-3-2-6-22-66-23-24-67-25-26-68-27-28-69-29-30-70-41-14-7-13-39-43(41)51(65)59(50(39)64)40-19-20-42(61)56-48(40)62/h1,4-5,7,9,11-18,33,36,40H,2-3,6,8,10,19-30,32H2,(H2,53,54,55)(H,56,61,62)/b35-9-/t36-,40?/m1/s1",JLHRNNVFNFHLTO-BYLADGCCSA-N,215,3,661,CCCCOCCOCCOCCOCCO,[R1]CCCCOCCOCCOCCOCCO[R2],250.335,250.1780239,0.2,17,0,5,1,14,57.15,C12H26O5,"InChI=1S/C12H26O5/c1-2-3-5-14-7-9-16-11-12-17-10-8-15-6-4-13/h13H,2-12H2,1H3",MXVMODFDROLTFD-UHFFFAOYSA-N,P03372,ER,,C[C@@H]1CC2=C([NH]C3=CC=CC=C23)[C@@H](C2=CN=C(Cl)N=C2)N1CC(C)(C)F,,,,,,,,,,372.875,372.1517026,4.29,26,4,3,1,3,44.81,C20H22ClFN4,"InChI=1S/C20H22ClFN4/c1-12-8-15-14-6-4-5-7-16(14)25-17(15)18(26(12)11-20(2,3)22)13-9-23-19(21)24-10-13/h4-7,9-10,12,18,25H,8,11H2,1-3H3/t12-,18-/m1/s1",COWURNTXICZXOE-KZULUSFZSA-N,,155166674,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.66,35,6.839608045,6.771809586,144.6745,169.1182
1385,6,85,6,85,Q06187,BTK,CRBN,,,CC(C)(/C=C(/C#N)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C1)CCCOCCOCCOCCOCCOC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK in Mino cells after 24 h treatment,,,0.4,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/jacs.9b13907,998.107,997.4334037,4.5,73,8,17,2,24,252.65,C53H59N9O11,"InChI=1S/C53H59N9O11/c1-53(2,20-8-22-68-23-24-69-25-26-70-27-28-71-29-30-72-42-13-6-12-40-44(42)52(67)61(51(40)66)41-18-19-43(63)58-49(41)64)31-36(32-54)50(65)60-21-7-9-37(33-60)62-48-45(47(55)56-34-57-48)46(59-62)35-14-16-39(17-15-35)73-38-10-4-3-5-11-38/h3-6,10-17,31,34,37,41H,7-9,18-30,33H2,1-2H3,(H2,55,56,57)(H,58,63,64)/b36-31-/t37-,41?/m1/s1",DEABZGHTSXTNRF-DTNILNBBSA-N,215,3,662,CC(C)CCCOCCOCCOCCOCCO,[R1]C(C)(C)CCCOCCOCCOCCOCCO[R2],278.389,278.2093241,1,19,0,5,1,15,57.15,C14H30O5,"InChI=1S/C14H30O5/c1-14(2)4-3-6-16-8-10-18-12-13-19-11-9-17-7-5-15/h14-15H,3-13H2,1-2H3",FVNOIEMNRONTEK-UHFFFAOYSA-N,P03372,ER,,C[C@@H]1CC2=C([NH]C3=CC=CC=C23)[C@@H](C2=CN=C(Cl)N=C2)N1CC(C)(C)F,,,,,,,,,,372.875,372.1517026,4.29,26,4,3,1,3,44.81,C20H22ClFN4,"InChI=1S/C20H22ClFN4/c1-12-8-15-14-6-4-5-7-16(14)25-17(15)18(26(12)11-20(2,3)22)13-9-23-19(21)24-10-13/h4-7,9-10,12,18,25H,8,11H2,1-3H3/t12-,18-/m1/s1",COWURNTXICZXOE-KZULUSFZSA-N,,155166674,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,6,7.226273077,6.580570447,59.3919,262.6815
2005,485,92,485,92,Q9NWZ3,IRAK4,CRBN,,,CC(C)NC1=CC(N2C=CC3=CC(C#N)=CN=C32)=NC=C1C(=O)N[C@H]1CC[C@H](C(=O)NCCCNC(=O)COC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of IRAK4 in HEK293T cells after 24 h treatment,,,5,IC50 was assessed by Caliper biochemistry assay,,,,,,,,,,,,,,,,,,,490,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2020.08.010,816.876,816.3343584,2.64,60,7,13,5,14,246.61,C42H44N10O8,"InChI=1S/C42H44N10O8/c1-23(2)48-30-18-33(51-16-13-26-17-24(19-43)20-47-37(26)51)46-21-29(30)39(56)49-27-9-7-25(8-10-27)38(55)45-15-4-14-44-35(54)22-60-32-6-3-5-28-36(32)42(59)52(41(28)58)31-11-12-34(53)50-40(31)57/h3,5-6,13,16-18,20-21,23,25,27,31H,4,7-12,14-15,22H2,1-2H3,(H,44,54)(H,45,55)(H,46,48)(H,49,56)(H,50,53,57)/t25-,27-,31?",DHVQDOJINANBTP-NYHQYBDOSA-N,336,3,343,CCCNC(=O)CO,[R1]CCCNC(=O)CO[R2],117.148,117.0789786,-0.22,8,0,2,2,3,49.33,C5H11NO2,"InChI=1S/C5H11NO2/c1-2-3-6-5(8)4-7/h7H,2-4H2,1H3,(H,6,8)",AVMYPXOTVDWXBQ-UHFFFAOYSA-N,P10275,AR,,C[C@H]1CC2(CCNCC2)CN1C1=CC=C(C#N)C(Cl)=C1,,,,,,,,,,289.81,289.1345753,3.13,20,3,3,1,1,39.06,C16H20ClN3,"InChI=1S/C16H20ClN3/c1-12-9-16(4-6-19-7-5-16)11-20(12)14-3-2-13(10-18)15(17)8-14/h2-3,8,12,19H,4-7,9,11H2,1H3/t12-/m0/s1",VIWFUEBSMLFMNH-LBPRGKRZSA-N,,156180657,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.92,485,7.899533982,7.38278329,12.6028,41.4206
2006,190,93,190,93,Q9NWZ3,IRAK4,CRBN,,,CC(C)NC1=CC(N2C=CC3=CC(C#N)=CN=C32)=NC=C1C(=O)N[C@H]1CC[C@H](C(=O)NCCCCNC(=O)COC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of IRAK4 in HEK293T cells after 24 h treatment,,,7,IC50 was assessed by Caliper biochemistry assay,,,,,,,,,,,,,,,,,,,768,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2020.08.010,830.903,830.3500084,3,61,7,13,5,15,246.61,C43H46N10O8,"InChI=1S/C43H46N10O8/c1-24(2)49-31-19-34(52-17-14-27-18-25(20-44)21-48-38(27)52)47-22-30(31)40(57)50-28-10-8-26(9-11-28)39(56)46-16-4-3-15-45-36(55)23-61-33-7-5-6-29-37(33)43(60)53(42(29)59)32-12-13-35(54)51-41(32)58/h5-7,14,17-19,21-22,24,26,28,32H,3-4,8-13,15-16,23H2,1-2H3,(H,45,55)(H,46,56)(H,47,49)(H,50,57)(H,51,54,58)/t26-,28-,32?",HTWBTPRKNVRYHW-OAMJFVEXSA-N,336,3,51,CCCCNC(=O)CO,[R1]CCCCNC(=O)CO[R2],131.175,131.0946287,0.14,9,0,2,2,4,49.33,C6H13NO2,"InChI=1S/C6H13NO2/c1-2-3-4-7-6(9)5-8/h8H,2-5H2,1H3,(H,7,9)",WFYNRXPMFUYIDC-UHFFFAOYSA-N,P10275,AR,,C[C@H]1CC2(CCNCC2)CN1C1=CC=C(C#N)C(Cl)=C1,,,,,,,,,,289.81,289.1345753,3.13,20,3,3,1,1,39.06,C16H20ClN3,"InChI=1S/C16H20ClN3/c1-12-9-16(4-6-19-7-5-16)11-20(12)14-3-2-13(10-18)15(17)8-14/h2-3,8,12,19H,4-7,9,11H2,1H3/t12-/m0/s1",VIWFUEBSMLFMNH-LBPRGKRZSA-N,,156180657,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,190,7.825391679,7.763932437,14.9489,17.2214
2007,293,97,293,97,Q9NWZ3,IRAK4,CRBN,,,CC(C)NC1=CC(N2C=CC3=CC(C#N)=CN=C32)=NC=C1C(=O)N[C@H]1CC[C@H](C(=O)NCCCCCNC(=O)COC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of IRAK4 in HEK293T cells after 24 h treatment,,,26,IC50 was assessed by Caliper biochemistry assay,,,,,,,,,,,,,,,,,,,1030,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2020.08.010,844.93,844.3656585,3.36,62,7,13,5,16,246.61,C44H48N10O8,"InChI=1S/C44H48N10O8/c1-25(2)50-32-20-35(53-18-15-28-19-26(21-45)22-49-39(28)53)48-23-31(32)41(58)51-29-11-9-27(10-12-29)40(57)47-17-5-3-4-16-46-37(56)24-62-34-8-6-7-30-38(34)44(61)54(43(30)60)33-13-14-36(55)52-42(33)59/h6-8,15,18-20,22-23,25,27,29,33H,3-5,9-14,16-17,24H2,1-2H3,(H,46,56)(H,47,57)(H,48,50)(H,51,58)(H,52,55,59)/t27-,29-,33?",NOGGUZVPDPKPMG-SNOFGSQBSA-N,336,3,353,CCCCCNC(=O)CO,[R1]CCCCCNC(=O)CO[R2],145.202,145.1102787,0.68,10,0,2,2,5,49.33,C7H15NO2,"InChI=1S/C7H15NO2/c1-2-3-4-5-8-7(10)6-9/h9H,2-6H2,1H3,(H,8,10)",BOELJSPAIXVQPX-UHFFFAOYSA-N,P10275,AR,,C[C@H]1CC2(CCNCC2)CN1C1=CC=C(C#N)C(Cl)=C1,,,,,,,,,,289.81,289.1345753,3.13,20,3,3,1,1,39.06,C16H20ClN3,"InChI=1S/C16H20ClN3/c1-12-9-16(4-6-19-7-5-16)11-20(12)14-3-2-13(10-18)15(17)8-14/h2-3,8,12,19H,4-7,9,11H2,1H3/t12-/m0/s1",VIWFUEBSMLFMNH-LBPRGKRZSA-N,,156180657,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,293,7.902217455,7.592256672,12.5251,25.5707
2008,405,90,405,90,Q9NWZ3,IRAK4,CRBN,,,CC(C)NC1=CC(N2C=CC3=CC(C#N)=CN=C32)=NC=C1C(=O)N[C@H]1CC[C@H](C(=O)NCCOCCNC(=O)COC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of IRAK4 in HEK293T cells after 24 h treatment,,,7,IC50 was assessed by Caliper biochemistry assay,,,,,,,,,,,,,,,,,,,609,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2020.08.010,846.902,846.3449231,2.14,62,7,14,5,16,255.84,C43H46N10O9,"InChI=1S/C43H46N10O9/c1-24(2)49-31-19-34(52-15-12-27-18-25(20-44)21-48-38(27)52)47-22-30(31)40(57)50-28-8-6-26(7-9-28)39(56)46-14-17-61-16-13-45-36(55)23-62-33-5-3-4-29-37(33)43(60)53(42(29)59)32-10-11-35(54)51-41(32)58/h3-5,12,15,18-19,21-22,24,26,28,32H,6-11,13-14,16-17,23H2,1-2H3,(H,45,55)(H,46,56)(H,47,49)(H,50,57)(H,51,54,58)/t26-,28-,32?",YNNBDJQWDDDBRU-OAMJFVEXSA-N,336,3,972,CCOCCNC(=O)CO,[R1]CCOCCNC(=O)CO[R2],147.174,147.0895433,-0.89,10,0,3,2,5,58.56,C6H13NO3,"InChI=1S/C6H13NO3/c1-2-10-4-3-7-6(9)5-8/h8H,2-5H2,1H3,(H,7,9)",BOQCRSNIDAXGBH-UHFFFAOYSA-N,P10275,AR,,C[C@H]1CC2(CCNCC2)CN1C1=CC=C(C#N)C(Cl)=C1,,,,,,,,,,289.81,289.1345753,3.13,20,3,3,1,1,39.06,C16H20ClN3,"InChI=1S/C16H20ClN3/c1-12-9-16(4-6-19-7-5-16)11-20(12)14-3-2-13(10-18)15(17)8-14/h2-3,8,12,19H,4-7,9,11H2,1H3/t12-/m0/s1",VIWFUEBSMLFMNH-LBPRGKRZSA-N,,156180657,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9,405,7.525955668,7.219469129,29.7882,60.3297
2009,7420,71,7420,71,Q9NWZ3,IRAK4,CRBN,,,CC(C)NC1=CC(N2C=CC3=CC(C#N)=CN=C32)=NC=C1C(=O)N[C@H]1CC[C@H](C(=O)NCCOCCOCCNC(=O)COC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of IRAK4 in HEK293T cells after 24 h treatment,,,12,IC50 was assessed by Caliper biochemistry assay,,,,,,,,,,,,,,,,,,,680,TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2020.08.010,890.955,890.3711378,1.99,65,7,15,5,19,265.07,C45H50N10O10,"InChI=1S/C45H50N10O10/c1-26(2)51-33-21-36(54-15-12-29-20-27(22-46)23-50-40(29)54)49-24-32(33)42(59)52-30-8-6-28(7-9-30)41(58)48-14-17-64-19-18-63-16-13-47-38(57)25-65-35-5-3-4-31-39(35)45(62)55(44(31)61)34-10-11-37(56)53-43(34)60/h3-5,12,15,20-21,23-24,26,28,30,34H,6-11,13-14,16-19,25H2,1-2H3,(H,47,57)(H,48,58)(H,49,51)(H,52,59)(H,53,56,60)/t28-,30-,34?",OLRLOHZCSMMOCS-BVRPOGDGSA-N,336,3,973,CCOCCOCCNC(=O)CO,[R1]CCOCCOCCNC(=O)CO[R2],191.227,191.115758,-1.04,13,0,4,2,8,67.79,C8H17NO4,"InChI=1S/C8H17NO4/c1-2-12-5-6-13-4-3-9-8(11)7-10/h10H,2-7H2,1H3,(H,9,11)",YSJMRGUNPOPSRN-UHFFFAOYSA-N,P10275,AR,,C[C@H]1CC2(CCNCC2)CN1C1=CC=C(C#N)C(Cl)=C1,,,,,,,,,,289.81,289.1345753,3.13,20,3,3,1,1,39.06,C16H20ClN3,"InChI=1S/C16H20ClN3/c1-12-9-16(4-6-19-7-5-16)11-20(12)14-3-2-13(10-18)15(17)8-14/h2-3,8,12,19H,4-7,9,11H2,1H3/t12-/m0/s1",VIWFUEBSMLFMNH-LBPRGKRZSA-N,,156180657,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,7420,7.254924322,7.020423729,55.6001,95.4061
2690,1,99,<1/<1,>99/>99,O60885,BRD4,CRBN,,WWL0245,CC[C@@H]1C2=NN=C(C)N2C2=CN=C(NC3=CC=C(C(=O)NC4CCN(C(=O)COC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)C=C3OC)N=C2N1CC1CCCCC1,Degradation of BRD4 in 22Rv1/VCaP cells after 24 h treatment,,,254,IC50 was assessed by a radiometric ATP-competitive kinase assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/20.8/52.9,Inhibit proliferation of MV4-11/LNCaP/22Rv1 cells,,,,,,,,12a(WWL0245),,,,,,,10.1016/j.ejmech.2021.113922,873.972,873.3922076,4.21,64,9,15,3,12,223.18,C45H51N11O8,"InChI=1S/C45H51N11O8/c1-4-31-40-52-51-25(2)55(40)33-22-46-45(50-39(33)54(31)23-26-9-6-5-7-10-26)48-30-14-13-27(21-35(30)63-3)41(59)47-28-17-19-53(20-18-28)37(58)24-64-34-12-8-11-29-38(34)44(62)56(43(29)61)32-15-16-36(57)49-42(32)60/h8,11-14,21-22,26,28,31-32H,4-7,9-10,15-20,23-24H2,1-3H3,(H,47,59)(H,46,48,50)(H,49,57,60)/t31-,32?/m1/s1",AORZPRLVKUMTOJ-XGDNGBMYSA-N,430,3,22,O=CCO,[R1]C(=O)CO[R2],60.052,60.02112937,-0.93,4,0,2,1,1,37.3,C2H4O2,"InChI=1S/C2H4O2/c3-1-2-4/h1,4H,2H2",WGCNASOHLSPBMP-UHFFFAOYSA-N,P35968,VEGFR-2,Sorafenib,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=CC=N1,1282/8260,Inhibit the proliferation of U87/A549 cells,,,,,,,10.1186/s13046-021-02208-x,464.831,464.0863027,4.07,32,3,4,3,5,92.35,C21H16ClF3N4O3,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,16673,216239,CHEMBL1336,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,1,7.380984806,6.98384503,41.5925,103.7899
3362,2,96.7,2,96.7,Q16342,PDCD2,CRBN,,,C[C@H](NC(=O)C1=CC=C2C(C3=CC=C(C(F)(F)F)C=C3)=CC=CC2=C1)C1=CC=CC(NC2CCN(C(=O)COC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)=N1,Degradation of PDCD2 in MOLT-4 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1002/anie.202308292,832.836,832.2832322,6.09,61,8,9,3,10,167.11,C45H39F3N6O7,"InChI=1S/C45H39F3N6O7/c1-25(49-41(57)28-13-16-32-27(23-28)5-2-6-31(32)26-11-14-29(15-12-26)45(46,47)48)34-8-4-10-37(51-34)50-30-19-21-53(22-20-30)39(56)24-61-36-9-3-7-33-40(36)44(60)54(43(33)59)35-17-18-38(55)52-42(35)58/h2-16,23,25,30,35H,17-22,24H2,1H3,(H,49,57)(H,50,51)(H,52,55,58)/t25-,35?/m0/s1",FHYJXONYZYZLTJ-LLIHCOLESA-N,563,3,1554,NC1CCN(C(=O)CO)CC1,[R1]NC1CCN(CC1)C(=O)CO[R2],158.201,158.1055277,-1.32,11,1,3,2,1,66.56,C7H14N2O2,"InChI=1S/C7H14N2O2/c8-6-1-3-9(4-2-6)7(11)5-10/h6,10H,1-5,8H2",XOMJXGKEJVCZEO-UHFFFAOYSA-N,P53350,PLK1,,CC(C)C[C@H](NC(=O)[C@H]1CCCN1)C(=O)N[C@@H](CC1=CN=C[NH]1)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)[C@@H](C)OP(=O)(O)O,,,,,,,,,10.1021/acs.jmedchem.3c01493,633.596,633.2523417,-5.06,43,2,10,10,17,281.4,C24H40N7O11P,"InChI=1S/C24H40N7O11P/c1-12(2)7-16(28-20(33)15-5-4-6-26-15)21(34)29-17(8-14-9-25-11-27-14)22(35)30-18(10-32)23(36)31-19(24(37)38)13(3)42-43(39,40)41/h9,11-13,15-19,26,32H,4-8,10H2,1-3H3,(H,25,27)(H,28,33)(H,29,34)(H,30,35)(H,31,36)(H,37,38)(H2,39,40,41)/t13-,15-,16+,17+,18+,19+/m1/s1",WXGBWHLFXXMZRD-VAFLDVPESA-N,,,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.967,2,6.000560925,6.656735237,998.7093,220.427
3565,3.46,84.47,3.46,84.47,Q9UBN7,HDAC6,CRBN,,,O=C(CCCCCCNC(=O)C1=CC=C(NC(=O)CCCCCCCNC(=O)COC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1)NO,Degradation of HDAC6 in HL-60 cells after 6h treatment,,,4.86,Inhibit of HDAC6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,31170/17550/24460,Inhibition of cell proliferation of MV4-11/Molm-13/SKNO-1 cells,400,dose-dependent alpha-tubulin hyperacetylation,,,,,,,,,,,,,10.1021/acs.jmedchem.2c01659,734.807,734.3275417,2.05,53,4,10,6,21,229.41,C37H46N6O10,"InChI=1S/C37H46N6O10/c44-29(40-25-17-15-24(16-18-25)34(48)39-22-9-5-3-7-14-31(46)42-52)13-6-2-1-4-8-21-38-32(47)23-53-28-12-10-11-26-33(28)37(51)43(36(26)50)27-19-20-30(45)41-35(27)49/h10-12,15-18,27,52H,1-9,13-14,19-23H2,(H,38,47)(H,39,48)(H,40,44)(H,42,46)(H,41,45,49)",FQLCLMHMOFLVSV-UHFFFAOYSA-N,345,3,1665,NC(=O)CCCCCCCNC(=O)CO,[R1]NC(=O)CCCCCCCNC(=O)CO[R2],216.281,216.1473925,-0.11,15,0,3,3,9,92.42,C10H20N2O3,"InChI=1S/C10H20N2O3/c11-9(14)6-4-2-1-3-5-7-12-10(15)8-13/h13H,1-8H2,(H2,11,14)(H,12,15)",UILMSVHHSHBBIS-UHFFFAOYSA-N,Q9H8M2,BRD9,,CCCCN1C=C(C2=CC(OC)=C(C)C(OC)=C2)C2=CC=NC=C2C1=O,,,,,,,,,,352.434,352.1786926,3.18,26,3,5,0,6,53.35,C21H24N2O3,"InChI=1S/C21H24N2O3/c1-5-6-9-23-13-18(16-7-8-22-12-17(16)21(23)24)15-10-19(25-3)14(2)20(11-15)26-4/h7-8,10-13H,5-6,9H2,1-4H3",FWBLIZCCLZTRMH-UHFFFAOYSA-N,,156187666,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,62.33,0.011118242,1,1,1,1,1,0.011118242,0.8447,3.46,7.750368744,6.750338627,17.7677,177.6893
3566,130,67.5,130,67.5,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCCN4C=C(CCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,240/1290/500,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,847.761,846.2771491,4.41,59,7,12,4,17,213.61,C40H44Cl2N10O7,"InChI=1S/C40H44Cl2N10O7/c41-27-10-7-11-28(42)34(27)37(55)45-29-22-43-48-35(29)38(56)44-24-15-19-50(20-16-24)17-4-2-8-25-23-51(49-47-25)18-3-1-5-21-59-31-12-6-9-26-33(31)40(58)52(39(26)57)30-13-14-32(53)46-36(30)54/h6-7,9-12,22-24,30H,1-5,8,13-21H2,(H,43,48)(H,44,56)(H,45,55)(H,46,53,54)",WQYDJYODLBQPRD-UHFFFAOYSA-N,109,3,1666,CCCCC1=CN(CCCCCO)N=N1,[R1]CCCCC1=CN(N=N1)CCCCCO[R2],211.309,211.1684623,1.74,15,1,4,1,8,50.94,C11H21N3O,"InChI=1S/C11H21N3O/c1-2-3-7-11-10-14(13-12-11)8-5-4-6-9-15/h10,15H,2-9H2,1H3",LOEAYKUOBVRMTQ-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.675,130,7.454868585,7.270815771,35.0858,53.6024
3567,70,79.1,70,79.1,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCN4C=C(CCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190/720/500,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,833.734,832.261499,4.05,58,7,12,4,16,213.61,C39H42Cl2N10O7,"InChI=1S/C39H42Cl2N10O7/c40-26-9-6-10-27(41)33(26)36(54)44-28-21-42-47-34(28)37(55)43-23-14-18-49(19-15-23)16-2-1-7-24-22-50(48-46-24)17-3-4-20-58-30-11-5-8-25-32(30)39(57)51(38(25)56)29-12-13-31(52)45-35(29)53/h5-6,8-11,21-23,29H,1-4,7,12-20H2,(H,42,47)(H,43,55)(H,44,54)(H,45,52,53)",RWZUENRHOXLKRD-UHFFFAOYSA-N,109,3,1667,CCCCC1=CN(CCCCO)N=N1,[R1]CCCCC1=CN(N=N1)CCCCO[R2],197.282,197.1528122,1.38,14,1,4,1,7,50.94,C10H19N3O,"InChI=1S/C10H19N3O/c1-2-3-6-10-9-13(12-11-10)7-4-5-8-14/h9,14H,2-8H2,1H3",JSRCAHMNEWDCGG-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.791,70,7.434331097,7.140641313,36.7848,72.3367
3568,400,58.6,400,58.6,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCN4C=C(CCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190/690/400,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,847.761,846.2771491,4.41,59,7,12,4,17,213.61,C40H44Cl2N10O7,"InChI=1S/C40H44Cl2N10O7/c41-27-10-7-11-28(42)34(27)37(55)45-29-22-43-48-35(29)38(56)44-24-15-19-50(20-16-24)17-3-1-2-8-25-23-51(49-47-25)18-4-5-21-59-31-12-6-9-26-33(31)40(58)52(39(26)57)30-13-14-32(53)46-36(30)54/h6-7,9-12,22-24,30H,1-5,8,13-21H2,(H,43,48)(H,44,56)(H,45,55)(H,46,53,54)",IFGRJEDDLDJVFO-UHFFFAOYSA-N,109,3,1668,CCCCCC1=CN(CCCCO)N=N1,[R1]CCCCCC1=CN(N=N1)CCCCO[R2],211.309,211.1684623,1.93,15,1,4,1,8,50.94,C11H21N3O,"InChI=1S/C11H21N3O/c1-2-3-4-7-11-10-14(13-12-11)8-5-6-9-15/h10,15H,2-9H2,1H3",QDGZRKQXNRGKQB-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.586,400,7.776997582,7.151142668,16.711,70.6086
3569,60,88.3,60,88.3,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCCCCCN4C=C(CCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50/250/100,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,861.788,860.2927992,5.13,60,7,12,4,18,213.61,C41H46Cl2N10O7,"InChI=1S/C41H46Cl2N10O7/c42-28-10-8-11-29(43)35(28)38(56)46-30-23-44-49-36(30)39(57)45-25-15-19-51(20-16-25)21-17-26-24-52(50-48-26)18-5-3-1-2-4-6-22-60-32-12-7-9-27-34(32)41(59)53(40(27)58)31-13-14-33(54)47-37(31)55/h7-12,23-25,31H,1-6,13-22H2,(H,44,49)(H,45,57)(H,46,56)(H,47,54,55)",KQYIIOGMBKKCCZ-UHFFFAOYSA-N,109,3,1669,CCC1=CN(CCCCCCCCO)N=N1,[R1]CCC1=CN(N=N1)CCCCCCCCO[R2],225.336,225.1841124,2.28,16,1,4,1,9,50.94,C12H23N3O,"InChI=1S/C12H23N3O/c1-2-12-11-15(14-13-12)9-7-5-3-4-6-8-10-16/h11,16H,2-10H2,1H3",SFTNJMJZMXAAHY-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.883,60,7.551619598,7.632173117,28.0789,23.3253
3570,950,68.5,950,68.5,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCCN4C=C(CCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,130/450/260,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,861.788,860.2927992,4.77,60,7,12,4,18,213.61,C41H46Cl2N10O7,"InChI=1S/C41H46Cl2N10O7/c42-28-11-8-12-29(43)35(28)38(56)46-30-23-44-49-36(30)39(57)45-25-16-20-51(21-17-25)18-4-1-3-9-26-24-52(50-48-26)19-5-2-6-22-60-32-13-7-10-27-34(32)41(59)53(40(27)58)31-14-15-33(54)47-37(31)55/h7-8,10-13,23-25,31H,1-6,9,14-22H2,(H,44,49)(H,45,57)(H,46,56)(H,47,54,55)",RVWBTXSGZFJYEH-UHFFFAOYSA-N,109,3,1670,CCCCCC1=CN(CCCCCO)N=N1,[R1]CCCCCC1=CN(N=N1)CCCCCO[R2],225.336,225.1841124,2.28,16,1,4,1,9,50.94,C12H23N3O,"InChI=1S/C12H23N3O/c1-2-3-5-8-12-11-15(14-13-12)9-6-4-7-10-16/h11,16H,2-10H2,1H3",FREPSKNECXQSGY-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.685,950,7.848920536,7.133698018,14.1605,73.5025
3571,100,75.3,100,75.3,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCN4C=C(CCCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70/260/120,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,861.788,860.2927992,4.95,60,7,12,4,18,213.61,C41H46Cl2N10O7,"InChI=1S/C41H46Cl2N10O7/c42-28-11-8-12-29(43)35(28)38(56)46-30-23-44-49-36(30)39(57)45-25-16-20-51(21-17-25)18-4-2-1-3-9-26-24-52(50-48-26)19-5-6-22-60-32-13-7-10-27-34(32)41(59)53(40(27)58)31-14-15-33(54)47-37(31)55/h7-8,10-13,23-25,31H,1-6,9,14-22H2,(H,44,49)(H,45,57)(H,46,56)(H,47,54,55)",ZIUVTWBLWUJBEY-UHFFFAOYSA-N,109,3,1671,CCCCCCC1=CN(CCCCO)N=N1,[R1]CCCCCCC1=CN(N=N1)CCCCO[R2],225.336,225.1841124,2.47,16,1,4,1,9,50.94,C12H23N3O,"InChI=1S/C12H23N3O/c1-2-3-4-5-8-12-11-15(14-13-12)9-6-7-10-16/h11,16H,2-10H2,1H3",QWDBESMZAWWPLX-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.753,100,7.829267308,7.391335006,14.8161,40.613
3572,70,86.2,70,86.2,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCCCCCN4C=C(CCCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70/340/230,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,917.896,916.3553994,6.75,64,7,12,4,22,213.61,C45H54Cl2N10O7,"InChI=1S/C45H54Cl2N10O7/c46-32-15-12-16-33(47)39(32)42(60)50-34-27-48-53-40(34)43(61)49-29-20-24-55(25-21-29)22-8-5-3-7-13-30-28-56(54-52-30)23-9-4-1-2-6-10-26-64-36-17-11-14-31-38(36)45(63)57(44(31)62)35-18-19-37(58)51-41(35)59/h11-12,14-17,27-29,35H,1-10,13,18-26H2,(H,48,53)(H,49,61)(H,50,60)(H,51,58,59)",RFWQGGOBVSJKDT-UHFFFAOYSA-N,109,3,1672,CCCCCCC1=CN(CCCCCCCCO)N=N1,[R1]CCCCCCC1=CN(N=N1)CCCCCCCCO[R2],281.444,281.2467126,4.26,20,1,4,1,13,50.94,C16H31N3O,"InChI=1S/C16H31N3O/c1-2-3-4-9-12-16-15-19(18-17-16)13-10-7-5-6-8-11-14-20/h15,20H,2-14H2,1H3",CYDMHLGPVBMSQK-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.862,70,7.53617305,7.157980966,29.0956,69.5055
3573,60,78,60,78,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCCCCN4C=C(CCCCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60/110/90,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,917.896,916.3553994,6.75,64,7,12,4,22,213.61,C45H54Cl2N10O7,"InChI=1S/C45H54Cl2N10O7/c46-32-15-12-16-33(47)39(32)42(60)50-34-27-48-53-40(34)43(61)49-29-20-24-55(25-21-29)22-8-4-1-3-7-13-30-28-56(54-52-30)23-9-5-2-6-10-26-64-36-17-11-14-31-38(36)45(63)57(44(31)62)35-18-19-37(58)51-41(35)59/h11-12,14-17,27-29,35H,1-10,13,18-26H2,(H,48,53)(H,49,61)(H,50,60)(H,51,58,59)",UJUPYASGRVZCKP-UHFFFAOYSA-N,109,3,1673,CCCCCCCC1=CN(CCCCCCCO)N=N1,[R1]CCCCCCCC1=CN(N=N1)CCCCCCCO[R2],281.444,281.2467126,4.26,20,1,4,1,13,50.94,C16H31N3O,"InChI=1S/C16H31N3O/c1-2-3-4-6-9-12-16-15-19(18-17-16)13-10-7-5-8-11-14-20/h15,20H,2-14H2,1H3",SCZDCCKHEHYFDP-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.78,60,7.602653426,7.862293532,24.9659,13.7311
3574,40,88.6,40,88.6,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCN4C=C(CCCCCCCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10/20/20,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,917.896,916.3553994,7.12,64,7,12,4,22,213.61,C45H54Cl2N10O7,"InChI=1S/C45H54Cl2N10O7/c46-32-15-12-16-33(47)39(32)42(60)50-34-27-48-53-40(34)43(61)49-29-20-24-55(25-21-29)22-8-6-4-2-1-3-5-7-13-30-28-56(54-52-30)23-9-10-26-64-36-17-11-14-31-38(36)45(63)57(44(31)62)35-18-19-37(58)51-41(35)59/h11-12,14-17,27-29,35H,1-10,13,18-26H2,(H,48,53)(H,49,61)(H,50,60)(H,51,58,59)",CSNPVEIUSQQSBW-UHFFFAOYSA-N,109,3,1674,CCCCCCCCCCC1=CN(CCCCO)N=N1,[R1]CCCCCCCCCCC1=CN(N=N1)CCCCO[R2],281.444,281.2467126,4.63,20,1,4,1,13,50.94,C16H31N3O,"InChI=1S/C16H31N3O/c1-2-3-4-5-6-7-8-9-12-16-15-19(18-17-16)13-10-11-14-20/h15,20H,2-14H2,1H3",UKQPSENXNJHMLZ-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.886,40,7.469295376,7.373283378,33.9394,42.3367
3575,100,70.1,100,70.1,P50750,CDK9,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(OCCCCCCCN4C=C(CCCCCN5CCC(NC(=O)C6=C(NC(=O)C7=C(Cl)C=CC=C7Cl)C=N[NH]6)CC5)N=N4)=C3C2=O)C(=O)N1,Degradation of CDK9 in MOLM-13 cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50/80/80,Cell cytotoxicity (IC50) was determined in MV4-11 cells after 48 h treatment/Post-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h/No-WO IC50 was determined after 6 h treatment and a total incubation time of 48 h,,,,,,,,,,,,,,,10.1021/acsmedchemlett.3c00082,889.842,888.3240993,5.66,62,7,12,4,20,213.61,C43H50Cl2N10O7,"InChI=1S/C43H50Cl2N10O7/c44-30-13-10-14-31(45)37(30)40(58)48-32-25-46-51-38(32)41(59)47-27-18-22-53(23-19-27)20-6-4-5-11-28-26-54(52-50-28)21-7-2-1-3-8-24-62-34-15-9-12-29-36(34)43(61)55(42(29)60)33-16-17-35(56)49-39(33)57/h9-10,12-15,25-27,33H,1-8,11,16-24H2,(H,46,51)(H,47,59)(H,48,58)(H,49,56,57)",VUUHHNWFNGGVNN-UHFFFAOYSA-N,109,3,1675,CCCCCC1=CN(CCCCCCCO)N=N1,[R1]CCCCCC1=CN(N=N1)CCCCCCCO[R2],253.39,253.2154125,3.18,18,1,4,1,11,50.94,C14H27N3O,"InChI=1S/C14H27N3O/c1-2-3-7-10-14-13-17(16-15-14)11-8-5-4-6-9-12-18/h13,18H,2-12H2,1H3",CDKONJWHHKELEB-UHFFFAOYSA-N,Q12834,Cdc20,Apcin-A,NCCCOC(=O)NC(NC1=NC=CC=N1)C(Cl)(Cl)Cl,,,,,,,,,10.1038/nature13660,342.614,341.0213077,2.22,20,1,6,3,6,102.16,C10H14Cl3N5O2,"InChI=1S/C10H14Cl3N5O2/c11-10(12,13)7(17-8-15-4-2-5-16-8)18-9(19)20-6-1-3-14/h2,4-5,7H,1,3,6,14H2,(H,18,19)(H,15,16,17)",JQTSJVDIFMKETH-UHFFFAOYSA-N,,127243466,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,17.41,0.03980471,1,1,1,1,1,0.03980471,0.701,100,7.343157506,7.576021679,45.3777,26.5447
5402,876,91,876,91,Q9BY41,HDAC8,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(N4CCC(N5CCN(C(=O)CCCCOC6=CC=C(CCNC(=O)C7=CC=CC(C(=O)NO)=C7)C=C6)CC5)CC4)=C3C2=O)C(=O)N1,Degradation of HDAC8 in HCT-116 cells after 10 h treatment,74.4,% HDAC8 degradation in HCT-116 cells at 5000 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2022,807.905,807.3591761,2.45,59,7,11,4,14,198,C43H49N7O9,"InChI=1S/C43H49N7O9/c51-36-15-14-35(41(55)45-36)50-42(56)33-7-4-8-34(38(33)43(50)57)48-20-17-31(18-21-48)47-22-24-49(25-23-47)37(52)9-1-2-26-59-32-12-10-28(11-13-32)16-19-44-39(53)29-5-3-6-30(27-29)40(54)46-58/h3-8,10-13,27,31,35,58H,1-2,9,14-26H2,(H,44,53)(H,46,54)(H,45,51,55)",QSDRZGJBNUYGJE-UHFFFAOYSA-N,350,3,2457,CCC1=CC=C(OCCCCC(=O)N2CCN(C3CCNCC3)CC2)C=C1,[R1]CCC1=CC=C(C=C1)OCCCCC(=O)N2CCN(CC2)C3CCN(CC3)[R2],373.541,373.2729274,2.77,27,3,4,1,8,44.81,C22H35N3O2,"InChI=1S/C22H35N3O2/c1-2-19-6-8-21(9-7-19)27-18-4-3-5-22(26)25-16-14-24(15-17-25)20-10-12-23-13-11-20/h6-9,20,23H,2-5,10-18H2,1H3",PRQDRUHODDDBFY-UHFFFAOYSA-N,P51531,SMARCA2,,NC1=NN=C(C2=CC=CC=C2O)C=C1N1CCC(C2=CC=CC=C2)CC1,,,,,,,,,,346.434,346.1793613,3.16,26,4,5,2,3,75.27,C21H22N4O,"InChI=1S/C21H22N4O/c22-21-19(14-18(23-24-21)17-8-4-5-9-20(17)26)25-12-10-16(11-13-25)15-6-2-1-3-7-15/h1-9,14,16,26H,10-13H2,(H2,22,24)",JTBGUMSOPXOHEX-UHFFFAOYSA-N,394417,137029533,,3CRBN,3,Q96SW2,CRBN,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,,,,,250,FP,,,10.1038/nature13527,258.233,258.0640568,0.13,19,3,4,1,1,83.55,C13H10N2O4,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,50070114,5426,CHEMBL468,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,876,7.350580973,6.646329771,44.6086,225.7721
1360,46,96.2,46,96.2,Q07817,BCL-xL,CRBN,,PZ15227,CC1(C)CCC(C2=CC=C(Cl)C=C2)=C(CN2CCN(C3=CC=C(C(=O)NS(=O)(=O)C4=CC=C(N[C@H](CCN5CCN(C(=O)CCCN6C=C(COCCOCCNC7=CC=CC8=C7C(=O)N(C7CCC(=O)NC7=O)C8=O)N=N6)CC5)CSC5=CC=CC=C5)C(S(=O)(=O)C(F)(F)F)=C4)C=C3)CC2)C1,Degradation of BCL-xL in WI38 cells after 16 h treatment,,,,,,,,,1.9,Ki was tested by the AlphaScreen competitive binding assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,290/>10000/>3000,Inhibit viability of IR-SC/WI38/platelets cells,,,,,,,,,,,,,10.1038/s41467-020-15838-0,1484.157,1482.497791,8.88,102,11,21,4,30,284.19,C71H82ClF3N12O12S3,"InChI=1S/C71H82ClF3N12O12S3/c1-70(2)27-25-57(48-13-17-51(72)18-14-48)50(43-70)44-83-33-35-84(36-34-83)54-19-15-49(16-20-54)66(90)80-102(96,97)56-21-22-59(62(42-56)101(94,95)71(73,74)75)77-52(47-100-55-8-4-3-5-9-55)26-30-82-31-37-85(38-32-82)64(89)12-7-29-86-45-53(79-81-86)46-99-41-40-98-39-28-76-60-11-6-10-58-65(60)69(93)87(68(58)92)61-23-24-63(88)78-67(61)91/h3-6,8-11,13-22,42,45,52,61,76-77H,7,12,23-41,43-44,46-47H2,1-2H3,(H,80,90)(H,78,88,91)/t52-,61?/m1/s1",OWEARFNXBBNNKR-ADXOFTSBSA-N,111,2,324,CCOCCOCC1=CN(CCCC=O)N=N1,[R1]C(=O)CCCN1C=C(N=N1)COCCOCC[R2],241.291,241.1426415,-0.68,17,1,6,0,10,66.24,C11H19N3O3,"InChI=1S/C11H19N3O3/c1-2-16-7-8-17-10-11-9-14(13-12-11)5-3-4-6-15/h6,9H,2-5,7-8,10H2,1H3",IWWAUXMBDMJSSV-UHFFFAOYSA-N,P40337,VHL,VH298,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(C#N)CC3)C(C)(C)C)C=C2)SC=N1,,,,,90/80,ITC/FP,,,10.1038/ncomms13312,523.659,523.2253255,2.54,37,4,7,3,7,135.42,C27H33N5O4S,"InChI=1S/C27H33N5O4S/c1-16-21(37-15-30-16)18-7-5-17(6-8-18)12-29-23(34)20-11-19(33)13-32(20)24(35)22(26(2,3)4)31-25(36)27(14-28)9-10-27/h5-8,15,19-20,22,33H,9-13H2,1-4H3,(H,29,34)(H,31,36)/t19-,20+,22-/m1/s1",NDVQUNZCNAMROD-RZUBCFFCSA-N,50459944,122199236,CHEMBL4225537,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.962,46,7.404783153,6.634157039,39.3747,232.1897
159,0.2,98,0.2,98,O60885,BRD4,CRBN,,BD-764,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,686.754,686.2059871,3.41,50,8,12,2,7,153.34,C36H30N8O5S,"InChI=1S/C36H30N8O5S/c1-21-40-41-30-20-49-19-26-25(16-22-6-3-2-4-7-22)29(50-36(26)43(21)30)12-10-23-17-38-42(18-23)15-14-37-27-9-5-8-24-32(27)35(48)44(34(24)47)28-11-13-31(45)39-33(28)46/h2-9,17-18,28,37H,11,13-16,19-20H2,1H3,(H,39,45,46)",OCRZEXONTRGXJJ-UHFFFAOYSA-N,46,2,24,CC,[R1]CC[R2],30.07,30.04695019,1.3,2,0,0,0,0,0,C2H6,InChI=1S/C2H6/c1-2/h1-2H3,OTMSDBZUPAUEDD-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.2,6.925313541,6.207319652,118.7644,620.4122
159,0.2,98,0.2,98,O60885,BRD4,CRBN,,BD-764,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,686.754,686.2059871,3.41,50,8,12,2,7,153.34,C36H30N8O5S,"InChI=1S/C36H30N8O5S/c1-21-40-41-30-20-49-19-26-25(16-22-6-3-2-4-7-22)29(50-36(26)43(21)30)12-10-23-17-38-42(18-23)15-14-37-27-9-5-8-24-32(27)35(48)44(34(24)47)28-11-13-31(45)39-33(28)46/h2-9,17-18,28,37H,11,13-16,19-20H2,1H3,(H,39,45,46)",OCRZEXONTRGXJJ-UHFFFAOYSA-N,46,2,24,CC,[R1]CC[R2],30.07,30.04695019,1.3,2,0,0,0,0,0,C2H6,InChI=1S/C2H6/c1-2/h1-2H3,OTMSDBZUPAUEDD-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.2,6.73809061,6.207319652,182.7719,620.4122
159,0.2,98,0.2,98,O60885,BRD4,CRBN,,BD-764,CC1=NN=C2COCC3=C(SC(C#CC4=CN(CCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,686.754,686.2059871,3.41,50,8,12,2,7,153.34,C36H30N8O5S,"InChI=1S/C36H30N8O5S/c1-21-40-41-30-20-49-19-26-25(16-22-6-3-2-4-7-22)29(50-36(26)43(21)30)12-10-23-17-38-42(18-23)15-14-37-27-9-5-8-24-32(27)35(48)44(34(24)47)28-11-13-31(45)39-33(28)46/h2-9,17-18,28,37H,11,13-16,19-20H2,1H3,(H,39,45,46)",OCRZEXONTRGXJJ-UHFFFAOYSA-N,46,2,24,CC,[R1]CC[R2],30.07,30.04695019,1.3,2,0,0,0,0,0,C2H6,InChI=1S/C2H6/c1-2/h1-2H3,OTMSDBZUPAUEDD-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.2,7.186972206,6.207319652,65.0171,620.4122
1655,3,95,398/3/13,30/95/90,Q05397,FAK,CRBN,,BI-3663,COC1=CC(C(=O)NCCOCCOCCOCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in HLF/SNU-398/HUCCT1 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,>25119/>25119/>25119,Inhibit proliferation of HLF/SNU-398/HUCCT1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01826,917.851,917.2843544,2.93,66,7,15,4,20,242.78,C44H42F3N7O12,"InChI=1S/C44H42F3N7O12/c1-62-33-22-25(8-10-28(33)51-43-49-23-27(44(45,46)47)40(53-43)66-32-7-2-4-24-9-12-31(55)36(24)32)38(58)48-15-17-64-19-21-65-20-18-63-16-14-35(57)50-29-6-3-5-26-37(29)42(61)54(41(26)60)30-11-13-34(56)52-39(30)59/h2-8,10,22-23,30H,9,11-21H2,1H3,(H,48,58)(H,50,57)(H,49,51,53)(H,52,56,59)",ADTXLFJKQHYGPM-UHFFFAOYSA-N,262,2,805,CCOCCOCCOCCC=O,[R1]CCOCCOCCOCCC(=O)[R2],190.239,190.1205091,-0.42,13,0,4,0,10,44.76,C9H18O4,"InChI=1S/C9H18O4/c1-2-11-6-7-13-9-8-12-5-3-4-10/h4H,2-3,5-9H2,1H3",AJMGGIZNAPWJIH-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,3,7.125060292,6.633995068,74.979,232.2763
1655,13,96,27/13/25,95/96/90,Q05397,FAK,CRBN,,BI-3663,COC1=CC(C(=O)NCCOCCOCCOCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in A549/Hep3B2.1-7/SNU-387 cells after 18 h treatment,,,18,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,>25119/25119,Inhibit proliferation of SNU-387/Hep3B2.1-7 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01826,917.851,917.2843544,2.93,66,7,15,4,20,242.78,C44H42F3N7O12,"InChI=1S/C44H42F3N7O12/c1-62-33-22-25(8-10-28(33)51-43-49-23-27(44(45,46)47)40(53-43)66-32-7-2-4-24-9-12-31(55)36(24)32)38(58)48-15-17-64-19-21-65-20-18-63-16-14-35(57)50-29-6-3-5-26-37(29)42(61)54(41(26)60)30-11-13-34(56)52-39(30)59/h2-8,10,22-23,30H,9,11-21H2,1H3,(H,48,58)(H,50,57)(H,49,51,53)(H,52,56,59)",ADTXLFJKQHYGPM-UHFFFAOYSA-N,262,2,805,CCOCCOCCOCCC=O,[R1]CCOCCOCCOCCC(=O)[R2],190.239,190.1205091,-0.42,13,0,4,0,10,44.76,C9H18O4,"InChI=1S/C9H18O4/c1-2-11-6-7-13-9-8-12-5-3-4-10/h4H,2-3,5-9H2,1H3",AJMGGIZNAPWJIH-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,13,7.125060292,6.633995068,74.979,232.2763
1655,13,93,158/50/13,79/93/93,Q05397,FAK,CRBN,,BI-3663,COC1=CC(C(=O)NCCOCCOCCOCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in HLE/HuH-7/SNU-423 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,>25119/>25119/19953,Inhibit proliferation of HLE/HuH-7/SNU-423 cells,,,,,,,,,,,1,Compounds were administered at 10000 nM and incubated for 2 h,17,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acs.jmedchem.8b01826,917.851,917.2843544,2.93,66,7,15,4,20,242.78,C44H42F3N7O12,"InChI=1S/C44H42F3N7O12/c1-62-33-22-25(8-10-28(33)51-43-49-23-27(44(45,46)47)40(53-43)66-32-7-2-4-24-9-12-31(55)36(24)32)38(58)48-15-17-64-19-21-65-20-18-63-16-14-35(57)50-29-6-3-5-26-37(29)42(61)54(41(26)60)30-11-13-34(56)52-39(30)59/h2-8,10,22-23,30H,9,11-21H2,1H3,(H,48,58)(H,50,57)(H,49,51,53)(H,52,56,59)",ADTXLFJKQHYGPM-UHFFFAOYSA-N,262,2,805,CCOCCOCCOCCC=O,[R1]CCOCCOCCOCCC(=O)[R2],190.239,190.1205091,-0.42,13,0,4,0,10,44.76,C9H18O4,"InChI=1S/C9H18O4/c1-2-11-6-7-13-9-8-12-5-3-4-10/h4H,2-3,5-9H2,1H3",AJMGGIZNAPWJIH-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,13,7.125060292,6.633995068,74.979,232.2763
1655,32,89,251/32/32,50/89/89,Q05397,FAK,CRBN,,BI-3663,COC1=CC(C(=O)NCCOCCOCCOCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,Degradation of Fak in HUH-1/HepG2/SK-Hep-1 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,25119/>25119/1585,Inhibit proliferation of HUH-1/HepG2/SK-Hep-1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01826,917.851,917.2843544,2.93,66,7,15,4,20,242.78,C44H42F3N7O12,"InChI=1S/C44H42F3N7O12/c1-62-33-22-25(8-10-28(33)51-43-49-23-27(44(45,46)47)40(53-43)66-32-7-2-4-24-9-12-31(55)36(24)32)38(58)48-15-17-64-19-21-65-20-18-63-16-14-35(57)50-29-6-3-5-26-37(29)42(61)54(41(26)60)30-11-13-34(56)52-39(30)59/h2-8,10,22-23,30H,9,11-21H2,1H3,(H,48,58)(H,50,57)(H,49,51,53)(H,52,56,59)",ADTXLFJKQHYGPM-UHFFFAOYSA-N,262,2,805,CCOCCOCCOCCC=O,[R1]CCOCCOCCOCCC(=O)[R2],190.239,190.1205091,-0.42,13,0,4,0,10,44.76,C9H18O4,"InChI=1S/C9H18O4/c1-2-11-6-7-13-9-8-12-5-3-4-10/h4H,2-3,5-9H2,1H3",AJMGGIZNAPWJIH-UHFFFAOYSA-N,O60760,HPGDS,TFC-007,O=C(NC1=CC=C(N2CCC(C(=O)N3CCOCC3)CC2)C=C1)C1=CN=C(OC2=CC=CC=C2)N=C1,,,,,0.37,SPR,,,10.1016/j.bmc.2018.08.014,487.56,487.2219544,2.6,36,5,7,1,6,96.89,C27H29N5O4,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,50463722,16040067,CHEMBL4238186,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.89,32,7.125060292,6.633995068,74.979,232.2763
280,80.6,96,80.6,96,Q06187,BTK,CRBN,,MT-540,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCCCCCOCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of BTK in NAMALWA cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.biochem.8b00391,843.942,843.3704095,4.31,62,8,14,3,18,213.2,C45H49N9O8,"InChI=1S/C45H49N9O8/c46-41-39-40(29-13-15-32(16-14-29)62-31-9-4-3-5-10-31)51-54(42(39)48-28-47-41)30-19-22-52(23-20-30)21-6-1-2-7-24-60-25-26-61-27-37(56)49-34-12-8-11-33-38(34)45(59)53(44(33)58)35-17-18-36(55)50-43(35)57/h3-5,8-16,28,30,35H,1-2,6-7,17-27H2,(H,49,56)(H2,46,47,48)(H,50,55,57)",YFWKTWXPNMNMSC-UHFFFAOYSA-N,51,2,152,CCCCCCOCCOCC=O,[R1]CCCCCCOCCOCC(=O)[R2],188.267,188.1412445,1.8,13,0,3,0,10,35.53,C10H20O3,"InChI=1S/C10H20O3/c1-2-3-4-5-7-12-9-10-13-8-6-11/h6H,2-5,7-10H2,1H3",MDCZWRMRSILCQG-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,80.6,6.895003024,6.709485674,127.3494,195.2155
281,90.1,93,90.1,93,Q06187,BTK,CRBN,,MT-541,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCCCOCCCCOCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of BTK in NAMALWA cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.biochem.8b00391,843.942,843.3704095,4.31,62,8,14,3,18,213.2,C45H49N9O8,"InChI=1S/C45H49N9O8/c46-41-39-40(29-13-15-32(16-14-29)62-31-9-2-1-3-10-31)51-54(42(39)48-28-47-41)30-19-22-52(23-20-30)21-4-5-24-60-25-6-7-26-61-27-37(56)49-34-12-8-11-33-38(34)45(59)53(44(33)58)35-17-18-36(55)50-43(35)57/h1-3,8-16,28,30,35H,4-7,17-27H2,(H,49,56)(H2,46,47,48)(H,50,55,57)",JJEBSGCXKQODDX-UHFFFAOYSA-N,51,2,153,CCCCOCCCCOCC=O,[R1]CCCCOCCCCOCC(=O)[R2],188.267,188.1412445,1.43,13,0,3,0,10,35.53,C10H20O3,"InChI=1S/C10H20O3/c1-2-3-7-12-8-4-5-9-13-10-6-11/h6H,2-5,7-10H2,1H3",GAIQORAOHTYFOZ-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,90.1,6.591723672,6.95171253,256.0214,111.7603
282,68.3,95,68.3,95,Q06187,BTK,CRBN,,MT-781,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCCOCCCOCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of BTK in NAMALWA cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.biochem.8b00391,829.915,829.3547595,3.5,61,8,14,3,17,213.2,C44H47N9O8,"InChI=1S/C44H47N9O8/c45-40-38-39(28-11-13-31(14-12-28)61-30-7-2-1-3-8-30)50-53(41(38)47-27-46-40)29-17-21-51(22-18-29)20-5-23-59-24-6-25-60-26-19-36(55)48-33-10-4-9-32-37(33)44(58)52(43(32)57)34-15-16-35(54)49-42(34)56/h1-4,7-14,27,29,34H,5-6,15-26H2,(H,48,55)(H2,45,46,47)(H,49,54,56)",CESHFJRNQNNGLW-UHFFFAOYSA-N,51,2,154,CCCOCCCOCCC=O,[R1]CCCOCCCOCCC(=O)[R2],174.24,174.1255944,0.62,12,0,3,0,9,35.53,C9H18O3,"InChI=1S/C9H18O3/c1-2-6-11-8-4-9-12-7-3-5-10/h5H,2-4,6-9H2,1H3",DDVUDFQFSHPIKB-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,68.3,6.81439354,7.109274064,153.3227,77.7546
214,1487,64,1487/(n/a),64/36,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)OCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,1150,SPR,,,,,,,,,,,,,,,8800,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,844.829,844.299196,3.2,61,7,14,4,16,239.74,C41H42F2N8O10,"InChI=1S/C41H42F2N8O10/c42-24-8-12-31(28(43)21-24)61-26-9-6-23(7-10-26)35-34(37(45)53)36(44)51(48-35)25-3-2-15-49(22-25)41(57)60-20-19-59-18-17-58-16-14-46-29-5-1-4-27-33(29)40(56)50(39(27)55)30-11-13-32(52)47-38(30)54/h1,4-10,12,21,25,30,46H,2-3,11,13-20,22,44H2,(H2,45,53)(H,47,52,54)/t25-,30?/m1/s1",MAECKIKUFSSWJT-GOWJNXQMSA-N,55,2,99,CCOCCOCCO,[R1]OCCOCCOCC[R2],134.175,134.0942943,-0.39,9,0,3,1,6,38.69,C6H14O3,"InChI=1S/C6H14O3/c1-2-8-5-6-9-4-3-7/h7H,2-6H2,1H3",XXJWXESWEXIICW-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.64,1487,7.51269758,6.722134027,30.7116,189.6121
215,36.9,85,36.9/398.5,85/68,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,71,SPR,,,,,,,,,,,,,,,2500,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,888.882,888.3254107,3.05,64,7,15,4,19,248.97,C43H46F2N8O11,"InChI=1S/C43H46F2N8O11/c44-26-8-12-33(30(45)23-26)64-28-9-6-25(7-10-28)37-36(39(47)55)38(46)53(50-37)27-3-2-15-51(24-27)43(59)63-22-21-62-20-19-61-18-17-60-16-14-48-31-5-1-4-29-35(31)42(58)52(41(29)57)32-11-13-34(54)49-40(32)56/h1,4-10,12,23,27,32,48H,2-3,11,13-22,24,46H2,(H2,47,55)(H,49,54,56)/t27-,32?/m1/s1",IDIGRNKYBBGIKH-XIDOUCRZSA-N,55,2,100,CCOCCOCCOCCO,[R1]OCCOCCOCCOCC[R2],178.228,178.1205091,-0.53,12,0,4,1,9,47.92,C8H18O4,"InChI=1S/C8H18O4/c1-2-10-5-6-12-8-7-11-4-3-9/h9H,2-8H2,1H3",WFSMVVDJSNMRAR-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,36.9,7.512327996,7.171797007,30.7377,67.3291
216,21.8,84,21.8/469.9,84/63,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)COCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,79,SPR,,,,,,,,,,,,,,,2700,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,902.909,902.3410608,2.53,65,7,15,4,21,248.97,C44H48F2N8O11,"InChI=1S/C44H48F2N8O11/c45-27-8-12-34(31(46)23-27)65-29-9-6-26(7-10-29)39-38(41(48)57)40(47)54(51-39)28-3-2-15-52(24-28)36(56)25-64-22-21-63-20-19-62-18-17-61-16-14-49-32-5-1-4-30-37(32)44(60)53(43(30)59)33-11-13-35(55)50-42(33)58/h1,4-10,12,23,28,33,49H,2-3,11,13-22,24-25,47H2,(H2,48,57)(H,50,55,58)/t28-,33?/m1/s1",PZNXLFVCWNTMGE-TUDONDPESA-N,55,2,101,CCOCCOCCOCCOC,[R1]COCCOCCOCCOCC[R2],192.255,192.1361591,0,13,0,4,0,10,36.92,C9H20O4,"InChI=1S/C9H20O4/c1-3-11-6-7-13-9-8-12-5-4-10-2/h3-9H2,1-2H3",JRRDISHSXWGFRF-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.84,21.8,7.157644473,6.939504159,69.5594,114.9465
217,4.5,87,4.5/90.5,87/75,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)OCCOCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,80,SPR,,,,,,,,,,,,,,,3600,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,932.935,932.3516255,2.91,67,7,16,4,22,258.2,C45H50F2N8O12,"InChI=1S/C45H50F2N8O12/c46-28-8-12-35(32(47)25-28)67-30-9-6-27(7-10-30)39-38(41(49)57)40(48)55(52-39)29-3-2-15-53(26-29)45(61)66-24-23-65-22-21-64-20-19-63-18-17-62-16-14-50-33-5-1-4-31-37(33)44(60)54(43(31)59)34-11-13-36(56)51-42(34)58/h1,4-10,12,25,29,34,50H,2-3,11,13-24,26,48H2,(H2,49,57)(H,51,56,58)/t29-,34?/m1/s1",HIEUPGKCAGGMLO-QMUARQKKSA-N,55,2,102,CCOCCOCCOCCOCCO,[R1]OCCOCCOCCOCCOCC[R2],222.281,222.1467238,-0.68,15,0,5,1,12,57.15,C10H22O5,"InChI=1S/C10H22O5/c1-2-12-5-6-14-9-10-15-8-7-13-4-3-11/h11H,2-10H2,1H3",GTAKOUPXIUWZIA-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.87,4.5,7.02853472,6.823252246,93.6408,150.2269
218,5.9,85,5.9/217.7,85/71,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)COCCOCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,74,SPR,,,,,,,,,,,,,,,3200,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,946.962,946.3672755,2.39,68,7,16,4,24,258.2,C46H52F2N8O12,"InChI=1S/C46H52F2N8O12/c47-29-8-12-36(33(48)25-29)68-31-9-6-28(7-10-31)41-40(43(50)59)42(49)56(53-41)30-3-2-15-54(26-30)38(58)27-67-24-23-66-22-21-65-20-19-64-18-17-63-16-14-51-34-5-1-4-32-39(34)46(62)55(45(32)61)35-11-13-37(57)52-44(35)60/h1,4-10,12,25,30,35,51H,2-3,11,13-24,26-27,49H2,(H2,50,59)(H,52,57,60)/t30-,35?/m1/s1",PDQGUWCWGITGBA-OSRRZMJMSA-N,55,2,103,CCOCCOCCOCCOCCOC,[R1]COCCOCCOCCOCCOCC[R2],236.308,236.1623739,-0.15,16,0,5,0,13,46.15,C11H24O5,"InChI=1S/C11H24O5/c1-3-13-6-7-15-10-11-16-9-8-14-5-4-12-2/h3-11H2,1-2H3",YZWVMKLQNYGKLJ-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,5.9,7.06352256,6.976263712,86.3928,105.6176
219,1.1,87,1.1/37.4,87/80,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)OCCOCCOCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,61,SPR,,,,,,,,,,,,,,,3000,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,976.988,976.3778402,2.76,70,7,17,4,25,267.43,C47H54F2N8O13,"InChI=1S/C47H54F2N8O13/c48-30-8-12-37(34(49)27-30)70-32-9-6-29(7-10-32)41-40(43(51)59)42(50)57(54-41)31-3-2-15-55(28-31)47(63)69-26-25-68-24-23-67-22-21-66-20-19-65-18-17-64-16-14-52-35-5-1-4-33-39(35)46(62)56(45(33)61)36-11-13-38(58)53-44(36)60/h1,4-10,12,27,31,36,52H,2-3,11,13-26,28,50H2,(H2,51,59)(H,53,58,60)/t31-,36?/m1/s1",XXNGOJVDXDGATG-RACIXVTASA-N,55,2,104,CCOCCOCCOCCOCCOCCO,[R1]OCCOCCOCCOCCOCCOCC[R2],266.334,266.1729386,-0.83,18,0,6,1,15,66.38,C12H26O6,"InChI=1S/C12H26O6/c1-2-14-5-6-16-9-10-18-12-11-17-8-7-15-4-3-13/h13H,2-12H2,1H3",NJRFAMBTWHGSDE-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.87,1.1,7.10879543,6.609469898,77.8403,245.7707
220,9.7,85,9.7/184.1,85/70,Q06187,BTK,CRBN,,,NC(=O)C1=C(N)N([C@@H]2CCCN(C(=O)COCCOCCOCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)N=C1C1=CC=C(OC2=CC=C(F)C=C2F)C=C1,Degradation of BTK in Ramos/THP-1 cells after 24 h treatment,,,,,,,138,SPR,,,,,,,,,,,,,,,3100,SPR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1073/pnas.1803662115,991.015,990.3934903,2.24,71,7,17,4,27,267.43,C48H56F2N8O13,"InChI=1S/C48H56F2N8O13/c49-31-8-12-38(35(50)27-31)71-33-9-6-30(7-10-33)43-42(45(52)61)44(51)58(55-43)32-3-2-15-56(28-32)40(60)29-70-26-25-69-24-23-68-22-21-67-20-19-66-18-17-65-16-14-53-36-5-1-4-34-41(36)48(64)57(47(34)63)37-11-13-39(59)54-46(37)62/h1,4-10,12,27,32,37,53H,2-3,11,13-26,28-29,51H2,(H2,52,61)(H,54,59,62)/t32-,37?/m1/s1",VRWPZJRZYSWRQV-ZIQZBVCVSA-N,55,2,105,CCOCCOCCOCCOCCOCCOC,[R1]COCCOCCOCCOCCOCCOCC[R2],280.361,280.1885886,-0.29,19,0,6,0,16,55.38,C13H28O6,"InChI=1S/C13H28O6/c1-3-15-6-7-17-10-11-19-13-12-18-9-8-16-5-4-14-2/h3-13H2,1-2H3",PJXDGFJDVVVXCY-UHFFFAOYSA-N,P11802,CDK4,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N1C1CCCC1,10,IC50 of CDK4,,,,,,,10.1016/j.bmcl.2015.05.100,434.548,434.2542576,2.19,32,5,8,2,5,91.21,C23H30N8O,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,148264,44631912,CHEMBL3545110,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,9.7,7.033332511,6.788371064,92.612,162.7905
227,9.12,84.07,9.12,84.07,Q9UBN7,HDAC6,CRBN,,dHDAC6,O=C(CCCCCCC(=O)N/N=C/C1=CC=C(OCCOCCOCCN2C=C(CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N2)C=C1)NO,Degradation of HDAC6 in MM1S cells after 6 h treatment,47.9/73.5,% HDAC6 degradation in MM1S cells after 6 h treatment at 10/100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.9b00516,775.82,775.3289386,1,56,5,15,5,23,244.77,C37H45N9O10,"InChI=1S/C37H45N9O10/c47-31-15-14-30(35(50)40-31)46-36(51)28-6-5-7-29(34(28)37(46)52)38-23-26-24-45(44-41-26)16-17-54-18-19-55-20-21-56-27-12-10-25(11-13-27)22-39-42-32(48)8-3-1-2-4-9-33(49)43-53/h5-7,10-13,22,24,30,38,53H,1-4,8-9,14-21,23H2,(H,42,48)(H,43,49)(H,40,47,50)/b39-22+",MHILTYZXXFOWJH-WVKHYPTHSA-N,57,2,112,CCOCCOCCN1C=C(C)N=N1,[R1]CCOCCOCCN1C=C(N=N1)C[R2],199.254,199.1320768,0.09,14,1,5,0,7,49.17,C9H17N3O2,"InChI=1S/C9H17N3O2/c1-3-13-6-7-14-5-4-12-8-9(2)10-11-12/h8H,3-7H2,1-2H3",IUKAVXDFGYPRJN-UHFFFAOYSA-N,P40763,STAT3,SI-109,CC(=O)N1CC[C@H]2CC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C3=CC=CC=C3)C3=CC=CC=C3)N2C(=O)[C@@H](NC(=O)C2=CC3=CC(C(F)(F)P(=O)(O)O)=CC=C3[NH]2)C1,,,,,,,14,FP,10.1021/acs.jmedchem.9b01530,835.802,835.2906191,1.27,59,6,7,7,13,244.33,C40H44F2N7O9P,"InChI=1S/C40H44F2N7O9P/c1-23(50)48-19-18-28-13-16-33(38(54)45-30(15-17-34(43)51)36(52)47-35(24-8-4-2-5-9-24)25-10-6-3-7-11-25)49(28)39(55)32(22-48)46-37(53)31-21-26-20-27(12-14-29(26)44-31)40(41,42)59(56,57)58/h2-12,14,20-21,28,30,32-33,35,44H,13,15-19,22H2,1H3,(H2,43,51)(H,45,54)(H,46,53)(H,47,52)(H2,56,57,58)/t28-,30+,32+,33+/m1/s1",HBICZHLVBCLHSV-VUCLUUCHSA-N,,139600322,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.8407,9.12,7.899348175,6.203103121,12.6082,626.4651
227,34,70.5,34,70.5,Q9UBN7,HDAC6,CRBN,,dHDAC6,O=C(CCCCCCC(=O)N/N=C/C1=CC=C(OCCOCCOCCN2C=C(CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N2)C=C1)NO,Degradation of HDAC6 in MCF-7 cells after 12 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.bmcl.2018.05.057,775.82,775.3289386,1,56,5,15,5,23,244.77,C37H45N9O10,"InChI=1S/C37H45N9O10/c47-31-15-14-30(35(50)40-31)46-36(51)28-6-5-7-29(34(28)37(46)52)38-23-26-24-45(44-41-26)16-17-54-18-19-55-20-21-56-27-12-10-25(11-13-27)22-39-42-32(48)8-3-1-2-4-9-33(49)43-53/h5-7,10-13,22,24,30,38,53H,1-4,8-9,14-21,23H2,(H,42,48)(H,43,49)(H,40,47,50)/b39-22+",MHILTYZXXFOWJH-WVKHYPTHSA-N,57,2,112,CCOCCOCCN1C=C(C)N=N1,[R1]CCOCCOCCN1C=C(N=N1)C[R2],199.254,199.1320768,0.09,14,1,5,0,7,49.17,C9H17N3O2,"InChI=1S/C9H17N3O2/c1-3-13-6-7-14-5-4-12-8-9(2)10-11-12/h8H,3-7H2,1-2H3",IUKAVXDFGYPRJN-UHFFFAOYSA-N,P40763,STAT3,SI-109,CC(=O)N1CC[C@H]2CC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C3=CC=CC=C3)C3=CC=CC=C3)N2C(=O)[C@@H](NC(=O)C2=CC3=CC(C(F)(F)P(=O)(O)O)=CC=C3[NH]2)C1,,,,,,,14,FP,10.1021/acs.jmedchem.9b01530,835.802,835.2906191,1.27,59,6,7,7,13,244.33,C40H44F2N7O9P,"InChI=1S/C40H44F2N7O9P/c1-23(50)48-19-18-28-13-16-33(38(54)45-30(15-17-34(43)51)36(52)47-35(24-8-4-2-5-9-24)25-10-6-3-7-11-25)49(28)39(55)32(22-48)46-37(53)31-21-26-20-27(12-14-29(26)44-31)40(41,42)59(56,57)58/h2-12,14,20-21,28,30,32-33,35,44H,13,15-19,22H2,1H3,(H2,43,51)(H,45,54)(H,46,53)(H,47,52)(H2,56,57,58)/t28-,30+,32+,33+/m1/s1",HBICZHLVBCLHSV-VUCLUUCHSA-N,,139600322,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.705,34,7.899348175,6.203103121,12.6082,626.4651
329,0.31,95,0.31,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in Namalwa cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/d2cb00223j,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.31,6.333955493,6.21095861,463.4944,615.2355
329,0.31,95,0.31,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in Namalwa cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/d2cb00223j,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.31,6.465315659,6.21095861,342.5187,615.2355
329,0.31,95,0.31,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in Namalwa cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1039/d2cb00223j,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.31,6.313769781,6.21095861,485.5458,615.2355
329,0.57,95,0.57,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in 22RV1 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2019.01.023,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.57,6.333955493,6.21095861,463.4944,615.2355
329,0.57,95,0.57,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in 22RV1 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2019.01.023,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.57,6.465315659,6.21095861,342.5187,615.2355
329,0.57,95,0.57,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in 22RV1 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2019.01.023,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,0.57,6.313769781,6.21095861,485.5458,615.2355
329,0.6,97,0.6/1,97/100,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17/35,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.97,0.6,6.333955493,6.21095861,463.4944,615.2355
329,0.6,97,0.6/1,97/100,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17/35,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.97,0.6,6.465315659,6.21095861,342.5187,615.2355
329,0.6,97,0.6/1,97/100,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 short/long in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17/35,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.97,0.6,6.313769781,6.21095861,485.5458,615.2355
329,0.8,98,0.8,98,Q15059,BRD3,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17/35,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,47.09,0.0147165,1,1,1,1,1,0.0147165,0.98,0.8,6.333955493,6.21095861,463.4944,615.2355
329,0.8,98,0.8,98,Q15059,BRD3,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17/35,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,47.09,0.0147165,1,1,1,1,1,0.0147165,0.98,0.8,6.465315659,6.21095861,342.5187,615.2355
329,0.8,98,0.8,98,Q15059,BRD3,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD3 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17/35,Inhibit proliferation of MV4;11/HL60 cells,,,,,,,,,,,,,10.1021/acs.jmedchem.6b01912,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,47.09,0.0147165,1,1,1,1,1,0.0147165,0.98,0.8,6.313769781,6.21095861,485.5458,615.2355
329,1,95,<1/<1,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in Namalwa/CA-46 cells after overnight treatment,,,,,,,90/28,Kd of BRD4 BD1/2 was determined with BROMOscan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2015.05.009,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,1,6.333955493,6.21095861,463.4944,615.2355
329,1,95,<1/<1,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in Namalwa/CA-46 cells after overnight treatment,,,,,,,90/28,Kd of BRD4 BD1/2 was determined with BROMOscan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2015.05.009,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,1,6.465315659,6.21095861,342.5187,615.2355
329,1,95,<1/<1,,O60885,BRD4,CRBN,,ARV-825,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(OCCOCCOCCOCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C1)N=C2C1=CC=C(Cl)C=C1,Degradation of BRD4 in Namalwa/CA-46 cells after overnight treatment,,,,,,,90/28,Kd of BRD4 BD1/2 was determined with BROMOscan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.chembiol.2015.05.009,923.449,922.2875238,4.81,65,8,15,3,19,204.67,C46H47ClN8O9S,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,35-36,48H,15-25H2,1-3H3,(H,49,57)(H,51,56,58)/t35-,36?/m0/s1",RWLOGRLTDKDANT-TYIYNAFKSA-N,81,2,14,CCOCCOCCOCC,[R1]CCOCCOCCOCC[R2],162.229,162.1255944,0.52,11,0,3,0,8,27.69,C8H18O3,"InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3",RRQYJINTUHWNHW-UHFFFAOYSA-N,P06730,eIF4E,GDP,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2019.01.080,443.202,443.0243296,-5.47,28,3,12,7,6,252.57,C10H15N5O11P2,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",QGWNDRXFNXRZMB-UUOKFMHZSA-N,92459,135398619,CHEMBL384759,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,32.66,0.021218616,1,1,1,1,1,0.021218616,0.95,1,6.313769781,6.21095861,485.5458,615.2355
2843,108.9,88,108.9,88,Q9UBN7,HDAC6,CRBN,,,O=C(CCCO/N=C1C(=C2/C(=O)N(CC3=CN(CCOCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)N=N3)C3=CC=CC=C23)/NC2=CC=CC=C/12)NO,Degradation of HDAC6 in K562 cells after 8 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.1c00681,802.805,802.2823228,1.71,59,8,15,5,15,238.78,C40H38N10O9,"InChI=1S/C40H38N10O9/c51-31-15-14-30(37(53)43-31)50-38(54)26-9-5-11-28(33(26)40(50)56)41-16-19-58-20-17-48-21-23(44-47-48)22-49-29-12-4-2-8-25(29)34(39(49)55)36-35(24-7-1-3-10-27(24)42-36)46-59-18-6-13-32(52)45-57/h1-5,7-12,21,30,41-42,57H,6,13-20,22H2,(H,45,52)(H,43,51,53)/b36-34-,46-35+",DLBCMVGHLAVPJQ-ZQEKUULESA-N,454,2,211,CCOCCN1C=C(C)N=N1,[R1]CC1=CN(N=N1)CCOCC[R2],155.201,155.105862,0.24,11,1,4,0,4,39.94,C7H13N3O,"InChI=1S/C7H13N3O/c1-3-11-5-4-10-6-7(2)8-9-10/h6H,3-5H2,1-2H3",ZSUBJILEBOCSPA-UHFFFAOYSA-N,P18031,PTP1B,DI-03,COC1=CC(CC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(C(F)(F)P(=O)(O)O)C=C2)C(=O)N[C@@H](CCCCNC(=O)C2=CC=C(C)C(Br)=C2)C(N)=O)=CC=C1O,4.7,Inhibition of PTP1B,,,,,2.4,ki of PTP1B,10.1002/anie.202303818,930.737,929.2211979,4.22,61,4,8,8,21,246.48,C42H47BrF2N5O10P,"InChI=1S/C42H47BrF2N5O10P/c1-25-11-15-29(24-31(25)43)39(54)47-19-7-6-10-32(38(46)53)49-41(56)34(21-27-12-16-30(17-13-27)42(44,45)61(57,58)59)50-40(55)33(20-26-8-4-3-5-9-26)48-37(52)23-28-14-18-35(51)36(22-28)60-2/h3-5,8-9,11-18,22,24,32-34,51H,6-7,10,19-21,23H2,1-2H3,(H2,46,53)(H,47,54)(H,48,52)(H,49,56)(H,50,55)(H2,57,58,59)/t32-,33-,34-/m0/s1",OADLYFBQFFZCCM-AFEGWXKPSA-N,,,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.88,108.9,7.979428925,5.519525218,10.4851,3023.255
4002,4.6,92.28,4.6/357.6,92.28/81.34,Q9UM73,ALK,CRBN,,AP-1,COC1=CC(N2CCN(C(=O)CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,Degradation of ALK in Karpas299/H3122 cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.1469/2704/>200000,Inhibition of cell viability in Karpas299/THP-1/HeLa cells after 60/60/48 h treatment,,,,,,,,,,,,,,,10.1016/j.bioorg.2023.106556,830.324,829.2409079,5,58,7,14,4,12,212.34,C39H40ClN9O8S,"InChI=1S/C39H40ClN9O8S/c1-22(2)58(55,56)31-10-5-4-8-27(31)43-35-25(40)20-42-39(46-35)44-26-12-11-23(19-30(26)57-3)47-15-17-48(18-16-47)33(51)21-41-28-9-6-7-24-34(28)38(54)49(37(24)53)29-13-14-32(50)45-36(29)52/h4-12,19-20,22,29,41H,13-18,21H2,1-3H3,(H,45,50,52)(H2,42,43,44,46)",MCCIEZLYIAJGSE-UHFFFAOYSA-N,103,2,298,CC=O,[R1]C(=O)C[R2],44.053,44.02621475,-0.27,3,0,1,0,0,17.07,C2H4O,"InChI=1S/C2H4O/c1-2-3/h2H,1H3",IKHGUXGNUITLKF-UHFFFAOYSA-N,O75530,EED,EED226,CS(=O)(=O)C1=CC=C(C2=CN=C(NCC3=CC=CO3)N3C=NN=C23)C=C1,22,IC50 of EED was tested by AlphaScreen competition binding assay,,,,,,,10.1021/acs.jmedchem.6b01576,369.406,369.0895603,2.3,26,4,8,1,5,102.39,C17H15N5O3S,"InChI=1S/C17H15N5O3S/c1-26(23,24)14-6-4-12(5-7-14)15-10-19-17(22-11-20-21-16(15)22)18-9-13-3-2-8-25-13/h2-8,10-11H,9H2,1H3,(H,18,19)",DYIRSNMPIZZNBK-UHFFFAOYSA-N,225230,123132228,CHEMBL4065484,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9228,4.6,7.156721554,6.682460498,69.7073,207.7493
714,48,83.4,48,83.4,O43924,PDEdelta,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCNC(=O)C4=CC=C(CN(CC5CCNCC5)S(=O)(=O)C5=CC=C(S(=O)(=O)N(CC6=CC=C(Cl)C=C6)C6CCCC6)C=C5)C=C4)=C3C2=O)C(=O)N1,Degradation of PDEdelta in Panc Tu-I cells after 24 h treatment,,,,,,,64.3,Kd was determined by competitive fluorescent polarization analysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,92.9,Kd between CRBN and the complex of protac and PDEdelta was tested by FP,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1002/anie.201913904,1134.772,1133.400505,4.54,78,8,15,4,29,248.39,C55H68ClN7O13S2,"InChI=1S/C55H68ClN7O13S2/c56-43-14-10-40(11-15-43)38-62(44-4-1-2-5-44)78(71,72)46-18-16-45(17-19-46)77(69,70)61(37-41-22-24-57-25-23-41)36-39-8-12-42(13-9-39)52(65)59-27-29-74-31-33-76-35-34-75-32-30-73-28-26-58-48-7-3-6-47-51(48)55(68)63(54(47)67)49-20-21-50(64)60-53(49)66/h3,6-19,41,44,49,57-58H,1-2,4-5,20-38H2,(H,59,65)(H,60,64,66)",OWYXKRGXEAHYMU-UHFFFAOYSA-N,125,2,346,CCOCCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCCOCC[R2],249.307,249.1576228,-0.08,17,0,5,1,14,66.02,C11H23NO5,"InChI=1S/C11H23NO5/c1-2-14-5-6-16-9-10-17-8-7-15-4-3-12-11-13/h11H,2-10H2,1H3,(H,12,13)",USNKTLYDYCQPIY-UHFFFAOYSA-N,O60885,BRD4,GSK-39,COC1=CC=C(C2=CN(C)C(=O)C3=C2SC(C(=N)NC2CCS(=O)(=O)CC2)=C3)C=C1OC,50,IC50 of BRD4 BD1 was tested by the TR-FRET assay,,,,,,,10.1021/acs.jmedchem.5b00256,475.592,475.1235629,1.98,32,4,8,2,5,110.48,C22H25N3O5S2,"InChI=1S/C22H25N3O5S2/c1-25-12-16(13-4-5-17(29-2)18(10-13)30-3)20-15(22(25)26)11-19(31-20)21(23)24-14-6-8-32(27,28)9-7-14/h4-5,10-12,14H,6-9H2,1-3H3,(H2,23,24)",KCZMLIMZGLNMQN-UHFFFAOYSA-N,50148456,127025420,CHEMBL3770188,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,40.25,0.017217391,1,1,1,1,1,0.017217391,0.834,48,8.89774761,6.712422529,1.2655,193.8998
2841,12.1,78,12.1,78,Q06187,BTK,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,6.9,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,39.5,Inhibit proliferation of TMD8 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,980.476,979.3631312,4.8,70,8,15,6,24,253.53,C49H54ClN9O11,"InChI=1S/C49H54ClN9O11/c50-37-27-33(70-32-5-2-1-3-6-32)13-14-34(37)43(61)36-28-53-44-42(36)45(55-29-54-44)56-30-9-11-31(12-10-30)57-49(65)52-18-20-67-22-24-69-26-25-68-23-21-66-19-17-51-38-8-4-7-35-41(38)48(64)59(47(35)63)39-15-16-40(60)58-46(39)62/h1-8,13-14,27-31,39,51H,9-12,15-26H2,(H2,52,57,65)(H,58,60,62)(H2,53,54,55,56)/t30-,31+,39?",QJZSKXPDZKWNIF-ZMZOSUEXSA-N,453,2,346,CCOCCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCCOCC[R2],249.307,249.1576228,-0.08,17,0,5,1,14,66.02,C11H23NO5,"InChI=1S/C11H23NO5/c1-2-14-5-6-16-9-10-17-8-7-15-4-3-12-11-13/h11H,2-10H2,1H3,(H,12,13)",USNKTLYDYCQPIY-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.78,12.1,7.168479557,7.208797316,67.8454,61.8305
2841,37.9,83.5,37.9,83.5,Q06187,BTK C481S,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK C481S in TMD8 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,290.1,Inhibit proliferation of TMD8 (BTK C481S) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,980.476,979.3631312,4.8,70,8,15,6,24,253.53,C49H54ClN9O11,"InChI=1S/C49H54ClN9O11/c50-37-27-33(70-32-5-2-1-3-6-32)13-14-34(37)43(61)36-28-53-44-42(36)45(55-29-54-44)56-30-9-11-31(12-10-30)57-49(65)52-18-20-67-22-24-69-26-25-68-23-21-66-19-17-51-38-8-4-7-35-41(38)48(64)59(47(35)63)39-15-16-40(60)58-46(39)62/h1-8,13-14,27-31,39,51H,9-12,15-26H2,(H2,52,57,65)(H,58,60,62)(H2,53,54,55,56)/t30-,31+,39?",QJZSKXPDZKWNIF-ZMZOSUEXSA-N,453,2,346,CCOCCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCCOCC[R2],249.307,249.1576228,-0.08,17,0,5,1,14,66.02,C11H23NO5,"InChI=1S/C11H23NO5/c1-2-14-5-6-16-9-10-17-8-7-15-4-3-12-11-13/h11H,2-10H2,1H3,(H,12,13)",USNKTLYDYCQPIY-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.835,37.9,7.168479557,7.208797316,67.8454,61.8305
2840,30.1,84.3,30.1,84.3,Q06187,BTK C481S,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK C481S in TMD8 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,936.423,935.3369165,4.95,67,8,14,6,21,244.3,C47H50ClN9O10,"InChI=1S/C47H50ClN9O10/c48-35-25-31(67-30-5-2-1-3-6-30)13-14-32(35)41(59)34-26-51-42-40(34)43(53-27-52-42)54-28-9-11-29(12-10-28)55-47(63)50-18-20-65-22-24-66-23-21-64-19-17-49-36-8-4-7-33-39(36)46(62)57(45(33)61)37-15-16-38(58)56-44(37)60/h1-8,13-14,25-29,37,49H,9-12,15-24H2,(H2,50,55,63)(H,56,58,60)(H2,51,52,53,54)/t28-,29+,37?",HTWXOMYINZDUGN-JNLNXYSYSA-N,453,2,345,CCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCC[R2],205.254,205.1314081,0.07,14,0,4,1,11,56.79,C9H19NO4,"InChI=1S/C9H19NO4/c1-2-12-5-6-14-8-7-13-4-3-10-9-11/h9H,2-8H2,1H3,(H,10,11)",PMJXDYYSGBCCKN-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.843,30.1,7.128659024,7.42319947,74.3603,37.7399
2840,32.3,76.9,32.3,76.9,Q06187,BTK,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,22.3,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,936.423,935.3369165,4.95,67,8,14,6,21,244.3,C47H50ClN9O10,"InChI=1S/C47H50ClN9O10/c48-35-25-31(67-30-5-2-1-3-6-30)13-14-32(35)41(59)34-26-51-42-40(34)43(53-27-52-42)54-28-9-11-29(12-10-28)55-47(63)50-18-20-65-22-24-66-23-21-64-19-17-49-36-8-4-7-33-39(36)46(62)57(45(33)61)37-15-16-38(58)56-44(37)60/h1-8,13-14,25-29,37,49H,9-12,15-24H2,(H2,50,55,63)(H,56,58,60)(H2,51,52,53,54)/t28-,29+,37?",HTWXOMYINZDUGN-JNLNXYSYSA-N,453,2,345,CCOCCOCCOCCNC=O,[R1]C(=O)NCCOCCOCCOCC[R2],205.254,205.1314081,0.07,14,0,4,1,11,56.79,C9H19NO4,"InChI=1S/C9H19NO4/c1-2-12-5-6-14-8-7-13-4-3-10-9-11/h9H,2-8H2,1H3,(H,10,11)",PMJXDYYSGBCCKN-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.769,32.3,7.128659024,7.42319947,74.3603,37.7399
1154,3.41,88.01,3.41,88.01,Q9UBN7,HDAC6,CRBN,,,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=C(OCCN2C=C(CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N2)C=C1,Degradation of HDAC6 in MM1S cells after 6 h treatment,62.1/81.3,% HDAC6 degradation in MM1S cells after 6 h treatment at 10/100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.9b00516,737.774,737.2921592,2.28,54,6,12,5,15,217.19,C37H39N9O8,"InChI=1S/C37H39N9O8/c1-2-3-17-44(21-23-7-9-24(10-8-23)33(48)42-53)37(52)39-25-11-13-27(14-12-25)54-19-18-45-22-26(41-43-45)20-38-29-6-4-5-28-32(29)36(51)46(35(28)50)30-15-16-31(47)40-34(30)49/h4-14,22,30,38,53H,2-3,15-21H2,1H3,(H,39,52)(H,42,48)(H,40,47,49)",YVMSHPWOPPUCHZ-UHFFFAOYSA-N,127,2,567,CC1=CN(CCO)N=N1,[R1]OCCN1C=C(N=N1)C[R2],127.147,127.0745619,-0.66,9,1,4,1,2,50.94,C5H9N3O,"InChI=1S/C5H9N3O/c1-5-4-8(2-3-9)7-6-5/h4,9H,2-3H2,1H3",NRWUEYNWZWYICS-UHFFFAOYSA-N,P42858,Htt,,COC1=CC=C2N=C(/N=N/C3=CC=C(N(C)C)C=C3)SC2=C1,,,,,,,,,10.1002/anie.201706529,312.398,312.1044821,4.58,22,3,6,0,4,50.08,C16H16N4OS,"InChI=1S/C16H16N4OS/c1-20(2)12-6-4-11(5-7-12)18-19-16-17-14-9-8-13(21-3)10-15(14)22-16/h4-10H,1-3H3/b19-18+",AVPFTROGVGTTEC-VHEBQXMUSA-N,50363719,77390,CHEMBL1378812,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.8801,3.41,7.682447482,6.237891415,20.7755,578.2406
1157,1.64,86.26,1.64,86.26,Q9UBN7,HDAC6,CRBN,,,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=C(OCCCCCN2C=C(CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N2)C=C1,Degradation of HDAC6 in MM1S cells after 6 h treatment,74.9/82.7,% HDAC6 degradation in MM1S cells after 6 h treatment at 10/100 nM,8.7,IC50 of HDAC6 was determined using a fluorescence-based assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,74.9,Inhibit proliferation of MM1S cells,,,,,,,,,,,,,10.1021/acs.jmedchem.9b00516,779.855,779.3391094,3.35,57,6,12,5,18,217.19,C40H45N9O8,"InChI=1S/C40H45N9O8/c1-2-3-20-47(24-26-10-12-27(13-11-26)36(51)45-56)40(55)42-28-14-16-30(17-15-28)57-22-6-4-5-21-48-25-29(44-46-48)23-41-32-9-7-8-31-35(32)39(54)49(38(31)53)33-18-19-34(50)43-37(33)52/h7-17,25,33,41,56H,2-6,18-24H2,1H3,(H,42,55)(H,45,51)(H,43,50,52)",DQGQXFRCIYCGOE-UHFFFAOYSA-N,127,2,570,CC1=CN(CCCCCO)N=N1,[R1]OCCCCCN1C=C(N=N1)C[R2],169.228,169.1215121,0.41,12,1,4,1,5,50.94,C8H15N3O,"InChI=1S/C8H15N3O/c1-8-7-11(10-9-8)5-3-2-4-6-12/h7,12H,2-6H2,1H3",IUUPUASDOPLFAW-UHFFFAOYSA-N,P42858,Htt,,COC1=CC=C2N=C(/N=N/C3=CC=C(N(C)C)C=C3)SC2=C1,,,,,,,,,10.1002/anie.201706529,312.398,312.1044821,4.58,22,3,6,0,4,50.08,C16H16N4OS,"InChI=1S/C16H16N4OS/c1-20(2)12-6-4-11(5-7-12)18-19-16-17-14-9-8-13(21-3)10-15(14)22-16/h4-10H,1-3H3/b19-18+",AVPFTROGVGTTEC-VHEBQXMUSA-N,50363719,77390,CHEMBL1378812,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.8626,1.64,7.937204285,6.74221509,11.5557,181.0443
1157,2.2,86,2.2/18,86/45,Q9UBN7,HDAC6,CRBN,,,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=C(OCCCCCN2C=C(CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N2)C=C1,Degradation of HDAC6 in MM1S/Mouse 4935 cells after 4/6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,74.9,Inhibit proliferation of MM1S cells,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00046,779.855,779.3391094,3.35,57,6,12,5,18,217.19,C40H45N9O8,"InChI=1S/C40H45N9O8/c1-2-3-20-47(24-26-10-12-27(13-11-26)36(51)45-56)40(55)42-28-14-16-30(17-15-28)57-22-6-4-5-21-48-25-29(44-46-48)23-41-32-9-7-8-31-35(32)39(54)49(38(31)53)33-18-19-34(50)43-37(33)52/h7-17,25,33,41,56H,2-6,18-24H2,1H3,(H,42,55)(H,45,51)(H,43,50,52)",DQGQXFRCIYCGOE-UHFFFAOYSA-N,127,2,570,CC1=CN(CCCCCO)N=N1,[R1]OCCCCCN1C=C(N=N1)C[R2],169.228,169.1215121,0.41,12,1,4,1,5,50.94,C8H15N3O,"InChI=1S/C8H15N3O/c1-8-7-11(10-9-8)5-3-2-4-6-12/h7,12H,2-6H2,1H3",IUUPUASDOPLFAW-UHFFFAOYSA-N,P42858,Htt,,COC1=CC=C2N=C(/N=N/C3=CC=C(N(C)C)C=C3)SC2=C1,,,,,,,,,10.1002/anie.201706529,312.398,312.1044821,4.58,22,3,6,0,4,50.08,C16H16N4OS,"InChI=1S/C16H16N4OS/c1-20(2)12-6-4-11(5-7-12)18-19-16-17-14-9-8-13(21-3)10-15(14)22-16/h4-10H,1-3H3/b19-18+",AVPFTROGVGTTEC-VHEBQXMUSA-N,50363719,77390,CHEMBL1378812,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.86,2.2,7.937204285,6.74221509,11.5557,181.0443
1162,2.54,86.3,2.54,86.3,Q9UBN7,HDAC6,CRBN,,,CCCCN(CC1=CC=C(C(=O)NO)C=C1)C(=O)NC1=CC=C(OCCN2C=C(CCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N2)C=C1,Degradation of HDAC6 in MM1S cells after 6 h treatment,70.6/83.1,% HDAC6 degradation in MM1S cells after 6 h treatment at 10/100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.9b00516,765.828,765.3234593,3.1,56,6,12,5,17,217.19,C39H43N9O8,"InChI=1S/C39H43N9O8/c1-2-3-20-46(23-25-9-11-26(12-10-25)35(50)44-55)39(54)41-27-13-15-29(16-14-27)56-22-21-47-24-28(43-45-47)6-5-19-40-31-8-4-7-30-34(31)38(53)48(37(30)52)32-17-18-33(49)42-36(32)51/h4,7-16,24,32,40,55H,2-3,5-6,17-23H2,1H3,(H,41,54)(H,44,50)(H,42,49,51)",HKHMBOOYLKOYAW-UHFFFAOYSA-N,127,2,575,CCCC1=CN(CCO)N=N1,[R1]OCCN1C=C(N=N1)CCC[R2],155.201,155.105862,0.13,11,1,4,1,4,50.94,C7H13N3O,"InChI=1S/C7H13N3O/c1-2-3-7-6-10(4-5-11)9-8-7/h6,11H,2-5H2,1H3",CSMMGTBVKLOOHC-UHFFFAOYSA-N,P42858,Htt,,COC1=CC=C2N=C(/N=N/C3=CC=C(N(C)C)C=C3)SC2=C1,,,,,,,,,10.1002/anie.201706529,312.398,312.1044821,4.58,22,3,6,0,4,50.08,C16H16N4OS,"InChI=1S/C16H16N4OS/c1-20(2)12-6-4-11(5-7-12)18-19-16-17-14-9-8-13(21-3)10-15(14)22-16/h4-10H,1-3H3/b19-18+",AVPFTROGVGTTEC-VHEBQXMUSA-N,50363719,77390,CHEMBL1378812,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.863,2.54,8.204503517,6.408743918,6.2445,390.172
1099,70,82,70,82,P15056,BRAF V600E,CRBN,,P5B,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,25,Inhibition of BRAF V600E,,,,,,,,,,,,,,,850,FP,,,,,,,,,,,,,,,2170,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1089.189,1088.423745,2.78,77,8,18,3,28,255.05,C52H62F2N10O12S,"InChI=1S/C52H62F2N10O12S/c1-3-29-77(70,71)60-40-8-7-38(53)49(47(40)54)63-32-37(34-30-55-33-56-31-34)48-41(63)9-11-43(58-48)61(2)35-13-17-62(18-14-35)45(66)15-19-72-21-23-74-25-27-76-28-26-75-24-22-73-20-16-57-39-6-4-5-36-46(39)52(69)64(51(36)68)42-10-12-44(65)59-50(42)67/h4-9,11,30-33,35,42,57,60H,3,10,12-29H2,1-2H3,(H,59,65,67)",RQROXFBXOKHLAH-UHFFFAOYSA-N,172,2,264,CCOCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCOCC[R2],278.345,278.1729386,-0.71,19,0,6,0,16,63.22,C13H26O6,"InChI=1S/C13H26O6/c1-2-15-6-7-17-10-11-19-13-12-18-9-8-16-5-3-4-14/h4H,2-3,5-13H2,1H3",XYLCAEDVEIYMPO-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.82,70,7.121244187,6.32037838,75.6407,478.2133
1081,100,65,100,65,P15056,BRAF V600E,CRBN,,Pmd-PEG3-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,65,Inhibition of BRAF V600E,,,,,,,,,,,,,,,1520,FP,,,,,,,,,,,,,,,3750,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1001.083,1000.371315,3.08,71,8,16,3,22,236.59,C48H54F2N10O10S,"InChI=1S/C48H54F2N10O10S/c1-3-25-71(66,67)56-36-8-7-34(49)45(43(36)50)59-28-33(30-26-51-29-52-27-30)44-37(59)9-11-39(54-44)57(2)31-13-17-58(18-14-31)41(62)15-19-68-21-23-70-24-22-69-20-16-53-35-6-4-5-32-42(35)48(65)60(47(32)64)38-10-12-40(61)55-46(38)63/h4-9,11,26-29,31,38,53,56H,3,10,12-25H2,1-2H3,(H,55,61,63)",FMUGAZVOOIUFAT-UHFFFAOYSA-N,172,2,266,CCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCC[R2],190.239,190.1205091,-0.42,13,0,4,0,10,44.76,C9H18O4,"InChI=1S/C9H18O4/c1-2-11-6-7-13-9-8-12-5-3-4-10/h4H,2-3,5-9H2,1H3",AJMGGIZNAPWJIH-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.65,100,6.813398301,6.747473294,153.6745,178.8656
1098,15,82,15,82,P15056,BRAF V600E,CRBN,,P4B,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,12,Inhibition of BRAF V600E,,,5.6,SPR,,,,,,,1.4,0.77,,,900,FP,,,,,,,,,,,,,,,2570,FP,,,,,,,,,,,,,,,71/75/147,Inhibit proliferation of A375/WM266-4/RKO cells,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1045.136,1044.39753,2.93,74,8,17,3,25,245.82,C50H58F2N10O11S,"InChI=1S/C50H58F2N10O11S/c1-3-27-74(68,69)58-38-8-7-36(51)47(45(38)52)61-30-35(32-28-53-31-54-29-32)46-39(61)9-11-41(56-46)59(2)33-13-17-60(18-14-33)43(64)15-19-70-21-23-72-25-26-73-24-22-71-20-16-55-37-6-4-5-34-44(37)50(67)62(49(34)66)40-10-12-42(63)57-48(40)65/h4-9,11,28-31,33,40,55,58H,3,10,12-27H2,1-2H3,(H,57,63,65)",GJCIYFAPQUEGNE-UHFFFAOYSA-N,172,2,265,CCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCC[R2],234.292,234.1467238,-0.56,16,0,5,0,13,53.99,C11H22O5,"InChI=1S/C11H22O5/c1-2-13-6-7-15-10-11-16-9-8-14-5-3-4-12/h4H,2-3,5-11H2,1H3",QNYDWCLUZIEJKP-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.82,15,6.734581959,6.318912566,184.2545,479.83
2048,90,84,90,84,P15056,BRAF V600E,CRBN,,Pmd-PEG6-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCOCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,83,Inhibition of BRAF V600E,,,,,,,,,,,,,,,1180,FP,,,,,,,,,,,,,,,3040,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1133.242,1132.44996,2.63,80,8,19,3,31,264.28,C54H66F2N10O13S,"InChI=1S/C54H66F2N10O13S/c1-3-31-80(72,73)62-42-8-7-40(55)51(49(42)56)65-34-39(36-32-57-35-58-33-36)50-43(65)9-11-45(60-50)63(2)37-13-17-64(18-14-37)47(68)15-19-74-21-23-76-25-27-78-29-30-79-28-26-77-24-22-75-20-16-59-41-6-4-5-38-48(41)54(71)66(53(38)70)44-10-12-46(67)61-52(44)69/h4-9,11,32-35,37,44,59,62H,3,10,12-31H2,1-2H3,(H,61,67,69)",PHBHADRVFSMQAN-UHFFFAOYSA-N,172,2,479,CCOCCOCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCOCCOCC[R2],322.398,322.1991533,-0.86,22,0,7,0,19,72.45,C15H30O7,"InChI=1S/C15H30O7/c1-2-17-6-7-19-10-11-21-14-15-22-13-12-20-9-8-18-5-3-4-16/h4H,2-3,5-15H2,1H3",YAMDEEMOVZPPRF-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.84,90,6.582208676,6.038135239,261.6925,915.9352
2049,45,65,45,65,P15056,BRAF V600E,CRBN,,Pmd-PEG8-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,85,Inhibition of BRAF V600E,,,,,,,,,,,,,,,1070,FP,,,,,,,,,,,,,,,2980,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1221.348,1220.502389,2.34,86,8,21,3,37,282.74,C58H74F2N10O15S,"InChI=1S/C58H74F2N10O15S/c1-3-35-86(76,77)66-46-8-7-44(59)55(53(46)60)69-38-43(40-36-61-39-62-37-40)54-47(69)9-11-49(64-54)67(2)41-13-17-68(18-14-41)51(72)15-19-78-21-23-80-25-27-82-29-31-84-33-34-85-32-30-83-28-26-81-24-22-79-20-16-63-45-6-4-5-42-52(45)58(75)70(57(42)74)48-10-12-50(71)65-56(48)73/h4-9,11,36-39,41,48,63,66H,3,10,12-35H2,1-2H3,(H,65,71,73)",UGQUDUNSDGAZIO-UHFFFAOYSA-N,172,2,992,CCOCCOCCOCCOCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCOCCOCCOCCOCC[R2],410.504,410.2515828,-1.15,28,0,9,0,25,90.91,C19H38O9,"InChI=1S/C19H38O9/c1-2-21-6-7-23-10-11-25-14-15-27-18-19-28-17-16-26-13-12-24-9-8-22-5-3-4-20/h4H,2-3,5-19H2,1H3",NSIIVBKTTWZVBU-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.65,45,6.39233488,6.118788601,405.196,760.6965
2050,100,51,100,51,P15056,BRAF V600E,CRBN,,Pmd-1C-PEG3-1C-2C-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCC(=O)NCCCOCCOCCOCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,82,Inhibition of BRAF V600E,,,,,,,,,,,,,,,1010,FP,,,,,,,,,,,,,,,2460,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1100.216,1099.439729,3.04,78,8,17,4,27,265.69,C53H63F2N11O11S,"InChI=1S/C53H63F2N11O11S/c1-3-29-78(73,74)62-40-10-9-38(54)50(48(40)55)65-32-37(34-30-56-33-57-31-34)49-41(65)11-13-43(60-49)63(2)35-17-21-64(22-18-35)46(69)16-15-44(67)59-20-6-24-76-26-28-77-27-25-75-23-5-19-58-39-8-4-7-36-47(39)53(72)66(52(36)71)42-12-14-45(68)61-51(42)70/h4,7-11,13,30-33,35,42,58,62H,3,5-6,12,14-29H2,1-2H3,(H,59,67)(H,61,68,70)",GVOFKFUVWFBDKE-UHFFFAOYSA-N,172,2,993,CCCOCCOCCOCCCNC(=O)CCC=O,[R1]C(=O)CCC(=O)NCCCOCCOCCOCCC[R2],289.372,289.188923,-0.28,20,0,5,1,15,73.86,C14H27NO5,"InChI=1S/C14H27NO5/c1-2-8-18-10-12-20-13-11-19-9-4-6-15-14(17)5-3-7-16/h7H,2-6,8-13H2,1H3,(H,15,17)",KAZVYKPEGHVBSS-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.51,100,6.564779587,6.565330383,272.4083,272.0631
2063,25,71,25,71,P15056,BRAF V600E,CRBN,,Pmd-DODA-C1-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(CC(=O)NCCCOCCCCOCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,25,Inhibition of BRAF V600E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1042.18,1041.43425,4.61,74,8,16,4,25,239.39,C51H61F2N11O9S,"InChI=1S/C51H61F2N11O9S/c1-3-27-74(70,71)60-39-12-11-37(52)48(46(39)53)63-30-36(33-28-54-32-55-29-33)47-40(63)13-15-42(58-47)61(2)34-17-21-62(22-18-34)31-44(66)57-20-8-26-73-24-5-4-23-72-25-7-19-56-38-10-6-9-35-45(38)51(69)64(50(35)68)41-14-16-43(65)59-49(41)67/h6,9-13,15,28-30,32,34,41,56,60H,3-5,7-8,14,16-27,31H2,1-2H3,(H,57,66)(H,59,65,67)",DAQQIWJQNSGFLU-UHFFFAOYSA-N,172,2,1005,CCCOCCCCOCCCNC(C)=O,[R1]CC(=O)NCCCOCCCCOCCC[R2],231.336,231.1834437,1.21,16,0,3,1,11,47.56,C12H25NO3,"InChI=1S/C12H25NO3/c1-3-8-15-9-4-5-10-16-11-6-7-13-12(2)14/h3-11H2,1-2H3,(H,13,14)",QXBRTKUNDWWBCM-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,25,6.563992611,6.645465057,272.9024,226.2221
2064,80,72,80,72,P15056,BRAF V600E,CRBN,,Pmd-PEG1-Trz-PEG2-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCN5C=C(COCCNC6=CC=CC7=C6C(=O)N(C6CCC(=O)NC6=O)C7=O)N=N5)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,15,Inhibition of BRAF V600E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1082.161,1081.404012,2.31,77,9,19,3,24,267.3,C51H57F2N13O10S,"InChI=1S/C51H57F2N13O10S/c1-3-25-77(72,73)60-39-8-7-37(52)48(46(39)53)65-29-36(32-26-54-31-55-27-32)47-40(65)9-11-42(57-47)62(2)34-13-17-63(18-14-34)44(68)15-20-74-23-24-75-22-19-64-28-33(59-61-64)30-76-21-16-56-38-6-4-5-35-45(38)51(71)66(50(35)70)41-10-12-43(67)58-49(41)69/h4-9,11,26-29,31,34,41,56,60H,3,10,12-25,30H2,1-2H3,(H,58,67,69)",VFSRJJPNEQKSQQ-UHFFFAOYSA-N,172,2,1006,CCOCC1=CN(CCOCCOCCC=O)N=N1,[R1]C(=O)CCOCCOCCN1C=C(N=N1)COCC[R2],271.317,271.1532062,-1.19,19,1,7,0,12,75.47,C12H21N3O4,"InChI=1S/C12H21N3O4/c1-2-17-11-12-10-15(14-13-12)4-7-19-9-8-18-6-3-5-16/h5,10H,2-4,6-9,11H2,1H3",VRVRIXZCPFKIQB-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.72,80,6.966104497,6.824296367,108.1174,149.8662
3259,37,95,37,95,Q03111,MLLT1,CRBN,,,C[C@H]1CCCN1CC1=NC2=CC=C(NC(=O)C3=CC=C4C(=C3)C=NN4CCCCCCCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2[NH]1,Degradation of ENL in MV4;11 cells after 24 h treatment,,,170,Inhibition of ENL YEATS-H3K27ac interaction was tested by an Alpha assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,320/570/1100,Inhibit proliferation of Molm-13/MV4;11/Kasumi-1 cells,,,,,,,,,,,,,10.1186/s13045-022-01258-8,757.896,757.3700156,5.64,56,8,10,4,15,174.42,C42H47N9O5,"InChI=1S/C42H47N9O5/c1-26-10-9-20-49(26)25-36-46-31-15-14-29(23-33(31)47-36)45-39(53)27-13-16-34-28(22-27)24-44-50(34)21-7-5-3-2-4-6-19-43-32-12-8-11-30-38(32)42(56)51(41(30)55)35-17-18-37(52)48-40(35)54/h8,11-16,22-24,26,35,43H,2-7,9-10,17-21,25H2,1H3,(H,45,53)(H,46,47)(H,48,52,54)/t26-,35?/m0/s1",SCZWWJDUQGVEMY-HJYWNDIWSA-N,537,2,32,CCCCCCCC,[R1]CCCCCCCC[R2],114.232,114.1408506,4.55,8,0,0,0,5,0,C8H18,"InChI=1S/C8H18/c1-3-5-7-8-6-4-2/h3-8H2,1-2H3",TVMXDCGIABBOFY-UHFFFAOYSA-N,P00533,EGFR,,O=C1[NH][NH]C2=NC3=CC=CC=C3N=C12,,,,,,,,,10.1080/14756366.2022.2062338,186.174,186.0541608,1.1,14,3,3,2,0,74.43,C9H6N4O,"InChI=1S/C9H6N4O/c14-9-7-8(12-13-9)11-6-4-2-1-3-5(6)10-7/h1-4H,(H2,11,12,13,14)",PYBOWKRHRSYSBL-UHFFFAOYSA-N,,2755892,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,14.9,0.046510067,1,1,1,1,1,0.046510067,0.95,37,7.833239353,7.099162845,14.6812,79.5861
3259,37,95,37,95,Q03111,MLLT1,CRBN,,,C[C@H]1CCCN1CC1=NC2=CC=C(NC(=O)C3=CC=C4C(=C3)C=NN4CCCCCCCCNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)C=C2[NH]1,Degradation of ENL in MV4;11 cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,320/570/1100,Inhibit cell proliferation of Molm-13/MV4;11/Kasumi-1 cells,,,,,,,,,,,,,10.1186/s13045-022-01258-8,757.896,757.3700156,5.64,56,8,10,4,15,174.42,C42H47N9O5,"InChI=1S/C42H47N9O5/c1-26-10-9-20-49(26)25-36-46-31-15-14-29(23-33(31)47-36)45-39(53)27-13-16-34-28(22-27)24-44-50(34)21-7-5-3-2-4-6-19-43-32-12-8-11-30-38(32)42(56)51(41(30)55)35-17-18-37(52)48-40(35)54/h8,11-16,22-24,26,35,43H,2-7,9-10,17-21,25H2,1H3,(H,45,53)(H,46,47)(H,48,52,54)/t26-,35?/m0/s1",SCZWWJDUQGVEMY-HJYWNDIWSA-N,537,2,32,CCCCCCCC,[R1]CCCCCCCC[R2],114.232,114.1408506,4.55,8,0,0,0,5,0,C8H18,"InChI=1S/C8H18/c1-3-5-7-8-6-4-2/h3-8H2,1-2H3",TVMXDCGIABBOFY-UHFFFAOYSA-N,P00533,EGFR,,O=C1[NH][NH]C2=NC3=CC=CC=C3N=C12,,,,,,,,,10.1080/14756366.2022.2062338,186.174,186.0541608,1.1,14,3,3,2,0,74.43,C9H6N4O,"InChI=1S/C9H6N4O/c14-9-7-8(12-13-9)11-6-4-2-1-3-5(6)10-7/h1-4H,(H2,11,12,13,14)",PYBOWKRHRSYSBL-UHFFFAOYSA-N,,2755892,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,14.9,0.046510067,1,1,1,1,1,0.046510067,0.95,37,7.833239353,7.099162845,14.6812,79.5861
1223,0.9,99,0.9,99,Q06187,BTK,CRBN,,DD-03-171,CC1=C(NC(=O)C2=CC=C(C(C)(C)C)C=C2)C=CC=C1C1=CN(C)C(=O)C(NC2=CC=C(C(=O)N3CCN(CCCCCCNC(=O)CNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)C=C2)=N1,Degradation of BTK in Mino cells after 24h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.crchbi.2022.100029,991.163,990.4752089,5.83,73,8,13,5,17,224.25,C55H62N10O8,"InChI=1S/C55H62N10O8/c1-34-39(12-10-14-41(34)60-49(68)35-16-20-37(21-17-35)55(2,3)4)43-33-62(5)54(73)48(59-43)58-38-22-18-36(19-23-38)51(70)64-30-28-63(29-31-64)27-9-7-6-8-26-56-46(67)32-57-42-15-11-13-40-47(42)53(72)65(52(40)71)44-24-25-45(66)61-50(44)69/h10-23,33,44,57H,6-9,24-32H2,1-5H3,(H,56,67)(H,58,59)(H,60,68)(H,61,66,69)",QBPVFCNYKUENHU-UHFFFAOYSA-N,185,2,387,CCCCCCNC(C)=O,[R1]CCCCCCNC(=O)C[R2],143.23,143.1310142,1.87,10,0,1,1,5,29.1,C8H17NO,"InChI=1S/C8H17NO/c1-3-4-5-6-7-9-8(2)10/h3-7H2,1-2H3,(H,9,10)",SYIOXNGUUYGIIF-UHFFFAOYSA-N,P37840,Alpha-syn,BTA-1,CNC1=CC=C(C2=NC3=CC=CC=C3S2)C=C1,,,,,,,,,10.1021/acsmedchemlett.0c00192,240.331,240.0721194,4.02,17,3,3,1,2,24.92,C14H12N2S,"InChI=1S/C14H12N2S/c1-15-11-8-6-10(7-9-11)14-16-12-4-2-3-5-13(12)17-14/h2-9,15H,1H3",FHJRKGXJBXPBGA-UHFFFAOYSA-N,50109052,9837643,CHEMBL93334,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.9,6.863546497,7.113718095,136.9158,76.963
1299,35.7,90,35.7,90,P09874,PARP1,CRBN,,iRucaparib-AP5,CN(CCOCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)CC1=CC=C(C2=C3CCNC(=O)C4=C3C(=CC(F)=C4)[NH]2)C=C1,Degradation of PARP1 in Primary Cardiomyocytes after 24 h treatment,,,24.6,IC50 was tested by using a PARP universal chemiluminescent assay kit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-019-0379-2,842.922,842.3650701,2.66,61,7,12,4,23,189.86,C44H51FN6O10,"InChI=1S/C44H51FN6O10/c1-50(27-28-5-7-29(8-6-28)40-31-11-12-47-41(53)33-25-30(45)26-35(48-40)38(31)33)14-16-58-18-20-60-22-24-61-23-21-59-19-17-57-15-13-46-34-4-2-3-32-39(34)44(56)51(43(32)55)36-9-10-37(52)49-42(36)54/h2-8,25-26,36,46,48H,9-24,27H2,1H3,(H,47,53)(H,49,52,54)",CDKSZVJXSCKNQN-UHFFFAOYSA-N,191,2,221,CCOCCOCCOCCOCCOCC,[R1]CCOCCOCCOCCOCCOCC[R2],250.335,250.1780239,0.22,17,0,5,0,14,46.15,C12H26O5,"InChI=1S/C12H26O5/c1-3-13-5-7-15-9-11-17-12-10-16-8-6-14-4-2/h3-12H2,1-2H3",HYDWALOBQJFOMS-UHFFFAOYSA-N,P10275,AR,,CC1(C)C(=O)N(C2=CN=C(C#N)C(C(F)(F)F)=C2)C(=S)N1C1=CC=C(O)C=C1,,,,,,,,,,406.389,406.0711313,3.14,28,3,5,1,2,80.46,C18H13F3N4O2S,"InChI=1S/C18H13F3N4O2S/c1-17(2)15(27)24(16(28)25(17)10-3-5-12(26)6-4-10)11-7-13(18(19,20)21)14(8-22)23-9-11/h3-7,9,26H,1-2H3",XDMFMJFVWVJZOL-UHFFFAOYSA-N,,88917586,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,208.78,0.003319283,1,1,1,1,1,0.003319283,0.9,35.7,6.673689165,6.293498737,211.9878,508.7463
1300,81.8,92,81.8,92,P09874,PARP1,CRBN,,iRucaparib-AP6,CN(CCOCCOCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)CC1=CC=C(C2=C3CCNC(=O)C4=C3C(=CC(F)=C4)[NH]2)C=C1,Degradation of PARP1 in Primary Cardiomyocytes after 24 h treatment,,,28.5,IC50 was tested by using a PARP universal chemiluminescent assay kit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-019-0379-2,886.975,886.3912848,2.51,64,7,13,4,26,199.09,C46H55FN6O11,"InChI=1S/C46H55FN6O11/c1-52(29-30-5-7-31(8-6-30)42-33-11-12-49-43(55)35-27-32(47)28-37(50-42)40(33)35)14-16-60-18-20-62-22-24-64-26-25-63-23-21-61-19-17-59-15-13-48-36-4-2-3-34-41(36)46(58)53(45(34)57)38-9-10-39(54)51-44(38)56/h2-8,27-28,38,48,50H,9-26,29H2,1H3,(H,49,55)(H,51,54,56)",YHMDCINUVWULST-UHFFFAOYSA-N,191,2,222,CCOCCOCCOCCOCCOCCOCC,[R1]CCOCCOCCOCCOCCOCCOCC[R2],294.388,294.2042387,0.07,20,0,6,0,17,55.38,C14H30O6,"InChI=1S/C14H30O6/c1-3-15-5-7-17-9-11-19-13-14-20-12-10-18-8-6-16-4-2/h3-14H2,1-2H3",IXFAFGFZFQHRLB-UHFFFAOYSA-N,P10275,AR,,CC1(C)C(=O)N(C2=CN=C(C#N)C(C(F)(F)F)=C2)C(=S)N1C1=CC=C(O)C=C1,,,,,,,,,,406.389,406.0711313,3.14,28,3,5,1,2,80.46,C18H13F3N4O2S,"InChI=1S/C18H13F3N4O2S/c1-17(2)15(27)24(16(28)25(17)10-3-5-12(26)6-4-10)11-7-13(18(19,20)21)14(8-22)23-9-11/h3-7,9,26H,1-2H3",XDMFMJFVWVJZOL-UHFFFAOYSA-N,,88917586,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,208.78,0.003319283,1,1,1,1,1,0.003319283,0.92,81.8,6.707577904,6.543579836,196.0749,286.0356
1675,0.228,99,0.578/1.08/0.228,>99/>99/>99,P09874,PARP1,CRBN,,SK-575,O=C(CCCCCCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=N[NH]C(=O)C4=CC=CC=C34)=CC=C2F)CC1)NCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of PARP1 in PC-3/LNCaP/MDA-MB-231 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5140/1440/4790,Inhibit growth of PC-3/LNCaP/MDA-MB-231 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c00821,876.987,876.3970389,5.03,64,7,10,4,19,211.05,C47H53FN8O8,"InChI=1S/C47H53FN8O8/c48-35-19-18-30(29-37-31-12-9-10-13-32(31)43(60)53-52-37)28-34(35)45(62)55-26-24-54(25-27-55)41(59)17-8-6-4-2-1-3-5-7-16-39(57)50-23-22-49-36-15-11-14-33-42(36)47(64)56(46(33)63)38-20-21-40(58)51-44(38)61/h9-15,18-19,28,38,49H,1-8,16-17,20-27,29H2,(H,50,57)(H,53,60)(H,51,58,61)",HPBWDZVXFSTVMR-UHFFFAOYSA-N,49,2,817,CCCCCCCCCCC(=O)NCC,[R1]CCCCCCCCCCC(=O)NCC[R2],213.365,213.2092645,4.53,15,0,1,1,10,29.1,C13H27NO,"InChI=1S/C13H27NO/c1-3-5-6-7-8-9-10-11-12-13(15)14-4-2/h3-12H2,1-2H3,(H,14,15)",QFZHIMKZKRGXQF-UHFFFAOYSA-N,P25440,BRD2,OTX015,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(O)C=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,,16.6/5.4,FP in BRD2 BD1/2,10.1021/acs.jmedchem.5b00613,492.004,491.1182736,4.5,34,5,7,2,4,92.4,C25H22ClN5O2S,"InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1",GNMUEVRJHCWKTO-FQEVSTJZSA-N,50092312,9936746,CHEMBL3581647,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,208.78,0.003319283,1,1,1,1,1,0.003319283,0.99,0.228,7.464302852,7.006715518,34.3318,98.4656
1675,0.263,99,0.384/0.512/0.263,>99/>99/>99,P09874,PARP1,CRBN,,SK-575,O=C(CCCCCCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=N[NH]C(=O)C4=CC=CC=C34)=CC=C2F)CC1)NCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of PARP1 in HCC1937/22RV1/MDA-MB-468 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8410/12300/4360,Inhibit growth of HCC1937/22RV1/MDA-MB-468 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c00821,876.987,876.3970389,5.03,64,7,10,4,19,211.05,C47H53FN8O8,"InChI=1S/C47H53FN8O8/c48-35-19-18-30(29-37-31-12-9-10-13-32(31)43(60)53-52-37)28-34(35)45(62)55-26-24-54(25-27-55)41(59)17-8-6-4-2-1-3-5-7-16-39(57)50-23-22-49-36-15-11-14-33-42(36)47(64)56(46(33)63)38-20-21-40(58)51-44(38)61/h9-15,18-19,28,38,49H,1-8,16-17,20-27,29H2,(H,50,57)(H,53,60)(H,51,58,61)",HPBWDZVXFSTVMR-UHFFFAOYSA-N,49,2,817,CCCCCCCCCCC(=O)NCC,[R1]CCCCCCCCCCC(=O)NCC[R2],213.365,213.2092645,4.53,15,0,1,1,10,29.1,C13H27NO,"InChI=1S/C13H27NO/c1-3-5-6-7-8-9-10-11-12-13(15)14-4-2/h3-12H2,1-2H3,(H,14,15)",QFZHIMKZKRGXQF-UHFFFAOYSA-N,P25440,BRD2,OTX015,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(O)C=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,,16.6/5.4,FP in BRD2 BD1/2,10.1021/acs.jmedchem.5b00613,492.004,491.1182736,4.5,34,5,7,2,4,92.4,C25H22ClN5O2S,"InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1",GNMUEVRJHCWKTO-FQEVSTJZSA-N,50092312,9936746,CHEMBL3581647,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,208.78,0.003319283,1,1,1,1,1,0.003319283,0.99,0.263,7.464302852,7.006715518,34.3318,98.4656
1675,0.509,99,1.26/6.72/0.509,>99/>99/>99,P09874,PARP1,CRBN,,SK-575,O=C(CCCCCCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=N[NH]C(=O)C4=CC=CC=C34)=CC=C2F)CC1)NCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of PARP1 in MDA-MB-436/Capan-1/SW620 cells after 24 h treatment,,,2.3,IC50 was tested using a PARP1 activity assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19/56/5130,Inhibit growth of MDA-MB-436/Capan-1/SW620 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c00821,876.987,876.3970389,5.03,64,7,10,4,19,211.05,C47H53FN8O8,"InChI=1S/C47H53FN8O8/c48-35-19-18-30(29-37-31-12-9-10-13-32(31)43(60)53-52-37)28-34(35)45(62)55-26-24-54(25-27-55)41(59)17-8-6-4-2-1-3-5-7-16-39(57)50-23-22-49-36-15-11-14-33-42(36)47(64)56(46(33)63)38-20-21-40(58)51-44(38)61/h9-15,18-19,28,38,49H,1-8,16-17,20-27,29H2,(H,50,57)(H,53,60)(H,51,58,61)",HPBWDZVXFSTVMR-UHFFFAOYSA-N,49,2,817,CCCCCCCCCCC(=O)NCC,[R1]CCCCCCCCCCC(=O)NCC[R2],213.365,213.2092645,4.53,15,0,1,1,10,29.1,C13H27NO,"InChI=1S/C13H27NO/c1-3-5-6-7-8-9-10-11-12-13(15)14-4-2/h3-12H2,1-2H3,(H,14,15)",QFZHIMKZKRGXQF-UHFFFAOYSA-N,P25440,BRD2,OTX015,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(O)C=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,,16.6/5.4,FP in BRD2 BD1/2,10.1021/acs.jmedchem.5b00613,492.004,491.1182736,4.5,34,5,7,2,4,92.4,C25H22ClN5O2S,"InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1",GNMUEVRJHCWKTO-FQEVSTJZSA-N,50092312,9936746,CHEMBL3581647,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,208.78,0.003319283,1,1,1,1,1,0.003319283,0.99,0.509,7.464302852,7.006715518,34.3318,98.4656
1675,2.89,99,2.89,,P09874,PARP1,CRBN,,SK-575,O=C(CCCCCCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=N[NH]C(=O)C4=CC=CC=C34)=CC=C2F)CC1)NCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of PARP1 in L-O2 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.bmc.2022.116908,876.987,876.3970389,5.03,64,7,10,4,19,211.05,C47H53FN8O8,"InChI=1S/C47H53FN8O8/c48-35-19-18-30(29-37-31-12-9-10-13-32(31)43(60)53-52-37)28-34(35)45(62)55-26-24-54(25-27-55)41(59)17-8-6-4-2-1-3-5-7-16-39(57)50-23-22-49-36-15-11-14-33-42(36)47(64)56(46(33)63)38-20-21-40(58)51-44(38)61/h9-15,18-19,28,38,49H,1-8,16-17,20-27,29H2,(H,50,57)(H,53,60)(H,51,58,61)",HPBWDZVXFSTVMR-UHFFFAOYSA-N,49,2,817,CCCCCCCCCCC(=O)NCC,[R1]CCCCCCCCCCC(=O)NCC[R2],213.365,213.2092645,4.53,15,0,1,1,10,29.1,C13H27NO,"InChI=1S/C13H27NO/c1-3-5-6-7-8-9-10-11-12-13(15)14-4-2/h3-12H2,1-2H3,(H,14,15)",QFZHIMKZKRGXQF-UHFFFAOYSA-N,P25440,BRD2,OTX015,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(O)C=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,,16.6/5.4,FP in BRD2 BD1/2,10.1021/acs.jmedchem.5b00613,492.004,491.1182736,4.5,34,5,7,2,4,92.4,C25H22ClN5O2S,"InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1",GNMUEVRJHCWKTO-FQEVSTJZSA-N,50092312,9936746,CHEMBL3581647,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,208.78,0.003319283,1,1,1,1,1,0.003319283,0.99,2.89,7.464302852,7.006715518,34.3318,98.4656
1834,2840,93,2840,93,P14902,IDO1,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCOCCOCCNCCNC4=NON=C4/C(=N\O)NC4=CC=C(F)C(Br)=C4)=C3C2=O)C(=O)N1,Degradation of IDO1 in HeLa cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35380,Inhibit viability of HeLa cells,,,,,,,,,,,,,,,10.1016/j.apsb.2020.02.010,966.816,965.2930231,1.26,64,5,19,6,32,267.79,C40H53BrFN9O13,"InChI=1S/C40H53BrFN9O13/c41-29-26-27(4-5-30(29)42)46-37(48-56)35-36(50-64-49-35)45-9-8-43-10-12-57-14-16-59-18-20-61-22-24-63-25-23-62-21-19-60-17-15-58-13-11-44-31-3-1-2-28-34(31)40(55)51(39(28)54)32-6-7-33(52)47-38(32)53/h1-5,26,32,43-44,56H,6-25H2,(H,45,50)(H,46,48)(H,47,52,53)",BVQZWOPTIZSOAW-UHFFFAOYSA-N,278,2,637,CCOCCOCCOCCOCCOCCOCCOCC,[R1]CCOCCOCCOCCOCCOCCOCCOCC[R2],338.441,338.2304534,-0.07,23,0,7,0,20,64.61,C16H34O7,"InChI=1S/C16H34O7/c1-3-17-5-7-19-9-11-21-13-15-23-16-14-22-12-10-20-8-6-18-4-2/h3-16H2,1-2H3",AETIPHBKCCVQJU-UHFFFAOYSA-N,P61964,WDR5,,O=C(CC1=CC=C(Cl)C(Cl)=C1)NCC1=CC=CC(C2=CN3CCCC3=N2)=C1,,,,,,,118,Ki was assessed by fluorescence-polarization anisotropy,10.1021/acs.jmedchem.8b00375,400.309,399.0905176,4,27,4,3,1,5,46.92,C21H19Cl2N3O,"InChI=1S/C21H19Cl2N3O/c22-17-7-6-14(10-18(17)23)11-21(27)24-12-15-3-1-4-16(9-15)19-13-26-8-2-5-20(26)25-19/h1,3-4,6-7,9-10,13H,2,5,8,11-12H2,(H,24,27)",QOIRVBBMKNKETR-UHFFFAOYSA-N,50465599,134369623,CHEMBL4288724,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,2840,9.376650414,6.535050477,0.4201,291.7088
1842,2860,94,2860,94,P35348,ADRA1A,CRBN,,,COC1=CC2=NC(N3CCN(C(=O)C4=CN(CCOCCOCCOCC(=O)NC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)N=N4)CC3)=NC(N)=C2C=C1OC,Degradation of ADRA1A in HEK293 cells after 12 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6120,Inhibit proliferation of PC-3 cells,,,,,,,,,,,,,,,10.1016/j.apsb.2020.01.014,829.828,829.3143512,-0.23,60,7,18,3,17,264.86,C38H43N11O11,"InChI=1S/C38H43N11O11/c1-56-28-18-23-25(19-29(28)57-2)41-38(43-33(23)39)47-10-8-46(9-11-47)36(54)26-20-48(45-44-26)12-13-58-14-15-59-16-17-60-21-31(51)40-24-5-3-4-22-32(24)37(55)49(35(22)53)27-6-7-30(50)42-34(27)52/h3-5,18-20,27H,6-17,21H2,1-2H3,(H,40,51)(H2,39,41,43)(H,42,50,52)",SFODRSARUJDQSA-UHFFFAOYSA-N,313,2,894,O=CCOCCOCCOCCN1C=CN=N1,[R1]C1=CN(N=N1)CCOCCOCCOCC(=O)[R2],243.263,243.121906,-1.29,17,1,7,0,11,75.47,C10H17N3O4,"InChI=1S/C10H17N3O4/c14-4-6-16-8-10-17-9-7-15-5-3-13-2-1-11-12-13/h1-2,4H,3,5-10H2",UJEFTVBPSIVESU-UHFFFAOYSA-N,P49840,GSK3A,AZD2858,CN1CCN(S(=O)(=O)C2=CC=C(C3=CN=C(N)C(C(=O)NC4=CC=CN=C4)=N3)C=C2)CC1,,,,,,,,,10.1016/j.ejmech.2021.113889,453.528,453.1583086,0.71,32,4,8,2,5,134.41,C21H23N7O3S,"InChI=1S/C21H23N7O3S/c1-27-9-11-28(12-10-27)32(30,31)17-6-4-15(5-7-17)18-14-24-20(22)19(26-18)21(29)25-16-3-2-8-23-13-16/h2-8,13-14H,9-12H2,1H3,(H2,22,24)(H,25,29)",FHCSBLWRGCOVPT-UHFFFAOYSA-N,50397745,10138980,CHEMBL2177161,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,2860,6.231248091,5.876607855,587.1538,1328.5936
2913,100,90,100,90-95,P14174,MIF,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCCCCCCC(=O)NC4=CC=C(N5CC6=CC=C(O)C=C6OC5=O)C=C4)=C3C2=O)C(=O)N1,Degradation of MIF in A549 cells after 12 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1002/anie.202101864,653.692,653.2485631,4.16,48,6,9,4,12,174.45,C35H35N5O8,"InChI=1S/C35H35N5O8/c41-24-15-10-21-20-39(35(47)48-28(21)19-24)23-13-11-22(12-14-23)37-29(42)9-4-2-1-3-5-18-36-26-8-6-7-25-31(26)34(46)40(33(25)45)27-16-17-30(43)38-32(27)44/h6-8,10-15,19,27,36,41H,1-5,9,16-18,20H2,(H,37,42)(H,38,43,44)",HAHDZDUOFHMMEA-UHFFFAOYSA-N,463,2,1328,CCCCCCCC(N)=O,[R1]NC(=O)CCCCCCC[R2],143.23,143.1310142,2.13,10,0,1,1,6,43.09,C8H17NO,"InChI=1S/C8H17NO/c1-2-3-4-5-6-7-8(9)10/h2-7H2,1H3,(H2,9,10)",LTHCSWBWNVGEFE-UHFFFAOYSA-N,Q07889,SOS1,,COC1=CC2=NC(C)=NC(N[C@H](C)C3=CC(N)=CC(C(F)(F)F)=C3)=C2C=C1C1CCN(C(C)=O)CC1,,,,,26.9/26.5,FP (with/without VCB),,,10.1021/acs.jmedchem.3c00075,501.553,501.2351599,4.37,36,4,6,2,5,93.37,C26H30F3N5O2,"InChI=1S/C26H30F3N5O2/c1-14(18-9-19(26(27,28)29)11-20(30)10-18)31-25-22-12-21(17-5-7-34(8-6-17)16(3)35)24(36-4)13-23(22)32-15(2)33-25/h9-14,17H,5-8,30H2,1-4H3,(H,31,32,33)/t14-/m1/s1",LLNGAMFFBFKOHI-CQSZACIVSA-N,,155546466,CHEMBL4532163,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,64.9,0.010677966,1,1,1,1,1,0.010677966,0.9,100,7.26975878,6.869120755,53.733,135.1697
2833,28.5,67.1,28.5,67.1,Q06187,BTK,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,1931.5,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,853.289,852.2634172,3.82,61,7,14,5,21,232.27,C42H41ClN8O10,"InChI=1S/C42H41ClN8O10/c43-30-21-26(61-25-5-2-1-3-6-25)9-10-27(30)37(54)29-22-46-38-36(29)39(49-24-48-38)47-23-34(53)45-14-16-59-18-20-60-19-17-58-15-13-44-31-8-4-7-28-35(31)42(57)51(41(28)56)32-11-12-33(52)50-40(32)55/h1-10,21-22,24,32,44H,11-20,23H2,(H,45,53)(H,50,52,55)(H2,46,47,48,49)",YUNXARYSBTUJHY-UHFFFAOYSA-N,452,2,455,CCOCCOCCOCCN,[R1]NCCOCCOCCOCC[R2],177.244,177.1364935,-0.79,12,0,4,1,9,53.71,C8H19NO3,"InChI=1S/C8H19NO3/c1-2-10-5-6-12-8-7-11-4-3-9/h2-9H2,1H3",WWJVRDMJNJTOBL-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.671,28.5,7.453503851,6.764945737,35.1962,171.8123
2834,9.4,66.5,9.4,66.5,Q06187,BTK,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,2203.5,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,897.342,896.2896319,3.67,64,7,15,5,24,241.5,C44H45ClN8O11,"InChI=1S/C44H45ClN8O11/c45-32-23-28(64-27-5-2-1-3-6-27)9-10-29(32)39(56)31-24-48-40-38(31)41(51-26-50-40)49-25-36(55)47-14-16-61-18-20-63-22-21-62-19-17-60-15-13-46-33-8-4-7-30-37(33)44(59)53(43(30)58)34-11-12-35(54)52-42(34)57/h1-10,23-24,26,34,46H,11-22,25H2,(H,47,55)(H,52,54,57)(H2,48,49,50,51)",IVICRPGKKOLGDE-UHFFFAOYSA-N,452,2,508,CCOCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOCC[R2],221.297,221.1627082,-0.94,15,0,5,1,12,62.94,C10H23NO4,"InChI=1S/C10H23NO4/c1-2-12-5-6-14-9-10-15-8-7-13-4-3-11/h2-11H2,1H3",LYKXJZZKGTXDRB-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.665,9.4,6.981918901,6.45408063,104.2512,351.4952
2834,52.7,68.6,52.7,68.6,Q06187,BTK C481S,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK C481S in TMD8 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,897.342,896.2896319,3.67,64,7,15,5,24,241.5,C44H45ClN8O11,"InChI=1S/C44H45ClN8O11/c45-32-23-28(64-27-5-2-1-3-6-27)9-10-29(32)39(56)31-24-48-40-38(31)41(51-26-50-40)49-25-36(55)47-14-16-61-18-20-63-22-21-62-19-17-60-15-13-46-33-8-4-7-30-37(33)44(59)53(43(30)58)34-11-12-35(54)52-42(34)57/h1-10,23-24,26,34,46H,11-22,25H2,(H,47,55)(H,52,54,57)(H2,48,49,50,51)",IVICRPGKKOLGDE-UHFFFAOYSA-N,452,2,508,CCOCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOCC[R2],221.297,221.1627082,-0.94,15,0,5,1,12,62.94,C10H23NO4,"InChI=1S/C10H23NO4/c1-2-12-5-6-14-9-10-15-8-7-13-4-3-11/h2-11H2,1H3",LYKXJZZKGTXDRB-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.686,52.7,6.981918901,6.45408063,104.2512,351.4952
2835,8.1,72.4,8.1,72.4,Q06187,BTK,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,1209.5,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,63.3,Inhibit proliferation of TMD8 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,941.395,940.3158467,3.52,67,7,16,5,27,250.73,C46H49ClN8O12,"InChI=1S/C46H49ClN8O12/c47-34-25-30(67-29-5-2-1-3-6-29)9-10-31(34)41(58)33-26-50-42-40(33)43(53-28-52-42)51-27-38(57)49-14-16-63-18-20-65-22-24-66-23-21-64-19-17-62-15-13-48-35-8-4-7-32-39(35)46(61)55(45(32)60)36-11-12-37(56)54-44(36)59/h1-10,25-26,28,36,48H,11-24,27H2,(H,49,57)(H,54,56,59)(H2,50,51,52,53)",SVBNVWQRLLLMHI-UHFFFAOYSA-N,452,2,1301,CCOCCOCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOCCOCC[R2],265.35,265.188923,-1.09,18,0,6,1,15,72.17,C12H27NO5,"InChI=1S/C12H27NO5/c1-2-14-5-6-16-9-10-18-12-11-17-8-7-15-4-3-13/h2-13H2,1H3",AWKGXTCDNRRIFL-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.724,8.1,6.934805969,6.530588012,116.1968,294.7216
2835,80.4,88.4,80.4,88.4,Q06187,BTK C481S,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK C481S in TMD8 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1689.3,Inhibit proliferation of TMD8 (BTK C481S) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,941.395,940.3158467,3.52,67,7,16,5,27,250.73,C46H49ClN8O12,"InChI=1S/C46H49ClN8O12/c47-34-25-30(67-29-5-2-1-3-6-29)9-10-31(34)41(58)33-26-50-42-40(33)43(53-28-52-42)51-27-38(57)49-14-16-63-18-20-65-22-24-66-23-21-64-19-17-62-15-13-48-35-8-4-7-32-39(35)46(61)55(45(32)60)36-11-12-37(56)54-44(36)59/h1-10,25-26,28,36,48H,11-24,27H2,(H,49,57)(H,54,56,59)(H2,50,51,52,53)",SVBNVWQRLLLMHI-UHFFFAOYSA-N,452,2,1301,CCOCCOCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOCCOCC[R2],265.35,265.188923,-1.09,18,0,6,1,15,72.17,C12H27NO5,"InChI=1S/C12H27NO5/c1-2-14-5-6-16-9-10-18-12-11-17-8-7-15-4-3-13/h2-13H2,1H3",AWKGXTCDNRRIFL-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.884,80.4,6.934805969,6.530588012,116.1968,294.7216
2836,8.3,92.4,8.3,92.4,Q06187,BTK,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,1390.5,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,104.5,Inhibit proliferation of TMD8 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,985.448,984.3420614,3.37,70,7,17,5,30,259.96,C48H53ClN8O13,"InChI=1S/C48H53ClN8O13/c49-36-27-32(70-31-5-2-1-3-6-31)9-10-33(36)43(60)35-28-52-44-42(35)45(55-30-54-44)53-29-40(59)51-14-16-65-18-20-67-22-24-69-26-25-68-23-21-66-19-17-64-15-13-50-37-8-4-7-34-41(37)48(63)57(47(34)62)38-11-12-39(58)56-46(38)61/h1-10,27-28,30,38,50H,11-26,29H2,(H,51,59)(H,56,58,61)(H2,52,53,54,55)",WJQKJTMVUALADJ-UHFFFAOYSA-N,452,2,1302,CCOCCOCCOCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOCCOCCOCC[R2],309.403,309.2151377,-1.23,21,0,7,1,18,81.4,C14H31NO6,"InChI=1S/C14H31NO6/c1-2-16-5-6-18-9-10-20-13-14-21-12-11-19-8-7-17-4-3-15/h2-15H2,1H3",INASOHJXFTUJLS-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.924,8.3,6.468326728,6.767725404,340.1522,170.7161
2836,52.3,84.8,52.3,84.8,Q06187,BTK C481S,CRBN,,,O=C(CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2)NCCOCCOCCOCCOCCOCCOCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of BTK C481S in TMD8 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,750,Inhibit proliferation of TMD8 (BTK C481S) cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113820,985.448,984.3420614,3.37,70,7,17,5,30,259.96,C48H53ClN8O13,"InChI=1S/C48H53ClN8O13/c49-36-27-32(70-31-5-2-1-3-6-31)9-10-33(36)43(60)35-28-52-44-42(35)45(55-30-54-44)53-29-40(59)51-14-16-65-18-20-67-22-24-69-26-25-68-23-21-66-19-17-64-15-13-50-37-8-4-7-34-41(37)48(63)57(47(34)62)38-11-12-39(58)56-46(38)61/h1-10,27-28,30,38,50H,11-26,29H2,(H,51,59)(H,56,58,61)(H2,52,53,54,55)",WJQKJTMVUALADJ-UHFFFAOYSA-N,452,2,1302,CCOCCOCCOCCOCCOCCOCCN,[R1]NCCOCCOCCOCCOCCOCCOCC[R2],309.403,309.2151377,-1.23,21,0,7,1,18,81.4,C14H31NO6,"InChI=1S/C14H31NO6/c1-2-16-5-6-18-9-10-20-13-14-21-12-11-19-8-7-17-4-3-15/h2-15H2,1H3",INASOHJXFTUJLS-UHFFFAOYSA-N,P40337,VHL,VHL-1,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C,196,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,486.638,486.2300766,2.71,34,3,6,3,6,111.63,C25H34N4O4S,"InChI=1S/C25H34N4O4S/c1-14(17-7-9-18(10-8-17)21-15(2)26-13-34-21)27-23(32)20-11-19(31)12-29(20)24(33)22(25(4,5)6)28-16(3)30/h7-10,13-14,19-20,22,31H,11-12H2,1-6H3,(H,27,32)(H,28,30)/t14-,19+,20-,22+/m0/s1",JAHUHEDUDMTTTF-COWZOJLOSA-N,,122529139,CHEMBL4565531,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.848,52.3,6.468326728,6.767725404,340.1522,170.7161
5634,42,77,42,77,P61964,WDR5,CRBN,,,CN1CCN(C2=CC=C(C3=CC=CC(CN4CCN(CCNC(=O)CCCCCCCNC5=CC=CC6=C5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)=C3)C=C2NC(=O)C2=C[NH]C(=O)C=C2C(F)(F)F)CC1,Degradation of WDR5 in MV4;11 cells after 18h treatment,,,,,,,125,ITC,,,,-9.381,,ITC,,,,,,,,,14800,ITC,,,,-11,,ITC,,,,,,,,,63.7,ITC,,,,-8.327,,ITC,,,,,,,,,180/510/540,Inhibit cell growth of MV4;11/EOL1/RS4;11 cells,,,,,,,,,,,10.1038/s41388-022-02340-8,995.117,994.467679,4.24,72,8,12,5,19,199.6,C52H61F3N10O7,"InChI=1S/C52H61F3N10O7/c1-61-21-27-64(28-22-61)42-15-14-36(30-41(42)59-48(69)38-32-58-46(68)31-39(38)52(53,54)55)35-10-7-9-34(29-35)33-63-25-23-62(24-26-63)20-19-57-44(66)13-5-3-2-4-6-18-56-40-12-8-11-37-47(40)51(72)65(50(37)71)43-16-17-45(67)60-49(43)70/h7-12,14-15,29-32,43,56H,2-6,13,16-28,33H2,1H3,(H,57,66)(H,58,68)(H,59,69)(H,60,67,70)",STBAQMSNPQNEBZ-UHFFFAOYSA-N,531,2,1282,CCCCCCCC(=O)NCC,[R1]CCNC(=O)CCCCCCC[R2],171.284,171.1623143,2.9,12,0,1,1,7,29.1,C10H21NO,"InChI=1S/C10H21NO/c1-3-5-6-7-8-9-10(12)11-4-2/h3-9H2,1-2H3,(H,11,12)",NUZLFHKAOQSBJG-UHFFFAOYSA-N,Q15910,EZH2,,CC1=CC(C)=C(CNC(=O)C2=CC(C3=CC=C(N4CCNCC4)N=C3)=CC3=C2C=NN3C(C)C)C(=O)[NH]1,,,,,,,,,10.1016/j.ejmech.2022.114462,499.619,499.2695733,2.54,37,5,7,3,6,107.94,C28H33N7O2,"InChI=1S/C28H33N7O2/c1-17(2)35-25-13-21(20-5-6-26(30-14-20)34-9-7-29-8-10-34)12-22(24(25)16-32-35)27(36)31-15-23-18(3)11-19(4)33-28(23)37/h5-6,11-14,16-17,29H,7-10,15H2,1-4H3,(H,31,36)(H,33,37)",VYFBRDJIRRTWMS-UHFFFAOYSA-N,,54596558,CHEMBL5179558,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,67.82,0.010218225,1,1,1,1,1,0.010218225,0.77,42,7.039167152,6.733483791,91.3761,184.721
5394,147,93,147,93,Q9BY41,HDAC8,CRBN,,,O=C(CCCCOC1=CC=C(CCNC(=O)C2=CC=CC(C(=O)NO)=C2)C=C1)NCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of HDAC8 in HCT-116 cells after 10 h treatment,85,% HDAC8 degradation in HCT-116 cells at 5000 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2022,754.841,754.3326271,3.74,55,5,10,6,20,212.34,C40H46N6O9,"InChI=1S/C40H46N6O9/c47-33(13-3-6-24-55-29-16-14-26(15-17-29)20-23-43-36(49)27-9-7-10-28(25-27)37(50)45-54)42-22-5-2-1-4-21-41-31-12-8-11-30-35(31)40(53)46(39(30)52)32-18-19-34(48)44-38(32)51/h7-12,14-17,25,32,41,54H,1-6,13,18-24H2,(H,42,47)(H,43,49)(H,45,50)(H,44,48,51)",WYWJHXKHDRJYLX-UHFFFAOYSA-N,350,2,2449,CCCCCCNC(=O)CCCCOC1=CC=C(CC)C=C1,[R1]CCC1=CC=C(C=C1)OCCCCC(=O)NCCCCCC[R2],305.462,305.2354792,4.99,22,1,2,1,12,38.33,C19H31NO2,"InChI=1S/C19H31NO2/c1-3-5-6-8-15-20-19(21)10-7-9-16-22-18-13-11-17(4-2)12-14-18/h11-14H,3-10,15-16H2,1-2H3,(H,20,21)",DWOKTOABSOKEIJ-UHFFFAOYSA-N,P51531,SMARCA2,,NC1=NN=C(C2=CC=CC=C2O)C=C1N1CCC(C2=CC=CC=C2)CC1,,,,,,,,,,346.434,346.1793613,3.16,26,4,5,2,3,75.27,C21H22N4O,"InChI=1S/C21H22N4O/c22-21-19(14-18(23-24-21)17-8-4-5-9-20(17)26)25-12-10-16(11-13-25)15-6-2-1-3-7-15/h1-9,14,16,26H,10-13H2,(H2,22,24)",JTBGUMSOPXOHEX-UHFFFAOYSA-N,394417,137029533,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,147,7.84210065,7.359980615,14.3847,43.6535
5394,4950,99,4950,,Q9UBN7,HDAC6,CRBN,,,O=C(CCCCOC1=CC=C(CCNC(=O)C2=CC=CC(C(=O)NO)=C2)C=C1)NCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Degradation of HDAC6 in HCT-116 cells after 10 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2022,754.841,754.3326271,3.74,55,5,10,6,20,212.34,C40H46N6O9,"InChI=1S/C40H46N6O9/c47-33(13-3-6-24-55-29-16-14-26(15-17-29)20-23-43-36(49)27-9-7-10-28(25-27)37(50)45-54)42-22-5-2-1-4-21-41-31-12-8-11-30-35(31)40(53)46(39(30)52)32-18-19-34(48)44-38(32)51/h7-12,14-17,25,32,41,54H,1-6,13,18-24H2,(H,42,47)(H,43,49)(H,45,50)(H,44,48,51)",WYWJHXKHDRJYLX-UHFFFAOYSA-N,350,2,2449,CCCCCCNC(=O)CCCCOC1=CC=C(CC)C=C1,[R1]CCC1=CC=C(C=C1)OCCCCC(=O)NCCCCCC[R2],305.462,305.2354792,4.99,22,1,2,1,12,38.33,C19H31NO2,"InChI=1S/C19H31NO2/c1-3-5-6-8-15-20-19(21)10-7-9-16-22-18-13-11-17(4-2)12-14-18/h11-14H,3-10,15-16H2,1-2H3,(H,20,21)",DWOKTOABSOKEIJ-UHFFFAOYSA-N,P51531,SMARCA2,,NC1=NN=C(C2=CC=CC=C2O)C=C1N1CCC(C2=CC=CC=C2)CC1,,,,,,,,,,346.434,346.1793613,3.16,26,4,5,2,3,75.27,C21H22N4O,"InChI=1S/C21H22N4O/c22-21-19(14-18(23-24-21)17-8-4-5-9-20(17)26)25-12-10-16(11-13-25)15-6-2-1-3-7-15/h1-9,14,16,26H,10-13H2,(H2,22,24)",JTBGUMSOPXOHEX-UHFFFAOYSA-N,394417,137029533,,2CRBN,2,Q96SW2,CRBN,pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,,,157,FP,,,10.1038/nature13527,273.248,273.0749558,0,20,3,5,2,1,109.57,C13H11N3O4,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,65456,134780,CHEMBL43452,62.33,0.011118242,1,1,1,1,1,0.011118242,0.99,4950,7.84210065,7.359980615,14.3847,43.6535
3258,85,96,85,96,P51531,SMARCA2,VHL,,AU-15330,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CN3CCN(C4=CC(C5=CC=CC=C5O)=NN=C4N)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5740000,0.034,20.2,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,755.946,755.3577367,3.25,54,6,12,5,10,190.14,C39H49N9O5S,"InChI=1S/C39H49N9O5S/c1-23(25-10-12-26(13-11-25)34-24(2)41-22-54-34)42-37(52)31-18-27(49)20-48(31)38(53)35(39(3,4)5)43-33(51)21-46-14-16-47(17-15-46)30-19-29(44-45-36(30)40)28-8-6-7-9-32(28)50/h6-13,19,22-23,27,31,35,49-50H,14-18,20-21H2,1-5H3,(H2,40,45)(H,42,52)(H,43,51)/t23-,27+,31-,35+/m0/s1",HDCCMCFIGHIDJR-TUDDPRDOSA-N,139,28,462,C,[R1]C[R2],16.043,16.03130013,0.65,1,0,0,0,0,0,CH4,InChI=1S/CH4/h1H4,VNWKTOKETHGBQD-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.96,85,4.933413077,5.219867889,11657.0034,6027.4291
3603,28,98,28,98,P51531,SMARCA2,VHL,8G1Q,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3=CC=NC(N4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3520000,0.017,41.5,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,819.005,818.3686357,4.23,59,7,13,5,10,203.03,C43H50N10O5S,"InChI=1S/C43H50N10O5S/c1-25(27-10-12-28(13-11-27)37-26(2)46-24-59-37)47-41(57)34-21-30(54)23-53(34)42(58)38(43(3,4)5)48-40(56)29-14-15-45-36(20-29)52-18-16-51(17-19-52)33-22-32(49-50-39(33)44)31-8-6-7-9-35(31)55/h6-15,20,22,24-25,30,34,38,54-55H,16-19,21,23H2,1-5H3,(H2,44,50)(H,47,57)(H,48,56)/t25-,30+,34-,38+/m0/s1",UTVJRQFHWBOCCR-IKYVMSNGSA-N,139,28,1687,C1=CC=NC=C1,[R1]C1=NC=CC(=C1)[R2],79.102,79.04219916,0.85,6,1,1,0,0,12.89,C5H5N,InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H,JUJWROOIHBZHMG-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.98,28,5.049442641,5.582601464,8923.9547,2614.5595
3604,95,95,95,95,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3=CC=CC(N4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)=N3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,870000,0.031,24.3,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,819.005,818.3686357,4.56,59,7,13,5,10,203.03,C43H50N10O5S,"InChI=1S/C43H50N10O5S/c1-25(27-13-15-28(16-14-27)37-26(2)45-24-59-37)46-41(57)34-21-29(54)23-53(34)42(58)38(43(3,4)5)48-40(56)31-10-8-12-36(47-31)52-19-17-51(18-20-52)33-22-32(49-50-39(33)44)30-9-6-7-11-35(30)55/h6-16,22,24-25,29,34,38,54-55H,17-21,23H2,1-5H3,(H2,44,50)(H,46,57)(H,48,56)/t25-,29+,34-,38+/m0/s1",CPUGPFMQNPPUFH-XYOATWAASA-N,139,28,1688,C1=CC=NC=C1,[R1]C1=NC(=CC=C1)[R2],79.102,79.04219916,0.85,6,1,1,0,0,12.89,C5H5N,InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H,JUJWROOIHBZHMG-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.95,95,5.417679913,5.380227587,3822.2588,4166.5099
3606,99,96,99,96,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3=CC=CC(N4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,590000,0.039,18.1,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,818.017,817.3733867,4.97,59,7,12,5,10,190.14,C44H51N9O5S,"InChI=1S/C44H51N9O5S/c1-26(28-13-15-29(16-14-28)38-27(2)46-25-59-38)47-42(57)36-22-32(54)24-53(36)43(58)39(44(3,4)5)48-41(56)30-9-8-10-31(21-30)51-17-19-52(20-18-51)35-23-34(49-50-40(35)45)33-11-6-7-12-37(33)55/h6-16,21,23,25-26,32,36,39,54-55H,17-20,22,24H2,1-5H3,(H2,45,50)(H,47,57)(H,48,56)/t26-,32+,36-,39+/m0/s1",VJSRTKOZKJSNOV-ZNWVETRHSA-N,139,28,1690,C1=CC=CC=C1,[R1]C1=CC(=CC=C1)[R2],78.114,78.04695019,1.92,6,1,0,0,0,0,C6H6,InChI=1S/C6H6/c1-2-4-6-5-3-1/h1-6H,UHOVQNZJYSORNB-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.96,99,5.377853403,5.784617459,4189.3495,1642.0355
3607,112,96,112,96,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3=CSC(N4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)=N3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2070000,0.09,7.4,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,825.034,824.3250566,4.66,58,7,14,5,10,203.03,C41H48N10O5S2,"InChI=1S/C41H48N10O5S2/c1-23(25-10-12-26(13-11-25)34-24(2)43-22-58-34)44-38(55)32-18-27(52)20-51(32)39(56)35(41(3,4)5)46-37(54)30-21-57-40(45-30)50-16-14-49(15-17-50)31-19-29(47-48-36(31)42)28-8-6-7-9-33(28)53/h6-13,19,21-23,27,32,35,52-53H,14-18,20H2,1-5H3,(H2,42,48)(H,44,55)(H,46,54)/t23-,27+,32-,35+/m0/s1",QSIFVPKHIDVWQB-OFGFXWDRSA-N,139,28,1691,C1=CSC=N1,[R1]C1=NC(=CS1)[R2],85.131,84.9986201,0.95,5,1,2,0,0,12.89,C3H3NS,InChI=1S/C3H3NS/c1-2-5-3-4-1/h1-3H,FZWLAAWBMGSTSO-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.96,112,4.936843516,5.598581084,11565.2888,2520.1066
3608,850,55,850,55,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CC3=CC=NC(N4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2170000,0.19,3.6,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,833.032,832.3842858,4.17,60,7,13,5,11,203.03,C44H52N10O5S,"InChI=1S/C44H52N10O5S/c1-26(29-10-12-30(13-11-29)39-27(2)47-25-60-39)48-42(58)35-22-31(55)24-54(35)43(59)40(44(3,4)5)49-38(57)21-28-14-15-46-37(20-28)53-18-16-52(17-19-53)34-23-33(50-51-41(34)45)32-8-6-7-9-36(32)56/h6-15,20,23,25-26,31,35,40,55-56H,16-19,21-22,24H2,1-5H3,(H2,45,51)(H,48,58)(H,49,57)/t26-,31+,35-,40+/m0/s1",JSJNRSSILOESKP-JQJHNVGOSA-N,139,28,1692,CC1=CC=NC=C1,[R1]C1=NC=CC(=C1)C[R2],93.129,93.05784922,1.22,7,1,1,0,0,12.89,C6H7N,"InChI=1S/C6H7N/c1-6-2-4-7-5-3-6/h2-5H,1H3",FKNQCJSGGFJEIZ-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.55,850,4.668308695,5.57157063,21463.0435,2681.8184
3609,379,80,379,80,P51531,SMARCA2,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCC3=CC=NC(N4CCN(C5=CC(C6=CC=CC=C6O)=NN=C5N)CC4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of SMARCA2 in A375 cells after 2 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3700000,0.11,6.3,SPR,,,,,,,,,,,,,,,,,10.1038/s41467-023-39904-5,847.059,846.3999358,4.46,61,7,13,5,12,203.03,C45H54N10O5S,"InChI=1S/C45H54N10O5S/c1-27(30-11-13-31(14-12-30)40-28(2)48-26-61-40)49-43(59)36-23-32(56)25-55(36)44(60)41(45(3,4)5)50-39(58)15-10-29-16-17-47-38(22-29)54-20-18-53(19-21-54)35-24-34(51-52-42(35)46)33-8-6-7-9-37(33)57/h6-9,11-14,16-17,22,24,26-27,32,36,41,56-57H,10,15,18-21,23,25H2,1-5H3,(H2,46,52)(H,49,59)(H,50,58)/t27-,32+,36-,41+/m0/s1",XMIOCXZSPKUWLC-SFQXCRKHSA-N,139,28,1693,CCC1=CC=NC=C1,[R1]C1=NC=CC(=C1)CC[R2],107.156,107.0734993,1.65,8,1,1,0,1,12.89,C7H9N,"InChI=1S/C7H9N/c1-2-7-3-5-8-6-4-7/h3-6H,2H2,1H3",VJXRKZJMGVSXPX-UHFFFAOYSA-N,Q9NZQ7,PD-L1,BMS-8,CC1=C(COC2=CC=C(CN3CCCCC3C(=O)O)C=C2Br)C=CC=C1C1=CC=CC=C1,146,IC50 was tested by the HTRF binding assay,,,,,,,10.1021/acs.jmedchem.7b00293,494.429,493.1252559,4.1,32,4,3,1,7,49.77,C27H28BrNO3,"InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)",QRXBPPWUGITQLE-UHFFFAOYSA-N,50239943,117941742,CHEMBL4099869,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,109.68,0.006318381,1,1,1,1,1,0.006318381,0.8,379,4.710708443,5.616907959,19466.6651,2415.9728
697,53,99,53,,Q07817,BCL-xL,VHL,,DT2216,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)N3CCN(CC[C@H](CSC4=CC=CC=C4)NC4=CC=C(S(=O)(=O)NC(=O)C5=CC=C(N6CCN(CC7=C(C8=CC=C(Cl)C=C8)CCC(C)(C)C7)CC6)C=C5)C=C4S(=O)(=O)C(F)(F)F)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in MOLT-4 cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77.1/213/278,Inhibit viability of MOLT-4/RS4;11/H146 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2020.112186,1542.39,1540.583436,12.83,105,10,17,5,28,251.07,C77H96ClF3N10O10S4,"InChI=1S/C77H96ClF3N10O10S4/c1-51(53-18-20-55(21-19-53)70-52(2)82-50-103-70)83-73(96)66-44-61(92)48-91(66)74(97)71(75(3,4)5)85-68(93)16-12-9-13-17-69(94)90-42-36-87(37-43-90)35-33-59(49-102-62-14-10-8-11-15-62)84-65-31-30-63(45-67(65)104(98,99)77(79,80)81)105(100,101)86-72(95)56-24-28-60(29-25-56)89-40-38-88(39-41-89)47-57-46-76(6,7)34-32-64(57)54-22-26-58(78)27-23-54/h8,10-11,14-15,18-31,45,50-51,59,61,66,71,84,92H,9,12-13,16-17,32-44,46-49H2,1-7H3,(H,83,96)(H,85,93)(H,86,95)/t51-,59+,61+,66-,71+/m0/s1",PXVFFBGSTYQHRO-REQIQPEASA-N,111,28,143,CCCCCC=O,[R1]C(=O)CCCCC[R2],100.161,100.088815,1.64,7,0,1,0,4,17.07,C6H12O,"InChI=1S/C6H12O/c1-2-3-4-5-6-7/h6H,2-5H2,1H3",JARKCYVAAOWBJS-UHFFFAOYSA-N,P40337,VHL,VH298,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(C#N)CC3)C(C)(C)C)C=C2)SC=N1,,,,,90/80,ITC/FP,,,10.1038/ncomms13312,523.659,523.2253255,2.54,37,4,7,3,7,135.42,C27H33N5O4S,"InChI=1S/C27H33N5O4S/c1-16-21(37-15-30-16)18-7-5-17(6-8-18)12-29-23(34)20-11-19(33)13-32(20)24(35)22(26(2,3)4)31-25(36)27(14-28)9-10-27/h5-8,15,19-20,22,33H,9-13H2,1-4H3,(H,29,34)(H,31,36)/t19-,20+,22-/m1/s1",NDVQUNZCNAMROD-RZUBCFFCSA-N,50459944,122199236,CHEMBL4225537,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,53,7.174454799,5.459115647,66.9183,3474.4363
697,63,90.8,63/>3000,90.8/26,Q07817,BCL-xL,VHL,,DT2216,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)N3CCN(CC[C@H](CSC4=CC=CC=C4)NC4=CC=C(S(=O)(=O)NC(=O)C5=CC=C(N6CCN(CC7=C(C8=CC=C(Cl)C=C8)CCC(C)(C)C7)CC6)C=C5)C=C4S(=O)(=O)C(F)(F)F)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in MOLT-4/platelets cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,52/23/160,Inhibit viability of MOLT-4/RS4;11/H146 cells,,,,,,,,,,,,,10.1038/s41591-019-0668-z,1542.39,1540.583436,12.83,105,10,17,5,28,251.07,C77H96ClF3N10O10S4,"InChI=1S/C77H96ClF3N10O10S4/c1-51(53-18-20-55(21-19-53)70-52(2)82-50-103-70)83-73(96)66-44-61(92)48-91(66)74(97)71(75(3,4)5)85-68(93)16-12-9-13-17-69(94)90-42-36-87(37-43-90)35-33-59(49-102-62-14-10-8-11-15-62)84-65-31-30-63(45-67(65)104(98,99)77(79,80)81)105(100,101)86-72(95)56-24-28-60(29-25-56)89-40-38-88(39-41-89)47-57-46-76(6,7)34-32-64(57)54-22-26-58(78)27-23-54/h8,10-11,14-15,18-31,45,50-51,59,61,66,71,84,92H,9,12-13,16-17,32-44,46-49H2,1-7H3,(H,83,96)(H,85,93)(H,86,95)/t51-,59+,61+,66-,71+/m0/s1",PXVFFBGSTYQHRO-REQIQPEASA-N,111,28,143,CCCCCC=O,[R1]C(=O)CCCCC[R2],100.161,100.088815,1.64,7,0,1,0,4,17.07,C6H12O,"InChI=1S/C6H12O/c1-2-3-4-5-6-7/h6H,2-5H2,1H3",JARKCYVAAOWBJS-UHFFFAOYSA-N,P40337,VHL,VH298,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)C3(C#N)CC3)C(C)(C)C)C=C2)SC=N1,,,,,90/80,ITC/FP,,,10.1038/ncomms13312,523.659,523.2253255,2.54,37,4,7,3,7,135.42,C27H33N5O4S,"InChI=1S/C27H33N5O4S/c1-16-21(37-15-30-16)18-7-5-17(6-8-18)12-29-23(34)20-11-19(33)13-32(20)24(35)22(26(2,3)4)31-25(36)27(14-28)9-10-27/h5-8,15,19-20,22,33H,9-13H2,1-4H3,(H,29,34)(H,31,36)/t19-,20+,22-/m1/s1",NDVQUNZCNAMROD-RZUBCFFCSA-N,50459944,122199236,CHEMBL4225537,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.908,63,7.174454799,5.459115647,66.9183,3474.4363
77,0.17,95,0.17/0.43,>95/>95,P03372,ER,VHL,,ERD-308,CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C2=C(C)N=CS2)C=C1)C(C)(C)C)CCOC1=CC=C(C(=O)C2=C(C3=CC=C(O)C=C3)SC3=CC(O)=CC=C23)C=C1,Degradation of ER in MCF-7/T47D cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.77,Inhibit proliferation of MCF-7 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.8b01572,1004.285,1003.422371,9.05,71,7,13,5,22,190.86,C55H65N5O9S2,"InChI=1S/C55H65N5O9S2/c1-7-59(26-28-69-43-22-17-37(18-23-43)49(65)48-44-24-21-41(62)30-46(44)71-51(48)39-15-19-40(61)20-16-39)25-9-8-10-27-68-32-47(64)58-52(55(4,5)6)54(67)60-31-42(63)29-45(60)53(66)57-34(2)36-11-13-38(14-12-36)50-35(3)56-33-70-50/h11-24,30,33-34,42,45,52,61-63H,7-10,25-29,31-32H2,1-6H3,(H,57,66)(H,58,64)/t34-,42+,45-,52+/m0/s1",BQXUPNKLZNSUMC-YUQWMIPFSA-N,10,28,34,CCCCCOC,[R1]CCCCCOC[R2],102.177,102.1044651,1.87,7,0,1,0,4,9.23,C6H14O,"InChI=1S/C6H14O/c1-3-4-5-6-7-2/h3-6H2,1-2H3",DBUJFULDVAZULB-UHFFFAOYSA-N,P03372,ER,Lasofoxifene,OC1=CC=C2C(=C1)CC[C@H](C1=CC=CC=C1)[C@@H]2C1=CC=C(OCCN2CCCC2)C=C1,4,Displacement of [3H]-17-beta-estradiol from ERalpha by competitive binding affinity assay,,,,,,,10.1021/jm030086h,413.561,413.2354792,6.1,31,5,3,1,6,32.7,C28H31NO2,"InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1",GXESHMAMLJKROZ-IAPPQJPRSA-N,20606,216416,CHEMBL328190,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,0.17,7.180991897,5.431159853,65.9186,3705.4431
1432,50,71,<=50,>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCCCNC3=CC=C(C(=O)N[C@H]4C(C)(C)[C@H](OC5=CC=C(C#N)C(Cl)=C5)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR in LNCaP cells after 2-4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00115,968.662,967.4432961,8.92,68,6,11,5,19,195.01,C52H66ClN7O7S,"InChI=1S/C52H66ClN7O7S/c1-31(33-13-15-34(16-14-33)43-32(2)56-30-68-43)57-46(64)41-25-38(61)28-60(41)47(65)44(50(3,4)5)58-42(62)29-66-24-12-10-11-23-55-37-20-17-35(18-21-37)45(63)59-48-51(6,7)49(52(48,8)9)67-39-22-19-36(27-54)40(53)26-39/h13-22,26,30-31,38,41,44,48-49,55,61H,10-12,23-25,28-29H2,1-9H3,(H,57,64)(H,58,62)(H,59,63)/t31-,38+,41-,44+,48-,49-/m0/s1",JQTRUKZGCBXQDD-IWHLCMBKSA-N,38,28,686,COCCCCCN,[R1]NCCCCCOC[R2],117.192,117.1153641,0.21,8,0,2,1,5,35.25,C6H15NO,"InChI=1S/C6H15NO/c1-8-6-4-2-3-5-7/h2-7H2,1H3",DMRHQYSRQGGRCK-UHFFFAOYSA-N,P00533,EGFR,gefitinib,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,,,,,1,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,446.91,446.1520965,4.11,31,4,7,1,8,68.74,C22H24ClFN4O3,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,5447,123631,CHEMBL939,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.085056696,5.513323876,822.1353,3066.7341
1585,50,71,<=50/<=50,>=71/51-70,P10275,AR,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3F)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,1052.227,1051.395917,7.95,73,6,12,3,21,186.66,C52H61F4N7O8S2,"InChI=1S/C52H61F4N7O8S2/c1-31(33-12-14-34(15-13-33)44-32(2)58-30-73-44)59-46(66)41-26-38(64)28-61(41)47(67)45(50(3,4)5)60-43(65)29-70-22-11-21-69-20-9-8-10-23-71-42-19-18-37(25-40(42)53)63-49(72)62(48(68)51(63,6)7)36-17-16-35(27-57)39(24-36)52(54,55)56/h12-19,24-25,30-31,38,41,45,64H,8-11,20-23,26,28-29H2,1-7H3,(H,59,66)(H,60,65)/t31-,38+,41-,45+/m0/s1",FLLKKIZFEMVEEL-OZSPHOIVSA-N,34,28,139,COCCCOCCCCCO,[R1]OCCCCCOCCCOC[R2],176.256,176.1412445,0.68,12,0,3,1,9,38.69,C9H20O3,"InChI=1S/C9H20O3/c1-11-7-5-9-12-8-4-2-3-6-10/h10H,2-9H2,1H3",XPPFZKCGEIHABQ-UHFFFAOYSA-N,P41182,BCL6,,CC(C)CCC(=O)N1CCN2C3=NC=C(Cl)C(=N3)NC3=CC4=C(C(=C3)OCCOC[C@H]2C1)N(C)C(=O)CC4,63,IC50 of BCL6 was assessed by a time resolved fluorescence resonance energy transfer assay,,,,,,,10.1021/acschembio.8b00698,543.068,542.2408313,3.05,38,5,8,1,3,100.13,C27H35ClN6O4,"InChI=1S/C27H35ClN6O4/c1-17(2)4-6-24(36)33-8-9-34-20(15-33)16-37-10-11-38-22-13-19(30-26-21(28)14-29-27(34)31-26)12-18-5-7-23(35)32(3)25(18)22/h12-14,17,20H,4-11,15-16H2,1-3H3,(H,29,30,31)/t20-/m1/s1",GPOLUVUMJCGZBW-HXUWFJFHSA-N,,,,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.383191099,5.569485904,413.8175,2694.7228
2625,0.49,82,0.49,82,P00533,EGFR e19d,VHL,,,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,Degradation of EGFR e19d in HCC827 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.6/298/105,Inhibit proliferation of HCC827 (EGFR del19)/HCT116/SU-DHL-6 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c01827,1092.429,1091.589134,8.86,79,9,15,5,21,206.08,C60H77N13O5S,"InChI=1S/C60H77N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h7,11-13,17-18,21-28,36,39-40,47-48,50,54,74H,1,8-10,14-16,19-20,29-35,37-38H2,2-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",RYXQXEGTLNBKEC-DKQRTKIFSA-N,409,28,27,CCCCCCC,[R1]CCCCCCC[R2],100.205,100.1252005,4.01,7,0,0,0,4,0,C7H16,"InChI=1S/C7H16/c1-3-5-7-6-4-2/h3-7H2,1-2H3",IMNFDUFMRHMDMM-UHFFFAOYSA-N,P15170,GSPT1,CC-885,CC1=CC=C(NC(=O)NCC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)C=C1Cl,,,,,,,,,10.1038/nature18611,440.887,440.1251328,1.67,31,4,4,3,4,107.61,C22H21ClN4O4,"InChI=1S/C22H21ClN4O4/c1-12-2-4-15(9-17(12)23)25-22(31)24-10-13-3-5-16-14(8-13)11-27(21(16)30)18-6-7-19(28)26-20(18)29/h2-5,8-9,18H,6-7,10-11H2,1H3,(H2,24,25,31)(H,26,28,29)",DOEVCIHTTTYVCC-UHFFFAOYSA-N,,24788636,CHEMBL4170596,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.82,0.49,6.603101719,5.093565947,249.4011,8061.8377
2625,1.56,86,1.56,86,P00533,EGFR L858R/T790M,VHL,,,C=CC(=O)N1CCC[C@H](N2C(NC3=CC=CC=C3)=NC3=CN=C(NC4=CC=C(N5CCN(CCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)C(C)(C)C)CC5)C=C4)N=C32)C1,Degradation of EGFR L858R/T790M in H1975 cells after 48 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32/298/105,Inhibit proliferation of H1975 (EGFR L858R/T790M)/HCT116/SU-DHL-6 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c01827,1092.429,1091.589134,8.86,79,9,15,5,21,206.08,C60H77N13O5S,"InChI=1S/C60H77N13O5S/c1-7-52(76)71-30-16-19-47(37-71)73-55-49(66-59(73)65-44-17-12-11-13-18-44)36-61-58(68-55)64-45-25-27-46(28-26-45)70-33-31-69(32-34-70)29-15-10-8-9-14-20-51(75)67-54(60(4,5)6)57(78)72-38-48(74)35-50(72)56(77)63-40(2)42-21-23-43(24-22-42)53-41(3)62-39-79-53/h7,11-13,17-18,21-28,36,39-40,47-48,50,54,74H,1,8-10,14-16,19-20,29-35,37-38H2,2-6H3,(H,63,77)(H,65,66)(H,67,75)(H,61,64,68)/t40-,47-,48+,50-,54+/m0/s1",RYXQXEGTLNBKEC-DKQRTKIFSA-N,409,28,27,CCCCCCC,[R1]CCCCCCC[R2],100.205,100.1252005,4.01,7,0,0,0,4,0,C7H16,"InChI=1S/C7H16/c1-3-5-7-6-4-2/h3-7H2,1-2H3",IMNFDUFMRHMDMM-UHFFFAOYSA-N,P15170,GSPT1,CC-885,CC1=CC=C(NC(=O)NCC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)C=C1Cl,,,,,,,,,10.1038/nature18611,440.887,440.1251328,1.67,31,4,4,3,4,107.61,C22H21ClN4O4,"InChI=1S/C22H21ClN4O4/c1-12-2-4-15(9-17(12)23)25-22(31)24-10-13-3-5-16-14(8-13)11-27(21(16)30)18-6-7-19(28)26-20(18)29/h2-5,8-9,18H,6-7,10-11H2,1H3,(H2,24,25,31)(H,26,28,29)",DOEVCIHTTTYVCC-UHFFFAOYSA-N,,24788636,CHEMBL4170596,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.86,1.56,6.603101719,5.093565947,249.4011,8061.8377
3300,5.6,88.9,22.7/23.5/5.6,86.7/89.4/88.9,Q13164,ERK5,VHL,,PPM-3,COC1=CC(N2CCN(CCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C2C(=N1)N(C)C1=CC=CC=C1C(=O)N2C,Degradation of ERK5 in MDA-MB-231/PC-3/HCT116 cells after 12h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00864,1000.284,999.5152999,7.13,72,8,14,4,17,188.7,C54H69N11O6S,"InChI=1S/C54H69N11O6S/c1-34(36-18-20-37(21-19-36)47-35(2)56-33-72-47)57-50(68)43-30-39(66)32-65(43)52(70)48(54(3,4)5)59-46(67)17-11-9-10-14-24-63-25-27-64(28-26-63)38-22-23-41(45(29-38)71-8)58-53-55-31-44-49(60-53)61(6)42-16-13-12-15-40(42)51(69)62(44)7/h12-13,15-16,18-23,29,31,33-34,39,43,48,66H,9-11,14,17,24-28,30,32H2,1-8H3,(H,57,68)(H,59,67)(H,55,58,60)/t34-,39+,43-,48+/m0/s1",QGJQNPNZAYRDMS-OESUUHGFSA-N,546,28,26,CCCCCC,[R1]CCCCCC[R2],86.178,86.10955045,3.47,6,0,0,0,3,0,C6H14,"InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3",VLKZOEOYAKHREP-UHFFFAOYSA-N,P00374,DHFR,Methotrexate,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C(=O)N[C@@H](CCC(=O)O)C(=O)O)C=C1,,,,,,,,,10.1038/s41584-020-0373-9,454.447,454.1713158,-0.46,33,3,10,5,9,210.54,C20H22N8O5,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",FBOZXECLQNJBKD-ZDUSSCGKSA-N,18050,126941,CHEMBL34259,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.889,5.6,5.710847813,5.125139193,1946.0419,7496.539
3300,11.5,94.7,41.4/11.5/13.7,91.4/94.7/92.7,Q13164,ERK5,VHL,,PPM-3,COC1=CC(N2CCN(CCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC1=NC=C2C(=N1)N(C)C1=CC=CC=C1C(=O)N2C,Degradation of ERK5 in A375/H1975/HepG2 cells after 12h treatment,,,62.4,IC50 of ERK5 (nM),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00864,1000.284,999.5152999,7.13,72,8,14,4,17,188.7,C54H69N11O6S,"InChI=1S/C54H69N11O6S/c1-34(36-18-20-37(21-19-36)47-35(2)56-33-72-47)57-50(68)43-30-39(66)32-65(43)52(70)48(54(3,4)5)59-46(67)17-11-9-10-14-24-63-25-27-64(28-26-63)38-22-23-41(45(29-38)71-8)58-53-55-31-44-49(60-53)61(6)42-16-13-12-15-40(42)51(69)62(44)7/h12-13,15-16,18-23,29,31,33-34,39,43,48,66H,9-11,14,17,24-28,30,32H2,1-8H3,(H,57,68)(H,59,67)(H,55,58,60)/t34-,39+,43-,48+/m0/s1",QGJQNPNZAYRDMS-OESUUHGFSA-N,546,28,26,CCCCCC,[R1]CCCCCC[R2],86.178,86.10955045,3.47,6,0,0,0,3,0,C6H14,"InChI=1S/C6H14/c1-3-5-6-4-2/h3-6H2,1-2H3",VLKZOEOYAKHREP-UHFFFAOYSA-N,P00374,DHFR,Methotrexate,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C(=O)N[C@@H](CCC(=O)O)C(=O)O)C=C1,,,,,,,,,10.1038/s41584-020-0373-9,454.447,454.1713158,-0.46,33,3,10,5,9,210.54,C20H22N8O5,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",FBOZXECLQNJBKD-ZDUSSCGKSA-N,18050,126941,CHEMBL34259,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.947,11.5,5.710847813,5.125139193,1946.0419,7496.539
825,7.7,95,7.7/10.3,95/98,P03372,ER,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCOC3=CC=C(/C=N/NC(=O)C4=CC=C(C(=O)C5=C(C6=CC=C(O)C=C6)SC6=CC(O)=CC=C56)C=C4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of ERalpha in MCF-7/T47D cells after 6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,69.1/65.2,Inhibit proliferation of MCF-7/T47D cells,,,,,,,,,,,,,,,10.1021/acschembio.0c00140,1035.258,1034.370669,9.25,74,8,13,6,18,219.85,C57H58N6O9S2,"InChI=1S/C57H58N6O9S2/c1-33(36-11-15-38(16-12-36)51-34(2)58-32-73-51)60-55(70)46-28-43(66)31-63(46)56(71)53(57(3,4)5)61-48(67)8-6-7-27-72-44-24-9-35(10-25-44)30-59-62-54(69)40-17-13-37(14-18-40)50(68)49-45-26-23-42(65)29-47(45)74-52(49)39-19-21-41(64)22-20-39/h9-26,29-30,32-33,43,46,53,64-66H,6-8,27-28,31H2,1-5H3,(H,60,70)(H,61,67)(H,62,69)/b59-30+/t33-,43+,46-,53+/m0/s1",VVAVIHDLCKOZJR-WFZPVKHBSA-N,19,28,403,CCCCOC1=CC=C(/C=N/NC=O)C=C1,[R1]C(=O)N/N=C/C1=CC=C(C=C1)OCCCC[R2],220.272,220.1211778,3,16,1,3,1,7,50.69,C12H16N2O2,"InChI=1S/C12H16N2O2/c1-2-3-8-16-12-6-4-11(5-7-12)9-13-14-10-15/h4-7,9-10H,2-3,8H2,1H3,(H,14,15)/b13-9+",QJOREBJFYYGLGD-UKTHLTGXSA-N,Q8IXJ6,SIRT2,,COCCN1C=C(COC2=CC=CC(CC3=CN=C(NC(=O)CSC4=NC(C)=CC(C)=N4)S3)=C2)N=N1,12,IC50 of Sirt2 was assessed by a fluorescence-based deacetylase activity assay,,,,,,,10.1021/acs.jmedchem.6b01872,525.66,525.1616797,3.13,36,4,11,1,12,116.94,C24H27N7O3S2,"InChI=1S/C24H27N7O3S2/c1-16-9-17(2)27-24(26-16)35-15-22(32)28-23-25-12-21(36-23)11-18-5-4-6-20(10-18)34-14-19-13-31(30-29-19)7-8-33-3/h4-6,9-10,12-13H,7-8,11,14-15H2,1-3H3,(H,25,28,32)",MAUGCLAAQLDMTD-UHFFFAOYSA-N,50459845,135397680,CHEMBL4227437,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,7.7,7.128551291,5.633017122,74.3787,2327.9995
920,1.1,98,1.1,98,P03372,ER,VHL,,AM-A3,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCOC3=CC=C(CCNC(=O)C4=CC=C(C(=O)C5=C(C6=CC=C(O)C=C6)SC6=CC(O)=CC=C56)C=C4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of ERalpha in MCF-7 cells after 6h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13.2/17,Inhibit proliferation of MCF-7/T47D cells,,,,,,,,,,,,,,,10.1021/acschembio.0c00140,1036.286,1035.391071,9.57,74,8,12,6,19,207.49,C58H61N5O9S2,"InChI=1S/C58H61N5O9S2/c1-34(37-11-15-39(16-12-37)52-35(2)60-33-73-52)61-56(70)47-30-44(66)32-63(47)57(71)54(58(3,4)5)62-49(67)8-6-7-29-72-45-24-9-36(10-25-45)27-28-59-55(69)41-17-13-38(14-18-41)51(68)50-46-26-23-43(65)31-48(46)74-53(50)40-19-21-42(64)22-20-40/h9-26,31,33-34,44,47,54,64-66H,6-8,27-30,32H2,1-5H3,(H,59,69)(H,61,70)(H,62,67)/t34-,44+,47-,54+/m0/s1",VXEYUCNJDJXFGM-BMAAPKIPSA-N,19,28,438,CCCCOC1=CC=C(CCNC=O)C=C1,[R1]C(=O)NCCC1=CC=C(C=C1)OCCCC[R2],221.3,221.1415788,3.32,16,1,2,1,8,38.33,C13H19NO2,"InChI=1S/C13H19NO2/c1-2-3-10-16-13-6-4-12(5-7-13)8-9-14-11-15/h4-7,11H,2-3,8-10H2,1H3,(H,14,15)",RXIJOEWSBXIZIM-UHFFFAOYSA-N,Q8IXJ6,SIRT2,,COCCN1C=C(COC2=CC=CC(CC3=CN=C(NC(=O)CSC4=NC(C)=CC(C)=N4)S3)=C2)N=N1,12,IC50 of Sirt2 was assessed by a fluorescence-based deacetylase activity assay,,,,,,,10.1021/acs.jmedchem.6b01872,525.66,525.1616797,3.13,36,4,11,1,12,116.94,C24H27N7O3S2,"InChI=1S/C24H27N7O3S2/c1-16-9-17(2)27-24(26-16)35-15-22(32)28-23-25-12-21(36-23)11-18-5-4-6-20(10-18)34-14-19-13-31(30-29-19)7-8-33-3/h4-6,9-10,12-13H,7-8,11,14-15H2,1-3H3,(H,25,28,32)",MAUGCLAAQLDMTD-UHFFFAOYSA-N,50459845,135397680,CHEMBL4227437,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,1.1,7.492480725,5.594214364,32.1751,2545.5735
860,5.2,75,5.2,75,P03372,ER,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCOC3=CC=C(/C=N/NC(=O)C4=CC=C(OC5=C(C6=CC=C(O)C=C6)SC6=CC(O)=CC=C56)C=C4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of ERalpha in MCF-7 cells after 6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.0c00140,1009.22,1008.355019,9.08,72,8,13,6,17,212.01,C55H56N6O9S2,"InChI=1S/C55H56N6O9S2/c1-32(35-10-12-36(13-11-35)49-33(2)56-31-71-49)58-53(67)45-27-41(64)30-61(45)54(68)51(55(3,4)5)59-47(65)7-6-26-69-42-21-8-34(9-22-42)29-57-60-52(66)38-16-23-43(24-17-38)70-48-44-25-20-40(63)28-46(44)72-50(48)37-14-18-39(62)19-15-37/h8-25,28-29,31-32,41,45,51,62-64H,6-7,26-27,30H2,1-5H3,(H,58,67)(H,59,65)(H,60,66)/b57-29+/t32-,41+,45-,51+/m0/s1",QCDUJVGYYULYRO-INUWBVJXSA-N,21,28,402,CCCOC1=CC=C(/C=N/NC=O)C=C1,[R1]C(=O)N/N=C/C1=CC=C(C=C1)OCCC[R2],206.245,206.1055277,2.64,15,1,3,1,6,50.69,C11H14N2O2,"InChI=1S/C11H14N2O2/c1-2-7-15-11-5-3-10(4-6-11)8-12-13-9-14/h3-6,8-9H,2,7H2,1H3,(H,13,14)/b12-8+",DDZUHXZWWDNROQ-XYOKQWHBSA-N,P09874,PARP1,NIRAPARIB,NC(=O)C1=CC=CC2=CN(C3=CC=C([C@@H]4CCCNC4)C=C3)N=C12,3.2,IC50 of human PARP1 was assessed by SPA,,,,,,,10.1021/jm901188v,320.396,320.1637113,2.22,24,4,4,2,3,72.94,C19H20N4O,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,50316226,24958200,CHEMBL1094636,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.75,5.2,6.742612669,5.518682059,180.8787,3029.1302
2878,4.35,85,4.35,85,P11362,FGFR1,VHL,,DGY-09-192,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,Degradation of FGFR1 in CCLP1 cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17,Inhibit proliferation of CCLP1 cells,,,,,,,,,,,,,,,10.1002/anie.202101328,1017.054,1015.36967,6.81,70,7,14,5,15,206.72,C49H59Cl2N11O7S,"InChI=1S/C49H59Cl2N11O7S/c1-28(30-9-11-31(12-10-30)44-29(2)54-27-70-44)55-46(65)35-21-34(63)24-62(35)47(66)45(49(3,4)5)57-40(64)25-60-17-19-61(20-18-60)33-15-13-32(14-16-33)56-38-23-39(53-26-52-38)59(6)48(67)58-43-41(50)36(68-7)22-37(69-8)42(43)51/h9-16,22-23,26-28,34-35,45,63H,17-21,24-25H2,1-8H3,(H,55,65)(H,57,64)(H,58,67)(H,52,53,56)/t28-,34+,35-,45+/m0/s1",WDBUEMWHXKHQNB-AURZXHAXSA-N,459,28,462,C,[R1]C[R2],16.043,16.03130013,0.65,1,0,0,0,0,0,CH4,InChI=1S/CH4/h1H4,VNWKTOKETHGBQD-UHFFFAOYSA-N,A0A384N6C2,IMPDH,Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C/C=C(\C)CCC(=O)OCCN1CCOCC1,,,,,,,,,10.1016/s1053-2498(00)00191-1,433.501,433.2100523,3.19,31,3,8,1,9,94.53,C23H31NO7,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,50248299,5281078,CHEMBL1456,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,4.35,6.553179702,5.018640742,279.7823,9579.8621
2878,4.35,85,4.35,85,P11362,FGFR1,VHL,,DGY-09-192,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,Degradation of FGFR1 in CCLP1 cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17,Inhibit proliferation of CCLP1 cells,,,,,,,,,,,,,,,10.1002/anie.202101328,1017.054,1015.36967,6.81,70,7,14,5,15,206.72,C49H59Cl2N11O7S,"InChI=1S/C49H59Cl2N11O7S/c1-28(30-9-11-31(12-10-30)44-29(2)54-27-70-44)55-46(65)35-21-34(63)24-62(35)47(66)45(49(3,4)5)57-40(64)25-60-17-19-61(20-18-60)33-15-13-32(14-16-33)56-38-23-39(53-26-52-38)59(6)48(67)58-43-41(50)36(68-7)22-37(69-8)42(43)51/h9-16,22-23,26-28,34-35,45,63H,17-21,24-25H2,1-8H3,(H,55,65)(H,57,64)(H,58,67)(H,52,53,56)/t28-,34+,35-,45+/m0/s1",WDBUEMWHXKHQNB-AURZXHAXSA-N,459,28,462,C,[R1]C[R2],16.043,16.03130013,0.65,1,0,0,0,0,0,CH4,InChI=1S/CH4/h1H4,VNWKTOKETHGBQD-UHFFFAOYSA-N,A0A384N6C2,IMPDH,Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C/C=C(\C)CCC(=O)OCCN1CCOCC1,,,,,,,,,10.1016/s1053-2498(00)00191-1,433.501,433.2100523,3.19,31,3,8,1,9,94.53,C23H31NO7,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,50248299,5281078,CHEMBL1456,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,4.35,7.771625268,5.018640742,16.919,9579.8621
2878,70,74,70,74,P21802,FGFR2,VHL,,DGY-09-192,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,Degradation of FGFR2 in KATO III cells after 6 h treatment,,,34,IC50 was assessed by Z'-LYTE kinase assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Inhibit proliferation of KATO III cells,,,,,,,,,,,,,,,10.1002/anie.202101328,1017.054,1015.36967,6.81,70,7,14,5,15,206.72,C49H59Cl2N11O7S,"InChI=1S/C49H59Cl2N11O7S/c1-28(30-9-11-31(12-10-30)44-29(2)54-27-70-44)55-46(65)35-21-34(63)24-62(35)47(66)45(49(3,4)5)57-40(64)25-60-17-19-61(20-18-60)33-15-13-32(14-16-33)56-38-23-39(53-26-52-38)59(6)48(67)58-43-41(50)36(68-7)22-37(69-8)42(43)51/h9-16,22-23,26-28,34-35,45,63H,17-21,24-25H2,1-8H3,(H,55,65)(H,57,64)(H,58,67)(H,52,53,56)/t28-,34+,35-,45+/m0/s1",WDBUEMWHXKHQNB-AURZXHAXSA-N,459,28,462,C,[R1]C[R2],16.043,16.03130013,0.65,1,0,0,0,0,0,CH4,InChI=1S/CH4/h1H4,VNWKTOKETHGBQD-UHFFFAOYSA-N,A0A384N6C2,IMPDH,Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C/C=C(\C)CCC(=O)OCCN1CCOCC1,,,,,,,,,10.1016/s1053-2498(00)00191-1,433.501,433.2100523,3.19,31,3,8,1,9,94.53,C23H31NO7,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,50248299,5281078,CHEMBL1456,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.74,70,6.553179702,5.018640742,279.7823,9579.8621
2878,70,74,70,74,P21802,FGFR2,VHL,,DGY-09-192,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(CC(=O)N[C@H](C(=O)N5C[C@H](O)C[C@H]5C(=O)N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)C(C)(C)C)CC4)C=C3)=NC=N2)=C1Cl,Degradation of FGFR2 in KATO III cells after 6 h treatment,,,34,IC50 was assessed by Z'-LYTE kinase assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Inhibit proliferation of KATO III cells,,,,,,,,,,,,,,,10.1002/anie.202101328,1017.054,1015.36967,6.81,70,7,14,5,15,206.72,C49H59Cl2N11O7S,"InChI=1S/C49H59Cl2N11O7S/c1-28(30-9-11-31(12-10-30)44-29(2)54-27-70-44)55-46(65)35-21-34(63)24-62(35)47(66)45(49(3,4)5)57-40(64)25-60-17-19-61(20-18-60)33-15-13-32(14-16-33)56-38-23-39(53-26-52-38)59(6)48(67)58-43-41(50)36(68-7)22-37(69-8)42(43)51/h9-16,22-23,26-28,34-35,45,63H,17-21,24-25H2,1-8H3,(H,55,65)(H,57,64)(H,58,67)(H,52,53,56)/t28-,34+,35-,45+/m0/s1",WDBUEMWHXKHQNB-AURZXHAXSA-N,459,28,462,C,[R1]C[R2],16.043,16.03130013,0.65,1,0,0,0,0,0,CH4,InChI=1S/CH4/h1H4,VNWKTOKETHGBQD-UHFFFAOYSA-N,A0A384N6C2,IMPDH,Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C/C=C(\C)CCC(=O)OCCN1CCOCC1,,,,,,,,,10.1016/s1053-2498(00)00191-1,433.501,433.2100523,3.19,31,3,8,1,9,94.53,C23H31NO7,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,50248299,5281078,CHEMBL1456,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.74,70,7.771625268,5.018640742,16.919,9579.8621
1586,50,71,<=50/<=50,>=71/51-70,P10275,AR,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCCOC3=C(F)C=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3F)C(C)(C)C)C=C2)SC=N1,"Degradation of AR in LNCaP/VCaP cells using ELISA assay (DC50: 15min, Dmax: 4h)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.0c00236,1070.217,1069.386495,8.05,74,6,12,3,21,186.66,C52H60F5N7O8S2,"InChI=1S/C52H60F5N7O8S2/c1-30(32-12-14-33(15-13-32)44-31(2)59-29-74-44)60-46(67)41-25-37(65)27-62(41)47(68)45(50(3,4)5)61-42(66)28-71-20-11-19-70-18-9-8-10-21-72-43-39(53)23-36(24-40(43)54)64-49(73)63(48(69)51(64,6)7)35-17-16-34(26-58)38(22-35)52(55,56)57/h12-17,22-24,29-30,37,41,45,65H,8-11,18-21,25,27-28H2,1-7H3,(H,60,67)(H,61,66)/t30-,37+,41-,45+/m0/s1",DKNBVZGJLBYCQJ-YCDRFOERSA-N,250,28,683,CCCCCOCCCOC,[R1]CCCCCOCCCOC[R2],160.257,160.1463299,2.08,11,0,2,0,8,18.46,C9H20O2,"InChI=1S/C9H20O2/c1-3-4-5-8-11-9-6-7-10-2/h3-9H2,1-2H3",SRNPGWZFBBKXEF-UHFFFAOYSA-N,P31749,AKT1,,NCC1=CC=C(N2C(C3=CC=CN=C3N)=NC3=CC=C(C4=CC=CC=C4)N=C32)C=C1,3.7,Inhibition of unphosphorylated AKT1 expressed in baculovirus infected Sf9 insect cells,,,,,,,10.1021/acs.jmedchem.6b00619,392.466,392.1749446,3.13,30,5,6,2,4,95.64,C24H20N6,"InChI=1S/C24H20N6/c25-15-16-8-10-18(11-9-16)30-23(19-7-4-14-27-22(19)26)29-21-13-12-20(28-24(21)30)17-5-2-1-3-6-17/h1-14H,15,25H2,(H2,26,27)",JAARXSVCUDUSTR-UHFFFAOYSA-N,,53262403,CHEMBL4597416,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.471313046,5.652206276,337.8212,2227.377
1782,1100,74,1100,74,O14744,PRMT5,VHL,,MS4322,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCC(=O)N3CC(NC4=CC(C(=O)NC[C@H](O)CN5CCC6=CC=CC=C6C5)=NC=N4)C3)C(C)(C)C)C=C2)SC=N1,Degradation of PRMT5 in MCF-7 cells after 6 d treatment,,,18,IC50 was assessed by a human PRMT5/MEP50 radioactive biochemical assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01111,1101.338,1100.536489,2.22,78,7,18,6,29,268.47,C55H76N10O12S,"InChI=1S/C55H76N10O12S/c1-36(38-10-12-40(13-11-38)50-37(2)59-35-78-50)60-53(71)46-24-43(66)31-65(46)54(72)51(55(3,4)5)62-48(68)32-76-22-20-74-18-16-73-17-19-75-21-23-77-33-49(69)64-28-42(29-64)61-47-25-45(57-34-58-47)52(70)56-26-44(67)30-63-15-14-39-8-6-7-9-41(39)27-63/h6-13,25,34-36,42-44,46,51,66-67H,14-24,26-33H2,1-5H3,(H,56,70)(H,60,71)(H,62,68)(H,57,58,61)/t36-,43+,44-,46-,51+/m0/s1",XUJMNOQMXWVXQE-STHBVIMFSA-N,334,28,870,COCCOCCOCCOCCOCC=O,[R1]C(=O)COCCOCCOCCOCCOC[R2],250.291,250.1416384,-0.98,17,0,6,0,14,63.22,C11H22O6,"InChI=1S/C11H22O6/c1-13-4-5-15-8-9-17-11-10-16-7-6-14-3-2-12/h2H,3-11H2,1H3",PERZZOPFAPJECS-UHFFFAOYSA-N,Q06124,SHP2,RMC-4550,CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl,31,Allosteric inhibition of SHP2,,,,,,,10.1021/acs.jmedchem.0c00249,437.371,436.1432814,2.49,29,4,6,2,3,84.5,C21H26Cl2N4O2,"InChI=1S/C21H26Cl2N4O2/c1-12-18(14-4-3-5-15(22)17(14)23)26-16(10-28)20(25-12)27-8-6-21(7-9-27)11-29-13(2)19(21)24/h3-5,13,19,28H,6-11,24H2,1-2H3/t13-,19+/m0/s1",IKUYEYLZXGGCRD-ORAYPTAESA-N,50546219,134183206,CHEMBL4752026,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,245.8,0.002819365,1,1,1,1,1,0.002819365,0.74,1100,7.437784026,4.926262125,36.4935,11850.5328
3213,316.2,56,316.2,56,Q07817,BCL-xL,VHL,,PPC5,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1599.442,1597.604899,10.87,109,11,19,5,28,263.54,C79H99ClF3N11O11S4,"InChI=1S/C79H99ClF3N11O11S4/c1-53(55-15-17-57(18-16-55)72-54(2)84-52-107-72)85-75(99)68-45-63(95)49-94(68)76(100)73(77(3,4)5)87-70(96)13-10-14-71(97)93-39-35-91(36-40-93)51-78(6)31-29-66(56-19-23-60(80)24-20-56)59(47-78)48-90-33-37-92(38-34-90)62-25-21-58(22-26-62)74(98)88-109(103,104)65-27-28-67(69(46-65)108(101,102)79(81,82)83)86-61(30-32-89-41-43-105-44-42-89)50-106-64-11-8-7-9-12-64/h7-9,11-12,15-28,46,52-53,61,63,68,73,86,95H,10,13-14,29-45,47-51H2,1-6H3,(H,85,99)(H,87,96)(H,88,98)/t53-,61+,63+,68-,73+,78?/m0/s1",BRIZMACXBJUXJT-UWPVXNPMSA-N,369,28,1482,CCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCC[R2],170.256,170.1419132,0.36,12,1,2,0,2,23.55,C9H18N2O,"InChI=1S/C9H18N2O/c1-3-4-9(12)11-7-5-10(2)6-8-11/h3-8H2,1-2H3",KZGIXRKCQDHVIX-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.56,316.2,6.90846774,5.76924318,123.4617,1701.2057
3214,39.9,91,39.9,91,Q07817,BCL-xL,VHL,,PPC6,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1613.469,1611.620549,11.23,110,11,19,5,29,263.54,C80H101ClF3N11O11S4,"InChI=1S/C80H101ClF3N11O11S4/c1-54(56-16-18-58(19-17-56)73-55(2)85-53-108-73)86-76(100)69-46-64(96)50-95(69)77(101)74(78(3,4)5)88-71(97)14-10-11-15-72(98)94-40-36-92(37-41-94)52-79(6)32-30-67(57-20-24-61(81)25-21-57)60(48-79)49-91-34-38-93(39-35-91)63-26-22-59(23-27-63)75(99)89-110(104,105)66-28-29-68(70(47-66)109(102,103)80(82,83)84)87-62(31-33-90-42-44-106-45-43-90)51-107-65-12-8-7-9-13-65/h7-9,12-13,16-29,47,53-54,62,64,69,74,87,96H,10-11,14-15,30-46,48-52H2,1-6H3,(H,86,100)(H,88,97)(H,89,99)/t54-,62+,64+,69-,74+,79?/m0/s1",KVQKGBLSBLWZKE-AAWIYDMSSA-N,369,28,1483,CCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCC[R2],184.283,184.1575633,0.9,13,1,2,0,3,23.55,C10H20N2O,"InChI=1S/C10H20N2O/c1-3-4-5-10(13)12-8-6-11(2)7-9-12/h3-9H2,1-2H3",JDNGEKSTTQZLHP-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,39.9,6.70805109,5.259770677,195.8614,5498.3113
3215,12.8,85,12.8,85,Q07817,BCL-xL,VHL,,PPC7,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1627.496,1625.636199,11.77,111,11,19,5,30,263.54,C81H103ClF3N11O11S4,"InChI=1S/C81H103ClF3N11O11S4/c1-55(57-17-19-59(20-18-57)74-56(2)86-54-109-74)87-77(101)70-47-65(97)51-96(70)78(102)75(79(3,4)5)89-72(98)15-11-8-12-16-73(99)95-41-37-93(38-42-95)53-80(6)33-31-68(58-21-25-62(82)26-22-58)61(49-80)50-92-35-39-94(40-36-92)64-27-23-60(24-28-64)76(100)90-111(105,106)67-29-30-69(71(48-67)110(103,104)81(83,84)85)88-63(32-34-91-43-45-107-46-44-91)52-108-66-13-9-7-10-14-66/h7,9-10,13-14,17-30,48,54-55,63,65,70,75,88,97H,8,11-12,15-16,31-47,49-53H2,1-6H3,(H,87,101)(H,89,98)(H,90,100)/t55-,63+,65+,70-,75+,80?/m0/s1",XXWWYTHQXVIKLW-WGWDJEQESA-N,369,28,1484,CCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCC[R2],198.31,198.1732133,1.45,14,1,2,0,4,23.55,C11H22N2O,"InChI=1S/C11H22N2O/c1-3-4-5-6-11(14)13-9-7-12(2)8-10-13/h3-10H2,1-2H3",TUBDWOUHWWRXLI-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,12.8,6.395175253,5.446642289,402.5546,3575.6723
3215,12.8,85,12.8,85,Q07817,BCL-xL,VHL,,PPC7,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1627.496,1625.636199,11.77,111,11,19,5,30,263.54,C81H103ClF3N11O11S4,"InChI=1S/C81H103ClF3N11O11S4/c1-55(57-17-19-59(20-18-57)74-56(2)86-54-109-74)87-77(101)70-47-65(97)51-96(70)78(102)75(79(3,4)5)89-72(98)15-11-8-12-16-73(99)95-41-37-93(38-42-95)53-80(6)33-31-68(58-21-25-62(82)26-22-58)61(49-80)50-92-35-39-94(40-36-92)64-27-23-60(24-28-64)76(100)90-111(105,106)67-29-30-69(71(48-67)110(103,104)81(83,84)85)88-63(32-34-91-43-45-107-46-44-91)52-108-66-13-9-7-10-14-66/h7,9-10,13-14,17-30,48,54-55,63,65,70,75,88,97H,8,11-12,15-16,31-47,49-53H2,1-6H3,(H,87,101)(H,89,98)(H,90,100)/t55-,63+,65+,70-,75+,80?/m0/s1",XXWWYTHQXVIKLW-WGWDJEQESA-N,369,28,1484,CCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCC[R2],198.31,198.1732133,1.45,14,1,2,0,4,23.55,C11H22N2O,"InChI=1S/C11H22N2O/c1-3-4-5-6-11(14)13-9-7-12(2)8-10-13/h3-10H2,1-2H3",TUBDWOUHWWRXLI-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,12.8,6.693722846,5.446642289,202.4311,3575.6723
3215,179.9,79,179.9,79,P10415,BCL2,VHL,,PPC7,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1627.496,1625.636199,11.77,111,11,19,5,30,263.54,C81H103ClF3N11O11S4,"InChI=1S/C81H103ClF3N11O11S4/c1-55(57-17-19-59(20-18-57)74-56(2)86-54-109-74)87-77(101)70-47-65(97)51-96(70)78(102)75(79(3,4)5)89-72(98)15-11-8-12-16-73(99)95-41-37-93(38-42-95)53-80(6)33-31-68(58-21-25-62(82)26-22-58)61(49-80)50-92-35-39-94(40-36-92)64-27-23-60(24-28-64)76(100)90-111(105,106)67-29-30-69(71(48-67)110(103,104)81(83,84)85)88-63(32-34-91-43-45-107-46-44-91)52-108-66-13-9-7-10-14-66/h7,9-10,13-14,17-30,48,54-55,63,65,70,75,88,97H,8,11-12,15-16,31-47,49-53H2,1-6H3,(H,87,101)(H,89,98)(H,90,100)/t55-,63+,65+,70-,75+,80?/m0/s1",XXWWYTHQXVIKLW-WGWDJEQESA-N,369,28,1484,CCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCC[R2],198.31,198.1732133,1.45,14,1,2,0,4,23.55,C11H22N2O,"InChI=1S/C11H22N2O/c1-3-4-5-6-11(14)13-9-7-12(2)8-10-13/h3-10H2,1-2H3",TUBDWOUHWWRXLI-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.79,179.9,6.395175253,5.446642289,402.5546,3575.6723
3215,179.9,79,179.9,79,P10415,BCL2,VHL,,PPC7,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1627.496,1625.636199,11.77,111,11,19,5,30,263.54,C81H103ClF3N11O11S4,"InChI=1S/C81H103ClF3N11O11S4/c1-55(57-17-19-59(20-18-57)74-56(2)86-54-109-74)87-77(101)70-47-65(97)51-96(70)78(102)75(79(3,4)5)89-72(98)15-11-8-12-16-73(99)95-41-37-93(38-42-95)53-80(6)33-31-68(58-21-25-62(82)26-22-58)61(49-80)50-92-35-39-94(40-36-92)64-27-23-60(24-28-64)76(100)90-111(105,106)67-29-30-69(71(48-67)110(103,104)81(83,84)85)88-63(32-34-91-43-45-107-46-44-91)52-108-66-13-9-7-10-14-66/h7,9-10,13-14,17-30,48,54-55,63,65,70,75,88,97H,8,11-12,15-16,31-47,49-53H2,1-6H3,(H,87,101)(H,89,98)(H,90,100)/t55-,63+,65+,70-,75+,80?/m0/s1",XXWWYTHQXVIKLW-WGWDJEQESA-N,369,28,1484,CCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCC[R2],198.31,198.1732133,1.45,14,1,2,0,4,23.55,C11H22N2O,"InChI=1S/C11H22N2O/c1-3-4-5-6-11(14)13-9-7-12(2)8-10-13/h3-10H2,1-2H3",TUBDWOUHWWRXLI-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.79,179.9,6.693722846,5.446642289,202.4311,3575.6723
3216,12.9,94,12.9,94,Q07817,BCL-xL,VHL,,PPC8,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1641.523,1639.65185,12.31,112,11,19,5,31,263.54,C82H105ClF3N11O11S4,"InChI=1S/C82H105ClF3N11O11S4/c1-56(58-18-20-60(21-19-58)75-57(2)87-55-110-75)88-78(102)71-48-66(98)52-97(71)79(103)76(80(3,4)5)90-73(99)16-12-7-8-13-17-74(100)96-42-38-94(39-43-96)54-81(6)34-32-69(59-22-26-63(83)27-23-59)62(50-81)51-93-36-40-95(41-37-93)65-28-24-61(25-29-65)77(101)91-112(106,107)68-30-31-70(72(49-68)111(104,105)82(84,85)86)89-64(33-35-92-44-46-108-47-45-92)53-109-67-14-10-9-11-15-67/h9-11,14-15,18-31,49,55-56,64,66,71,76,89,98H,7-8,12-13,16-17,32-48,50-54H2,1-6H3,(H,88,102)(H,90,99)(H,91,101)/t56-,64+,66+,71-,76+,81?/m0/s1",KQEMZZJSHJCPSI-KGENNJKMSA-N,369,28,1485,CCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCC[R2],212.337,212.1888634,1.99,15,1,2,0,5,23.55,C12H24N2O,"InChI=1S/C12H24N2O/c1-3-4-5-6-7-12(15)14-10-8-13(2)9-11-14/h3-11H2,1-2H3",LIJPNRGJBFZFFR-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,12.9,6.410219548,5.362807954,388.8485,4337.0262
3216,12.9,94,12.9,94,Q07817,BCL-xL,VHL,,PPC8,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1641.523,1639.65185,12.31,112,11,19,5,31,263.54,C82H105ClF3N11O11S4,"InChI=1S/C82H105ClF3N11O11S4/c1-56(58-18-20-60(21-19-58)75-57(2)87-55-110-75)88-78(102)71-48-66(98)52-97(71)79(103)76(80(3,4)5)90-73(99)16-12-7-8-13-17-74(100)96-42-38-94(39-43-96)54-81(6)34-32-69(59-22-26-63(83)27-23-59)62(50-81)51-93-36-40-95(41-37-93)65-28-24-61(25-29-65)77(101)91-112(106,107)68-30-31-70(72(49-68)111(104,105)82(84,85)86)89-64(33-35-92-44-46-108-47-45-92)53-109-67-14-10-9-11-15-67/h9-11,14-15,18-31,49,55-56,64,66,71,76,89,98H,7-8,12-13,16-17,32-48,50-54H2,1-6H3,(H,88,102)(H,90,99)(H,91,101)/t56-,64+,66+,71-,76+,81?/m0/s1",KQEMZZJSHJCPSI-KGENNJKMSA-N,369,28,1485,CCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCC[R2],212.337,212.1888634,1.99,15,1,2,0,5,23.55,C12H24N2O,"InChI=1S/C12H24N2O/c1-3-4-5-6-7-12(15)14-10-8-13(2)9-11-14/h3-11H2,1-2H3",LIJPNRGJBFZFFR-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,12.9,6.644754488,5.362807954,226.5925,4337.0262
3216,54,94,54,94,P10415,BCL2,VHL,,PPC8,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1641.523,1639.65185,12.31,112,11,19,5,31,263.54,C82H105ClF3N11O11S4,"InChI=1S/C82H105ClF3N11O11S4/c1-56(58-18-20-60(21-19-58)75-57(2)87-55-110-75)88-78(102)71-48-66(98)52-97(71)79(103)76(80(3,4)5)90-73(99)16-12-7-8-13-17-74(100)96-42-38-94(39-43-96)54-81(6)34-32-69(59-22-26-63(83)27-23-59)62(50-81)51-93-36-40-95(41-37-93)65-28-24-61(25-29-65)77(101)91-112(106,107)68-30-31-70(72(49-68)111(104,105)82(84,85)86)89-64(33-35-92-44-46-108-47-45-92)53-109-67-14-10-9-11-15-67/h9-11,14-15,18-31,49,55-56,64,66,71,76,89,98H,7-8,12-13,16-17,32-48,50-54H2,1-6H3,(H,88,102)(H,90,99)(H,91,101)/t56-,64+,66+,71-,76+,81?/m0/s1",KQEMZZJSHJCPSI-KGENNJKMSA-N,369,28,1485,CCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCC[R2],212.337,212.1888634,1.99,15,1,2,0,5,23.55,C12H24N2O,"InChI=1S/C12H24N2O/c1-3-4-5-6-7-12(15)14-10-8-13(2)9-11-14/h3-11H2,1-2H3",LIJPNRGJBFZFFR-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,54,6.410219548,5.362807954,388.8485,4337.0262
3216,54,94,54,94,P10415,BCL2,VHL,,PPC8,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1641.523,1639.65185,12.31,112,11,19,5,31,263.54,C82H105ClF3N11O11S4,"InChI=1S/C82H105ClF3N11O11S4/c1-56(58-18-20-60(21-19-58)75-57(2)87-55-110-75)88-78(102)71-48-66(98)52-97(71)79(103)76(80(3,4)5)90-73(99)16-12-7-8-13-17-74(100)96-42-38-94(39-43-96)54-81(6)34-32-69(59-22-26-63(83)27-23-59)62(50-81)51-93-36-40-95(41-37-93)65-28-24-61(25-29-65)77(101)91-112(106,107)68-30-31-70(72(49-68)111(104,105)82(84,85)86)89-64(33-35-92-44-46-108-47-45-92)53-109-67-14-10-9-11-15-67/h9-11,14-15,18-31,49,55-56,64,66,71,76,89,98H,7-8,12-13,16-17,32-48,50-54H2,1-6H3,(H,88,102)(H,90,99)(H,91,101)/t56-,64+,66+,71-,76+,81?/m0/s1",KQEMZZJSHJCPSI-KGENNJKMSA-N,369,28,1485,CCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCC[R2],212.337,212.1888634,1.99,15,1,2,0,5,23.55,C12H24N2O,"InChI=1S/C12H24N2O/c1-3-4-5-6-7-12(15)14-10-8-13(2)9-11-14/h3-11H2,1-2H3",LIJPNRGJBFZFFR-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,54,6.644754488,5.362807954,226.5925,4337.0262
3217,12.8,96,12.8,96,Q07817,BCL-xL,VHL,,PPC9,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1655.55,1653.6675,12.86,113,11,19,5,32,263.54,C83H107ClF3N11O11S4,"InChI=1S/C83H107ClF3N11O11S4/c1-57(59-19-21-61(22-20-59)76-58(2)88-56-111-76)89-79(103)72-49-67(99)53-98(72)80(104)77(81(3,4)5)91-74(100)17-13-8-7-9-14-18-75(101)97-43-39-95(40-44-97)55-82(6)35-33-70(60-23-27-64(84)28-24-60)63(51-82)52-94-37-41-96(42-38-94)66-29-25-62(26-30-66)78(102)92-113(107,108)69-31-32-71(73(50-69)112(105,106)83(85,86)87)90-65(34-36-93-45-47-109-48-46-93)54-110-68-15-11-10-12-16-68/h10-12,15-16,19-32,50,56-57,65,67,72,77,90,99H,7-9,13-14,17-18,33-49,51-55H2,1-6H3,(H,89,103)(H,91,100)(H,92,102)/t57-,65+,67+,72-,77+,82?/m0/s1",YCSHJMBQFQHZEP-BMNBLYSOSA-N,369,28,1486,CCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCC[R2],226.364,226.2045135,2.53,16,1,2,0,6,23.55,C13H26N2O,"InChI=1S/C13H26N2O/c1-3-4-5-6-7-8-13(16)15-11-9-14(2)10-12-15/h3-12H2,1-2H3",QXHNMHHWHZVDMC-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,12.8,5.919067958,5.454397764,1204.8474,3512.386
3217,12.8,96,12.8,96,Q07817,BCL-xL,VHL,,PPC9,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1655.55,1653.6675,12.86,113,11,19,5,32,263.54,C83H107ClF3N11O11S4,"InChI=1S/C83H107ClF3N11O11S4/c1-57(59-19-21-61(22-20-59)76-58(2)88-56-111-76)89-79(103)72-49-67(99)53-98(72)80(104)77(81(3,4)5)91-74(100)17-13-8-7-9-14-18-75(101)97-43-39-95(40-44-97)55-82(6)35-33-70(60-23-27-64(84)28-24-60)63(51-82)52-94-37-41-96(42-38-94)66-29-25-62(26-30-66)78(102)92-113(107,108)69-31-32-71(73(50-69)112(105,106)83(85,86)87)90-65(34-36-93-45-47-109-48-46-93)54-110-68-15-11-10-12-16-68/h10-12,15-16,19-32,50,56-57,65,67,72,77,90,99H,7-9,13-14,17-18,33-49,51-55H2,1-6H3,(H,89,103)(H,91,100)(H,92,102)/t57-,65+,67+,72-,77+,82?/m0/s1",YCSHJMBQFQHZEP-BMNBLYSOSA-N,369,28,1486,CCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCC[R2],226.364,226.2045135,2.53,16,1,2,0,6,23.55,C13H26N2O,"InChI=1S/C13H26N2O/c1-3-4-5-6-7-8-13(16)15-11-9-14(2)10-12-15/h3-12H2,1-2H3",QXHNMHHWHZVDMC-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,12.8,6.841655138,5.454397764,143.9942,3512.386
3217,316.2,79,316.2,79,P10415,BCL2,VHL,,PPC9,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1655.55,1653.6675,12.86,113,11,19,5,32,263.54,C83H107ClF3N11O11S4,"InChI=1S/C83H107ClF3N11O11S4/c1-57(59-19-21-61(22-20-59)76-58(2)88-56-111-76)89-79(103)72-49-67(99)53-98(72)80(104)77(81(3,4)5)91-74(100)17-13-8-7-9-14-18-75(101)97-43-39-95(40-44-97)55-82(6)35-33-70(60-23-27-64(84)28-24-60)63(51-82)52-94-37-41-96(42-38-94)66-29-25-62(26-30-66)78(102)92-113(107,108)69-31-32-71(73(50-69)112(105,106)83(85,86)87)90-65(34-36-93-45-47-109-48-46-93)54-110-68-15-11-10-12-16-68/h10-12,15-16,19-32,50,56-57,65,67,72,77,90,99H,7-9,13-14,17-18,33-49,51-55H2,1-6H3,(H,89,103)(H,91,100)(H,92,102)/t57-,65+,67+,72-,77+,82?/m0/s1",YCSHJMBQFQHZEP-BMNBLYSOSA-N,369,28,1486,CCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCC[R2],226.364,226.2045135,2.53,16,1,2,0,6,23.55,C13H26N2O,"InChI=1S/C13H26N2O/c1-3-4-5-6-7-8-13(16)15-11-9-14(2)10-12-15/h3-12H2,1-2H3",QXHNMHHWHZVDMC-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.79,316.2,5.919067958,5.454397764,1204.8474,3512.386
3217,316.2,79,316.2,79,P10415,BCL2,VHL,,PPC9,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1655.55,1653.6675,12.86,113,11,19,5,32,263.54,C83H107ClF3N11O11S4,"InChI=1S/C83H107ClF3N11O11S4/c1-57(59-19-21-61(22-20-59)76-58(2)88-56-111-76)89-79(103)72-49-67(99)53-98(72)80(104)77(81(3,4)5)91-74(100)17-13-8-7-9-14-18-75(101)97-43-39-95(40-44-97)55-82(6)35-33-70(60-23-27-64(84)28-24-60)63(51-82)52-94-37-41-96(42-38-94)66-29-25-62(26-30-66)78(102)92-113(107,108)69-31-32-71(73(50-69)112(105,106)83(85,86)87)90-65(34-36-93-45-47-109-48-46-93)54-110-68-15-11-10-12-16-68/h10-12,15-16,19-32,50,56-57,65,67,72,77,90,99H,7-9,13-14,17-18,33-49,51-55H2,1-6H3,(H,89,103)(H,91,100)(H,92,102)/t57-,65+,67+,72-,77+,82?/m0/s1",YCSHJMBQFQHZEP-BMNBLYSOSA-N,369,28,1486,CCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCC[R2],226.364,226.2045135,2.53,16,1,2,0,6,23.55,C13H26N2O,"InChI=1S/C13H26N2O/c1-3-4-5-6-7-8-13(16)15-11-9-14(2)10-12-15/h3-12H2,1-2H3",QXHNMHHWHZVDMC-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.79,316.2,6.841655138,5.454397764,143.9942,3512.386
3218,12.1,81,12.1,81,Q07817,BCL-xL,VHL,,PPC10,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1669.577,1667.68315,13.4,114,11,19,5,33,263.54,C84H109ClF3N11O11S4,"InChI=1S/C84H109ClF3N11O11S4/c1-58(60-20-22-62(23-21-60)77-59(2)89-57-112-77)90-80(104)73-50-68(100)54-99(73)81(105)78(82(3,4)5)92-75(101)18-14-9-7-8-10-15-19-76(102)98-44-40-96(41-45-98)56-83(6)36-34-71(61-24-28-65(85)29-25-61)64(52-83)53-95-38-42-97(43-39-95)67-30-26-63(27-31-67)79(103)93-114(108,109)70-32-33-72(74(51-70)113(106,107)84(86,87)88)91-66(35-37-94-46-48-110-49-47-94)55-111-69-16-12-11-13-17-69/h11-13,16-17,20-33,51,57-58,66,68,73,78,91,100H,7-10,14-15,18-19,34-50,52-56H2,1-6H3,(H,90,104)(H,92,101)(H,93,103)/t58-,66+,68+,73-,78+,83?/m0/s1",CGIQKSDNJNCLMP-PVVVILJQSA-N,369,28,1487,CCCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCCC[R2],240.391,240.2201635,3.07,17,1,2,0,7,23.55,C14H28N2O,"InChI=1S/C14H28N2O/c1-3-4-5-6-7-8-9-14(17)16-12-10-15(2)11-13-16/h3-13H2,1-2H3",FBLSADHLDNQWGN-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.81,12.1,6.128664404,5.431482502,743.5935,3702.6912
3218,12.1,81,12.1,81,Q07817,BCL-xL,VHL,,PPC10,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL-xL in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1669.577,1667.68315,13.4,114,11,19,5,33,263.54,C84H109ClF3N11O11S4,"InChI=1S/C84H109ClF3N11O11S4/c1-58(60-20-22-62(23-21-60)77-59(2)89-57-112-77)90-80(104)73-50-68(100)54-99(73)81(105)78(82(3,4)5)92-75(101)18-14-9-7-8-10-15-19-76(102)98-44-40-96(41-45-98)56-83(6)36-34-71(61-24-28-65(85)29-25-61)64(52-83)53-95-38-42-97(43-39-95)67-30-26-63(27-31-67)79(103)93-114(108,109)70-32-33-72(74(51-70)113(106,107)84(86,87)88)91-66(35-37-94-46-48-110-49-47-94)55-111-69-16-12-11-13-17-69/h11-13,16-17,20-33,51,57-58,66,68,73,78,91,100H,7-10,14-15,18-19,34-50,52-56H2,1-6H3,(H,90,104)(H,92,101)(H,93,103)/t58-,66+,68+,73-,78+,83?/m0/s1",CGIQKSDNJNCLMP-PVVVILJQSA-N,369,28,1487,CCCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCCC[R2],240.391,240.2201635,3.07,17,1,2,0,7,23.55,C14H28N2O,"InChI=1S/C14H28N2O/c1-3-4-5-6-7-8-9-14(17)16-12-10-15(2)11-13-16/h3-13H2,1-2H3",FBLSADHLDNQWGN-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.81,12.1,7.120682932,5.431482502,75.7386,3702.6912
3218,354.8,69,354.8,69,P10415,BCL2,VHL,,PPC10,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1669.577,1667.68315,13.4,114,11,19,5,33,263.54,C84H109ClF3N11O11S4,"InChI=1S/C84H109ClF3N11O11S4/c1-58(60-20-22-62(23-21-60)77-59(2)89-57-112-77)90-80(104)73-50-68(100)54-99(73)81(105)78(82(3,4)5)92-75(101)18-14-9-7-8-10-15-19-76(102)98-44-40-96(41-45-98)56-83(6)36-34-71(61-24-28-65(85)29-25-61)64(52-83)53-95-38-42-97(43-39-95)67-30-26-63(27-31-67)79(103)93-114(108,109)70-32-33-72(74(51-70)113(106,107)84(86,87)88)91-66(35-37-94-46-48-110-49-47-94)55-111-69-16-12-11-13-17-69/h11-13,16-17,20-33,51,57-58,66,68,73,78,91,100H,7-10,14-15,18-19,34-50,52-56H2,1-6H3,(H,90,104)(H,92,101)(H,93,103)/t58-,66+,68+,73-,78+,83?/m0/s1",CGIQKSDNJNCLMP-PVVVILJQSA-N,369,28,1487,CCCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCCC[R2],240.391,240.2201635,3.07,17,1,2,0,7,23.55,C14H28N2O,"InChI=1S/C14H28N2O/c1-3-4-5-6-7-8-9-14(17)16-12-10-15(2)11-13-16/h3-13H2,1-2H3",FBLSADHLDNQWGN-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.69,354.8,6.128664404,5.431482502,743.5935,3702.6912
3218,354.8,69,354.8,69,P10415,BCL2,VHL,,PPC10,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCC(=O)N3CCN(CC4(C)CCC(C5=CC=C(Cl)C=C5)=C(CN5CCN(C6=CC=C(C(=O)NS(=O)(=O)C7=CC=C(N[C@H](CCN8CCOCC8)CSC8=CC=CC=C8)C(S(=O)(=O)C(F)(F)F)=C7)C=C6)CC5)C4)CC3)C(C)(C)C)C=C2)SC=N1,Degradation of BCL2 in 293T cells after 16 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41467-021-27210-x,1669.577,1667.68315,13.4,114,11,19,5,33,263.54,C84H109ClF3N11O11S4,"InChI=1S/C84H109ClF3N11O11S4/c1-58(60-20-22-62(23-21-60)77-59(2)89-57-112-77)90-80(104)73-50-68(100)54-99(73)81(105)78(82(3,4)5)92-75(101)18-14-9-7-8-10-15-19-76(102)98-44-40-96(41-45-98)56-83(6)36-34-71(61-24-28-65(85)29-25-61)64(52-83)53-95-38-42-97(43-39-95)67-30-26-63(27-31-67)79(103)93-114(108,109)70-32-33-72(74(51-70)113(106,107)84(86,87)88)91-66(35-37-94-46-48-110-49-47-94)55-111-69-16-12-11-13-17-69/h11-13,16-17,20-33,51,57-58,66,68,73,78,91,100H,7-10,14-15,18-19,34-50,52-56H2,1-6H3,(H,90,104)(H,92,101)(H,93,103)/t58-,66+,68+,73-,78+,83?/m0/s1",CGIQKSDNJNCLMP-PVVVILJQSA-N,369,28,1487,CCCCCCCCC(=O)N1CCN(C)CC1,[R1]CN1CCN(CC1)C(=O)CCCCCCCC[R2],240.391,240.2201635,3.07,17,1,2,0,7,23.55,C14H28N2O,"InChI=1S/C14H28N2O/c1-3-4-5-6-7-8-9-14(17)16-12-10-15(2)11-13-16/h3-13H2,1-2H3",FBLSADHLDNQWGN-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=C[NH]N=N1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,591.71,591.3380468,1.69,42,3,9,5,14,193.5,C28H45N7O7,"InChI=1S/C28H45N7O7/c1-17(42-28(2,3)4)23(33-27(40)41-16-21-14-30-35-34-21)26(39)32-22(12-18-8-6-5-7-9-18)25(38)31-20(15-36)13-19-10-11-29-24(19)37/h14-15,17-20,22-23H,5-13,16H2,1-4H3,(H,29,37)(H,31,38)(H,32,39)(H,33,40)(H,30,34,35)/t17-,19+,20+,22+,23+/m1/s1",FNGFRQFQLDRNDV-ATPUAQIGSA-N,50592586,11844348,CHEMBL4852855,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.69,354.8,7.120682932,5.431482502,75.7386,3702.6912
3018,350,53,350,53,P10275,AR-V7,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCOC3=CC=C(C4=CSC(N5CCOCC5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR-V7 in 22RV1 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1360,Inhibit proliferation of 22Rv1 cells,,,,,,,,,,,,,10.1016/j.bmcl.2021.128448,775.01,774.3233253,5.44,54,6,11,3,13,146.22,C40H50N6O6S2,"InChI=1S/C40H50N6O6S2/c1-25(27-8-10-29(11-9-27)35-26(2)41-24-54-35)42-37(49)33-21-30(47)22-46(33)38(50)36(40(3,4)5)44-34(48)7-6-18-52-31-14-12-28(13-15-31)32-23-53-39(43-32)45-16-19-51-20-17-45/h8-15,23-25,30,33,36,47H,6-7,16-22H2,1-5H3,(H,42,49)(H,44,48)/t25-,30+,33-,36+/m0/s1",DNHMBIDODIOPOD-JJOXSQEKSA-N,476,28,1013,CCCO,[R1]OCCC[R2],60.096,60.05751488,0.44,4,0,1,1,1,20.23,C3H8O,"InChI=1S/C3H8O/c1-2-3-4/h4H,2-3H2,1H3",BDERNNFJNOPAEC-UHFFFAOYSA-N,O60885,BRD4,,CC1=CC(C2=CC=C(C=O)C(OC(C)C)=C2)=CN(C)C1=O,,,,,,,,,10.1021/acschembio.2c00797,285.343,285.1364935,2.17,21,2,4,0,4,48.3,C17H19NO3,"InChI=1S/C17H19NO3/c1-11(2)21-16-8-13(5-6-14(16)10-19)15-7-12(3)17(20)18(4)9-15/h5-11H,1-4H3",VSLYFAIHXZRTAZ-UHFFFAOYSA-N,,,,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.53,350,6.081058097,4.868949477,829.7398,13522.2986
3021,320,67,320,67,P10275,AR-V7,VHL,,,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCOC3=CC=C(C4=CSC(N5CCOCC5)=N4)C=C3)C(C)(C)C)C=C2)SC=N1,Degradation of AR-V7 in 22RV1 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,880,Inhibit proliferation of 22Rv1 cells,,,,,,,,,,,,,10.1016/j.bmcl.2021.128448,789.037,788.3389754,5.8,55,6,11,3,14,146.22,C41H52N6O6S2,"InChI=1S/C41H52N6O6S2/c1-26(28-9-11-30(12-10-28)36-27(2)42-25-55-36)43-38(50)34-22-31(48)23-47(34)39(51)37(41(3,4)5)45-35(49)8-6-7-19-53-32-15-13-29(14-16-32)33-24-54-40(44-33)46-17-20-52-21-18-46/h9-16,24-26,31,34,37,48H,6-8,17-23H2,1-5H3,(H,43,50)(H,45,49)/t26-,31+,34-,37+/m0/s1",GGBZAQUSRYNTSQ-ASCDMGAVSA-N,476,28,1073,CCCCO,[R1]OCCCC[R2],74.123,74.07316494,0.79,5,0,1,1,2,20.23,C4H10O,"InChI=1S/C4H10O/c1-2-3-4-5/h5H,2-4H2,1H3",LRHPLDYGYMQRHN-UHFFFAOYSA-N,O60885,BRD4,,CC1=CC(C2=CC=C(C=O)C(OC(C)C)=C2)=CN(C)C1=O,,,,,,,,,10.1021/acschembio.2c00797,285.343,285.1364935,2.17,21,2,4,0,4,48.3,C17H19NO3,"InChI=1S/C17H19NO3/c1-11(2)21-16-8-13(5-6-14(16)10-19)15-7-12(3)17(20)18(4)9-15/h5-11H,1-4H3",VSLYFAIHXZRTAZ-UHFFFAOYSA-N,,,,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.67,320,6.425060705,5.084657678,375.7849,8228.9102
3066,3,96,3,96,P51617,IRAK1,VHL,,,COC1=CC(N2CCC(OCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC(=O)C1=CC=CC(C2=CC=N[NH]2)=N1,Degradation of IRAK1 in HEK293T cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.1c00244,878.069,877.3945161,5.03,63,7,12,5,14,204,C46H55N9O7S,"InChI=1S/C46H55N9O7S/c1-27(29-10-12-30(13-11-29)41-28(2)47-26-63-41)49-44(59)38-23-32(56)24-55(38)45(60)42(46(3,4)5)52-40(57)25-62-33-17-20-54(21-18-33)31-14-15-36(39(22-31)61-6)51-43(58)37-9-7-8-34(50-37)35-16-19-48-53-35/h7-16,19,22,26-27,32-33,38,42,56H,17-18,20-21,23-25H2,1-6H3,(H,48,53)(H,49,59)(H,51,58)(H,52,57)/t27-,32+,38-,42+/m0/s1",MHRNVFQJUUXQIG-VIFUUBRESA-N,497,28,1391,CO,[R1]OC[R2],32.042,32.02621475,-0.46,2,0,1,1,0,20.23,CH4O,"InChI=1S/CH4O/c1-2/h2H,1H3",OKKJLVBELUTLKV-UHFFFAOYSA-N,P98170,XIAP,,CN[C@@H](C)C(=O)N[C@H](C(=O)N1CC2=CC(O)=CC=C2C[C@H]1C(=O)N[C@@H]1CCCC2=CC=CC=C21)C(C)(C)C,,,,,,,,,10.1016/j.ejmech.2022.114910,520.674,520.3049558,3.66,38,4,5,4,6,110.77,C30H40N4O4,"InChI=1S/C30H40N4O4/c1-18(31-5)27(36)33-26(30(2,3)4)29(38)34-17-21-15-22(35)14-13-20(21)16-25(34)28(37)32-24-12-8-10-19-9-6-7-11-23(19)24/h6-7,9,11,13-15,18,24-26,31,35H,8,10,12,16-17H2,1-5H3,(H,32,37)(H,33,36)/t18-,24+,25-,26+/m0/s1",HIBPHKLMOULUBF-YSQWDHOWSA-N,,170249997,,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,3,6.120178689,5.085594329,758.2655,8211.1819
3070,13,94,13,94,P51617,IRAK1,VHL,,,COC1=CC(N2CC[C@@H](OCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)C[C@@H]2C)=CC=C1NC(=O)C1=CC=CC(C2=CC=N[NH]2)=N1,Degradation of IRAK1 in HEK293T cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.1c00244,892.096,891.4101662,5.46,64,7,12,5,14,204,C47H57N9O7S,"InChI=1S/C47H57N9O7S/c1-27-21-34(18-20-55(27)32-15-16-37(40(22-32)62-7)52-44(59)38-10-8-9-35(51-38)36-17-19-49-54-36)63-25-41(58)53-43(47(4,5)6)46(61)56-24-33(57)23-39(56)45(60)50-28(2)30-11-13-31(14-12-30)42-29(3)48-26-64-42/h8-17,19,22,26-28,33-34,39,43,57H,18,20-21,23-25H2,1-7H3,(H,49,54)(H,50,60)(H,52,59)(H,53,58)/t27-,28-,33+,34+,39-,43+/m0/s1",ITIRIVDRAPMHII-LHJQLXEHSA-N,499,28,1391,CO,[R1]OC[R2],32.042,32.02621475,-0.46,2,0,1,1,0,20.23,CH4O,"InChI=1S/CH4O/c1-2/h2H,1H3",OKKJLVBELUTLKV-UHFFFAOYSA-N,Q06187,BTK,,CN1CCN([C@@H]2CCCN(C3=CN=C(C(N)=O)C(NC4=CC=C(C5CCNCC5)C=C4)=N3)C2)C1=O,,,,,,,,,10.1182/blood.2022016934,478.601,478.2804723,1.82,35,5,7,3,6,119.72,C25H34N8O2,"InChI=1S/C25H34N8O2/c1-31-13-14-33(25(31)35)20-3-2-12-32(16-20)21-15-28-22(23(26)34)24(30-21)29-19-6-4-17(5-7-19)18-8-10-27-11-9-18/h4-7,15,18,20,27H,2-3,8-14,16H2,1H3,(H2,26,34)(H,29,30)/t20-/m1/s1",JCGXVYWABUYORV-HXUWFJFHSA-N,309787,146559796,,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.94,13,5.883701308,5.251725949,1307.0695,5601.1093
3071,21,96,21,96,P51617,IRAK1,VHL,,,COC1=CC(N2CC[C@@H](OCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)[C@H](C)C2)=CC=C1NC(=O)C1=CC=CC(C2=CC=N[NH]2)=N1,Degradation of IRAK1 in HEK293T cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.1c00244,892.096,891.4101662,5.46,64,7,12,5,14,204,C47H57N9O7S,"InChI=1S/C47H57N9O7S/c1-27-23-55(32-15-16-36(40(21-32)62-7)52-44(59)37-10-8-9-34(51-37)35-17-19-49-54-35)20-18-39(27)63-25-41(58)53-43(47(4,5)6)46(61)56-24-33(57)22-38(56)45(60)50-28(2)30-11-13-31(14-12-30)42-29(3)48-26-64-42/h8-17,19,21,26-28,33,38-39,43,57H,18,20,22-25H2,1-7H3,(H,49,54)(H,50,60)(H,52,59)(H,53,58)/t27-,28+,33-,38+,39-,43-/m1/s1",GHFASOYKYKNVGE-YLSOEQEJSA-N,500,28,1391,CO,[R1]OC[R2],32.042,32.02621475,-0.46,2,0,1,1,0,20.23,CH4O,"InChI=1S/CH4O/c1-2/h2H,1H3",OKKJLVBELUTLKV-UHFFFAOYSA-N,Q00987,MDM2,Navtemadlin,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](C2=CC=CC(Cl)=C2)[C@H]1C1=CC=C(Cl)C=C1,,,,,,,,,10.1021/jm401753e,568.563,567.1612996,5.78,37,3,4,1,9,91.75,C28H35Cl2NO5S,"InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1",DRLCSJFKKILATL-YWCVFVGNSA-N,50448947,58573469,CHEMBL3125702,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,21,6.088115886,5.300791354,816.3645,5002.7482
3068,9,90,9,90,P51617,IRAK1,VHL,,,COC1=CC(N2CCN(C(=O)OCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=CC=C1NC(=O)C1=CC=CC(C2=CC=N[NH]2)=N1,Degradation of IRAK1 in HEK293T cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.1c00244,907.067,906.3846797,4.3,65,7,13,5,13,224.31,C46H54N10O8S,"InChI=1S/C46H54N10O8S/c1-27(29-10-12-30(13-11-29)40-28(2)47-26-65-40)49-43(60)37-23-32(57)24-56(37)44(61)41(46(3,4)5)52-39(58)25-64-45(62)55-20-18-54(19-21-55)31-14-15-35(38(22-31)63-6)51-42(59)36-9-7-8-33(50-36)34-16-17-48-53-34/h7-17,22,26-27,32,37,41,57H,18-21,23-25H2,1-6H3,(H,48,53)(H,49,60)(H,51,59)(H,52,58)/t27-,32+,37-,41+/m0/s1",MWQAAQOVPMFJQP-KTOUKBDOSA-N,498,28,1405,COC=O,[R1]C(=O)OC[R2],60.052,60.02112937,0.13,4,0,2,0,1,26.3,C2H4O2,"InChI=1S/C2H4O2/c1-4-2-3/h2H,1H3",TZIHFWKZFHZASV-UHFFFAOYSA-N,Q9ULX9,MAFF,Lathyrol,C=C1CC[C@H]2[C@@H](/C=C(\C)C(=O)[C@@]3(O)C[C@H](C)[C@H](O)[C@@H]3[C@H]1O)C2(C)C,,,,,20900/15500,MST/SPR,,,10.1021/acs.jnatprod.8b00600,334.456,334.2144094,2.18,24,3,4,3,0,77.76,C20H30O4,"InChI=1S/C20H30O4/c1-10-6-7-13-14(19(13,4)5)8-11(2)18(23)20(24)9-12(3)17(22)15(20)16(10)21/h8,12-17,21-22,24H,1,6-7,9H2,2-5H3/b11-8+/t12-,13-,14+,15-,16-,17-,20+/m0/s1",SDBITTRHSROXCY-SVSKDHLKSA-N,,15479845,CHEMBL3426445,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9,9,5.945083707,5.068827339,1134.7921,8534.3935
3255,3.7,94,3.7/45,94/85,P61964,WDR5,VHL,7JTP,MS67,CC1=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CNC(=O)C3=CC=C(F)C(C4=CC=C(N5C[C@H](C)N(C)[C@H](C)C5)C(NC(=O)C5=C[NH]C(=O)C=C5C(F)(F)F)=C4)=C3)C(C)(C)C)C=C2)SC=N1,Degradation of WDR5 in MV4;11/MIA PaCa-2 cells after 18 h treatment,,,,,,,63,ITC,,,,,,,,,,,,,,,140,ITC,,,,,,,,,,,,,,,52,Kd between VHL and the complex of protac and WDR5 was tested by ITC,,,,,,,,,,,,,,,15/38/110,Inhibit growth of MV4;11/EOL-1/MOLM13 cells,,,,,,,,,,,10.1126/scitranslmed.abj1578,1030.159,1029.419429,5.52,73,7,11,6,13,209.17,C52H59F4N9O7S,"InChI=1S/C52H59F4N9O7S/c1-27-23-64(24-28(2)63(27)8)41-16-14-33(18-40(41)61-48(70)37-21-57-43(67)20-38(37)52(54,55)56)36-17-34(13-15-39(36)53)47(69)58-22-44(68)62-46(51(5,6)7)50(72)65-25-35(66)19-42(65)49(71)60-29(3)31-9-11-32(12-10-31)45-30(4)59-26-73-45/h9-18,20-21,26-29,35,42,46,66H,19,22-25H2,1-8H3,(H,57,67)(H,58,69)(H,60,71)(H,61,70)(H,62,68)/t27-,28+,29-,35+,42-,46+/m0/s1",HBHSDSLZXDASLT-FLKKWHKHSA-N,535,28,1497,CNC=O,[R1]C(=O)NC[R2],59.068,59.03711378,0.14,4,0,1,1,1,29.1,C2H5NO,"InChI=1S/C2H5NO/c1-3-2-4/h2H,1H3,(H,3,4)",ATHHXGZTWNVVOU-UHFFFAOYSA-N,P15056,BRAF V600E,PLX8394-L,O=C(C1=C(F)C=CC(NS(=O)(=O)N2CC[C@@H](F)C2)=C1F)C1=C[NH]C2=NC=C(C3=CN=C(N4CCNCC4)N=C3)C=C12,,,,,,,,,10.1038/s41591-018-0274-5,586.6,586.1722423,1.98,41,6,8,3,7,136.21,C26H25F3N8O3S,"InChI=1S/C26H25F3N8O3S/c27-17-3-6-37(14-17)41(39,40)35-21-2-1-20(28)22(23(21)29)24(38)19-13-32-25-18(19)9-15(10-31-25)16-11-33-26(34-12-16)36-7-4-30-5-8-36/h1-2,9-13,17,30,35H,3-8,14H2,(H,31,32)/t17-/m1/s1",DHKOCXOHXNSNBX-QGZVFWFLSA-N,,,,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,67.82,0.010218225,1,1,1,1,1,0.010218225,0.94,3.7,6.736079584,5.933565787,183.6202,1165.2905
3319,8.1,97,8.1,97,Q86X55,CARM1,VHL,,,CNCCN1CCC(C2=CC(CN(C)C(=O)C3=CC=CC(OC4=CC=C(OCC(=O)N5CCC(CN6CCC(CN7CCN(CC(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)C8=CC=C(C9=C(C)N=CS9)C=C8)C(C)(C)C)CC7)CC6)CC5)C=C4)=C3)=CC=N2)CC1,Degradation of CARM1 in MCF7 Cells (nM),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00982,1279.708,1278.735129,6.91,92,10,16,4,24,208.59,C71H98N12O8S,"InChI=1S/C71H98N12O8S/c1-49(54-11-13-56(14-12-54)66-50(2)74-48-92-66)75-68(87)63-41-58(84)45-83(63)70(89)67(71(3,4)5)76-64(85)46-81-37-35-80(36-38-81)44-51-20-28-79(29-21-51)43-52-22-32-82(33-23-52)65(86)47-90-59-15-17-60(18-16-59)91-61-10-8-9-57(40-61)69(88)77(7)42-53-19-26-73-62(39-53)55-24-30-78(31-25-55)34-27-72-6/h8-19,26,39-40,48-49,51-52,55,58,63,67,72,84H,20-25,27-38,41-47H2,1-7H3,(H,75,87)(H,76,85)/t49-,58+,63-,67+/m0/s1",UVTQPVBDGGQLTA-YSPOSDDXSA-N,552,28,1533,CN1CCN(CC2CCN(CC3CCN(C(=O)CO)CC3)CC2)CC1,[R1]OCC(=O)N1CCC(CC1)CN2CCC(CC2)CN3CCN(CC3)C[R2],352.523,352.2838264,0.45,25,3,5,1,5,50.26,C19H36N4O2,"InChI=1S/C19H36N4O2/c1-20-10-12-22(13-11-20)15-17-2-6-21(7-3-17)14-18-4-8-23(9-5-18)19(25)16-24/h17-18,24H,2-16H2,1H3",CIJMBBZUHFYLIB-UHFFFAOYSA-N,P27361,ERK1,Ravoxertinib,CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C3=CC=C(Cl)C(F)=C3)C=C2)=N1,,,,,,,,,10.1021/acs.jmedchem.6b00389,440.866,440.1163797,1.98,31,4,8,2,6,97.86,C21H18ClFN6O2,"InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1",RZUOCXOYPYGSKL-GOSISDBHSA-N,120095,71727581,CHEMBL3544964,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,8.1,5.24614323,4.927047157,5673.5746,11829.131
3322,8.8,98,8.8,98,Q86X55,CARM1,VHL,,,CNCCN1CCC(C2=CC(CN(C)C(=O)C3=CC=CC(OC4=CC=C(CCC(=O)N5CCC(CN6CCC(CN7CCN(CC(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)C8=CC=C(C9=C(C)N=CS9)C=C8)C(C)(C)C)CC7)CC6)CC5)C=C4)=C3)=CC=N2)CC1,Degradation of CARM1 in MCF7 Cells (nM),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00982,1277.736,1276.755865,7.1,92,10,15,4,24,199.36,C72H100N12O7S,"InChI=1S/C72H100N12O7S/c1-50(56-14-16-58(17-15-56)67-51(2)75-49-92-67)76-69(88)64-43-60(85)47-84(64)71(90)68(72(3,4)5)77-65(86)48-82-39-37-81(38-40-82)46-53-22-30-80(31-23-53)45-54-24-34-83(35-25-54)66(87)20-13-52-11-18-61(19-12-52)91-62-10-8-9-59(42-62)70(89)78(7)44-55-21-28-74-63(41-55)57-26-32-79(33-27-57)36-29-73-6/h8-12,14-19,21,28,41-42,49-50,53-54,57,60,64,68,73,85H,13,20,22-27,29-40,43-48H2,1-7H3,(H,76,88)(H,77,86)/t50-,60+,64-,68+/m0/s1",WRQKOZXHYYEKER-KLLGSTGQSA-N,552,28,1536,CCC(=O)N1CCC(CN2CCC(CN3CCN(C)CC3)CC2)CC1,[R1]CCC(=O)N1CCC(CC1)CN2CCC(CC2)CN3CCN(CC3)C[R2],350.551,350.3045618,1.57,25,3,4,0,5,30.03,C20H38N4O,"InChI=1S/C20H38N4O/c1-3-20(25)24-10-6-19(7-11-24)16-22-8-4-18(5-9-22)17-23-14-12-21(2)13-15-23/h18-19H,3-17H2,1-2H3",VEDIJJAIHXGZTM-UHFFFAOYSA-N,P27361,ERK1,Ravoxertinib,CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C3=CC=C(Cl)C(F)=C3)C=C2)=N1,,,,,,,,,10.1021/acs.jmedchem.6b00389,440.866,440.1163797,1.98,31,4,8,2,6,97.86,C21H18ClFN6O2,"InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1",RZUOCXOYPYGSKL-GOSISDBHSA-N,120095,71727581,CHEMBL3544964,28VHL,28,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](NC(=O)C1(F)CC1)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,78,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,587.718,587.2577685,2.31,41,4,7,4,9,140.73,C29H38FN5O5S,"InChI=1S/C29H38FN5O5S/c1-16-23(41-15-32-16)18-8-6-17(7-9-18)20(13-22(37)31-5)33-25(38)21-12-19(36)14-35(21)26(39)24(28(2,3)4)34-27(40)29(30)10-11-29/h6-9,15,19-21,24,36H,10-14H2,1-5H3,(H,31,37)(H,33,38)(H,34,40)/t19-,20+,21+,24+/m1/s1",PTPPMFQIIPBSRV-XBJMDHIQSA-N,,153633178,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,8.8,5.311053761,5.123918895,4885.9187,7517.6327
2349,4.97,76,4.97/20.3,76/50,P33981,TTK,CRBN,,,CCC(=O)N[C@H]1CC[C@@H](N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)CC1,Degradation of TTK in COLO-205/HCT-116 cells after 6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c01768,884.051,883.4380952,4.39,65,8,12,3,13,188.17,C49H57N9O7,"InChI=1S/C49H57N9O7/c1-4-42(59)51-33-15-17-34(18-16-33)58-45(62)27-31(2)37-29-50-49(54-46(37)58)52-39-20-19-35(28-41(39)65-3)55-23-25-56(26-24-55)44(61)14-9-7-5-6-8-11-32-12-10-13-36-38(32)30-57(48(36)64)40-21-22-43(60)53-47(40)63/h10,12-13,19-20,27-29,33-34,40H,4-7,9,14-18,21-26,30H2,1-3H3,(H,51,59)(H,50,52,54)(H,53,60,63)/t33-,34+,40?",QEDFXQXPBXHVGU-RMDMJGLRSA-N,368,6,1134,C#CCCCCCC=O,[R1]C(=O)CCCCCC#C[R2],124.183,124.088815,1.68,9,0,1,0,5,17.07,C8H12O,"InChI=1S/C8H12O/c1-2-3-4-5-6-7-8-9/h1,8H,3-7H2",OEPKOGKYPMWNSI-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,600.757,600.3522999,3.9,43,3,7,4,14,151.93,C32H48N4O7,"InChI=1S/C32H48N4O7/c1-21(43-32(2,3)4)27(36-31(41)42-20-23-13-9-6-10-14-23)30(40)35-26(17-22-11-7-5-8-12-22)29(39)34-25(19-37)18-24-15-16-33-28(24)38/h6,9-10,13-14,19,21-22,24-27H,5,7-8,11-12,15-18,20H2,1-4H3,(H,33,38)(H,34,39)(H,35,40)(H,36,41)/t21-,24+,25+,26+,27+/m1/s1",YFUZVOLEKQFVCQ-FFXRMZKPSA-N,50592586,11844348,CHEMBL4852855,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.76,4.97,7.782703374,6.663056513,16.4929,217.2418
2350,7.05,84,7.05/58.1,84/53,P33981,TTK,CRBN,,,CCC(=O)N[C@H]1CC[C@@H](N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)CC1,Degradation of TTK in COLO-205/HCT-116 cells after 6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c01768,912.105,911.4693953,5.47,67,8,12,3,15,188.17,C51H61N9O7,"InChI=1S/C51H61N9O7/c1-4-44(61)53-35-17-19-36(20-18-35)60-47(64)29-33(2)39-31-52-51(56-48(39)60)54-41-22-21-37(30-43(41)67-3)57-25-27-58(28-26-57)46(63)16-11-9-7-5-6-8-10-13-34-14-12-15-38-40(34)32-59(50(38)66)42-23-24-45(62)55-49(42)65/h12,14-15,21-22,29-31,35-36,42H,4-9,11,16-20,23-28,32H2,1-3H3,(H,53,61)(H,52,54,56)(H,55,62,65)/t35-,36+,42?",OEMAZTSGRNBCPF-HUPKRMINSA-N,368,6,1135,C#CCCCCCCCC=O,[R1]C(=O)CCCCCCCC#C[R2],152.237,152.1201151,2.76,11,0,1,0,7,17.07,C10H16O,"InChI=1S/C10H16O/c1-2-3-4-5-6-7-8-9-10-11/h1,10H,3-9H2",NLWWQVPUYZRMKI-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,600.757,600.3522999,3.9,43,3,7,4,14,151.93,C32H48N4O7,"InChI=1S/C32H48N4O7/c1-21(43-32(2,3)4)27(36-31(41)42-20-23-13-9-6-10-14-23)30(40)35-26(17-22-11-7-5-8-12-22)29(39)34-25(19-37)18-24-15-16-33-28(24)38/h6,9-10,13-14,19,21-22,24-27H,5,7-8,11-12,15-18,20H2,1-4H3,(H,33,38)(H,34,39)(H,35,40)(H,36,41)/t21-,24+,25+,26+,27+/m1/s1",YFUZVOLEKQFVCQ-FFXRMZKPSA-N,50592586,11844348,CHEMBL4852855,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.84,7.05,7.350926527,6.564875475,44.5732,272.3482
2351,2.25,87,2.25/49.6,87/66,P33981,TTK,CRBN,,,CCC(=O)N[C@H]1CC[C@@H](N2C(=O)C=C(C)C3=CN=C(NC4=CC=C(N5CCN(C(=O)CCCCCCCCCC#CC6=CC=CC7=C6CN(C6CCC(=O)NC6=O)C7=O)CC5)C=C4OC)N=C32)CC1,Degradation of TTK in COLO-205/HCT-116 cells after 6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c01768,940.159,939.5006954,6.56,69,8,12,3,17,188.17,C53H65N9O7,"InChI=1S/C53H65N9O7/c1-4-46(63)55-37-19-21-38(22-20-37)62-49(66)31-35(2)41-33-54-53(58-50(41)62)56-43-24-23-39(32-45(43)69-3)59-27-29-60(30-28-59)48(65)18-13-11-9-7-5-6-8-10-12-15-36-16-14-17-40-42(36)34-61(52(40)68)44-25-26-47(64)57-51(44)67/h14,16-17,23-24,31-33,37-38,44H,4-11,13,18-22,25-30,34H2,1-3H3,(H,55,63)(H,54,56,58)(H,57,64,67)/t37-,38+,44?",LUPSPQQYVRGZLI-FPDSPUJPSA-N,368,6,1136,C#CCCCCCCCCCC=O,[R1]C(=O)CCCCCCCCCC#C[R2],180.291,180.1514153,3.84,13,0,1,0,9,17.07,C12H20O,"InChI=1S/C12H20O/c1-2-3-4-5-6-7-8-9-10-11-12-13/h1,12H,3-11H2",TUZQWBWNQPYHKL-UHFFFAOYSA-N,P0DTD1,Mpro,MPI8,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,105,Inhibition of Mpro,,,,,102.6,Ki of SC2MPro,10.1002/cmdc.202000924,600.757,600.3522999,3.9,43,3,7,4,14,151.93,C32H48N4O7,"InChI=1S/C32H48N4O7/c1-21(43-32(2,3)4)27(36-31(41)42-20-23-13-9-6-10-14-23)30(40)35-26(17-22-11-7-5-8-12-22)29(39)34-25(19-37)18-24-15-16-33-28(24)38/h6,9-10,13-14,19,21-22,24-27H,5,7-8,11-12,15-18,20H2,1-4H3,(H,33,38)(H,34,39)(H,35,40)(H,36,41)/t21-,24+,25+,26+,27+/m1/s1",YFUZVOLEKQFVCQ-FFXRMZKPSA-N,50592586,11844348,CHEMBL4852855,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.87,2.25,7.220164266,6.411996755,60.2332,387.2605
2222,3.9,70.3,3.9,70.3,Q9UM73,ALK,CRBN,,SIAIS001,CCC1=CC2=C(C=C1N1CCC(N3CCN(CCCC#CC4=CC=CC5=C4CN(C4CCC(=O)NC4=O)C5=O)CC3)CC1)C(C)(C)C1=C(C2=O)C2=CC=C(C#N)C=C2[NH]1,Degradation of ALK in SR cells,,,3.3,Inhibition of ALK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9,Inhibit proliferation of SR cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113335,789.981,789.4002531,6.4,59,9,8,2,7,132.85,C48H51N7O4,"InChI=1S/C48H51N7O4/c1-4-31-26-36-38(48(2,3)45-43(44(36)57)35-13-12-30(28-49)25-39(35)50-45)27-41(31)54-19-16-33(17-20-54)53-23-21-52(22-24-53)18-7-5-6-9-32-10-8-11-34-37(32)29-55(47(34)59)40-14-15-42(56)51-46(40)58/h8,10-13,25-27,33,40,50H,4-5,7,14-24,29H2,1-3H3,(H,51,56,58)",OGAOHACYLUBWJQ-UHFFFAOYSA-N,351,6,28,C#CCCC,[R1]CCCC#C[R2],68.119,68.06260026,1.88,5,0,0,0,1,0,C5H8,"InChI=1S/C5H8/c1-3-5-4-2/h1H,4-5H2,2H3",IBXNCJKFFQIKKY-UHFFFAOYSA-N,P15056,BRAF V600E,PLX7904,CCN(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C2=C[NH]C3=NC=C(C4=CN=C(C5CC5)N=C4)C=C23)=C1F,16,IC50 was assessed by AlphaScreen assay,,,,,,,10.1021/acs.jmedchem.7b01306,512.542,512.144216,2.58,36,5,6,2,8,120.94,C24H22F2N6O3S,"InChI=1S/C24H22F2N6O3S/c1-3-32(2)36(34,35)31-19-7-6-18(25)20(21(19)26)22(33)17-12-30-24-16(17)8-14(9-29-24)15-10-27-23(28-11-15)13-4-5-13/h6-13,31H,3-5H2,1-2H3,(H,29,30)",DKNZQPXIIHLUHU-UHFFFAOYSA-N,317744,90116945,CHEMBL4206836,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.703,3.9,7.298388486,6.371706232,50.305,424.9069
2222,200,99,200,,Q9UM73,ALK G1202R,CRBN,,SIAIS001,CCC1=CC2=C(C=C1N1CCC(N3CCN(CCCC#CC4=CC=CC5=C4CN(C4CCC(=O)NC4=O)C5=O)CC3)CC1)C(C)(C)C1=C(C2=O)C2=CC=C(C#N)C=C2[NH]1,Degradation of ALK G1202R in 293T cells,,,94.6,Inhibition of ALK G1202R,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9,Inhibit proliferation of SR cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2021.113335,789.981,789.4002531,6.4,59,9,8,2,7,132.85,C48H51N7O4,"InChI=1S/C48H51N7O4/c1-4-31-26-36-38(48(2,3)45-43(44(36)57)35-13-12-30(28-49)25-39(35)50-45)27-41(31)54-19-16-33(17-20-54)53-23-21-52(22-24-53)18-7-5-6-9-32-10-8-11-34-37(32)29-55(47(34)59)40-14-15-42(56)51-46(40)58/h8,10-13,25-27,33,40,50H,4-5,7,14-24,29H2,1-3H3,(H,51,56,58)",OGAOHACYLUBWJQ-UHFFFAOYSA-N,351,6,28,C#CCCC,[R1]CCCC#C[R2],68.119,68.06260026,1.88,5,0,0,0,1,0,C5H8,"InChI=1S/C5H8/c1-3-5-4-2/h1H,4-5H2,2H3",IBXNCJKFFQIKKY-UHFFFAOYSA-N,P15056,BRAF V600E,PLX7904,CCN(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C2=C[NH]C3=NC=C(C4=CN=C(C5CC5)N=C4)C=C23)=C1F,16,IC50 was assessed by AlphaScreen assay,,,,,,,10.1021/acs.jmedchem.7b01306,512.542,512.144216,2.58,36,5,6,2,8,120.94,C24H22F2N6O3S,"InChI=1S/C24H22F2N6O3S/c1-3-32(2)36(34,35)31-19-7-6-18(25)20(21(19)26)22(33)17-12-30-24-16(17)8-14(9-29-24)15-10-27-23(28-11-15)13-4-5-13/h6-13,31H,3-5H2,1-2H3,(H,29,30)",DKNZQPXIIHLUHU-UHFFFAOYSA-N,317744,90116945,CHEMBL4206836,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,200,7.298388486,6.371706232,50.305,424.9069
556,23,90,23,90,Q00987,MDM2,CRBN,,,CCOC1=CC(C(C)(C)C)=CC=C1C1=N[C@@H](C2=CC=C(Cl)C=C2)[C@@H](C2=CC=C(Cl)C=C2)N1C(=O)N1CCN(CC#CC2=CC=CC3=C2CN(C2CCC(=O)NC2=O)C3=O)CC1,Degradation of MDM2 in RS4; 11 cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.2,Inhibit proliferation of RS4; 11 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2019.05.046,859.855,858.306324,7.3,61,8,7,1,7,114.86,C48H48Cl2N6O5,"InChI=1S/C48H48Cl2N6O5/c1-5-61-40-28-33(48(2,3)4)15-20-37(40)44-52-42(31-11-16-34(49)17-12-31)43(32-13-18-35(50)19-14-32)56(44)47(60)54-26-24-53(25-27-54)23-7-9-30-8-6-10-36-38(30)29-55(46(36)59)39-21-22-41(57)51-45(39)58/h6,8,10-20,28,39,42-43H,5,21-27,29H2,1-4H3,(H,51,57,58)/t39?,42-,43+/m0/s1",SXPSRFOBNYZXKH-UZLVNVLGSA-N,105,6,297,C#CC,[R1]CC#C[R2],40.065,40.03130013,0.91,3,0,0,0,0,0,C3H4,"InChI=1S/C3H4/c1-3-2/h1H,2H3",MWWATHDPGQKSAR-UHFFFAOYSA-N,P01116,KRAS,,C=CC(=O)N1CCN(C2=NC=NC3=C(F)C(C4=CC(O)=CC5=CC=CC=C45)=C(Cl)C=C23)CC1,,,,,,,,,,462.912,462.1258818,5.11,33,5,5,1,3,69.56,C25H20ClFN4O2,"InChI=1S/C25H20ClFN4O2/c1-2-21(33)30-7-9-31(10-8-30)25-19-13-20(26)22(23(27)24(19)28-14-29-25)18-12-16(32)11-15-5-3-4-6-17(15)18/h2-6,11-14,32H,1,7-10H2",JIPIHCUZVBBERR-UHFFFAOYSA-N,,118019082,,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9,23,7.254182973,5.729082807,55.6951,1866.0239
2065,50,74,50,74,P15056,BRAF V600E,CRBN,,Len(C)PEG4-BI,CCCS(=O)(=O)NC1=CC=C(F)C(N2C=C(C3=CN=CN=C3)C3=NC(N(C)C4CCN(C(=O)CCOCCOCCOCCOCC#CC5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)=CC=C32)=C1F,Degradation of BRAF V600E in A375 cells after 24 h treatment,,,90,Inhibition of BRAF V600E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1038/s41589-020-0609-7,1026.133,1025.391716,2.64,73,8,15,2,22,216.72,C51H57F2N9O10S,"InChI=1S/C51H57F2N9O10S/c1-3-28-73(67,68)58-41-10-9-40(52)49(47(41)53)61-32-39(35-29-54-33-55-30-35)48-42(61)11-13-44(56-48)59(2)36-15-18-60(19-16-36)46(64)17-21-70-23-25-72-27-26-71-24-22-69-20-5-7-34-6-4-8-37-38(34)31-62(51(37)66)43-12-14-45(63)57-50(43)65/h4,6,8-11,13,29-30,32-33,36,43,58H,3,12,14-28,31H2,1-2H3,(H,57,63,65)",OURGGRRMESLKOS-UHFFFAOYSA-N,172,6,1007,C#CCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCC#C[R2],244.287,244.1310737,-0.82,17,0,5,0,13,53.99,C12H20O5,"InChI=1S/C12H20O5/c1-2-5-14-7-9-16-11-12-17-10-8-15-6-3-4-13/h1,4H,3,5-12H2",NEBHYQIAMLUJDI-UHFFFAOYSA-N,Q9NWZ3,IRAK4,,O=C(NC1=NC2=CC=C(CO)C=C2N1[C@H]1CC[C@@H](CO)CC1)C1=CC=CC(C(F)(F)F)=C1,,,,,,,0.48,Ki was tested by the ELISA assay,10.1016/j.bmcl.2015.10.060,447.457,447.1769763,3.35,32,4,5,3,5,87.38,C23H24F3N3O3,"InChI=1S/C23H24F3N3O3/c24-23(25,26)17-3-1-2-16(11-17)21(32)28-22-27-19-9-6-15(13-31)10-20(19)29(22)18-7-4-14(12-30)5-8-18/h1-3,6,9-11,14,18,30-31H,4-5,7-8,12-13H2,(H,27,28,32)/t14-,18+",FZAQHOQVGPMYDL-UJKQEGAGSA-N,50499205,10114595,CHEMBL3734814,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.74,50,6.578316207,6.352380868,264.0486,444.2415
3150,5,97,5,97,O60885,BRD4,CRBN,,CFT-1297,CC1=NN=C2N1C1=CC=C(C3=CN(CCCCCCCN4CCC(C5=CC=CC6=C5CN(C5CCC(=O)NC5=O)C6=O)CC4)N=C3)C=C1C(C1=CC=C(Cl)C=C1)=NC21CC1,Degradation of BRD4 in HEK293T cells after 3 h treatment,,,,,,,58,Kd of BRD4 BD1 was assessed by FP,,,,,,,,,,,,,,,2100,FP,,,,,,,,,,,,,,,4,Kd was tested by AlphaLISA assay,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acschembio.1c00376,824.43,823.3725141,5.95,60,10,10,1,12,130.61,C47H50ClN9O3,"InChI=1S/C47H50ClN9O3/c1-30-52-53-46-47(20-21-47)51-43(32-10-13-35(48)14-11-32)38-26-33(12-15-40(38)57(30)46)34-27-49-55(28-34)23-6-4-2-3-5-22-54-24-18-31(19-25-54)36-8-7-9-37-39(36)29-56(45(37)60)41-16-17-42(58)50-44(41)59/h7-15,26-28,31,41H,2-6,16-25,29H2,1H3,(H,50,58,59)",SDKKICDYRHTFNX-UHFFFAOYSA-N,222,6,1454,CCCCCCCN1CCCCC1,[R1]CCCCCCCN1CCC(CC1)[R2],183.339,183.1986998,3.98,13,1,1,0,6,3.24,C12H25N,"InChI=1S/C12H25N/c1-2-3-4-5-7-10-13-11-8-6-9-12-13/h2-12H2,1H3",PBCPROXTVFVOBC-UHFFFAOYSA-N,P00519,ABL1,GNF-7,CC1=CC=C(NC2=NC=C3CN(C4=CC(NC(=O)C5=CC=CC(C(F)(F)F)=C5)=CC=C4C)C(=O)N(C)C3=N2)C=N1,133,Inhibition of ABL1,,,,,,,10.1021/jm901808w,547.541,547.1943577,4.33,40,5,6,2,5,103.35,C28H24F3N7O2,"InChI=1S/C28H24F3N7O2/c1-16-7-9-21(34-25(39)18-5-4-6-20(11-18)28(29,30)31)12-23(16)38-15-19-13-33-26(36-24(19)37(3)27(38)40)35-22-10-8-17(2)32-14-22/h4-14H,15H2,1-3H3,(H,34,39)(H,33,35,36)",SZNYUUZOQHNEKB-UHFFFAOYSA-N,50323777,11478363,CHEMBL1214141,6CRBN,6,Q96SW2,CRBN,TD-106,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)N=N2,,,,,,,,,10.1016/j.ejmech.2019.01.023,273.252,273.0861892,0.66,20,3,7,2,1,119.97,C12H11N5O3,"InChI=1S/C12H11N5O3/c13-6-2-1-3-7-10(6)12(20)17(16-15-7)8-4-5-9(18)14-11(8)19/h1-3,8H,4-5,13H2,(H,14,18,19)",DXZBHVQOULDEPN-UHFFFAOYSA-N,,137628679,,32.66,0.021218616,1,1,1,1,1,0.021218616,0.97,5,6.482517154,6.473540979,329.2174,336.0927
284,11.6,99,11.6,>99,Q06187,BTK,CRBN,,MT-809,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCCCOCCCCOCC(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of BTK in NAMALWA cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.biochem.8b00391,843.942,843.3704095,3.76,62,8,14,3,18,213.2,C45H49N9O8,"InChI=1S/C45H49N9O8/c46-41-39-40(29-10-13-33(14-11-29)62-32-8-2-1-3-9-32)51-54(42(39)48-28-47-41)31-18-21-52(22-19-31)20-4-5-23-60-24-6-7-25-61-27-38(56)49-30-12-15-34-35(26-30)45(59)53(44(34)58)36-16-17-37(55)50-43(36)57/h1-3,8-15,26,28,31,36H,4-7,16-25,27H2,(H,49,56)(H2,46,47,48)(H,50,55,57)",VPGHQPSPNUQPLG-UHFFFAOYSA-N,51,76,153,CCCCOCCCCOCC=O,[R1]CCCCOCCCCOCC(=O)[R2],188.267,188.1412445,1.43,13,0,3,0,10,35.53,C10H20O3,"InChI=1S/C10H20O3/c1-2-3-7-12-8-4-5-9-13-10-6-11/h6H,2-5,7-10H2,1H3",GAIQORAOHTYFOZ-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,11.6,6.449208498,6.6952355,355.4606,201.7272
283,6.2,99,6.2,99,Q06187,BTK,CRBN,,MT-802,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCOCCOCC(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of BTK in NAMALWA cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.bmcl.2019.126877,787.834,787.3078093,2.33,58,8,14,3,14,213.2,C41H41N9O8,"InChI=1S/C41H41N9O8/c42-37-35-36(25-6-9-29(10-7-25)58-28-4-2-1-3-5-28)47-50(38(35)44-24-43-37)27-14-16-48(17-15-27)18-19-56-20-21-57-23-34(52)45-26-8-11-30-31(22-26)41(55)49(40(30)54)32-12-13-33(51)46-39(32)53/h1-11,22,24,27,32H,12-21,23H2,(H,45,52)(H2,42,43,44)(H,46,51,53)",AJTLGUJXIKEZCQ-UHFFFAOYSA-N,51,76,5,CCOCCOCC=O,[R1]CCOCCOCC(=O)[R2],132.159,132.0786442,-0.17,9,0,3,0,6,35.53,C6H12O3,"InChI=1S/C6H12O3/c1-2-8-5-6-9-4-3-7/h3H,2,4-6H2,1H3",VAKGZFIDFWQAJM-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,6.2,6.80549281,6.57320776,156.4974,267.1728
283,9.1,99,9.1/14.6,>99/(n/a),Q06187,BTK,CRBN,,MT-802,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCOCCOCC(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of BTK in NAMALWA/XLA cells after 24 h treatment,,,46.9,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.biochem.8b00391,787.834,787.3078093,2.33,58,8,14,3,14,213.2,C41H41N9O8,"InChI=1S/C41H41N9O8/c42-37-35-36(25-6-9-29(10-7-25)58-28-4-2-1-3-5-28)47-50(38(35)44-24-43-37)27-14-16-48(17-15-27)18-19-56-20-21-57-23-34(52)45-26-8-11-30-31(22-26)41(55)49(40(30)54)32-12-13-33(51)46-39(32)53/h1-11,22,24,27,32H,12-21,23H2,(H,45,52)(H2,42,43,44)(H,46,51,53)",AJTLGUJXIKEZCQ-UHFFFAOYSA-N,51,76,5,CCOCCOCC=O,[R1]CCOCCOCC(=O)[R2],132.159,132.0786442,-0.17,9,0,3,0,6,35.53,C6H12O3,"InChI=1S/C6H12O3/c1-2-8-5-6-9-4-3-7/h3H,2,4-6H2,1H3",VAKGZFIDFWQAJM-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,9.1,6.80549281,6.57320776,156.4974,267.1728
283,14.9,99,14.9,>99,Q06187,BTK C481S,CRBN,,MT-802,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCOCCOCC(=O)NC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of C481S BTK in XLA cells after 24 h treatment,,,20.9,Inhibition of C481S BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.biochem.8b00391,787.834,787.3078093,2.33,58,8,14,3,14,213.2,C41H41N9O8,"InChI=1S/C41H41N9O8/c42-37-35-36(25-6-9-29(10-7-25)58-28-4-2-1-3-5-28)47-50(38(35)44-24-43-37)27-14-16-48(17-15-27)18-19-56-20-21-57-23-34(52)45-26-8-11-30-31(22-26)41(55)49(40(30)54)32-12-13-33(51)46-39(32)53/h1-11,22,24,27,32H,12-21,23H2,(H,45,52)(H2,42,43,44)(H,46,51,53)",AJTLGUJXIKEZCQ-UHFFFAOYSA-N,51,76,5,CCOCCOCC=O,[R1]CCOCCOCC(=O)[R2],132.159,132.0786442,-0.17,9,0,3,0,6,35.53,C6H12O3,"InChI=1S/C6H12O3/c1-2-8-5-6-9-4-3-7/h3H,2,4-6H2,1H3",VAKGZFIDFWQAJM-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,14.9,6.80549281,6.57320776,156.4974,267.1728
2497,0.2,95,0.2,95,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,711.219,710.2619606,5.49,51,6,9,4,13,169.73,C38H39ClN6O6,"InChI=1S/C38H39ClN6O6/c39-32-21-29(12-6-24(32)22-40)51-28-13-9-26(10-14-28)43-35(47)23-4-7-25(8-5-23)41-18-2-1-3-19-42-27-11-15-30-31(20-27)38(50)45(37(30)49)33-16-17-34(46)44-36(33)48/h4-8,11-12,15,20-21,26,28,33,41-42H,1-3,9-10,13-14,16-19H2,(H,43,47)(H,44,46,48)/t26-,28-,33?",FZVBQSWNRMPEHR-NBAFNCFLSA-N,387,76,88,CCCCCN,[R1]NCCCCC[R2],87.166,87.10479942,1.08,6,0,1,1,3,26.02,C5H13N,"InChI=1S/C5H13N/c1-2-3-4-5-6/h2-6H2,1H3",DPBLXKKOBLCELK-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,0.2,7.080927543,7.354097017,82.9989,44.249
2500,1.5,97,1.5,97,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCCCCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,753.3,752.3089108,6.93,54,6,9,4,16,169.73,C41H45ClN6O6,"InChI=1S/C41H45ClN6O6/c42-35-24-32(15-9-27(35)25-43)54-31-16-12-29(13-17-31)46-38(50)26-7-10-28(11-8-26)44-21-5-3-1-2-4-6-22-45-30-14-18-33-34(23-30)41(53)48(40(33)52)36-19-20-37(49)47-39(36)51/h7-11,14-15,18,23-24,29,31,36,44-45H,1-6,12-13,16-17,19-22H2,(H,46,50)(H,47,49,51)/t29-,31-,36?",LIAPRZHHMHGLCS-NSGDDVBOSA-N,387,76,115,CCCCCCCCN,[R1]NCCCCCCCC[R2],129.247,129.1517496,2.7,9,0,1,1,6,26.02,C8H19N,"InChI=1S/C8H19N/c1-2-3-4-5-6-7-8-9/h2-9H2,1H3",IOQPZZOEVPZRBK-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,1.5,6.523321015,7.686585961,299.6946,20.5785
2498,0.6,99,0.6,99,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,725.246,724.2776107,5.84,52,6,9,4,14,169.73,C39H41ClN6O6,"InChI=1S/C39H41ClN6O6/c40-33-22-30(13-7-25(33)23-41)52-29-14-10-27(11-15-29)44-36(48)24-5-8-26(9-6-24)42-19-3-1-2-4-20-43-28-12-16-31-32(21-28)39(51)46(38(31)50)34-17-18-35(47)45-37(34)49/h5-9,12-13,16,21-22,27,29,34,42-43H,1-4,10-11,14-15,17-20H2,(H,44,48)(H,45,47,49)/t27-,29-,34?",SLYLTYLJUFVQPH-BKPPXGSPSA-N,387,76,173,CCCCCCN,[R1]NCCCCCC[R2],101.193,101.1204495,1.62,7,0,1,1,4,26.02,C6H15N,"InChI=1S/C6H15N/c1-2-3-4-5-6-7/h2-7H2,1H3",BMVXCPBXGZKUPN-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.6,6.721404283,7.512849731,189.9309,30.7008
2495,1,85,1,85,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,683.165,682.2306605,4.77,49,6,9,4,11,169.73,C36H35ClN6O6,"InChI=1S/C36H35ClN6O6/c37-30-19-27(10-4-22(30)20-38)49-26-11-7-24(8-12-26)41-33(45)21-2-5-23(6-3-21)39-16-1-17-40-25-9-13-28-29(18-25)36(48)43(35(28)47)31-14-15-32(44)42-34(31)46/h2-6,9-10,13,18-19,24,26,31,39-40H,1,7-8,11-12,14-17H2,(H,41,45)(H,42,44,46)/t24-,26-,31?",XLWFMSWFAKUJON-QYYYJOFJSA-N,387,76,196,CCCN,[R1]NCCC[R2],59.112,59.07349929,0.18,4,0,1,1,1,26.02,C3H9N,"InChI=1S/C3H9N/c1-2-3-4/h2-4H2,1H3",WGYKZJWCGVVSQN-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,1,6.988893624,7.833624794,102.5903,14.6681
2496,1.1,89,1.1,89,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,697.192,696.2463106,5.13,50,6,9,4,12,169.73,C37H37ClN6O6,"InChI=1S/C37H37ClN6O6/c38-31-20-28(11-5-23(31)21-39)50-27-12-8-25(9-13-27)42-34(46)22-3-6-24(7-4-22)40-17-1-2-18-41-26-10-14-29-30(19-26)37(49)44(36(29)48)32-15-16-33(45)43-35(32)47/h3-7,10-11,14,19-20,25,27,32,40-41H,1-2,8-9,12-13,15-18H2,(H,42,46)(H,43,45,47)/t25-,27-,32?",SEKBVYVWYRALIG-COJZMJFXSA-N,387,76,174,CCCCN,[R1]NCCCC[R2],73.139,73.08914935,0.54,5,0,1,1,2,26.02,C4H11N,"InChI=1S/C4H11N/c1-2-3-4-5/h2-5H2,1H3",HQABUPZFAYXKJW-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.89,1.1,7.129775866,7.790076867,74.1693,16.2152
2499,0.7,99,0.7,99,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCCCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,739.273,738.2932608,6.38,53,6,9,4,15,169.73,C40H43ClN6O6,"InChI=1S/C40H43ClN6O6/c41-34-23-31(14-8-26(34)24-42)53-30-15-11-28(12-16-30)45-37(49)25-6-9-27(10-7-25)43-20-4-2-1-3-5-21-44-29-13-17-32-33(22-29)40(52)47(39(32)51)35-18-19-36(48)46-38(35)50/h6-10,13-14,17,22-23,28,30,35,43-44H,1-5,11-12,15-16,18-21H2,(H,45,49)(H,46,48,50)/t28-,30-,35?",KLUHWCISGKYNHH-KGNGEQPNSA-N,387,76,657,CCCCCCCN,[R1]NCCCCCCC[R2],115.22,115.1360995,2.16,8,0,1,1,5,26.02,C7H17N,"InChI=1S/C7H17N/c1-2-3-4-5-6-7-8/h2-8H2,1H3",WJYIASZWHGOTOU-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.7,6.751158539,7.610788188,177.3542,24.5026
2501,3.2,96,3.2,96,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(NCCCCCCCCCNC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,767.327,766.3245609,7.47,55,6,9,4,17,169.73,C42H47ClN6O6,"InChI=1S/C42H47ClN6O6/c43-36-25-33(16-10-28(36)26-44)55-32-17-13-30(14-18-32)47-39(51)27-8-11-29(12-9-27)45-22-6-4-2-1-3-5-7-23-46-31-15-19-34-35(24-31)42(54)49(41(34)53)37-20-21-38(50)48-40(37)52/h8-12,15-16,19,24-25,30,32,37,45-46H,1-7,13-14,17-18,20-23H2,(H,47,51)(H,48,50,52)/t30-,32-,37?",VSYZSMLAOKWORE-GUJMKDNBSA-N,387,76,1190,CCCCCCCCCN,[R1]NCCCCCCCCC[R2],143.274,143.1673997,3.24,10,0,1,1,7,26.02,C9H21N,"InChI=1S/C9H21N/c1-2-3-4-5-6-7-8-9-10/h2-10H2,1H3",FJDUDHYHRVPMJZ-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,3.2,6.931176966,7.353669501,117.1718,44.2925
2504,0.8,77,0.8,77,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,738.245,737.2728597,4.36,53,7,10,3,10,164.18,C39H40ClN7O6,"InChI=1S/C39H40ClN7O6/c40-33-22-30(9-3-25(33)23-41)53-29-10-4-26(5-11-29)43-36(49)24-1-7-28(8-2-24)46-19-17-45(18-20-46)16-15-42-27-6-12-31-32(21-27)39(52)47(38(31)51)34-13-14-35(48)44-37(34)50/h1-3,6-9,12,21-22,26,29,34,42H,4-5,10-11,13-20H2,(H,43,49)(H,44,48,50)/t26-,29-,34?",KUCKATJPXILIRH-BPHARUEYSA-N,387,76,1111,CCN1CCNCC1,[R1]N1CCN(CC1)CC[R2],114.192,114.1156984,-0.03,8,1,2,1,1,15.27,C6H14N2,"InChI=1S/C6H14N2/c1-2-8-5-3-7-4-6-8/h7H,2-6H2,1H3",WGCYRFWNGRMRJA-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.77,0.8,6.89840087,6.905802342,126.3569,124.2218
2505,2.7,82,2.7,82,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CCCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,752.272,751.2885097,4.72,54,7,10,3,11,164.18,C40H42ClN7O6,"InChI=1S/C40H42ClN7O6/c41-34-23-31(10-4-26(34)24-42)54-30-11-5-27(6-12-30)44-37(50)25-2-8-29(9-3-25)47-20-18-46(19-21-47)17-1-16-43-28-7-13-32-33(22-28)40(53)48(39(32)52)35-14-15-36(49)45-38(35)51/h2-4,7-10,13,22-23,27,30,35,43H,1,5-6,11-12,14-21H2,(H,44,50)(H,45,49,51)/t27-,30-,35?",IOIPLMHHWKGICH-LFUVDIOQSA-N,387,76,1112,CCCN1CCNCC1,[R1]N1CCN(CC1)CCC[R2],128.219,128.1313485,0.5,9,1,2,1,2,15.27,C7H16N2,"InChI=1S/C7H16N2/c1-2-5-9-6-3-8-4-7-9/h8H,2-7H2,1H3",QLEIDMAURCRVCX-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.82,2.7,6.905967806,6.894703505,124.1744,127.4373
2506,16.2,67,16.2,67,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CCCCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,766.299,765.3041598,5.08,55,7,10,3,12,164.18,C41H44ClN7O6,"InChI=1S/C41H44ClN7O6/c42-35-24-32(11-5-27(35)25-43)55-31-12-6-28(7-13-31)45-38(51)26-3-9-30(10-4-26)48-21-19-47(20-22-48)18-2-1-17-44-29-8-14-33-34(23-29)41(54)49(40(33)53)36-15-16-37(50)46-39(36)52/h3-5,8-11,14,23-24,28,31,36,44H,1-2,6-7,12-13,15-22H2,(H,45,51)(H,46,50,52)/t28-,31-,36?",QFBDIBRAVHTJHW-HDGSNFBOSA-N,387,76,1065,CCCCN1CCNCC1,[R1]N1CCN(CC1)CCCC[R2],142.246,142.1469986,0.86,10,1,2,1,3,15.27,C8H18N2,"InChI=1S/C8H18N2/c1-2-3-6-10-7-4-9-5-8-10/h9H,2-8H2,1H3",YKSVXVKIYYQWBB-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.67,16.2,6.822856924,6.803586083,150.3637,157.186
2507,0.9,85,0.9,85,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CCCCCNC5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,780.326,779.3198099,5.44,56,7,10,3,13,164.18,C42H46ClN7O6,"InChI=1S/C42H46ClN7O6/c43-36-25-33(12-6-28(36)26-44)56-32-13-7-29(8-14-32)46-39(52)27-4-10-31(11-5-27)49-22-20-48(21-23-49)19-3-1-2-18-45-30-9-15-34-35(24-30)42(55)50(41(34)54)37-16-17-38(51)47-40(37)53/h4-6,9-12,15,24-25,29,32,37,45H,1-3,7-8,13-14,16-23H2,(H,46,52)(H,47,51,53)/t29-,32-,37?",RIBBYHBSLKRREX-MLUZTVPMSA-N,387,76,1066,CCCCCN1CCNCC1,[R1]N1CCN(CC1)CCCCC[R2],156.273,156.1626486,1.4,11,1,2,1,4,15.27,C9H20N2,"InChI=1S/C9H20N2/c1-2-3-4-7-11-8-5-10-6-9-11/h10H,2-9H2,1H3",MJWWNBHUIIRNDZ-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,76CRBN,76,Q96SW2,CRBN,,O=C1CCC(N2CC3=CC4=C(C=C3C2=O)CNC4)C(=O)N1,,,,,,,,,,285.303,285.1113413,-0.88,21,4,4,2,1,78.51,C15H15N3O3,"InChI=1S/C15H15N3O3/c19-13-2-1-12(14(20)17-13)18-7-10-3-8-5-16-6-9(8)4-11(10)15(18)21/h3-4,12,16H,1-2,5-7H2,(H,17,19,20)",JOFWTVIUJXDETL-UHFFFAOYSA-N,,156123552,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.85,0.9,6.801741434,7.317010231,157.8551,48.1936
1431,50,71,<=50,>=71,P10275,AR,VHL,,,CC(C)(C)[C@H](NC(=O)COCCCCCOC1=CC=C(C(=O)N[C@H]2C(C)(C)[C@H](OC3=CC=C(C#N)C(Cl)=C3)C2(C)C)C=C1)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=CN=CS2)C=C1,Degradation of AR in LNCaP cells after 2-4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00115,941.592,940.3960116,8.11,66,6,11,4,19,192.21,C50H61ClN6O8S,"InChI=1S/C50H61ClN6O8S/c1-48(2,3)42(45(62)57-28-35(58)23-39(57)44(61)54-26-31-11-13-32(14-12-31)40-27-53-30-66-40)55-41(59)29-63-21-9-8-10-22-64-36-18-15-33(16-19-36)43(60)56-46-49(4,5)47(50(46,6)7)65-37-20-17-34(25-52)38(51)24-37/h11-20,24,27,30,35,39,42,46-47,58H,8-10,21-23,26,28-29H2,1-7H3,(H,54,61)(H,55,59)(H,56,60)/t35-,39+,42-,46-,47-/m1/s1",AMPBLCGZRAITTM-RRMXYVBQSA-N,38,23,685,COCCCCCO,[R1]OCCCCCOC[R2],118.176,118.0993797,0.47,8,0,2,1,5,29.46,C6H14O2,"InChI=1S/C6H14O2/c1-8-6-4-2-3-5-7/h7H,2-6H2,1H3",OMNKOGMRWWOOFR-UHFFFAOYSA-N,P00533,EGFR,gefitinib,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN1CCOCC1,,,,,1,Kd was assessed by competition binding assays,,,10.1038/nbt.1990,446.91,446.1520965,4.11,31,4,7,1,8,68.74,C22H24ClFN4O3,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,5447,123631,CHEMBL939,23VHL,23,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(C)=O)C(C)(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,130,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,543.69,543.2515403,1.59,38,3,7,4,8,140.73,C27H37N5O5S,"InChI=1S/C27H37N5O5S/c1-15-23(38-14-29-15)18-9-7-17(8-10-18)20(12-22(35)28-6)31-25(36)21-11-19(34)13-32(21)26(37)24(27(3,4)5)30-16(2)33/h7-10,14,19-21,24,34H,11-13H2,1-6H3,(H,28,35)(H,30,33)(H,31,36)/t19-,20+,21+,24-/m1/s1",DHJHMRSRAVXNPQ-MDAIXWLXSA-N,,,,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.148964568,5.555540008,709.6357,2782.659
3746,0.2,99,0.2,99,P25440,BRD2,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.2,6.646769252,6.639259789,225.5437,229.4776
3746,0.2,99,0.2,99,P25440,BRD2,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.2,5.968564637,6.639259789,1075.0666,229.4776
3746,0.2,99,0.2,99,P25440,BRD2,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD2 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.2,7.328071946,6.639259789,46.9816,229.4776
3746,0.3,98,0.3,98,O60885,BRD4,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.3,6.646769252,6.639259789,225.5437,229.4776
3746,0.3,98,0.3,98,O60885,BRD4,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.3,5.968564637,6.639259789,1075.0666,229.4776
3746,0.3,98,0.3,98,O60885,BRD4,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD4 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,0.3,7.328071946,6.639259789,46.9816,229.4776
3746,0.7,99,0.7,99,Q15059,BRD3,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD3 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,47.09,0.0147165,1,1,1,1,1,0.0147165,0.99,0.7,6.646769252,6.639259789,225.5437,229.4776
3746,0.7,99,0.7,99,Q15059,BRD3,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD3 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,47.09,0.0147165,1,1,1,1,1,0.0147165,0.99,0.7,5.968564637,6.639259789,1075.0666,229.4776
3746,0.7,99,0.7,99,Q15059,BRD3,CRBN,,BD-7162,CC1=NN=C2COCC3=C(SC(C#CC4=CN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)N=C4)=C3CC3=CC=CC=C3)N12,Degradation of BRD3 in MV4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00520,698.765,698.2059871,2.81,51,9,12,1,5,144.55,C37H30N8O5S,"InChI=1S/C37H30N8O5S/c1-21-40-41-32-20-50-19-29-27(13-22-5-3-2-4-6-22)31(51-37(29)44(21)32)11-7-23-15-38-43(16-23)25-17-42(18-25)24-8-9-26-28(14-24)36(49)45(35(26)48)30-10-12-33(46)39-34(30)47/h2-6,8-9,14-16,25,30H,10,12-13,17-20H2,1H3,(H,39,46,47)",OJCRNHCUTYXXFI-UHFFFAOYSA-N,46,4,1751,C1CNC1,[R1]C1CN(C1)[R2],57.096,57.05784922,-0.07,4,1,1,1,0,12.03,C3H7N,"InChI=1S/C3H7N/c1-2-4-3-1/h4H,1-3H2",HONIICLYMWZJFZ-UHFFFAOYSA-N,P42336,PI3Kalpha,ZSTK474,FC(F)C1=NC2=CC=CC=C2N1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1,8.9,IC50 of human His-tagged PI3Kalpha was assessed by HTRF assay,,,,,,,10.1021/jm200688y,417.42,417.1724794,2.3,30,5,9,0,4,81.43,C19H21F2N7O2,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,50315213,11647372,CHEMBL586702,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,47.09,0.0147165,1,1,1,1,1,0.0147165,0.99,0.7,7.328071946,6.639259789,46.9816,229.4776
753,8.3,91,8.3,91,Q06187,BTK,CRBN,,SJF608,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CCOCCOCCOC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of BTK in NAMALWA cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.bmcl.2019.126877,774.835,774.3125603,3.1,57,8,14,2,15,193.33,C41H42N8O8,"InChI=1S/C41H42N8O8/c42-37-35-36(26-6-8-29(9-7-26)57-28-4-2-1-3-5-28)46-49(38(35)44-25-43-37)27-14-16-47(17-15-27)18-19-54-20-21-55-22-23-56-30-10-11-31-32(24-30)41(53)48(40(31)52)33-12-13-34(50)45-39(33)51/h1-11,24-25,27,33H,12-23H2,(H2,42,43,44)(H,45,50,51)",KCRCMDOSXFUJPF-UHFFFAOYSA-N,51,4,86,CCOCCOCCO,[R1]CCOCCOCCO[R2],134.175,134.0942943,-0.39,9,0,3,1,6,38.69,C6H14O3,"InChI=1S/C6H14O3/c1-2-8-5-6-9-4-3-7/h7H,2-6H2,1H3",XXJWXESWEXIICW-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.91,8.3,7.063324752,6.83976577,86.4321,144.622
3553,51.1,97.75,51.1,97.75,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(CC2=CC=C(C#CC3CCN(C4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)CC3)N=C2)CC1,Degradation of BTK in Ramos cells after 24 h treatment,62.68,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,840.945,840.3496145,4.94,63,10,13,2,8,181.77,C48H44N10O5,"InChI=1S/C48H44N10O5/c49-44-42-43(32-8-13-37(14-9-32)63-36-4-2-1-3-5-36)54-58(45(42)52-29-51-44)34-20-22-55(23-21-34)28-31-7-11-33(50-27-31)10-6-30-18-24-56(25-19-30)35-12-15-38-39(26-35)48(62)57(47(38)61)40-16-17-41(59)53-46(40)60/h1-5,7-9,11-15,26-27,29-30,34,40H,16-25,28H2,(H2,49,51,52)(H,53,59,60)",XMWSKICAFPPYSY-UHFFFAOYSA-N,51,4,1659,CC1=CC=C(C#CC2CCNCC2)N=C1,[R1]CC1=CN=C(C=C1)C#CC2CCN(CC2)[R2],200.285,200.1313485,1.76,15,2,2,1,0,24.92,C13H16N2,"InChI=1S/C13H16N2/c1-11-2-4-13(15-10-11)5-3-12-6-8-14-9-7-12/h2,4,10,12,14H,6-9H2,1H3",OFFLKOQQNZKIFZ-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9775,51.1,7.465657084,7.346541153,34.225,45.0255
3554,26.87,97.78,26.87,97.78,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(C(=O)C2=CC=C(N3CCN(C4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)CC3)N=C2)CC1,Degradation of BTK in Ramos cells after 24 h treatment,71.7,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,831.894,831.324128,3.82,62,10,14,2,8,202.08,C45H41N11O6,"InChI=1S/C45H41N11O6/c46-40-38-39(27-6-10-32(11-7-27)62-31-4-2-1-3-5-31)51-56(41(38)49-26-48-40)29-16-18-54(19-17-29)43(59)28-8-14-36(47-25-28)53-22-20-52(21-23-53)30-9-12-33-34(24-30)45(61)55(44(33)60)35-13-15-37(57)50-42(35)58/h1-12,14,24-26,29,35H,13,15-23H2,(H2,46,48,49)(H,50,57,58)",JNESGEBHIQTVTD-UHFFFAOYSA-N,51,4,1660,O=CC1=CC=C(N2CCNCC2)N=C1,[R1]C(=O)C1=CN=C(C=C1)N2CCN(CC2)[R2],191.234,191.105862,0.12,14,2,4,1,2,45.23,C10H13N3O,"InChI=1S/C10H13N3O/c14-8-9-1-2-10(12-7-9)13-5-3-11-4-6-13/h1-2,7-8,11H,3-6H2",MGVFUNNLLQJZKP-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9778,26.87,6.868069538,6.825867113,135.4972,149.3251
3555,2.93,99.73,6.11/2.93,99.73/99.73,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(C(=O)CN2CCN(CC3CCN(C4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)CC3)CC2)CC1,Degradation of BTK in Ramos/Mino cells after 24 h treatment,99.68,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,865.996,865.4023784,3.63,64,10,14,2,10,192.43,C47H51N11O6,"InChI=1S/C47H51N11O6/c48-43-41-42(31-6-9-35(10-7-31)64-34-4-2-1-3-5-34)52-58(44(41)50-29-49-43)32-16-20-56(21-17-32)40(60)28-54-24-22-53(23-25-54)27-30-14-18-55(19-15-30)33-8-11-36-37(26-33)47(63)57(46(36)62)38-12-13-39(59)51-45(38)61/h1-11,26,29-30,32,38H,12-25,27-28H2,(H2,48,49,50)(H,51,59,61)",LFNMIAGMJGUCIW-UHFFFAOYSA-N,51,4,1661,O=CCN1CCN(CC2CCNCC2)CC1,[R1]C(=O)CN1CCN(CC1)CC2CCN(CC2)[R2],225.336,225.1841124,-0.08,16,2,4,1,4,35.58,C12H23N3O,"InChI=1S/C12H23N3O/c16-10-9-14-5-7-15(8-6-14)11-12-1-3-13-4-2-12/h10,12-13H,1-9,11H2",ILQSVJSYQRDNRW-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9973,2.93,6.942906797,6.489946942,114.0495,323.6332
3556,3.18,99.9,3.18/7.07,99.9/99.99,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2C1CCN(C(=O)CN2CCN(CC3CN(C4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)C3)CC2)CC1,Degradation of BTK in Ramos/Mino cells after 24 h treatment,99.42,% BTK degradation in Ramos cells after 24 h treatment at 100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115664,837.942,837.3710782,2.91,62,10,14,2,10,192.43,C45H47N11O6,"InChI=1S/C45H47N11O6/c46-41-39-40(29-6-9-33(10-7-29)62-32-4-2-1-3-5-32)50-56(42(39)48-27-47-41)30-14-16-53(17-15-30)38(58)26-52-20-18-51(19-21-52)23-28-24-54(25-28)31-8-11-34-35(22-31)45(61)55(44(34)60)36-12-13-37(57)49-43(36)59/h1-11,22,27-28,30,36H,12-21,23-26H2,(H2,46,47,48)(H,49,57,59)",SPGWKNITNYHIGX-UHFFFAOYSA-N,51,4,1662,O=CCN1CCN(CC2CNC2)CC1,[R1]C(=O)CN1CCN(CC1)CC2CN(C2)[R2],197.282,197.1528122,-0.79,14,2,4,1,4,35.58,C10H19N3O,"InChI=1S/C10H19N3O/c14-6-5-12-1-3-13(4-2-12)9-10-7-11-8-10/h6,10-11H,1-5,7-9H2",DDYLSNUNYAOPJC-UHFFFAOYSA-N,P11474,ERRalpha,,COC1=CC(/C=C2\SC(=O)NC2=O)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F,0.6,IC50 of ERRalpha was assessed by two-hybrid reporter assay,,,,,,,10.1021/jm101063h,420.368,420.0391625,4.3,29,3,6,1,4,88.42,C19H11F3N2O4S,"InChI=1S/C19H11F3N2O4S/c1-27-15-7-10(8-16-17(25)24-18(26)29-16)2-5-14(15)28-13-4-3-11(9-23)6-12(13)19(20,21)22/h2-8H,1H3,(H,24,25,26)/b16-8-",OBBIOCQFTMNSJI-PXNMLYILSA-N,50336730,46916268,CHEMBL1671971,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.999,3.18,6.800297028,6.910788755,158.381,122.8036
2511,0.3,92,0.3,92,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CC5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.7,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,764.283,763.2885097,4.53,55,8,10,2,9,155.39,C41H42ClN7O6,"InChI=1S/C41H42ClN7O6/c42-35-20-32(9-3-27(35)21-43)55-31-10-4-28(5-11-31)44-38(51)26-1-6-29(7-2-26)47-17-15-46(16-18-47)22-25-23-48(24-25)30-8-12-33-34(19-30)41(54)49(40(33)53)36-13-14-37(50)45-39(36)52/h1-3,6-9,12,19-20,25,28,31,36H,4-5,10-11,13-18,22-24H2,(H,44,51)(H,45,50,52)/t28-,31-,36?",ZXOIALMBAAMQKG-HDGSNFBOSA-N,387,4,1114,C1CN(CC2CNC2)CCN1,[R1]N1CCN(CC1)CC2CN(C2)[R2],155.245,155.1422475,-0.32,11,2,3,2,2,27.3,C8H17N3,"InChI=1S/C8H17N3/c1-3-11(4-2-9-1)7-8-5-10-6-8/h8-10H,1-7H2",POYSZJGSBCKKHD-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.92,0.3,6.907880236,6.454619982,123.6288,351.0589
2509,0.3,88,0.3,88,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(C5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.9,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,778.31,777.3041598,5.06,56,8,10,2,8,155.39,C42H44ClN7O6,"InChI=1S/C42H44ClN7O6/c43-36-24-33(9-3-27(36)25-44)56-32-10-4-28(5-11-32)45-39(52)26-1-6-29(7-2-26)48-19-21-49(22-20-48)30-15-17-47(18-16-30)31-8-12-34-35(23-31)42(55)50(41(34)54)37-13-14-38(51)46-40(37)53/h1-3,6-9,12,23-24,28,30,32,37H,4-5,10-11,13-22H2,(H,45,52)(H,46,51,53)/t28-,32-,37?",SRMKEEIRTHASLG-MVHOYPFPSA-N,387,4,1115,C1CC(N2CCNCC2)CCN1,[R1]N1CCN(CC1)C2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.88,0.3,6.824307784,7.067718201,149.8622,85.5622
2508,0.2,97,0.2,97,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CC5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.7,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,792.337,791.3198099,5.25,57,8,10,2,9,155.39,C43H46ClN7O6,"InChI=1S/C43H46ClN7O6/c44-37-24-34(9-3-29(37)25-45)57-33-10-4-30(5-11-33)46-40(53)28-1-6-31(7-2-28)50-21-19-48(20-22-50)26-27-15-17-49(18-16-27)32-8-12-35-36(23-32)43(56)51(42(35)55)38-13-14-39(52)47-41(38)54/h1-3,6-9,12,23-24,27,30,33,38H,4-5,10-11,13-22,26H2,(H,46,53)(H,47,52,54)/t30-,33-,38?",QJZUVOHJKPMREF-SIOTYANSSA-N,387,4,1116,C1CC(CN2CCNCC2)CCN1,[R1]N1CCN(CC1)CC2CCN(CC2)[R2],183.299,183.1735477,-0.08,13,2,3,2,2,27.3,C10H21N3,"InChI=1S/C10H21N3/c1-3-11-4-2-10(1)9-13-7-5-12-6-8-13/h10-12H,1-9H2",INUYEZQAQSEPMT-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.97,0.2,6.829515027,6.952131409,148.0761,111.6525
2508,155.3,90,155.3,>90,P10275,AR,CRBN,,TJA-107,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(CC5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in human dermal papilla cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1002/smtd.202201293,792.337,791.3198099,5.25,57,8,10,2,9,155.39,C43H46ClN7O6,"InChI=1S/C43H46ClN7O6/c44-37-24-34(9-3-29(37)25-45)57-33-10-4-30(5-11-33)46-40(53)28-1-6-31(7-2-28)50-21-19-48(20-22-50)26-27-15-17-49(18-16-27)32-8-12-35-36(23-32)43(56)51(42(35)55)38-13-14-39(52)47-41(38)54/h1-3,6-9,12,23-24,27,30,33,38H,4-5,10-11,13-22,26H2,(H,46,53)(H,47,52,54)/t30-,33-,38?",QJZUVOHJKPMREF-SIOTYANSSA-N,387,4,1116,C1CC(CN2CCNCC2)CCN1,[R1]N1CCN(CC1)CC2CCN(CC2)[R2],183.299,183.1735477,-0.08,13,2,3,2,2,27.3,C10H21N3,"InChI=1S/C10H21N3/c1-3-11-4-2-10(1)9-13-7-5-12-6-8-13/h10-12H,1-9H2",INUYEZQAQSEPMT-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.9,155.3,6.829515027,6.952131409,148.0761,111.6525
2510,0.2,95,0.2,95,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCC(N5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.7,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,778.31,777.3041598,5.06,56,8,10,2,8,155.39,C42H44ClN7O6,"InChI=1S/C42H44ClN7O6/c43-36-24-33(9-3-27(36)25-44)56-32-10-4-28(5-11-32)45-39(52)26-1-6-29(7-2-26)47-17-15-30(16-18-47)48-19-21-49(22-20-48)31-8-12-34-35(23-31)42(55)50(41(34)54)37-13-14-38(51)46-40(37)53/h1-3,6-9,12,23-24,28,30,32,37H,4-5,10-11,13-22H2,(H,45,52)(H,46,51,53)/t28-,32-,37?",ZEEFAZNIKLZENT-MVHOYPFPSA-N,387,4,1121,C1CC(N2CCNCC2)CCN1,[R1]N1CCC(CC1)N2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,0.2,6.876577829,6.923867583,132.8685,119.1605
2512,0.1,76,0.1,76,P10275,AR,CRBN,,,N#CC1=CC=C(O[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCN(C5CN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)C5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,750.256,749.2728597,4.34,54,8,10,2,8,155.39,C40H40ClN7O6,"InChI=1S/C40H40ClN7O6/c41-34-20-31(9-3-25(34)21-42)54-30-10-4-26(5-11-30)43-37(50)24-1-6-27(7-2-24)45-15-17-46(18-16-45)29-22-47(23-29)28-8-12-32-33(19-28)40(53)48(39(32)52)35-13-14-36(49)44-38(35)51/h1-3,6-9,12,19-20,26,29-30,35H,4-5,10-11,13-18,22-23H2,(H,43,50)(H,44,49,51)/t26-,30-,35?",IFCKDGNCNVHZTM-KEQPVMAKSA-N,387,4,1113,C1CN(C2CNC2)CCN1,[R1]N1CCN(CC1)C2CN(C2)[R2],141.218,141.1265975,-0.98,10,2,3,2,1,27.3,C7H15N3,"InChI=1S/C7H15N3/c1-3-10(4-2-8-1)7-5-9-6-7/h7-9H,1-6H2",YOFQVUAASHWECH-UHFFFAOYSA-N,P03406,Nef,,OC1=C(CCC2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=NC2=CC(Cl)=CC=C2[NH]1,,,,,,,,,10.1101/2023.08.14.553289,414.896,414.1247389,6.27,30,5,4,2,5,66.73,C24H19ClN4O,"InChI=1S/C24H19ClN4O/c25-18-12-14-20-21(15-18)27-24(26-20)29-23(30)19(13-11-16-7-3-1-4-8-16)22(28-29)17-9-5-2-6-10-17/h1-10,12,14-15,30H,11,13H2,(H,26,27)",XKIYEOQHLWXHBC-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.76,0.1,7.256837645,6.747961953,55.3557,178.6644
3171,75,75,75/77,>75/>85,P10275,AR,CRBN,,,CC1(C)C(=O)N(C2=CC=C(C#N)C(C(F)(F)F)=C2)C(=S)N1C1=CC=C(C2=CC=C(O[C@@H]3CCN(C(=O)C4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C3)C=C2)C=C1,Degradation of AR in A549/LNCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1002/ardp.202100467,917.967,917.2818523,6,66,9,10,1,8,163.67,C48H42F3N7O7S,"InChI=1S/C48H42F3N7O7S/c1-47(2)45(64)56(33-10-5-30(25-52)38(24-33)48(49,50)51)46(66)58(47)31-8-3-27(4-9-31)28-6-12-34(13-7-28)65-35-19-22-55(26-35)42(61)29-17-20-54(21-18-29)32-11-14-36-37(23-32)44(63)57(43(36)62)39-15-16-40(59)53-41(39)60/h3-14,23-24,29,35,39H,15-22,26H2,1-2H3,(H,53,59,60)/t35-,39?/m1/s1",PMTYRQFZOZEPEI-QQKHLPPFSA-N,33,4,1467,O=C(C1CCNCC1)N1CC[C@@H](OC2=CC=CC=C2)C1,[R1]C1=CC=C(C=C1)O[C@@H]2CCN(C2)C(=O)C3CCN(CC3)[R2],274.364,274.1681279,1.61,20,3,3,1,3,41.57,C16H22N2O2,"InChI=1S/C16H22N2O2/c19-16(13-6-9-17-10-7-13)18-11-8-15(12-18)20-14-4-2-1-3-5-14/h1-5,13,15,17H,6-12H2/t15-/m1/s1",FQJMUWAQAHWFMC-OAHLLOKOSA-N,Q06187,BTK,Spebrutinib,C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(OCCOC)C=C3)=NC=C2F)=C1,0.72,IC50 of BTK was assessed by ADP-Glo luminescence assay,,,,,,,10.1016/j.ejmech.2016.11.047,423.448,423.1706678,3.64,31,3,7,3,10,97.4,C22H22FN5O3,"InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)",KXBDTLQSDKGAEB-UHFFFAOYSA-N,50161162,59174488,CHEMBL3301625,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.75,75,7.176322373,6.846871948,66.6312,142.2748
3997,8.8,94.1,8.8,94.1,Q06187,BTK,CRBN,,,O=C1CCC(N2C(=O)C3=CC=C(N4CCC(CCN5CCC(CC(=O)N[C@H]6CC[C@@H](NC7=NC=NC8=C7C(C(=O)C7=CC=C(OC9=CC=CC=C9)C=C7Cl)=C[NH]8)CC6)CC5)CC4)C=C3C2=O)C(=O)N1,Degradation of BTK in JeKo-1 cells after 24 h treatment,85.0/82.5,% BTK degradation in JeKo-1 cells after 24 h treatment at 100/1000 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.4/82.1/59.5,Inhibition of cell proliferation in OCI-ly10/TMD8/JeKo-1 cells,,,,,,,,,,,,,,,10.1016/j.ejmech.2023.115403,954.529,953.3991228,6.97,69,10,12,4,14,199.03,C52H56ClN9O7,"InChI=1S/C52H56ClN9O7/c53-42-28-37(69-36-4-2-1-3-5-36)11-13-39(42)47(65)41-29-54-48-46(41)49(56-30-55-48)58-34-8-6-33(7-9-34)57-45(64)26-32-17-22-60(23-18-32)21-16-31-19-24-61(25-20-31)35-10-12-38-40(27-35)52(68)62(51(38)67)43-14-15-44(63)59-50(43)66/h1-5,10-13,27-34,43H,6-9,14-26H2,(H,57,64)(H,59,63,66)(H2,54,55,56,58)/t33-,34+,43?",VWELFQOMWDAJDG-TWZCHNMGSA-N,453,4,1866,O=CCC1CCN(CCC2CCNCC2)CC1,[R1]C(=O)CC1CCN(CC1)CCC2CCN(CC2)[R2],238.375,238.2045135,1.12,17,2,3,1,5,32.34,C14H26N2O,"InChI=1S/C14H26N2O/c17-12-6-14-4-10-16(11-5-14)9-3-13-1-7-15-8-2-13/h12-15H,1-11H2",OFOQFHISAGVRRH-UHFFFAOYSA-N,P40337,VHL,VL285,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@H](C(C)C)N3CC4=CC=CC=C4C3=O)C=C2)SC=N1,340,Displacement of FAM-DEALA-Hyp-YIPD from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acschembio.5b00442,532.666,532.2144265,3.33,38,5,6,2,7,102.84,C29H32N4O4S,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)/t22-,24+,25+/m1/s1",HEDFFPYRFJKXQP-VJTSUQJLSA-N,,71667162,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.941,8.8,7.698405379,6.825871006,20.026,149.3238
3889,11.8,80,11.8,80,P21802,FGFR2,CRBN,,LC-MB12,COC1=CC(OC)=C(Cl)C(NC(=O)N(C)C2=CC(NC3=CC=C(N4CCN(C(=O)C5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)=NC=N2)=C1Cl,Degradation of FGFR2 in KATO III cells after 6 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.3/29.1/3.7,Inhibit the proliferation of Ba/F3-TEL-FGFR2/KATO III/SNU16 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00150,899.793,898.2720637,4.23,63,8,13,3,10,198.95,C43H44Cl2N10O8,"InChI=1S/C43H44Cl2N10O8/c1-51(43(61)50-38-36(44)31(62-2)21-32(63-3)37(38)45)34-22-33(46-23-47-34)48-25-4-6-26(7-5-25)53-16-18-54(19-17-53)40(58)24-12-14-52(15-13-24)27-8-9-28-29(20-27)42(60)55(41(28)59)30-10-11-35(56)49-39(30)57/h4-9,20-24,30H,10-19H2,1-3H3,(H,50,61)(H,46,47,48)(H,49,56,57)",BUEXWHUMUYQITQ-UHFFFAOYSA-N,459,4,1550,O=CC1CCNCC1,[R1]C(=O)C1CCN(CC1)[R2],113.16,113.084064,-0.25,8,1,2,1,1,29.1,C6H11NO,"InChI=1S/C6H11NO/c8-5-6-1-3-7-4-2-6/h5-7H,1-4H2",HRVXPXCISZSDCC-UHFFFAOYSA-N,A0A384N6C2,IMPDH,Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C/C=C(\C)CCC(=O)OCCN1CCOCC1,,,,,,,,,10.1016/s1053-2498(00)00191-1,433.501,433.2100523,3.19,31,3,8,1,9,94.53,C23H31NO7,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,50248299,5281078,CHEMBL1456,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.8,11.8,8.069570643,6.177427273,8.5198,664.619
1461,30,70,<30,>70,Q9NWZ3,IRAK4,CRBN,,,O=C1CCC(N2C(=O)C3=CC=C(OCCOCCOCCN4CCN(CC5=CC=C6N=C(NC(=O)C7=CC=CC(C(F)(F)F)=C7)N([C@H]7CC[C@@H](CO)CC7)C6=C5)CC4)C=C3C2=O)C(=O)N1,Degradation of IRAK4 in MCF7 cells,,,<30,IC50 was tested by FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00385,903.956,903.3778609,3.46,65,8,13,3,17,184.87,C46H52F3N7O9,"InChI=1S/C46H52F3N7O9/c47-46(48,49)32-3-1-2-31(25-32)41(59)52-45-50-37-11-6-30(24-39(37)55(45)33-7-4-29(28-57)5-8-33)27-54-16-14-53(15-17-54)18-19-63-20-21-64-22-23-65-34-9-10-35-36(26-34)44(62)56(43(35)61)38-12-13-40(58)51-42(38)60/h1-3,6,9-11,24-26,29,33,38,57H,4-5,7-8,12-23,27-28H2,(H,50,52,59)(H,51,58,60)/t29-,33+,38?",DRSGINHARUFRQE-CDUPFHCPSA-N,231,4,702,CN1CCN(CCOCCOCCO)CC1,[R1]CN1CCN(CC1)CCOCCOCCO[R2],232.324,232.1786926,-0.9,16,1,5,1,8,45.17,C11H24N2O3,"InChI=1S/C11H24N2O3/c1-12-2-4-13(5-3-12)6-8-15-10-11-16-9-7-14/h14H,2-11H2,1H3",ORNJSISNUBXZAT-UHFFFAOYSA-N,Q15910,EZH2,EPZ6438,CCN(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(C(=O)NCC2=C(C)C=C(C)[NH]C2=O)=C1C)C1CCOCC1,3.7,IC50 was assessed by an Alpha-Screen assay,,,,,,,10.1021/acs.jmedchem.0c02234,572.75,572.3362559,4.18,42,5,6,2,9,86.9,C34H44N4O4,"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",NSQSAUGJQHDYNO-UHFFFAOYSA-N,172038,66558664,CHEMBL3414621,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,30,7.31995956,6.620421236,47.8675,239.6507
1462,30,70,<30,>70,Q9NWZ3,IRAK4,CRBN,,,O=C1CCC(N2C(=O)C3=CC=C(OCCOCCOCCOCCN4CCN(CC5=CC=C6N=C(NC(=O)C7=CC=CC(C(F)(F)F)=C7)N([C@H]7CC[C@@H](CO)CC7)C6=C5)CC4)C=C3C2=O)C(=O)N1,Degradation of IRAK4 in MCF7 cells,,,<30,IC50 was tested by FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00385,948.009,947.4040757,3.31,68,8,14,3,20,194.1,C48H56F3N7O10,"InChI=1S/C48H56F3N7O10/c49-48(50,51)34-3-1-2-33(27-34)43(61)54-47-52-39-11-6-32(26-41(39)57(47)35-7-4-31(30-59)5-8-35)29-56-16-14-55(15-17-56)18-19-65-20-21-66-22-23-67-24-25-68-36-9-10-37-38(28-36)46(64)58(45(37)63)40-12-13-42(60)53-44(40)62/h1-3,6,9-11,26-28,31,35,40,59H,4-5,7-8,12-25,29-30H2,(H,52,54,61)(H,53,60,62)/t31-,35+,40?",ADNQFJRANZZPKY-RGDYMFDWSA-N,231,4,703,CN1CCN(CCOCCOCCOCCO)CC1,[R1]CN1CCN(CC1)CCOCCOCCOCCO[R2],276.377,276.2049074,-1.05,19,1,6,1,11,54.4,C13H28N2O4,"InChI=1S/C13H28N2O4/c1-14-2-4-15(5-3-14)6-8-17-10-12-19-13-11-18-9-7-16/h16H,2-13H2,1H3",AHDKSJCZGIBPOH-UHFFFAOYSA-N,Q15910,EZH2,EPZ6438,CCN(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(C(=O)NCC2=C(C)C=C(C)[NH]C2=O)=C1C)C1CCOCC1,3.7,IC50 was assessed by an Alpha-Screen assay,,,,,,,10.1021/acs.jmedchem.0c02234,572.75,572.3362559,4.18,42,5,6,2,9,86.9,C34H44N4O4,"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",NSQSAUGJQHDYNO-UHFFFAOYSA-N,172038,66558664,CHEMBL3414621,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,30,7.184126595,6.564302287,65.4445,272.7079
1463,30,70,<30,>70,Q9NWZ3,IRAK4,CRBN,,,O=C1CCC(N2C(=O)C3=CC=C(N4CCC(CN5CCN(CC6=CC=C7N=C(NC(=O)C8=CC=CC(C(F)(F)F)=C8)N([C@H]8CC[C@@H](CO)CC8)C7=C6)CC5)CC4)C=C3C2=O)C(=O)N1,Degradation of IRAK4 in MCF7 cells,,,<30,IC50 was tested by FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00385,868.958,868.388366,4.65,63,9,11,3,10,160.42,C46H51F3N8O6,"InChI=1S/C46H51F3N8O6/c47-46(48,49)32-3-1-2-31(23-32)41(60)52-45-50-37-11-6-30(22-39(37)56(45)33-7-4-29(27-58)5-8-33)26-54-20-18-53(19-21-54)25-28-14-16-55(17-15-28)34-9-10-35-36(24-34)44(63)57(43(35)62)38-12-13-40(59)51-42(38)61/h1-3,6,9-11,22-24,28-29,33,38,58H,4-5,7-8,12-21,25-27H2,(H,50,52,60)(H,51,59,61)/t29-,33+,38?",RJDRFOSUZYUZBV-CDUPFHCPSA-N,231,4,704,CN1CCN(CC2CCNCC2)CC1,[R1]CN1CCN(CC1)CC2CCN(CC2)[R2],197.326,197.1891977,0.39,14,2,3,1,2,18.51,C11H23N3,"InChI=1S/C11H23N3/c1-13-6-8-14(9-7-13)10-11-2-4-12-5-3-11/h11-12H,2-10H2,1H3",MIRBDUREIHMEMK-UHFFFAOYSA-N,Q15910,EZH2,EPZ6438,CCN(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(C(=O)NCC2=C(C)C=C(C)[NH]C2=O)=C1C)C1CCOCC1,3.7,IC50 was assessed by an Alpha-Screen assay,,,,,,,10.1021/acs.jmedchem.0c02234,572.75,572.3362559,4.18,42,5,6,2,9,86.9,C34H44N4O4,"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",NSQSAUGJQHDYNO-UHFFFAOYSA-N,172038,66558664,CHEMBL3414621,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,30,7.131715858,6.77768833,73.8387,166.8444
1466,30,70,30-100,>70,Q9NWZ3,IRAK4,CRBN,,,O=C1CCC(N2C(=O)C3=CC=C(OC4CCC(CN5CCN(CC6=CC=C7N=C(NC(=O)C8=CC=CC(C(F)(F)F)=C8)N([C@H]8CC[C@@H](CO)CC8)C7=C6)CC5)CC4)C=C3C2=O)C(=O)N1,Degradation of IRAK4 in MCF7 cells,,,<30,IC50 was tested by FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00385,883.969,883.3880317,5.28,64,9,11,3,11,166.41,C47H52F3N7O7,"InChI=1S/C47H52F3N7O7/c48-47(49,50)32-3-1-2-31(23-32)42(60)53-46-51-38-15-8-30(22-40(38)56(46)33-9-4-29(27-58)5-10-33)26-55-20-18-54(19-21-55)25-28-6-11-34(12-7-28)64-35-13-14-36-37(24-35)45(63)57(44(36)62)39-16-17-41(59)52-43(39)61/h1-3,8,13-15,22-24,28-29,33-34,39,58H,4-7,9-12,16-21,25-27H2,(H,51,53,60)(H,52,59,61)/t28?,29-,33+,34?,39?",LGAMKMQUDXCHFO-RIOIAMSCSA-N,231,4,706,CN1CCN(CC2CCC(O)CC2)CC1,[R1]CN1CCN(CC1)CC2CCC(CC2)O[R2],212.337,212.1888634,0.92,15,2,3,1,2,26.71,C12H24N2O,"InChI=1S/C12H24N2O/c1-13-6-8-14(9-7-13)10-11-2-4-12(15)5-3-11/h11-12,15H,2-10H2,1H3",ARPHSRLZPCLRNY-UHFFFAOYSA-N,Q15910,EZH2,EPZ6438,CCN(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(C(=O)NCC2=C(C)C=C(C)[NH]C2=O)=C1C)C1CCOCC1,3.7,IC50 was assessed by an Alpha-Screen assay,,,,,,,10.1021/acs.jmedchem.0c02234,572.75,572.3362559,4.18,42,5,6,2,9,86.9,C34H44N4O4,"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",NSQSAUGJQHDYNO-UHFFFAOYSA-N,172038,66558664,CHEMBL3414621,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,30,7.391794365,6.706434514,40.5701,196.5918
1464,30,70,<30,50-70,Q9NWZ3,IRAK4,CRBN,,,COC1=CC2=NN(C3CCN(CCOCCOC4=CC=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=C4)CC3)C=C2C=C1NC(=O)C1=CC=CC(C(F)(F)F)=N1,Degradation of IRAK4 in MCF7 cells,,,<30,IC50 was tested by FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00385,763.73,763.2577458,2.78,55,7,12,2,12,174.29,C37H36F3N7O8,"InChI=1S/C37H36F3N7O8/c1-53-30-19-27-21(17-28(30)42-33(49)26-3-2-4-31(41-26)37(38,39)40)20-46(44-27)22-9-11-45(12-10-22)13-14-54-15-16-55-23-5-6-24-25(18-23)36(52)47(35(24)51)29-7-8-32(48)43-34(29)50/h2-6,17-20,22,29H,7-16H2,1H3,(H,42,49)(H,43,48,50)",XXKSDGIIEAJWCB-UHFFFAOYSA-N,232,4,705,CCOCCO,[R1]CCOCCO[R2],90.122,90.06807956,-0.24,6,0,2,1,3,29.46,C4H10O2,"InChI=1S/C4H10O2/c1-2-6-4-3-5/h5H,2-4H2,1H3",ZNQVEEAIQZEUHB-UHFFFAOYSA-N,Q5S007,LRRK2,GNE-7915,CCNC1=NC(NC2=CC(F)=C(C(=O)N3CCOCC3)C=C2OC)=NC=C1C(F)(F)F,,,,,,,1,Ki was assessed by microfluidic capillary electrophoresis assay,10.1021/jm301020q,443.401,443.1580524,2.8,31,3,7,2,6,88.61,C19H21F4N5O3,"InChI=1S/C19H21F4N5O3/c1-3-24-16-12(19(21,22)23)10-25-18(27-16)26-14-9-13(20)11(8-15(14)30-2)17(29)28-4-6-31-7-5-28/h8-10H,3-7H2,1-2H3,(H2,24,25,26,27)",XCFLWTZSJYBCPF-UHFFFAOYSA-N,50398668,58539171,CHEMBL2178134,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.7,30,7.570582966,6.84247943,26.8792,143.7211
1716,52,74,52,74,Q9Y616,IRAK3,CRBN,,,CC(C)C1=C2C(N[C@H]3CC[C@@H](N4CCN(C(=O)CCC(=O)N5CCC(CN6CCN(C7=CC=C8C(=O)N(C9CCC(=O)NC9=O)C(=O)C8=C7)CC6)CC5)CC4)CC3)=NC=NN2C=C1,Degradation of IRAK3 in THP1 cells after 16 h treatment,,,6.3,LanthaScreen Eu IRAK3 binding displacement assay using an Alexa Fluor conjugate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01125,864.065,863.4806287,2.44,63,9,13,2,11,176.11,C46H61N11O6,"InChI=1S/C46H61N11O6/c1-30(2)35-15-18-56-42(35)43(47-29-48-56)49-32-3-5-33(6-4-32)52-23-25-55(26-24-52)41(60)12-11-40(59)54-16-13-31(14-17-54)28-51-19-21-53(22-20-51)34-7-8-36-37(27-34)46(63)57(45(36)62)38-9-10-39(58)50-44(38)61/h7-8,15,18,27,29-33,38H,3-6,9-14,16-17,19-26,28H2,1-2H3,(H,47,48,49)(H,50,58,61)/t32-,33+,38?",PVLXFMAKABZOPF-YVLRYLSESA-N,283,4,831,CCC(=O)N1CCC(CN2CCNCC2)CC1,[R1]CCC(=O)N1CCC(CC1)CN2CCN(CC2)[R2],239.363,239.1997624,0.32,17,2,3,1,3,35.58,C13H25N3O,"InChI=1S/C13H25N3O/c1-2-13(17)16-7-3-12(4-8-16)11-15-9-5-14-6-10-15/h12,14H,2-11H2,1H3",BSMXDYCSRGWMMS-UHFFFAOYSA-N,P50750,CDK9,BS-181,CC(C)C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1,2180,Inhibition of CDK9,,,,,,,10.1016/j.ejmech.2016.01.011,380.54,380.268845,4.07,28,3,6,3,11,80.27,C22H32N6,"InChI=1S/C22H32N6/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27)",DNYBIOICMDTDAP-UHFFFAOYSA-N,50347389,49867929,CHEMBL1801932,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.74,52,8.77337635,6.519963023,1.6851,302.0209
1717,2,98,2,98,Q9Y616,IRAK3,CRBN,,,CC(C)C1=C2C(N[C@H]3CC[C@@H](N4CCN(C(=O)CCC(=O)N5CCC(CCN6CCN(C7=CC=C8C(=O)N(C9CCC(=O)NC9=O)C(=O)C8=C7)CC6)CC5)CC4)CC3)=NC=NN2C=C1,Degradation of IRAK3 in THP1 cells after 16 h treatment,,,4.9,LanthaScreen Eu IRAK3 binding displacement assay using an Alexa Fluor conjugate,,,34,Kd apparent of IRAK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01125,878.092,877.4962787,2.8,64,9,13,2,12,176.11,C47H63N11O6,"InChI=1S/C47H63N11O6/c1-31(2)36-16-20-57-43(36)44(48-30-49-57)50-33-3-5-34(6-4-33)53-25-27-56(28-26-53)42(61)12-11-41(60)55-18-14-32(15-19-55)13-17-52-21-23-54(24-22-52)35-7-8-37-38(29-35)47(64)58(46(37)63)39-9-10-40(59)51-45(39)62/h7-8,16,20,29-34,39H,3-6,9-15,17-19,21-28H2,1-2H3,(H,48,49,50)(H,51,59,62)/t33-,34+,39?",ZUODKONSNNHSAJ-AMLBMYBGSA-N,283,4,832,CCC(=O)N1CCC(CCN2CCNCC2)CC1,[R1]CCC(=O)N1CCC(CC1)CCN2CCN(CC2)[R2],253.39,253.2154125,0.68,18,2,3,1,4,35.58,C14H27N3O,"InChI=1S/C14H27N3O/c1-2-14(18)17-9-4-13(5-10-17)3-8-16-11-6-15-7-12-16/h13,15H,2-12H2,1H3",RHOGJCWLCZMMFS-UHFFFAOYSA-N,P50750,CDK9,BS-181,CC(C)C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1,2180,Inhibition of CDK9,,,,,,,10.1016/j.ejmech.2016.01.011,380.54,380.268845,4.07,28,3,6,3,11,80.27,C22H32N6,"InChI=1S/C22H32N6/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27)",DNYBIOICMDTDAP-UHFFFAOYSA-N,50347389,49867929,CHEMBL1801932,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,2,8.131143692,6.443815307,7.3936,359.9024
2003,0.75,96,0.75,96,Q92793,CBP,CRBN,,dCBP-1,CNC(=O)N1CCC2=C(C1)C(N1CCCC3=CC(C4=CN(C)N=C4)=C(C(F)F)C=C31)=NN2C1CCN(C(=O)CCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of CBP in RS4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.8,Inhibit of cell growth of RS4;11 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00492,1028.128,1027.472744,1.57,74,9,16,3,21,224.03,C51H63F2N11O10,"InChI=1S/C51H63F2N11O10/c1-54-51(70)61-17-11-41-40(31-61)47(62-14-3-4-32-26-37(33-29-56-59(2)30-33)38(46(52)53)28-43(32)62)58-64(41)35-9-15-60(16-10-35)45(66)12-18-71-20-22-73-24-25-74-23-21-72-19-13-55-34-5-6-36-39(27-34)50(69)63(49(36)68)42-7-8-44(65)57-48(42)67/h5-6,26-30,35,42,46,55H,3-4,7-25,31H2,1-2H3,(H,54,70)(H,57,65,67)",ILVRLRGBSSFKIE-UHFFFAOYSA-N,311,4,971,NCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCN[R2],249.307,249.1576228,-1.87,17,0,6,1,14,80.01,C11H23NO5,"InChI=1S/C11H23NO5/c12-2-5-15-7-9-17-11-10-16-8-6-14-4-1-3-13/h3H,1-2,4-12H2",ORBOSPTWQGKEDA-UHFFFAOYSA-N,Q9NYV4,CDK12,,COCCOCCOC1=CC2=C(C=C1F)N=C(CNC1=NC(N3CCOCC3)=NC3=C1N=CN3C(C)C)[NH]2,236.9,Inhibition of CDK12/cyclinK,,,,,,,10.1016/j.ejmech.2021.114012,528.589,528.2608798,2.03,38,5,11,2,12,124.47,C25H33FN8O4,"InChI=1S/C25H33FN8O4/c1-16(2)34-15-28-22-23(31-25(32-24(22)34)33-4-6-36-7-5-33)27-14-21-29-18-12-17(26)20(13-19(18)30-21)38-11-10-37-9-8-35-3/h12-13,15-16H,4-11,14H2,1-3H3,(H,29,30)(H,27,31,32)",KHWWVAVHHRPPQY-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,0.75,6.279713064,6.785658214,525.1543,163.8105
2003,0.75,96,0.75,96,Q92793,CBP,CRBN,,dCBP-1,CNC(=O)N1CCC2=C(C1)C(N1CCCC3=CC(C4=CN(C)N=C4)=C(C(F)F)C=C31)=NN2C1CCN(C(=O)CCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of CBP in RS4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.8,Inhibit of cell growth of RS4;11 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00492,1028.128,1027.472744,1.57,74,9,16,3,21,224.03,C51H63F2N11O10,"InChI=1S/C51H63F2N11O10/c1-54-51(70)61-17-11-41-40(31-61)47(62-14-3-4-32-26-37(33-29-56-59(2)30-33)38(46(52)53)28-43(32)62)58-64(41)35-9-15-60(16-10-35)45(66)12-18-71-20-22-73-24-25-74-23-21-72-19-13-55-34-5-6-36-39(27-34)50(69)63(49(36)68)42-7-8-44(65)57-48(42)67/h5-6,26-30,35,42,46,55H,3-4,7-25,31H2,1-2H3,(H,54,70)(H,57,65,67)",ILVRLRGBSSFKIE-UHFFFAOYSA-N,311,4,971,NCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCN[R2],249.307,249.1576228,-1.87,17,0,6,1,14,80.01,C11H23NO5,"InChI=1S/C11H23NO5/c12-2-5-15-7-9-17-11-10-16-8-6-14-4-1-3-13/h3H,1-2,4-12H2",ORBOSPTWQGKEDA-UHFFFAOYSA-N,Q9NYV4,CDK12,,COCCOCCOC1=CC2=C(C=C1F)N=C(CNC1=NC(N3CCOCC3)=NC3=C1N=CN3C(C)C)[NH]2,236.9,Inhibition of CDK12/cyclinK,,,,,,,10.1016/j.ejmech.2021.114012,528.589,528.2608798,2.03,38,5,11,2,12,124.47,C25H33FN8O4,"InChI=1S/C25H33FN8O4/c1-16(2)34-15-28-22-23(31-25(32-24(22)34)33-4-6-36-7-5-33)27-14-21-29-18-12-17(26)20(13-19(18)30-21)38-11-10-37-9-8-35-3/h12-13,15-16H,4-11,14H2,1-3H3,(H,29,30)(H,27,31,32)",KHWWVAVHHRPPQY-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,0.75,6.2641478,6.785658214,544.3174,163.8105
2003,1.85,90,1.85,90,Q09472,EP300,CRBN,,dCBP-1,CNC(=O)N1CCC2=C(C1)C(N1CCCC3=CC(C4=CN(C)N=C4)=C(C(F)F)C=C31)=NN2C1CCN(C(=O)CCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of p300 in RS4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00492,1028.128,1027.472744,1.57,74,9,16,3,21,224.03,C51H63F2N11O10,"InChI=1S/C51H63F2N11O10/c1-54-51(70)61-17-11-41-40(31-61)47(62-14-3-4-32-26-37(33-29-56-59(2)30-33)38(46(52)53)28-43(32)62)58-64(41)35-9-15-60(16-10-35)45(66)12-18-71-20-22-73-24-25-74-23-21-72-19-13-55-34-5-6-36-39(27-34)50(69)63(49(36)68)42-7-8-44(65)57-48(42)67/h5-6,26-30,35,42,46,55H,3-4,7-25,31H2,1-2H3,(H,54,70)(H,57,65,67)",ILVRLRGBSSFKIE-UHFFFAOYSA-N,311,4,971,NCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCN[R2],249.307,249.1576228,-1.87,17,0,6,1,14,80.01,C11H23NO5,"InChI=1S/C11H23NO5/c12-2-5-15-7-9-17-11-10-16-8-6-14-4-1-3-13/h3H,1-2,4-12H2",ORBOSPTWQGKEDA-UHFFFAOYSA-N,Q9NYV4,CDK12,,COCCOCCOC1=CC2=C(C=C1F)N=C(CNC1=NC(N3CCOCC3)=NC3=C1N=CN3C(C)C)[NH]2,236.9,Inhibition of CDK12/cyclinK,,,,,,,10.1016/j.ejmech.2021.114012,528.589,528.2608798,2.03,38,5,11,2,12,124.47,C25H33FN8O4,"InChI=1S/C25H33FN8O4/c1-16(2)34-15-28-22-23(31-25(32-24(22)34)33-4-6-36-7-5-33)27-14-21-29-18-12-17(26)20(13-19(18)30-21)38-11-10-37-9-8-35-3/h12-13,15-16H,4-11,14H2,1-3H3,(H,29,30)(H,27,31,32)",KHWWVAVHHRPPQY-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,19.3,0.035906736,1,1,1,1,1,0.035906736,0.9,1.85,6.279713064,6.785658214,525.1543,163.8105
2003,1.85,90,1.85,90,Q09472,EP300,CRBN,,dCBP-1,CNC(=O)N1CCC2=C(C1)C(N1CCCC3=CC(C4=CN(C)N=C4)=C(C(F)F)C=C31)=NN2C1CCN(C(=O)CCOCCOCCOCCOCCNC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=C2)CC1,Degradation of p300 in RS4;11 cells after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.3c00492,1028.128,1027.472744,1.57,74,9,16,3,21,224.03,C51H63F2N11O10,"InChI=1S/C51H63F2N11O10/c1-54-51(70)61-17-11-41-40(31-61)47(62-14-3-4-32-26-37(33-29-56-59(2)30-33)38(46(52)53)28-43(32)62)58-64(41)35-9-15-60(16-10-35)45(66)12-18-71-20-22-73-24-25-74-23-21-72-19-13-55-34-5-6-36-39(27-34)50(69)63(49(36)68)42-7-8-44(65)57-48(42)67/h5-6,26-30,35,42,46,55H,3-4,7-25,31H2,1-2H3,(H,54,70)(H,57,65,67)",ILVRLRGBSSFKIE-UHFFFAOYSA-N,311,4,971,NCCOCCOCCOCCOCCC=O,[R1]C(=O)CCOCCOCCOCCOCCN[R2],249.307,249.1576228,-1.87,17,0,6,1,14,80.01,C11H23NO5,"InChI=1S/C11H23NO5/c12-2-5-15-7-9-17-11-10-16-8-6-14-4-1-3-13/h3H,1-2,4-12H2",ORBOSPTWQGKEDA-UHFFFAOYSA-N,Q9NYV4,CDK12,,COCCOCCOC1=CC2=C(C=C1F)N=C(CNC1=NC(N3CCOCC3)=NC3=C1N=CN3C(C)C)[NH]2,236.9,Inhibition of CDK12/cyclinK,,,,,,,10.1016/j.ejmech.2021.114012,528.589,528.2608798,2.03,38,5,11,2,12,124.47,C25H33FN8O4,"InChI=1S/C25H33FN8O4/c1-16(2)34-15-28-22-23(31-25(32-24(22)34)33-4-6-36-7-5-33)27-14-21-29-18-12-17(26)20(13-19(18)30-21)38-11-10-37-9-8-35-3/h12-13,15-16H,4-11,14H2,1-3H3,(H,29,30)(H,27,31,32)",KHWWVAVHHRPPQY-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,19.3,0.035906736,1,1,1,1,1,0.035906736,0.9,1.85,6.2641478,6.785658214,544.3174,163.8105
2523,0.5,96,0.5,96,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCC(CN4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,805.38,804.3514443,5.4,58,8,10,2,9,149.4,C44H49ClN8O5,"InChI=1S/C44H49ClN8O5/c1-49(34-9-4-30(26-46)38(45)25-34)32-10-5-31(6-11-32)47-41(55)29-2-7-33(8-3-29)51-18-16-28(17-19-51)27-50-20-22-52(23-21-50)35-12-13-36-37(24-35)44(58)53(43(36)57)39-14-15-40(54)48-42(39)56/h2-4,7-9,12-13,24-25,28,31-32,39H,5-6,10-11,14-23,27H2,1H3,(H,47,55)(H,48,54,56)/t31-,32-,39?",XLQOXOVXCNIRJP-WIDQNFKDSA-N,394,4,1052,C1CC(CN2CCNCC2)CCN1,[R1]N1CCC(CC1)CN2CCN(CC2)[R2],183.299,183.1735477,-0.08,13,2,3,2,2,27.3,C10H21N3,"InChI=1S/C10H21N3/c1-3-11-4-2-10(1)9-13-7-5-12-6-8-13/h10-12H,1-9H2",INUYEZQAQSEPMT-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,0.5,6.447260298,6.60058449,357.0588,250.8508
2525,0.01,99,0.01,99,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(CC4CN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)C4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.1,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,777.326,776.3201442,4.69,56,8,10,2,9,149.4,C42H45ClN8O5,"InChI=1S/C42H45ClN8O5/c1-47(32-9-4-28(22-44)36(43)21-32)30-10-5-29(6-11-30)45-39(53)27-2-7-31(8-3-27)49-18-16-48(17-19-49)23-26-24-50(25-26)33-12-13-34-35(20-33)42(56)51(41(34)55)37-14-15-38(52)46-40(37)54/h2-4,7-9,12-13,20-21,26,29-30,37H,5-6,10-11,14-19,23-25H2,1H3,(H,45,53)(H,46,52,54)/t29-,30-,37?",YYULHFDWXXZSRM-VZASAIHWSA-N,394,4,1114,C1CN(CC2CNC2)CCN1,[R1]N1CCN(CC1)CC2CN(C2)[R2],155.245,155.1422475,-0.32,11,2,3,2,2,27.3,C8H17N3,"InChI=1S/C8H17N3/c1-3-11(4-2-9-1)7-8-5-10-6-8/h8-10H,1-7H2",POYSZJGSBCKKHD-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.01,6.931570581,6.673491668,117.0656,212.0842
2525,0.9,99,0.9,99,P10275,AR T878A,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(CC4CN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)C4)CC3)C=C2)CC1,Degradation of AR T878A in LNCaP (AR T878A) cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.4,Inhibit growth of LNCaP (AR T878A) cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,777.326,776.3201442,4.69,56,8,10,2,9,149.4,C42H45ClN8O5,"InChI=1S/C42H45ClN8O5/c1-47(32-9-4-28(22-44)36(43)21-32)30-10-5-29(6-11-30)45-39(53)27-2-7-31(8-3-27)49-18-16-48(17-19-49)23-26-24-50(25-26)33-12-13-34-35(20-33)42(56)51(41(34)55)37-14-15-38(52)46-40(37)54/h2-4,7-9,12-13,20-21,26,29-30,37H,5-6,10-11,14-19,23-25H2,1H3,(H,45,53)(H,46,52,54)/t29-,30-,37?",YYULHFDWXXZSRM-VZASAIHWSA-N,394,4,1114,C1CN(CC2CNC2)CCN1,[R1]N1CCN(CC1)CC2CN(C2)[R2],155.245,155.1422475,-0.32,11,2,3,2,2,27.3,C8H17N3,"InChI=1S/C8H17N3/c1-3-11(4-2-9-1)7-8-5-10-6-8/h8-10H,1-7H2",POYSZJGSBCKKHD-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.9,6.931570581,6.673491668,117.0656,212.0842
2524,0.1,96,0.1,96,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(C4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,791.353,790.3357943,5.21,57,8,10,2,8,149.4,C43H47ClN8O5,"InChI=1S/C43H47ClN8O5/c1-48(33-9-4-28(26-45)37(44)25-33)30-10-5-29(6-11-30)46-40(54)27-2-7-31(8-3-27)50-20-22-51(23-21-50)32-16-18-49(19-17-32)34-12-13-35-36(24-34)43(57)52(42(35)56)38-14-15-39(53)47-41(38)55/h2-4,7-9,12-13,24-25,29-30,32,38H,5-6,10-11,14-23H2,1H3,(H,46,54)(H,47,53,55)/t29-,30-,38?",WHJVBMNCPUFBSX-KIIACXQNSA-N,394,4,1115,C1CC(N2CCNCC2)CCN1,[R1]N1CCN(CC1)C2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,0.1,6.708904938,6.526947481,195.4767,297.2025
2524,0.4,95,0.4,95,P10275,AR T878A,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(C4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR T878A in LNCaP (AR T878A) cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22.3,Inhibit growth of LNCaP (AR T878A) cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,791.353,790.3357943,5.21,57,8,10,2,8,149.4,C43H47ClN8O5,"InChI=1S/C43H47ClN8O5/c1-48(33-9-4-28(26-45)37(44)25-33)30-10-5-29(6-11-30)46-40(54)27-2-7-31(8-3-27)50-20-22-51(23-21-50)32-16-18-49(19-17-32)34-12-13-35-36(24-34)43(57)52(42(35)56)38-14-15-39(53)47-41(38)55/h2-4,7-9,12-13,24-25,29-30,32,38H,5-6,10-11,14-23H2,1H3,(H,46,54)(H,47,53,55)/t29-,30-,38?",WHJVBMNCPUFBSX-KIIACXQNSA-N,394,4,1115,C1CC(N2CCNCC2)CCN1,[R1]N1CCN(CC1)C2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,0.4,6.708904938,6.526947481,195.4767,297.2025
2522,1.4,93,1.4,93,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(CC4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,805.38,804.3514443,5.4,58,8,10,2,9,149.4,C44H49ClN8O5,"InChI=1S/C44H49ClN8O5/c1-49(34-9-4-30(26-46)38(45)25-34)32-10-5-31(6-11-32)47-41(55)29-2-7-33(8-3-29)52-22-20-50(21-23-52)27-28-16-18-51(19-17-28)35-12-13-36-37(24-35)44(58)53(43(36)57)39-14-15-40(54)48-42(39)56/h2-4,7-9,12-13,24-25,28,31-32,39H,5-6,10-11,14-23,27H2,1H3,(H,47,55)(H,48,54,56)/t31-,32-,39?",FSMCKEYFGVIYBM-WIDQNFKDSA-N,394,4,1116,C1CC(CN2CCNCC2)CCN1,[R1]N1CCN(CC1)CC2CCN(CC2)[R2],183.299,183.1735477,-0.08,13,2,3,2,2,27.3,C10H21N3,"InChI=1S/C10H21N3/c1-3-11-4-2-10(1)9-13-7-5-12-6-8-13/h10-12H,1-9H2",INUYEZQAQSEPMT-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.93,1.4,6.578606339,6.616009461,263.8722,242.0976
2519,0.09,99,0.09,99,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCC(N4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.8,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,791.353,790.3357943,5.21,57,8,10,2,8,149.4,C43H47ClN8O5,"InChI=1S/C43H47ClN8O5/c1-48(33-9-4-28(26-45)37(44)25-33)30-10-5-29(6-11-30)46-40(54)27-2-7-31(8-3-27)49-18-16-32(17-19-49)50-20-22-51(23-21-50)34-12-13-35-36(24-34)43(57)52(42(35)56)38-14-15-39(53)47-41(38)55/h2-4,7-9,12-13,24-25,29-30,32,38H,5-6,10-11,14-23H2,1H3,(H,46,54)(H,47,53,55)/t29-,30-,38?",BEEAHZAQHFFDHP-KIIACXQNSA-N,394,4,1121,C1CC(N2CCNCC2)CCN1,[R1]N1CCC(CC1)N2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.09,6.486165376,6.50238244,326.4635,314.4978
2519,0.3,95,0.3,95,P10275,AR T878A,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCC(N4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR T878A in LNCaP (AR T878A) cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.3,Inhibit growth of LNCaP (AR T878A) cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,791.353,790.3357943,5.21,57,8,10,2,8,149.4,C43H47ClN8O5,"InChI=1S/C43H47ClN8O5/c1-48(33-9-4-28(26-45)37(44)25-33)30-10-5-29(6-11-30)46-40(54)27-2-7-31(8-3-27)49-18-16-32(17-19-49)50-20-22-51(23-21-50)34-12-13-35-36(24-34)43(57)52(42(35)56)38-14-15-39(53)47-41(38)55/h2-4,7-9,12-13,24-25,29-30,32,38H,5-6,10-11,14-23H2,1H3,(H,46,54)(H,47,53,55)/t29-,30-,38?",BEEAHZAQHFFDHP-KIIACXQNSA-N,394,4,1121,C1CC(N2CCNCC2)CCN1,[R1]N1CCC(CC1)N2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.95,0.3,6.486165376,6.50238244,326.4635,314.4978
2526,0.04,99,0.04,99,P10275,AR,CRBN,,ARD-2585,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(C4CN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)C4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,763.299,762.3044942,4.5,55,8,10,2,8,149.4,C41H43ClN8O5,"InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)47-16-18-48(19-17-47)32-23-49(24-32)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53)/t27-,28-,36?",LUCHABJUYSYJAT-RVWRWSNSSA-N,394,4,1113,C1CN(C2CNC2)CCN1,[R1]N1CCN(CC1)C2CN(C2)[R2],141.218,141.1265975,-0.98,10,2,3,2,1,27.3,C7H15N3,"InChI=1S/C7H15N3/c1-3-10(4-2-8-1)7-5-9-6-7/h7-9H,1-6H2",YOFQVUAASHWECH-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.04,6.91430669,6.724434599,121.8129,188.6103
2526,0.1,98,0.1,98,P10275,AR T878A,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCN(C4CN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)C4)CC3)C=C2)CC1,Degradation of AR T878A in LNCaP (AR T878A) cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16.2,Inhibit growth of LNCaP (AR T878A) cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,763.299,762.3044942,4.5,55,8,10,2,8,149.4,C41H43ClN8O5,"InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)47-16-18-48(19-17-47)32-23-49(24-32)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53)/t27-,28-,36?",LUCHABJUYSYJAT-RVWRWSNSSA-N,394,4,1113,C1CN(C2CNC2)CCN1,[R1]N1CCN(CC1)C2CN(C2)[R2],141.218,141.1265975,-0.98,10,2,3,2,1,27.3,C7H15N3,"InChI=1S/C7H15N3/c1-3-10(4-2-8-1)7-5-9-6-7/h7-9H,1-6H2",YOFQVUAASHWECH-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.98,0.1,6.91430669,6.724434599,121.8129,188.6103
2527,0.1,99.9,0.1,100,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CC(CN4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.3,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,777.326,776.3201442,4.69,56,8,10,2,9,149.4,C42H45ClN8O5,"InChI=1S/C42H45ClN8O5/c1-47(32-9-4-28(22-44)36(43)21-32)30-10-5-29(6-11-30)45-39(53)27-2-7-31(8-3-27)50-24-26(25-50)23-48-16-18-49(19-17-48)33-12-13-34-35(20-33)42(56)51(41(34)55)37-14-15-38(52)46-40(37)54/h2-4,7-9,12-13,20-21,26,29-30,37H,5-6,10-11,14-19,23-25H2,1H3,(H,45,53)(H,46,52,54)/t29-,30-,37?",LOFIFWMXRZZLIL-VZASAIHWSA-N,394,4,1193,C1CN(CC2CNC2)CCN1,[R1]N1CC(C1)CN2CCN(CC2)[R2],155.245,155.1422475,-0.79,11,2,3,2,2,27.3,C8H17N3,"InChI=1S/C8H17N3/c1-3-11(4-2-9-1)7-8-5-10-6-8/h8-10H,1-7H2",POYSZJGSBCKKHD-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.999,0.1,6.703208294,6.749730803,198.0577,177.9382
2527,1.9,99,1.9,99,P10275,AR T878A,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CC(CN4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C3)C=C2)CC1,Degradation of AR T878A in LNCaP (AR T878A) cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.6,Inhibit growth of LNCaP (AR T878A) cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,777.326,776.3201442,4.69,56,8,10,2,9,149.4,C42H45ClN8O5,"InChI=1S/C42H45ClN8O5/c1-47(32-9-4-28(22-44)36(43)21-32)30-10-5-29(6-11-30)45-39(53)27-2-7-31(8-3-27)50-24-26(25-50)23-48-16-18-49(19-17-48)33-12-13-34-35(20-33)42(56)51(41(34)55)37-14-15-38(52)46-40(37)54/h2-4,7-9,12-13,20-21,26,29-30,37H,5-6,10-11,14-19,23-25H2,1H3,(H,45,53)(H,46,52,54)/t29-,30-,37?",LOFIFWMXRZZLIL-VZASAIHWSA-N,394,4,1193,C1CN(CC2CNC2)CCN1,[R1]N1CC(C1)CN2CCN(CC2)[R2],155.245,155.1422475,-0.79,11,2,3,2,2,27.3,C8H17N3,"InChI=1S/C8H17N3/c1-3-11(4-2-9-1)7-8-5-10-6-8/h8-10H,1-7H2",POYSZJGSBCKKHD-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,1.9,6.703208294,6.749730803,198.0577,177.9382
2528,0.2,96,0.2,96,P10275,AR,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CC(N4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.1,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,763.299,762.3044942,4.5,55,8,10,2,8,149.4,C41H43ClN8O5,"InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)49-23-32(24-49)48-18-16-47(17-19-48)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53)/t27-,28-,36?",RNZSZCNUPQYOIX-RVWRWSNSSA-N,394,4,1194,C1CN(C2CNC2)CCN1,[R1]N1CC(C1)N2CCN(CC2)[R2],141.218,141.1265975,-0.98,10,2,3,2,1,27.3,C7H15N3,"InChI=1S/C7H15N3/c1-3-10(4-2-8-1)7-5-9-6-7/h7-9H,1-6H2",YOFQVUAASHWECH-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.96,0.2,6.825550413,6.615463673,149.4341,242.4021
2528,1.3,64,1.3,64,P10275,AR T878A,CRBN,,,CN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CC(N4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)C3)C=C2)CC1,Degradation of AR T878A in LNCaP (AR T878A) cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,21.7,Inhibit growth of LNCaP (AR T878A) cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,763.299,762.3044942,4.5,55,8,10,2,8,149.4,C41H43ClN8O5,"InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)49-23-32(24-49)48-18-16-47(17-19-48)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53)/t27-,28-,36?",RNZSZCNUPQYOIX-RVWRWSNSSA-N,394,4,1194,C1CN(C2CNC2)CCN1,[R1]N1CC(C1)N2CCN(CC2)[R2],141.218,141.1265975,-0.98,10,2,3,2,1,27.3,C7H15N3,"InChI=1S/C7H15N3/c1-3-10(4-2-8-1)7-5-9-6-7/h7-9H,1-6H2",YOFQVUAASHWECH-UHFFFAOYSA-N,Q9Y2I7,PIKfyve,Apilimod,CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC3=CC=CC=N3)=N2)=C1,14,Inhibition of human PIKfyve,,,,,,,10.1021/acs.jmedchem.1c00302,418.501,418.2117241,3.83,31,4,8,1,8,84.76,C23H26N6O2,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+",HSKAZIJJKRAJAV-KOEQRZSOSA-N,50590927,10173277,CHEMBL4297643,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.64,1.3,6.825550413,6.615463673,149.4341,242.4021
2518,0.3,78,0.3,78,P10275,AR,CRBN,,,N#CC1=CC=C(N[C@H]2CC[C@H](NC(=O)C3=CC=C(N4CCC(N5CCN(C6=CC=C7C(=O)N(C8CCC(=O)NC8=O)C(=O)C7=C6)CC5)CC4)C=C3)CC2)C=C1Cl,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16.6,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,777.326,776.3201442,5.07,56,8,10,3,8,158.19,C42H45ClN8O5,"InChI=1S/C42H45ClN8O5/c43-36-23-30(4-1-27(36)25-44)45-28-5-7-29(8-6-28)46-39(53)26-2-9-31(10-3-26)48-17-15-32(16-18-48)49-19-21-50(22-20-49)33-11-12-34-35(24-33)42(56)51(41(34)55)37-13-14-38(52)47-40(37)54/h1-4,9-12,23-24,28-29,32,37,45H,5-8,13-22H2,(H,46,53)(H,47,52,54)/t28-,29-,37?",IRDHCECVXOCRLY-QZHRDHLUSA-N,393,4,1121,C1CC(N2CCNCC2)CCN1,[R1]N1CCC(CC1)N2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,P22736,NR4A1,Celastrol,CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]3(C)CC[C@@]4(C)CC[C@@](C)(C(=O)O)C[C@H]4[C@]3(C)CC[C@@]21C,,,,,,,,,10.1016/j.ejmech.2019.05.009,450.619,450.2770097,5.94,33,5,3,2,1,74.6,C29H38O4,"InChI=1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1",KQJSQWZMSAGSHN-JJWQIEBTSA-N,205457,122724,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.78,0.3,6.617762356,6.682242999,241.1224,207.8533
2520,0.1,99,0.1,99,P10275,AR,CRBN,,,CCN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCC(N4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.1,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,805.38,804.3514443,5.58,58,8,10,2,9,149.4,C44H49ClN8O5,"InChI=1S/C44H49ClN8O5/c1-2-52(35-10-5-29(27-46)38(45)26-35)33-11-6-30(7-12-33)47-41(55)28-3-8-31(9-4-28)49-19-17-32(18-20-49)50-21-23-51(24-22-50)34-13-14-36-37(25-34)44(58)53(43(36)57)39-15-16-40(54)48-42(39)56/h3-5,8-10,13-14,25-26,30,32-33,39H,2,6-7,11-12,15-24H2,1H3,(H,47,55)(H,48,54,56)/t30-,33-,39?",VZVAWYNZTBXESG-BULKPCKOSA-N,395,4,1121,C1CC(N2CCNCC2)CCN1,[R1]N1CCC(CC1)N2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,Q5S007,LRRK2,MLi-2,C[C@H]1CN(C2=CC(C3=N[NH]C4=CC=C(OC5(C)CC5)C=C34)=NC=N2)C[C@@H](C)O1,,,,,,,,,10.1016/j.bmcl.2023.129449,379.464,379.200825,3.19,28,5,6,1,4,76.16,C21H25N5O2,"InChI=1S/C21H25N5O2/c1-13-10-26(11-14(2)27-13)19-9-18(22-12-23-19)20-16-8-15(28-21(3)6-7-21)4-5-17(16)24-25-20/h4-5,8-9,12-14H,6-7,10-11H2,1-3H3,(H,24,25)/t13-,14+",ATUUNJCZCOMUKD-OKILXGFUSA-N,,,CHEMBL4098877,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.99,0.1,6.911265489,6.630169329,122.6689,234.3315
2521,1.4,88,1.4,88,P10275,AR,CRBN,,,CCCN(C1=CC=C(C#N)C(Cl)=C1)[C@H]1CC[C@H](NC(=O)C2=CC=C(N3CCC(N4CCN(C5=CC=C6C(=O)N(C7CCC(=O)NC7=O)C(=O)C6=C5)CC4)CC3)C=C2)CC1,Degradation of AR in VCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,83.5,Inhibit growth of VCaP cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c00900,819.407,818.3670944,6.1,59,8,10,2,10,149.4,C45H51ClN8O5,"InChI=1S/C45H51ClN8O5/c1-2-19-53(36-10-5-30(28-47)39(46)27-36)34-11-6-31(7-12-34)48-42(56)29-3-8-32(9-4-29)50-20-17-33(18-21-50)51-22-24-52(25-23-51)35-13-14-37-38(26-35)45(59)54(44(37)58)40-15-16-41(55)49-43(40)57/h3-5,8-10,13-14,26-27,31,33-34,40H,2,6-7,11-12,15-25H2,1H3,(H,48,56)(H,49,55,57)/t31-,34-,40?",FVEFTVCRDXCSLR-MLTFQQHKSA-N,396,4,1121,C1CC(N2CCNCC2)CCN1,[R1]N1CCC(CC1)N2CCN(CC2)[R2],169.272,169.1578976,-0.27,12,2,3,2,1,27.3,C9H19N3,"InChI=1S/C9H19N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h9-11H,1-8H2",ZHYYBDZASCMDMP-UHFFFAOYSA-N,O15379,HDAC3,,CCCNNC(=O)C1=CC=C(N2CCN(C)CC2)C=C1,10.8,Inhibition of HDAC3,,,,,,,10.1016/j.chembiol.2023.07.010,276.384,276.1950114,1.79,20,2,4,2,5,47.61,C15H24N4O,"InChI=1S/C15H24N4O/c1-3-8-16-17-15(20)13-4-6-14(7-5-13)19-11-9-18(2)10-12-19/h4-7,16H,3,8-12H2,1-2H3,(H,17,20)",KBNQDACHNKIYHV-UHFFFAOYSA-N,,,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.88,1.4,6.595372883,6.444135464,253.8792,359.6371
5406,441,77,441,77,Q9BY41,HDAC8,CRBN,,,O=C(CCCCOC1=CC=C(CCNC(=O)C2=CC=CC(C(=O)NO)=C2)C=C1)NCCCCCCNC1=CC=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=C1,Degradation of HDAC8 in HCT-116 cells after 10 h treatment,68.9,% HDAC8 degradation in HCT-116 cells at 5000 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1016/j.ejmech.2022,754.841,754.3326271,3.19,55,5,10,6,20,212.34,C40H46N6O9,"InChI=1S/C40H46N6O9/c47-34(10-3-6-23-55-30-14-11-26(12-15-30)19-22-43-36(49)27-8-7-9-28(24-27)37(50)45-54)42-21-5-2-1-4-20-41-29-13-16-31-32(25-29)40(53)46(39(31)52)33-17-18-35(48)44-38(33)51/h7-9,11-16,24-25,33,41,54H,1-6,10,17-23H2,(H,42,47)(H,43,49)(H,45,50)(H,44,48,51)",HIMPUSAONKTVMA-UHFFFAOYSA-N,350,4,2461,CCC1=CC=C(OCCCCC(=O)NCCCCCCN)C=C1,[R1]CCC1=CC=C(C=C1)OCCCCC(=O)NCCCCCCN[R2],320.477,320.2463783,3.14,23,1,3,2,13,64.35,C19H32N2O2,"InChI=1S/C19H32N2O2/c1-2-17-10-12-18(13-11-17)23-16-8-5-9-19(22)21-15-7-4-3-6-14-20/h10-13H,2-9,14-16,20H2,1H3,(H,21,22)",SVCVBVMXHQPYHY-UHFFFAOYSA-N,P51531,SMARCA2,,NC1=NN=C(C2=CC=CC=C2O)C=C1N1CCC(C2=CC=CC=C2)CC1,,,,,,,,,,346.434,346.1793613,3.16,26,4,5,2,3,75.27,C21H22N4O,"InChI=1S/C21H22N4O/c22-21-19(14-18(23-24-21)17-8-4-5-9-20(17)26)25-12-10-16(11-13-25)15-6-2-1-3-7-15/h1-9,14,16,26H,10-13H2,(H2,22,24)",JTBGUMSOPXOHEX-UHFFFAOYSA-N,394417,137029533,,4CRBN,4,Q96SW2,CRBN,lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,,,,,178,FP,,,10.1038/nature13527,259.265,259.0956913,-0.5,19,3,4,2,1,92.5,C13H13N3O3,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,65454,216326,CHEMBL848,63.641,0.010889207,1,1,1,1,1,0.010889207,0.77,441,7.868029193,7.245861529,13.551,56.7726
1791,780,99,780,99,O60885,BRD4,VHL,,,CNCCOC1=CC(C2=C(C)N=CS2)=CC=C1CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C2=C(SC(C)=C2C)N2C(C)=NN=C12)C(C)(C)C,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,Oct-34,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,720,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2800,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1075.756,1074.422243,4.51,74,7,17,5,24,232.75,C52H67ClN10O9S2,"InChI=1S/C52H67ClN10O9S2/c1-30-32(3)74-51-44(30)45(34-11-13-37(53)14-12-34)58-39(48-61-60-33(4)63(48)51)25-42(65)55-16-17-69-19-20-70-21-22-71-28-43(66)59-47(52(5,6)7)50(68)62-27-38(64)24-40(62)49(67)56-26-36-10-9-35(46-31(2)57-29-73-46)23-41(36)72-18-15-54-8/h9-14,23,29,38-40,47,54,64H,15-22,24-28H2,1-8H3,(H,55,65)(H,56,67)(H,59,66)/t38-,39+,40+,47-/m1/s1",AFQYUHBTQNKWIU-KVLVHDNBSA-N,42,85,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,85VHL,85,P40337,VHL,,CC1=C(C2=CC=C(C3=C[NH]C([C@@H]4C[C@@H](O)CN4C(=O)[C@@H](N)C(C)(C)C)=N3)C=C2)SC=N1,,,,,,,,,10.1021/acs.jmedchem.3c01144,439.585,439.2041962,2.55,31,4,6,3,4,108.13,C23H29N5O2S,"InChI=1S/C23H29N5O2S/c1-13-19(31-12-26-13)15-7-5-14(6-8-15)17-10-25-21(27-17)18-9-16(29)11-28(18)22(30)20(24)23(2,3)4/h5-8,10,12,16,18,20,29H,9,11,24H2,1-4H3,(H,25,27)/t16-,18+,20-/m1/s1",CBSLJZDEUVECFG-IMFGXOCKSA-N,,146501962,,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,780,6.017065707,5.588887923,961.4668,2576.9861
1792,350,99.9,350,100,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C(OC3CCNCC3)=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,Nov-35,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,520,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2700,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01845,1101.794,1100.437893,5.06,76,8,17,5,22,232.75,C54H69ClN10O9S2,"InChI=1S/C54H69ClN10O9S2/c1-31-33(3)76-53-46(31)47(35-10-12-38(55)13-11-35)60-41(50-63-62-34(4)65(50)53)26-44(67)57-18-19-71-20-21-72-22-23-73-29-45(68)61-49(54(5,6)7)52(70)64-28-39(66)25-42(64)51(69)58-27-37-9-8-36(48-32(2)59-30-75-48)24-43(37)74-40-14-16-56-17-15-40/h8-13,24,30,39-42,49,56,66H,14-23,25-29H2,1-7H3,(H,57,67)(H,58,69)(H,61,68)/t39-,41+,42+,49-/m1/s1",FOJOYRKGPBBUCX-BCSSRTCSSA-N,42,84,114,COCCOCCOCCN,[R1]NCCOCCOCCOC[R2],163.217,163.1208434,-1.16,11,0,4,1,8,53.71,C7H17NO3,"InChI=1S/C7H17NO3/c1-9-4-5-11-7-6-10-3-2-8/h2-8H2,1H3",OKUWOEKJQRUMBW-UHFFFAOYSA-N,Q92830,GCN5,GSK4027,CN1C[C@H](NC2=C(Br)C(=O)N(C)N=C2)C[C@H](C2=CC=CC=C2)C1,,,,,,,1.4,BROMOscan panel,10.1021/acs.jmedchem.6b01566,377.286,376.0898734,2.55,23,3,5,1,3,50.16,C17H21BrN4O,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,50234923,126961735,CHEMBL4069412,84VHL,84,P40337,VHL,,CC1=NC(C)=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](N)C(C)(C)C)C=C2)S1,,,,,,,,,10.1021/acs.jmedchem.3c01144,458.628,458.2351619,2.86,32,3,6,3,5,108.55,C24H34N4O3S,"InChI=1S/C24H34N4O3S/c1-13(16-7-9-17(10-8-16)20-14(2)26-15(3)32-20)27-22(30)19-11-18(29)12-28(19)23(31)21(25)24(4,5)6/h7-10,13,18-19,21,29H,11-12,25H2,1-6H3,(H,27,30)/t13-,18+,19-,21+/m0/s1",FRYBPIKQFAXEAL-DXRQPORESA-N,,,,32.66,0.021218616,1,1,1,1,1,0.021218616,0.999,350,6.16588547,5.957964002,682.5187,1101.6306
1785,180,99,180,99,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C3=CC4=C(C=C3CS(C)(=O)=O)C3=CN(C)C(=O)C5=C3C(=C[NH]5)CN4C3=NC=C(F)C=C3F)C(C)(C)C)C(OC3CCNCC3)=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,1.2/1.6,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,383,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,220,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01846,1201.386,1200.458416,2.75,84,9,18,6,23,277.74,C58H70F2N10O12S2,"InChI=1S/C58H70F2N10O12S2/c1-33-51(83-32-66-33)34-7-8-35(47(20-34)82-40-9-11-61-12-10-40)24-65-55(74)46-22-39(71)28-70(46)57(76)52(58(2,3)4)67-48(72)30-81-18-17-80-16-15-79-14-13-62-54(73)41-23-45-42(19-36(41)31-84(6,77)78)43-29-68(5)56(75)50-49(43)37(25-63-50)27-69(45)53-44(60)21-38(59)26-64-53/h7-8,19-21,23,25-26,29,32,39-40,46,52,61,63,71H,9-18,22,24,27-28,30-31H2,1-6H3,(H,62,73)(H,65,74)(H,67,72)/t39-,46+,52-/m1/s1",QZSIUKWWOMOSBP-MHQZIYKSSA-N,317,84,9,CCOCCOCCOC,[R1]CCOCCOCCOC[R2],148.202,148.1099444,0.15,10,0,3,0,7,27.69,C7H16O3,"InChI=1S/C7H16O3/c1-3-9-6-7-10-5-4-8-2/h3-7H2,1-2H3",CNJRPYFBORAQAU-UHFFFAOYSA-N,Q06187,BTK,,O=C(O)CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2,81.4,Inhibition of BTK,,,,,,,10.1016/j.ejmech.2021.113820,422.828,422.0781826,4.07,30,4,6,3,7,117.2,C21H15ClN4O4,"InChI=1S/C21H15ClN4O4/c22-16-8-13(30-12-4-2-1-3-5-12)6-7-14(16)19(29)15-9-23-20-18(15)21(26-11-25-20)24-10-17(27)28/h1-9,11H,10H2,(H,27,28)(H2,23,24,25,26)",GTFCZHOGJFHOEX-UHFFFAOYSA-N,,156770693,,84VHL,84,P40337,VHL,,CC1=NC(C)=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](N)C(C)(C)C)C=C2)S1,,,,,,,,,10.1021/acs.jmedchem.3c01144,458.628,458.2351619,2.86,32,3,6,3,5,108.55,C24H34N4O3S,"InChI=1S/C24H34N4O3S/c1-13(16-7-9-17(10-8-16)20-14(2)26-15(3)32-20)27-22(30)19-11-18(29)12-28(19)23(31)21(25)24(4,5)6/h7-10,13,18-19,21,29H,11-12,25H2,1-6H3,(H,27,30)/t13-,18+,19-,21+/m0/s1",FRYBPIKQFAXEAL-DXRQPORESA-N,,,,32.66,0.021218616,1,1,1,1,1,0.021218616,0.99,180,6.032444388,6.063333742,928.0163,864.3035
1786,3.4,98,3.4,98,O60885,BRD4,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)C3=CC4=C(C=C3CS(C)(=O)=O)C3=CN(C)C(=O)C5=C3C(=C[NH]5)CN4C3=NC=C(F)C=C3F)C(C)(C)C)C(OC3CCNCC3)=C2)SC=N1,Degradation of BRD4 in PC3-S1 cells after 4 h treatment,,,2/2.7,IC50 of BRD4 BD1/BD2 was tested by TR-FRET,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40,Inhibit proliferation of PC3-S1 cells,,,,,,,,,,,,,,,10.1021/acs.jmedchem.0c01846,1195.47,1194.520622,6.88,84,9,15,6,23,250.05,C61H76F2N10O9S2,"InChI=1S/C61H76F2N10O9S2/c1-36-54(83-35-69-36)37-16-17-38(50(24-37)82-43-18-21-64-22-19-43)28-68-58(77)49-26-42(74)32-73(49)60(79)55(61(2,3)4)70-51(75)15-13-11-9-7-8-10-12-14-20-65-57(76)44-27-48-45(23-39(44)34-84(6,80)81)46-33-71(5)59(78)53-52(46)40(29-66-53)31-72(48)56-47(63)25-41(62)30-67-56/h16-17,23-25,27,29-30,33,35,42-43,49,55,64,66,74H,7-15,18-22,26,28,31-32,34H2,1-6H3,(H,65,76)(H,68,77)(H,70,75)/t42-,49+,55-/m1/s1",QJBZJBJONOIDIV-GSTUPHOUSA-N,317,84,40,CCCCCCCCCC,[R1]CCCCCCCCCC[R2],142.286,142.1721507,5.63,10,0,0,0,7,0,C10H22,"InChI=1S/C10H22/c1-3-5-7-9-10-8-6-4-2/h3-10H2,1-2H3",DIOQZVSQGTUSAI-UHFFFAOYSA-N,Q06187,BTK,,O=C(O)CNC1=NC=NC2=C1C(C(=O)C1=CC=C(OC3=CC=CC=C3)C=C1Cl)=C[NH]2,81.4,Inhibition of BTK,,,,,,,10.1016/j.ejmech.2021.113820,422.828,422.0781826,4.07,30,4,6,3,7,117.2,C21H15ClN4O4,"InChI=1S/C21H15ClN4O4/c22-16-8-13(30-12-4-2-1-3-5-12)6-7-14(16)19(29)15-9-23-20-18(15)21(26-11-25-20)24-10-17(27)28/h1-9,11H,10H2,(H,27,28)(H2,23,24,25,26)",GTFCZHOGJFHOEX-UHFFFAOYSA-N,,156770693,,84VHL,84,P40337,VHL,,CC1=NC(C)=C(C2=CC=C([C@H](C)NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](N)C(C)(C)C)C=C2)S1,,,,,,,,,10.1021/acs.jmedchem.3c01144,458.628,458.2351619,2.86,32,3,6,3,5,108.55,C24H34N4O3S,"InChI=1S/C24H34N4O3S/c1-13(16-7-9-17(10-8-16)20-14(2)26-15(3)32-20)27-22(30)19-11-18(29)12-28(19)23(31)21(25)24(4,5)6/h7-10,13,18-19,21,29H,11-12,25H2,1-6H3,(H,27,30)/t13-,18+,19-,21+/m0/s1",FRYBPIKQFAXEAL-DXRQPORESA-N,,,,32.66,0.021218616,1,1,1,1,1,0.021218616,0.98,3.4,6.148164128,5.896701355,710.9448,1268.5239
2438,1380,76,1380,76,O15379,HDAC3,VHL,,JPS035,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1OCCCCCCCCCCCC(=O)NC1=CC=C(C(=O)NC2=CC=CC=C2N)C=C1)C(C)(C)C,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,3810,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,896.168,895.4666184,7.56,64,5,10,6,22,205.08,C49H65N7O7S,"InChI=1S/C49H65N7O7S/c1-32-44(64-31-52-32)35-20-21-36(29-51-47(61)41-28-38(58)30-56(41)48(62)45(49(3,4)5)53-33(2)57)42(27-35)63-26-16-12-10-8-6-7-9-11-13-19-43(59)54-37-24-22-34(23-25-37)46(60)55-40-18-15-14-17-39(40)50/h14-15,17-18,20-25,27,31,38,41,45,58H,6-13,16,19,26,28-30,50H2,1-5H3,(H,51,61)(H,53,57)(H,54,59)(H,55,60)/t38-,41+,45-/m1/s1",XPJGKIYHVFVWKJ-XVYMMXEDSA-N,129,18,41,CCCCCCCCCCC,[R1]CCCCCCCCCCC[R2],156.313,156.1878008,6.17,11,0,0,0,8,0,C11H24,"InChI=1S/C11H24/c1-3-5-7-9-11-10-8-6-4-2/h3-11H2,1-2H3",RSJKGSCJYJTIGS-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,18VHL,18,P40337,VHL,,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C#N)C=C1)C(C)(C)C,4827,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,414.506,414.2267054,1.34,30,2,5,3,5,122.53,C22H30N4O4,"InChI=1S/C22H30N4O4/c1-13(16-8-6-15(11-23)7-9-16)24-20(29)18-10-17(28)12-26(18)21(30)19(22(3,4)5)25-14(2)27/h6-9,13,17-19,28H,10,12H2,1-5H3,(H,24,29)(H,25,27)/t13-,17+,18-,19+/m0/s1",OXUULQVWMAOYDZ-NUDXDXSLSA-N,,153633177,CHEMBL4435205,62.9,0.011017488,1,1,1,1,1,0.011017488,0.76,1380,6.665998994,6.096484869,215.7749,800.7835
2438,1380,76,1380,76,O15379,HDAC3,VHL,,JPS035,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1OCCCCCCCCCCCC(=O)NC1=CC=C(C(=O)NC2=CC=CC=C2N)C=C1)C(C)(C)C,Degradation of HDAC3 in HCT116 cells after 24 h treatment,,,3810,IC50 of HDAC3-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,896.168,895.4666184,7.56,64,5,10,6,22,205.08,C49H65N7O7S,"InChI=1S/C49H65N7O7S/c1-32-44(64-31-52-32)35-20-21-36(29-51-47(61)41-28-38(58)30-56(41)48(62)45(49(3,4)5)53-33(2)57)42(27-35)63-26-16-12-10-8-6-7-9-11-13-19-43(59)54-37-24-22-34(23-25-37)46(60)55-40-18-15-14-17-39(40)50/h14-15,17-18,20-25,27,31,38,41,45,58H,6-13,16,19,26,28-30,50H2,1-5H3,(H,51,61)(H,53,57)(H,54,59)(H,55,60)/t38-,41+,45-/m1/s1",XPJGKIYHVFVWKJ-XVYMMXEDSA-N,129,18,41,CCCCCCCCCCC,[R1]CCCCCCCCCCC[R2],156.313,156.1878008,6.17,11,0,0,0,8,0,C11H24,"InChI=1S/C11H24/c1-3-5-7-9-11-10-8-6-4-2/h3-11H2,1-2H3",RSJKGSCJYJTIGS-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,18VHL,18,P40337,VHL,,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C#N)C=C1)C(C)(C)C,4827,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,414.506,414.2267054,1.34,30,2,5,3,5,122.53,C22H30N4O4,"InChI=1S/C22H30N4O4/c1-13(16-8-6-15(11-23)7-9-16)24-20(29)18-10-17(28)12-26(18)21(30)19(22(3,4)5)25-14(2)27/h6-9,13,17-19,28H,10,12H2,1-5H3,(H,24,29)(H,25,27)/t13-,17+,18-,19+/m0/s1",OXUULQVWMAOYDZ-NUDXDXSLSA-N,,153633177,CHEMBL4435205,62.9,0.011017488,1,1,1,1,1,0.011017488,0.76,1380,6.905998496,6.096484869,124.1657,800.7835
2438,3580,68,3580,68,Q13547,HDAC1,VHL,,JPS035,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1OCCCCCCCCCCCC(=O)NC1=CC=C(C(=O)NC2=CC=CC=C2N)C=C1)C(C)(C)C,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,1810,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,896.168,895.4666184,7.56,64,5,10,6,22,205.08,C49H65N7O7S,"InChI=1S/C49H65N7O7S/c1-32-44(64-31-52-32)35-20-21-36(29-51-47(61)41-28-38(58)30-56(41)48(62)45(49(3,4)5)53-33(2)57)42(27-35)63-26-16-12-10-8-6-7-9-11-13-19-43(59)54-37-24-22-34(23-25-37)46(60)55-40-18-15-14-17-39(40)50/h14-15,17-18,20-25,27,31,38,41,45,58H,6-13,16,19,26,28-30,50H2,1-5H3,(H,51,61)(H,53,57)(H,54,59)(H,55,60)/t38-,41+,45-/m1/s1",XPJGKIYHVFVWKJ-XVYMMXEDSA-N,129,18,41,CCCCCCCCCCC,[R1]CCCCCCCCCCC[R2],156.313,156.1878008,6.17,11,0,0,0,8,0,C11H24,"InChI=1S/C11H24/c1-3-5-7-9-11-10-8-6-4-2/h3-11H2,1-2H3",RSJKGSCJYJTIGS-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,18VHL,18,P40337,VHL,,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C#N)C=C1)C(C)(C)C,4827,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,414.506,414.2267054,1.34,30,2,5,3,5,122.53,C22H30N4O4,"InChI=1S/C22H30N4O4/c1-13(16-8-6-15(11-23)7-9-16)24-20(29)18-10-17(28)12-26(18)21(30)19(22(3,4)5)25-14(2)27/h6-9,13,17-19,28H,10,12H2,1-5H3,(H,24,29)(H,25,27)/t13-,17+,18-,19+/m0/s1",OXUULQVWMAOYDZ-NUDXDXSLSA-N,,153633177,CHEMBL4435205,18.57,0.037318255,1,1,1,1,1,0.037318255,0.68,3580,6.665998994,6.096484869,215.7749,800.7835
2438,3580,68,3580,68,Q13547,HDAC1,VHL,,JPS035,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC1=CC=C(C2=C(C)N=CS2)C=C1OCCCCCCCCCCCC(=O)NC1=CC=C(C(=O)NC2=CC=CC=C2N)C=C1)C(C)(C)C,Degradation of HDAC1 in HCT116 cells after 24 h treatment,,,1810,IC50 of HDAC1-CoREST-LSD1 was assessed by a fluorescent HDAC assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acs.jmedchem.1c02179,896.168,895.4666184,7.56,64,5,10,6,22,205.08,C49H65N7O7S,"InChI=1S/C49H65N7O7S/c1-32-44(64-31-52-32)35-20-21-36(29-51-47(61)41-28-38(58)30-56(41)48(62)45(49(3,4)5)53-33(2)57)42(27-35)63-26-16-12-10-8-6-7-9-11-13-19-43(59)54-37-24-22-34(23-25-37)46(60)55-40-18-15-14-17-39(40)50/h14-15,17-18,20-25,27,31,38,41,45,58H,6-13,16,19,26,28-30,50H2,1-5H3,(H,51,61)(H,53,57)(H,54,59)(H,55,60)/t38-,41+,45-/m1/s1",XPJGKIYHVFVWKJ-XVYMMXEDSA-N,129,18,41,CCCCCCCCCCC,[R1]CCCCCCCCCCC[R2],156.313,156.1878008,6.17,11,0,0,0,8,0,C11H24,"InChI=1S/C11H24/c1-3-5-7-9-11-10-8-6-4-2/h3-11H2,1-2H3",RSJKGSCJYJTIGS-UHFFFAOYSA-N,P06493,CDK1,TMX-3013,NC(=O)C1=C(F)C=CC=C1NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NC=C1Br,0.9,IC50 of CDK1/cyclin B was tested by the Z'-LYTE assays,,,,,,,10.1002/anie.202004087,481.307,480.0015496,2.74,29,3,7,4,6,153.09,C17H14BrFN6O3S,"InChI=1S/C17H14BrFN6O3S/c18-11-8-22-17(23-9-4-6-10(7-5-9)29(21,27)28)25-16(11)24-13-3-1-2-12(19)14(13)15(20)26/h1-8H,(H2,20,26)(H2,21,27,28)(H2,22,23,24,25)",VCPYDRGRPKSEOJ-UHFFFAOYSA-N,,155184510,,18VHL,18,P40337,VHL,,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)C1=CC=C(C#N)C=C1)C(C)(C)C,4827,Displacement of a fluorencently tagged VHL ligand from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01572,414.506,414.2267054,1.34,30,2,5,3,5,122.53,C22H30N4O4,"InChI=1S/C22H30N4O4/c1-13(16-8-6-15(11-23)7-9-16)24-20(29)18-10-17(28)12-26(18)21(30)19(22(3,4)5)25-14(2)27/h6-9,13,17-19,28H,10,12H2,1-5H3,(H,24,29)(H,25,27)/t13-,17+,18-,19+/m0/s1",OXUULQVWMAOYDZ-NUDXDXSLSA-N,,153633177,CHEMBL4435205,18.57,0.037318255,1,1,1,1,1,0.037318255,0.68,3580,6.905998496,6.096484869,124.1657,800.7835
1434,50,71,<=50,>=71,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCC3=CC=C(OC(=O)N[C@H]4C(C)(C)[C@H](OC5=CC=C(C#N)C(Cl)=C5)C4(C)C)C=C3)C(C)(C)C)C=C2)OC=N1,Degradation of AR in LNCaP cells after 2-4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.1021/acsmedchemlett.9b00115,883.443,882.371905,6.95,63,6,11,4,14,205.35,C47H55ClN6O9,"InChI=1S/C47H55ClN6O9/c1-27-38(61-26-51-27)30-13-9-28(10-14-30)22-50-40(57)36-19-32(55)23-54(36)41(58)39(45(2,3)4)52-37(56)25-60-24-29-11-16-33(17-12-29)63-44(59)53-42-46(5,6)43(47(42,7)8)62-34-18-15-31(21-49)35(48)20-34/h9-18,20,26,32,36,39,42-43,55H,19,22-25H2,1-8H3,(H,50,57)(H,52,56)(H,53,59)/t32-,36+,39-,42-,43-/m1/s1",VEFDAFDSPLDCMS-RCOCDALESA-N,221,24,688,COCC1=CC=CC=C1,[R1]C1=CC=C(C=C1)COC[R2],122.167,122.0731649,1.57,9,1,1,0,2,9.23,C8H10O,"InChI=1S/C8H10O/c1-9-7-8-5-3-2-4-6-8/h2-6H,7H2,1H3",GQKZBCPTCWJTAS-UHFFFAOYSA-N,P49840,GSK3A,,CC1=C(C)C(NC2=CC=NC(NC3=CC=C(CC#N)C=C3)=N2)=N[NH]1,,,,,,,,,10.1016/j.cell.2020.10.038,319.372,319.1545435,3,24,3,6,3,5,102.31,C17H17N7,"InChI=1S/C17H17N7/c1-11-12(2)23-24-16(11)21-15-8-10-19-17(22-15)20-14-5-3-13(4-6-14)7-9-18/h3-6,8,10H,7H2,1-2H3,(H3,19,20,21,22,23,24)",QZALFSCNUOYHAP-UHFFFAOYSA-N,,,,24VHL,24,P40337,VHL,,CNC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](C1=CC(C)=NO1)C(C)C)C1=CC=C(C2=C(C)N=CS2)C=C1,26.8,Displacement of a fluorescent probe from VHL by fluorescence polarization based competitive binding affinity assay,,,,,,,10.1021/acs.jmedchem.8b01631,553.685,553.2358902,2.33,39,4,8,3,9,137.66,C28H35N5O5S,"InChI=1S/C28H35N5O5S/c1-15(2)25(23-10-16(3)32-38-23)28(37)33-13-20(34)11-22(33)27(36)31-21(12-24(35)29-5)18-6-8-19(9-7-18)26-17(4)30-14-39-26/h6-10,14-15,20-22,25,34H,11-13H2,1-5H3,(H,29,35)(H,31,36)/t20-,21+,22+,25-/m1/s1",BUFJKORGWVCZBG-HXKBJWFLSA-N,,155521301,CHEMBL4449823,63.641,0.010889207,1,1,1,1,1,0.010889207,0.71,50,6.728401613,5.54718305,186.8953,2836.7231
